CN1328277C - Substituted pyrimidinone and pyridinone compounds and their use - Google Patents

Substituted pyrimidinone and pyridinone compounds and their use Download PDF

Info

Publication number
CN1328277C
CN1328277C CNB971815585A CN97181558A CN1328277C CN 1328277 C CN1328277 C CN 1328277C CN B971815585 A CNB971815585 A CN B971815585A CN 97181558 A CN97181558 A CN 97181558A CN 1328277 C CN1328277 C CN 1328277C
Authority
CN
China
Prior art keywords
amino
group
alkyl
pyridyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB971815585A
Other languages
Chinese (zh)
Other versions
CN1246857A (en
Inventor
U·D·斯波尔
M·J·马隆
N·B·曼特罗
J·A·扎布洛基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CN1246857A publication Critical patent/CN1246857A/en
Application granted granted Critical
Publication of CN1328277C publication Critical patent/CN1328277C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Selected novel substituted pyrimidinone and pyridone compounds are effective for prophylaxis and treatment of diseases, such as TNF- alpha, IL-1 beta, IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving inflammation, pain, diabetes and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Description

Pyrimidone that replaces and pyridinone compounds and their application
Background of invention
The application is a non-provisional application, based on the U.S. Provisional Application 60/032 that proposed on December 5th, 1996,128, the U.S. Provisional Application 60/050 that proposed on June 13rd, 1997, U.S.'s non-provisional application of not assigning as yet that on November 21st, 950 and 1997 proposed, above-mentioned each application is incorporated this paper into as this paper reference in full with it.The present invention relates to a kind of for example disease of THF-α, IL-1 β, IL-6 and/or IL-8 mediation and other diseases new compound of pain and diabetes for example of disease that is used for the treatment of.Particularly, The compounds of this invention is used to prevent and the disease or the illness of treatment and inflammation-related.The invention still further relates to the intermediate and the method that are used to prepare this compounds.
Interleukin 1 (IL-1) and tumor necrosis factor alpha (THF-α) be many inflammatory stimulus elements (during for example lipopolysaccharides-LPS) or outside cellular stress (for example osmotic shock and superoxide) are replied, comprise monocyte and scavenger cell excretory by various different cells before-inflammatory cytokine.
The relative basal level of TNF-α and/or IL-1 level raises with the mediation of numerous disease or increases the weight of relevantly, and described disease comprises rheumatoid arthritis; Paget's disease; Osteoporosis; Multiple myeloma; Uveitis; Acute and chronic lymphocytic leukemia; Pancreatic; Osteoarthritis; Rheumatoid osteomyelitis; Urarthritis; Enteritis; Adult respiratory distress syndrome (ARDS); Psoriasis; Crohn disease; Rhinallergosis; Ulcerative colitis; Irritated; Contact dermatitis; Asthma; Muscle deterioration; Emaciation; Reiter syndrome; I type and type ii diabetes; Bone resorption disease; Graft-vs-host reaction; The ischemia reperfusion damage; Atherosclerosis; Cerebral trauma; Multiple sclerosis; Cerebral malaria; Sepsis; Septic shock; Toxic shock syndrome; The myalgia and the fever that cause because of infection.TNF-α also can make HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, simplexvirus (comprising HSV-1, HSV-2) and zoster worsen.
Existing report, in cerebral trauma, shock and local asphyxia, TNF-α plays an important role.For example, in cerebral trauma animal model (rat), the TNF-alpha levels of dampening hemisphere raise people such as (, J.Cereb.Blood Flow Metab.14,615 (1994)) Shohami.Cerebral arteries is by in the rat local asphyxia model of obturation therein, the TNF-α mRNA level of TNF-α raise (people such as Feurstein, Neurosci.Lett.164,125 (1993).Report is arranged, use TNF-α, found that wicking action and the adhesion at little blood vessel obviously has neutrophilic leukocyte to build up on to rat layer.TNF-α can promote the infiltration of other cytokines (IL-1 β, IL-6) and chemokines, and it can promote neutrophilic leukocyte to infiltrate infarct (Feurstein, Stroke25,1481 (1994)).TNF-α also plays an important role in type ii diabetes.(Endocrinol.130,43-52,1994; And Endocrinol.136,1474-1481,1995).
In some viral life cycle of enhancement and aspect their diseases associated, TNF-α plays an important role.For example, monocyte excretory TNF-α can induce that the HIV expression level raises in the chronically infected T-cell system people such as (, J.Immunol.142,431 (1989)) Clouse.People such as Lahdevirta (Am.J.Med.85,289 (1988)) have discussed the effect to TNF-α in HIV related cachexia and muscle deterioration illness.
In the cytokine cascade reaction of inflammation, TNF-α is in the upper end.As a result, the rising of TNF-alpha levels can cause for example rising of IL-1, IL-6 and IL-8 level of other inflammation and preceding-inflammatory cytokine.
The relative basal level of IL-1 level raises with the mediation of many illnesss and increases the weight of relevantly, and described illness comprises rheumatoid arthritis; Osteoporosis; Rheumatoid osteomyelitis; Urarthritis; Enteritis; Adult respiratory distress syndrome (ARDS); Psoriasis; Crohn disease; Ulcerative colitis; Irritated; Muscle deterioration; Emaciation; Reiter syndrome; I type and type ii diabetes; Bone resorption disease; The ischemia reperfusion damage; Atherosclerosis; Cerebral trauma; Multiple sclerosis; Sepsis; Septic shock and toxic shock syndrome.IL-1 also can influence the virus of TNF-α restraining effect sensitivity for example HIV-1, HIV-2, HIV-3.
TNF-α and IL-1 play an important role in pancreatic and diabetes.Pancreatic beta cell can produce Regular Insulin, and it can help blood glucose balance in the control agent.Type i diabetes is followed in the degeneration of pancreatic beta cell usually.The dysfunction of pancreatic beta cell may occur on one's body the type ii diabetes patient.The characteristics of type ii diabetes are the functional tolerance to Regular Insulin.In addition, type ii diabetes is also often followed the rising of blood plasma hyperglycemic-glycogenolytic factor level and the raising that hepatic glucose produces speed.Hyperglycemic-glycogenolytic factor is a kind of adjusting hormone, and it can make Regular Insulin that the restraining effect of liver gluconeogenesis is weakened.In liver, kidney and fatty tissue, found glucagon receptor now.Therefore glucagon antagonist can be used for reducing glucose level in the blood plasma (WO 97/16442, and it incorporates this paper in full as this paper reference).Can suspect that by the antagonism glucagon receptor, the responsiveness of Regular Insulin will improve in the liver, thereby reduce gluconeogenesis and hepatic glucose generation speed is reduced.
In the rheumatoid arthritis animal model, a plurality of intra-articular injection IL-1 will cause acute, arthritis mutilans (people such as Chandrasekhar, Clinical Immunol Immunopathol.55,382 (1990)).In the test of carrying out with the rheumatoid synovial fluid cell of cultivating, IL-1 is a kind of inductor (Firestein, Am.J.Pathol.140.1309 (1992)) of more effective stromelysin than TNF-α.In the injection site, observe neutrophilic leukocyte, lymphocyte and monocytic white corpuscle and ooze out.It is that chemokines (as IL-8) is induced the result (Dinarello, Eur.Cytokine Netw.5,517-531 (1994)) who excessively regulates with adhesion molecule that white corpuscle oozes out.
Aspect some viral life cycle of promotion, IL-1 also plays an important role.For example, in chronically infected macrophage system, the HIV of cytokine induction express to strengthen with occur together and optionally IL-1 produce enhancing relevant people such as (, J.Immunol.136,40 (1986)) Folks.People such as Beutler (J.Immunol.135,3969 (1985)) have discussed the effect of IL-1 in emaciation.People such as Baracos (New Eng.J.Med.308,553 (1983)) have discussed the effect of IL-1 in muscle deterioration.
In rheumatoid arthritis, IL-1 and TNF-α all can induce synovial cell and chondrocyte to produce collagenase and neutral protease, and it can cause disorganization in suffering from arthritic joint.In arthritis model (collagen protein in rat and the mouse-inductive sacroiliitis (CIA)), before or after CIA induces, use TNF-α in intraarticular, can cause sacroiliitis outbreak to quicken and make the more serious (people such as Brahn of described disease, Lymphokine Cytokine Res.11,253 (1992); And Cooper, Clin.Exp.Immunol.898,244 (1992)).
The generation of IL-8 and many illnesss and/or worsen relevant, wherein a large amount of neutrophilic leukocytes are to regulate by the chemotaxis characteristic of IL-8 to inflammation and the infiltration of damage (for example local asphyxia) position, these illnesss include but not limited to following illness: asthma, enteritis, psoriasis, grownup's respiratory distress syndrome, the heart and renal reperfusion injury, myocardial infarction and glomerulonephritis.Except to the leukocytic chemotaxis effect of neutrality, IL-8 can also activate neutrophilic leukocyte.Therefore, reduce the level of IL-8, can cause neutrophilic leukocyte to infiltrate and reduce.
Now existing several method is used to block the effect of TNF-α.A kind of method is, uses the soluble receptors (for example TNFR-55 or TNFR-75) of TNF-α, shows that in the animal model of the alpha mediated disease of TNF-it is effective.Second method is, with among the monoclonal antibody cA2 of TNF-alpha specific and TNF-α, shown that there is improvement effect (people such as Feldmann, Immunological Reviews, pp.195-223 (1995)) in its joint to swelling in people II phase rheumatoid arthritis test.These methods are blocked the effect of TNF-α and IL-1 by albumen isolation or receptor antagonism.
US 5,100, and 897 (incorporate in full as this paper with reference to) disclosed the pyrimidinone compound as the Angiotensin II antagonist, and the substituted phenmethyl of nitrogen-atoms or the styroyl group of wherein said pyrimidone ring replace.
US 5,162, and 325 (incorporating the reference as this paper in full into) disclosed the pyrimidinone compound as the Angiotensin II antagonist, and the substituted benzyl group of a nitrogen-atoms of wherein said pyrimidone ring replaces.
EP 481448 (incorporating the reference as this paper in full into) discloses the pyrimidinone compound as the Angiotensin II antagonist, and a substituted phenyl of nitrogen-atoms of wherein said pyrimidone ring, phenmethyl or styroyl group replace.
CA 2,020, and 370 (incorporating the reference as this paper in full into) disclosed the pyrimidinone compound as the Angiotensin II antagonist, and the substituted xenyl aliphatic hydrocarbon group of a nitrogen-atoms of wherein said pyrimidone ring replaces.
Summary of the invention
The present invention relates to a class is used to prevent and treats for example disease of THF-α, IL-1 β, IL-6 and/or IL-8 mediation and other diseases new compound of pain and diabetes for example of disease.Particularly, The compounds of this invention is used to prevent and the disease or the illness of treatment and inflammation-related.Thereby, the invention still further relates to the pharmaceutical composition that contains described compound, the disease of using prevention of compound of the present invention and composition and treatment TNF-α, IL-1 β, IL-6 and/or IL-8 mediation is the method for inflammation, pain and diabetes for example, and the intermediate and the method that are used to prepare compound of the present invention.
Compound of the present invention is by following general formula:
Figure C9718155800301
Wherein dotted line represent between C (R) and V or the W two keys (promptly-V=C (R)-or-W=C (R)-) and V, W, X, R, R 11And R 12As following definition.
Above, do not attempt, should not constitute any qualification yet the present invention just to the general introduction of some aspect of the present invention.The document of all patents that this paper quoted and wherein citation all is incorporated herein by reference in full.
Detailed Description Of The Invention
The invention provides following formula: compound or its pharmaceutically acceptable salt:
Wherein
X is O, S or NR 5Preferably, X is O or S; And most preferably, X is O;
Figure C9718155800312
Be
Figure C9718155800314
Or
Figure C9718155800315
Condition is, among-VC (R) W-aryl, heteroaryl, cycloalkyl and heterocycloalkyl add up to 0-3, preferred 0-2, most preferably 0-1;
The first preferred subgroup
Be
Figure C9718155800322
The second preferred subgroup
Be
Figure C9718155800324
Or
The 3rd preferred subgroup
Figure C9718155800326
Be
Figure C9718155800328
Or
Figure C9718155800329
More preferably
Figure C9718155800331
Or
Most preferably
Or
Figure C9718155800334
U is NR 21Or CHR 21Preferably, U is NR 21
N is the integer of 1-3;
R 1And R 2Be independently of one another-Y or-Z-Y, and R 3And R 4Be independently of one another-Z-Y; Condition is R 4Be not the aryl that replaces, (replacement-aryl) methyl or (replacement-aryl) ethyl, and each-Y and-aryl, heteroaryl, cycloalkyl and heterocyclic radical among the Z-Y add up to 0-3; Preferred 0-2; More preferably 0-1;
Preferably, R 2Be hydrogen, C 1-C 4Alkyl, halogen, cyano group, hydroxyl, C 1-C 4Alkoxyl group, contain the C of 1-3 halogen 1-C 2Halogenated alkoxy, C 1-C 4Alkylthio, amino, C 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino or contain the C of 1-3 halogen 1-C 2Halogenated alkyl group; More preferably, R 2Be hydrogen, C 1-C 4Alkyl, halogen, cyano group, hydroxyl, C 1-C 4Alkoxyl group, trifluoromethoxy or trifluoromethyl; Most preferably, R 2Be hydrogen;
Preferably, R 3Be hydrogen or
(1) C that is replaced arbitrarily by following group 1-C 8Alkyl or C 2-C 8Thiazolinyl: (a) 1-3 is selected from amino, C 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4The group of alkylthio or halogen and (b) 1-2 be selected from the group of heterocyclic radical, aryl or heteroaryl, it can be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, halogen, C 1-C 4The group of alkyl, trifluoromethoxy or trifluoromethyl replaces arbitrarily; Perhaps
(2) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, C 1-C 4Aryl or heteroaryl that the group of alkyl, trifluoromethoxy or trifluoromethyl replaces arbitrarily;
More preferably, R 3Be hydrogen or
(1) is selected from the C that following group replaces arbitrarily by 1-2 1-C 8Alkyl, described group are amino, C 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, hydroxyl, C 1-C 4Alkoxyl group or be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, halogen, C 1-C 4Aryl or heteroaryl that the group of alkyl, trifluoromethoxy or trifluoromethyl replaces arbitrarily; Perhaps
(2) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, C 1-C 4Aryl or heteroaryl that the group of alkyl, trifluoromethoxy or trifluoromethyl replaces arbitrarily;
More preferably, R 3Be hydrogen or be selected from the C that following group replaces arbitrarily by 1-2 1-C 8Alkyl, described group are amino, C 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, hydroxyl, C 1-C 4Alkoxyl group or be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, halogen, C 1-C 4Aryl or heteroaryl that the group of alkyl, trifluoromethoxy or trifluoromethyl replaces arbitrarily;
More preferably, R 3Be hydrogen or C 1-C 4Alkyl; More preferably, R 3Be hydrogen, methyl or ethyl;
Preferably, R 4Be
(1) C that is replaced arbitrarily by following group 1-C 8Alkyl or C 2-C 8Thiazolinyl: (a) 1-3 is selected from amino, C 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4The group of alkylthio or halogen and (b) 1-2 be selected from the group of heterocyclic radical, aryl or heteroaryl, it can be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, halogen, C 1-C 4The group of alkyl, trifluoromethoxy or trifluoromethyl replaces arbitrarily; Perhaps
(2) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, C 1-C 4The heteroaryl that the group of alkyl, trifluoromethoxy or trifluoromethyl replaces arbitrarily;
More preferably, R 4Be
(1) is selected from the C that following group replaces arbitrarily by 1-2 1-C 8Alkyl, described group are amino, C 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, hydroxyl, C 1-C 4Alkoxyl group or be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, halogen, C 1-C 4Aryl or heteroaryl that the group of alkyl, trifluoromethoxy or trifluoromethyl replaces arbitrarily; Perhaps
(2) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, C 1-C 4The heteroaryl that the group of alkyl, trifluoromethoxy or trifluoromethyl replaces arbitrarily;
More preferably, R 4Be selected from the C that following group replaces arbitrarily by 1-2 1-C 8Alkyl, described group are amino, C 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, hydroxyl, C 1-C 4Alkoxyl group or be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, halogen, C 1-C 4Aryl or heteroaryl that the group of alkyl, trifluoromethoxy or trifluoromethyl replaces arbitrarily;
More preferably, R 4Be C 1-C 4Alkyl; Most preferably, R 4Be methyl or ethyl;
Wherein each Z is independently
(1) alkyl, the alkenyl or alkynyl that is replaced arbitrarily by following group: (a) 1-3 group that is selected from amino, alkylamino, dialkylamino, alkanoyl amido, alkoxycarbonyl amido, alkyl sulfonyl amino, hydroxyl, alkoxyl group, alkylthio or halogen, (b) 1-2 group that is selected from heterocyclic radical, aryl or heteroaryl, it can be replaced arbitrarily by 1-3 group that is selected from amino, alkylamino, dialkylamino, alkanoyl amido, alkoxycarbonyl amido, alkyl sulfonyl amino, hydroxyl, alkoxyl group, alkylthio, halogen, alkyl or haloalkyl;
(2) by 1-3 any heterocyclic radical that replaces of group that is selected from amino, alkylamino, dialkylamino, alkanoyl amido, alkoxycarbonyl amido, alkyl sulfonyl amino, hydroxyl, alkoxyl group, alkylthio, alkyl or haloalkyl; Perhaps
(3) by 1-3 any aryl or the heteroaryl that replaces of group that is selected from amino, alkylamino, dialkylamino, alkanoyl amido, alkoxycarbonyl amido, alkyl sulfonyl amino, hydroxyl, alkoxyl group, alkylthio, cyano group, halogen, alkyl or haloalkyl;
Preferably, each Z is independently
(1) C that is replaced arbitrarily by following group 1-C 8Alkyl, C 2-C 8Thiazolinyl or C 2-C 8Alkynyl: (a) 1-3 is selected from amino, C 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4The group of alkylthio or halogen and (b) 1-2 be selected from the group of heterocyclic radical, aryl or heteroaryl, it can be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, halogen, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4The group of haloalkyl replaces arbitrarily;
(2) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4The heterocyclic radical that the group of haloalkyl replaces arbitrarily; Perhaps
(3) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4Aryl or heteroaryl that the group of haloalkyl replaces arbitrarily;
More preferably, each Z is independently
(1) C that is replaced arbitrarily by following group 1-C 8Alkyl, C 2-C 8Thiazolinyl or C 2-C 8Alkynyl: (a) 1-3 is selected from amino, C 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4The group of alkylthio or halogen and (b) 1-2 be selected from the group of heterocyclic radical, aryl or heteroaryl, it can be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, halogen, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4The group of haloalkyl replaces arbitrarily;
(2) be selected from amino, C by 1-2 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4The heterocyclic radical that the group of haloalkyl replaces arbitrarily; Perhaps
(3) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4Aryl or heteroaryl that the group of haloalkyl replaces arbitrarily;
More preferably, each Z is independently
(1) C that is replaced arbitrarily by following group 1-C 8Alkyl or C 2-C 8Thiazolinyl: (a) 1-3 is selected from amino, C 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4The group of alkylthio or halogen and (b) 1-2 be selected from the group of heterocyclic radical, aryl or heteroaryl, it can be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, halogen, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 2The group of haloalkyl replaces arbitrarily;
(2) be selected from amino, two-(C by 1-2 1-C 4Alkyl) amino, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio or C 1-C 4The heterocyclic radical that the group of alkyl replaces arbitrarily; Perhaps
(3) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 2Aryl or heteroaryl that the group of haloalkyl replaces arbitrarily;
More preferably, each Z is independently
(1) C that is replaced arbitrarily by following group 1-C 4Alkyl or C 2-C 5Thiazolinyl: (a) 1-3 is selected from amino, two-(C 1-C 2Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 2Alkoxyl group, C 1-C 2The group of alkylthio or halogen and (b) 1-2 be selected from the group of heterocyclic radical, aryl or heteroaryl, it can be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 2Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, halogen, C 1-C 4The group of alkyl or trifluoromethyl replaces arbitrarily;
(2) be selected from amino, two-(C by 1-2 1-C 2Alkyl) amino, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 2Alkoxyl group, C 1-C 2Alkylthio or C 1-C 4The heterocyclic radical that the group of alkyl replaces arbitrarily; Perhaps
(3) be selected from amino, two-(C by 1-3 1-C 2Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 2Alkoxyl group, C 1-C 2Alkylthio, cyano group, halogen, C 1-C 4Aryl or heteroaryl that the group of alkyl or trifluoromethyl replaces arbitrarily;
More preferably, each Z is independently
(1) C that is replaced arbitrarily by following group 1-C 4Alkyl or C 2-C 5Thiazolinyl: (a) 1-3 is selected from amino, two-(C 1-C 2Alkyl) amino, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 2Alkoxyl group, C 1-C 2The group of alkylthio or halogen and (b) 1-2 be selected from the group of aryl or heteroaryl, it can be selected from amino, two-(C by 1-2 1-C 2Alkyl) amino, kharophen, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 2Alkoxyl group, C 1-C 2Alkylthio, halogen, C 1-C 4The group of alkyl or trifluoromethyl replaces arbitrarily; Perhaps
(2) be selected from amino, two-(C by 1-3 1-C 2Alkyl) amino, kharophen, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 2Alkoxyl group, C 1-C 2Alkylthio, cyano group, halogen, C 1-C 4Aryl or heteroaryl that the group of alkyl or trifluoromethyl replaces arbitrarily;
More preferably, each Z is selected from the C that following group replaces arbitrarily by 1-2 independently 1-C 4Alkyl, described group are amino, two-(C 1-C 2Alkyl) amino, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 2Alkoxyl group, C 1-C 2Alkylthio, halogen or be selected from hydroxyl, C by 1-2 1-C 2Alkoxyl group, C 1-C 2Alkylthio, halogen, C 1-C 4Aryl or heteroaryl that the group of alkyl or trifluoromethyl replaces arbitrarily; With
Most preferably, each Z is independently by 1-2 any C that replaces of group that is selected from amino, t-butoxycarbonyl amino, dimethylamino, hydroxyl, methoxyl group, methylthio group or halogen 1-C 4Alkyl;
Each Y is independently
(1) hydrogen;
(2) halogen or nitro;
(3)-C (O)-R 20Or-C (NR 5)-NR 5R 21Group;
(4)-OR 21,-O-C (O)-R 21,-O-C (O)-NR 5R 21Or-O-C (O)-NR 22-S (O) 2-R 20Group;
(5)-SR 21,-S (O)-R 20,-S (O) 2-R 20,-S (O) 2-NR 5R 21,-S (O) 2-NR 22-C (O)-R 21,-S (O) 2-NR 22-C (O)-OR 20Or-S (O) 2-NR 22-C (O)-NR 5R 21Group; Or
(6)-NR 5R 21,-NR 22-C (O)-R 21,-NR 22-C (O)-OR 20,-NR 22-C (O)-NR 5R 21,-NR 22-C (NR 5)-NR 5R 21,-NR 22-S (O) 2-R 20Or-NR 22-S (O) 2-NR 5R 21Group;
Preferably, each Y is independently
(1) hydrogen;
(2) halogen;
(3)-C (O)-R 20Or-C (NR 5)-NR 5R 21Group;
(4)-OR 21,-O-C (O)-R 21Or-O-C (O)-NR 5R 21Group;
(5)-SR 21,-S (O)-R 20,-S (O) 2-R 20Or-S (O) 2-NR 5R 21Group; Or
(6)-NR 5R 21,-NR 22-C (O)-R 21,-NR 22-C (O)-OR 20,-NR 22-C (O)-NR 5R 21,-NR 22-C (NR 5)-NR 5R 21,-NR 22-S (O) 2-R 20Or-NR 22-S (O) 2-NR 5R 21Group;
More preferably, each Y is independently
(1) hydrogen;
(2)-C (O)-R 20Group;
(3)-OR 21,-SR 21,-S (O)-R 20,-S (O) 2-R 20Or-S (O) 2-NR 5R 21Group; Or
(4)-NR 5R 21,-NR 22-C (O)-R 21,-NR 22-C (O)-OR 20,-NR 22-C (O)-NR 5R 21,-NR 22-S (O) 2-R 20Or-NR 22-S (O) 2-NR 5R 21Group;
More preferably, each Y is independently
(1) hydrogen;
(2)-C (O)-R 20Group;
(3)-OR 21,-SR 21,-S (O)-R 20,-S (O) 2-R 20Or-S (O) 2-NR 5R 21Group; Or
(4)-NR 5R 21,-NR 22-C (O)-R 21Or-NR 22-S (O) 2-R 20Group;
More preferably, each Y is independently
(1)-C (O)-R 20Group;
(2)-OR 21,-SR 21,-S (O)-R 20,-S (O) 2-R 20Or-S (O) 2-NR 5R 21Group; Or
(3)-NR 5R 21,-NR 22-C (O)-R 21Or-NR 22-S (O) 2-R 20Group.
Most preferably, each Y is-OR independently 21,-SR 21Or-NR 5R 21Group;
Each R wherein 5Be independently
(1) hydrogen;
(2) by 1-3 be selected from amino, alkylamino, dialkylamino, hydroxyl, alkoxyl group, alkylthio ,-SO 3Alkyl, alkenyl or alkynyl that the group of H or halogen replaces arbitrarily; Perhaps
(3) by 1-3 any aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclic radical, Heterocyclylalkyl, cycloalkyl or the cycloalkylalkyl that replaces of group that is selected from amino, alkylamino, dialkylamino, hydroxyl, alkoxyl group, alkylthio, alkyl or haloalkyl;
Preferably, each R 5Be independently
(1) hydrogen;
(2) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio ,-SO 3The C that the group of H or halogen replaces arbitrarily 1-C 8Alkyl, C 2-C 8Thiazolinyl or C 2-C 8Alkynyl; Perhaps
(3) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4Aryl, heteroaryl, aryl-C that the group of haloalkyl replaces arbitrarily 1-C 4-alkyl, heteroaryl-C 1-C 4-alkyl, heterocyclic radical, heterocyclic radical-C 1-C 4-alkyl, C 3-C 8Cycloalkyl or C 3-C 8-cycloalkyl-C 1-C 4-alkyl;
More preferably, each R 5Be independently
(1) hydrogen;
(2) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio ,-SO 3The C that the group of H or halogen replaces arbitrarily 1-C 4Alkyl, C 2-C 5Thiazolinyl or C 2-C 5Alkynyl; Perhaps
(3) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4Aryl, heteroaryl, aryl-C that the group of haloalkyl replaces arbitrarily 1-C 4-alkyl, heteroaryl-C 1-C 4-alkyl, heterocyclic radical, heterocyclic radical-C 1-C 4-alkyl, C 3-C 8Cycloalkyl or C 3-C 8-cycloalkyl-C 1-C 4-alkyl;
More preferably, each R 5Be independently
(1) hydrogen;
(2) be selected from amino, two-(C by 1-3 1-C 4Alkyl) amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio ,-SO 3The C that the group of H or halogen replaces arbitrarily 1-C 4Alkyl or C 2-C 5Thiazolinyl; Perhaps
(3) be selected from amino, two-(C by 1-3 1-C 4Alkyl) amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 2Phenyl-C that the group of haloalkyl replaces arbitrarily 1-C 2-alkyl, heteroaryl-C 1-C 2-alkyl, heterocyclic radical-C 1-C 2-alkyl or C 3-C 6-cycloalkyl-C 1-C 2-alkyl;
More preferably, each R 5Be independently
(1) hydrogen;
(2) be selected from amino, two-(C by 1-3 1-C 4Alkyl) amino, hydroxyl, C 1-C 2Alkoxyl group, C 1-C 2The C that the group of alkylthio or halogen replaces arbitrarily 1-C 4Alkyl; Perhaps
(3) be selected from amino, two-(C by 1-3 1-C 2Alkyl) amino, hydroxyl, C 1-C 2Alkoxyl group, C 1-C 2Alkylthio, methoxyl group, methylthio group, C 1-C 4Phenyl-C that the group of alkyl or trifluoromethyl replaces arbitrarily 1-C 2-alkyl, heteroaryl-C 1-C 2-alkyl, heterocyclic radical-C 1-C 2-alkyl or C 3-C 6-cycloalkyl-C 1-C 2-alkyl;
More preferably, each R 5Be independently
(1) hydrogen;
(2) C that is replaced arbitrarily by 1-3 halogen 1-C 4Alkyl; Perhaps
(3) by 1-3 any phenyl-C that replaces of group that is selected from amino, dimethylamino, hydroxyl, methoxyl group, methylthio group, methyl or trifluoromethyl 1-C 2-alkyl or heteroaryl-C 1-C 2-alkyl;
More preferably, each R 5Be hydrogen or C independently 1-C 4Alkyl; And most preferably, each R 5Be hydrogen independently;
Each R wherein 20Independently be
(1) is selected from the alkyl that following substituting group replaces arbitrarily by 1-3, alkenyl or alkynyl: amino, alkylamino, dialkylamino, alkanoyl amido, alkoxycarbonyl amido, N-(carbalkoxy)-N-(alkyl) amino, amino carbonyl amino, alkyl sulfonyl amino, hydroxyl, alkoxyl group, alkylthio, alkyl sulphinyl, alkyl sulphonyl, halogen or be selected from amino by 1-3, alkylamino, dialkylamino, alkanoyl amido, alkoxycarbonyl amido, alkyl sulfonyl amino, alkanoyl, hydroxyl, alkoxyl group, alkylthio, alkyl sulphinyl, alkyl sulphonyl, halogen, the group of alkyl or haloalkyl replaces arbitrarily; Aralkoxy, aromatic alkylthio, aralkyl alkylsulfonyl, cycloalkyl, heterocyclic radical, aryl or heteroaryl groups;
(2) by 1-3 any heterocyclic radical that replaces of group that is selected from amino, alkylamino, dialkylamino, alkanoyl amido, alkoxycarbonyl amido, alkyl sulfonyl amino, hydroxyl, alkoxyl group, alkylthio, alkyl or haloalkyl; Perhaps
(3) by 1-3 any aryl or the heteroaryl that replaces of group that is selected from amino, alkylamino, dialkylamino, alkanoyl amido, alkoxycarbonyl amido, alkyl sulfonyl amino, carbalkoxy, hydroxyl, alkoxyl group, alkylthio, cyano group, halogen, azido-, alkyl or haloalkyl;
Preferably, each R 20Be independently
(1) is selected from the C that following substituting group replaces arbitrarily by 1-3 1-C 8Alkyl, C 2-C 8Thiazolinyl or C 2-C 8Alkynyl: amino, C 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, N-((C 1-C 4Alkoxyl group) carbonyl)-N-(C 1-C 4Alkyl) amino, amino carbonyl amino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, C 1-C 4Alkyl sulphinyl, C 1-C 4Alkyl sulphonyl, halogen or be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, C 1-C 5Alkanoyl, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, C 1-C 4Alkyl sulphinyl, C 1-C 4Alkyl sulphonyl, halogen, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4Aryl-C that the group of haloalkyl replaces arbitrarily 1-C 4-alkoxyl group, aryl-C 1-C 4-alkylthio, aryl-C 1-C 4-alkyl sulphonyl, C 3-C 8Cycloalkyl, heterocyclic radical, aryl or heteroaryl groups;
(2) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4The heterocyclic radical that the group of haloalkyl replaces arbitrarily; Perhaps
(3) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, (C 1-C 4Alkoxyl group) carbonyl, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, azido-, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4Aryl or heteroaryl that the group of haloalkyl replaces arbitrarily;
More preferably, each R 20Be independently
(1) is selected from the C that following substituting group replaces arbitrarily by 1-3 1-C 8Alkyl, C 2-C 5Thiazolinyl or C 2-C 5Alkynyl: amino, C 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, N-((C 1-C 4Alkoxyl group) carbonyl)-N-(C 1-C 4Alkyl) amino, amino carbonyl amino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, C 1-C 4Alkyl sulphinyl, C 1-C 4Alkyl sulphonyl, halogen or be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, C 1-C 5Alkanoyl, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, C 1-C 4Alkyl sulphinyl, C 1-C 4Alkyl sulphonyl, halogen, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4Aryl-C that the group of haloalkyl replaces arbitrarily 1-C 4-alkoxyl group, aryl-C 1-C 4-alkylthio, aryl-C 1-C 4-alkyl sulphonyl, C 3-C 8Cycloalkyl, heterocyclic radical, aryl or heteroaryl groups;
(2) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4The heterocyclic radical that the group of haloalkyl replaces arbitrarily; Perhaps
(3) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, (C 1-C 4Alkoxyl group) carbonyl, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, azido-, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4Aryl or heteroaryl that the group of haloalkyl replaces arbitrarily;
More preferably, each R 20Be independently
(1) is selected from the C that following substituting group replaces arbitrarily by 1-3 1-C 8Alkyl or C 2-C 5Thiazolinyl: amino, C 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, N-((C 1-C 4Alkoxyl group) carbonyl)-N-(C 1-C 4Alkyl) amino, amino carbonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, C 1-C 4Alkyl sulphinyl, C 1-C 4Alkyl sulphonyl, halogen or be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, C 1-C 5Alkanoyl, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, halogen, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 2Aryl-C that the group of haloalkyl replaces arbitrarily 1-C 4-alkoxyl group, aryl-C 1-C 4-alkylthio, aryl-C 1-C 4-alkyl sulphonyl, C 3-C 6Cycloalkyl, heterocyclic radical, aryl or heteroaryl groups;
(2) be selected from amino, C by 1-2 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio or C 1-C 4The heterocyclic radical that the group of alkyl replaces arbitrarily; Perhaps
(3) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, (C 1-C 4Alkoxyl group) carbonyl, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, azido-, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 2Aryl or heteroaryl that the group of haloalkyl replaces arbitrarily;
More preferably, each R 20Be independently
(1) is selected from the C that following substituting group replaces arbitrarily by 1-3 1-C 8Alkyl or C 2-C 5Thiazolinyl: amino, C 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, N-((C 1-C 4Alkoxyl group) carbonyl)-N-(C 1-C 4Alkyl) amino, amino carbonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, C 1-C 4Alkyl sulphinyl, C 1-C 4Alkyl sulphonyl, halogen or be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, C 1-C 5Alkanoyl, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, halogen, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 2Aryl-C that the group of haloalkyl replaces arbitrarily 1-C 4-alkoxyl group, aryl-C 1-C 4-alkylthio, aryl-C 1-C 4-alkyl sulphonyl, C 3-C 6Cycloalkyl, heterocyclic radical, aryl or heteroaryl groups;
(2) be selected from amino, two-(C by 1-2 1-C 4Alkyl) amino, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio or C 1-C 4The heterocyclic radical that the group of alkyl replaces arbitrarily; Perhaps
(3) be selected from amino, C by 1-2 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, kharophen, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, (C 1-C 4Alkoxyl group) carbonyl, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, azido-, C 1-C 4Aryl or heteroaryl that the group of alkyl or trifluoromethyl replaces arbitrarily;
More preferably, each R 20Be independently
(1) is selected from the C that following substituting group replaces arbitrarily by 1-3 1-C 8Alkyl: amino, C 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, N-((C 1-C 4Alkoxyl group) carbonyl)-N-(C 1-C 4Alkyl) amino, amino carbonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, C 1-C 4Alkyl sulphinyl, C 1-C 4Alkyl sulphonyl, halogen or be selected from amino, two-(C by 1-2 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, halogen, C 1-C 4The C that the group of alkyl or trifluoromethyl replaces arbitrarily 3-C 6Cycloalkyl, heterocyclic radical, aryl or heteroaryl groups;
(2) be selected from hydroxyl, C by 1-2 1-C 4Alkoxyl group, C 1-C 4Alkylthio or C 1-C 4The heterocyclic radical that the group of alkyl replaces arbitrarily; Perhaps
(3) be selected from (C by 1-2 1-C 4Alkoxyl group) carbonyl, amino, C 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, azido-, C 1-C 4Aryl or heteroaryl that the group of alkyl or trifluoromethyl replaces arbitrarily;
More preferably, each R 20Be independently
(1) is selected from the C that following substituting group replaces arbitrarily by 1-3 1-C 6Alkyl: amino, methylamino-, dimethylamino, t-butoxycarbonyl amino, N-((tert.-butoxy) carbonyl)-N-(methyl) amino, amino carbonyl amino, hydroxyl, butoxy, methoxyl group, butylthio, methylthio group, methylsulfinyl, methylsulfonyl, halogen or the C that is replaced arbitrarily by the individual group that is selected from amino, dimethylamino, kharophen, hydroxyl, methoxyl group, methylthio group, halogen, methyl or trifluoromethyl of 1-2 5-C 6Cycloalkyl, heterocyclic radical, phenyl or heteroaryl groups;
(2) be selected from hydroxyl or C by 1-2 1-C 4The heterocyclic radical that the group of alkyl replaces arbitrarily; Perhaps
(3) by 1-2 any aryl or the heteroaryl that replaces of group that is selected from amino, dimethylamino, hydroxyl, methoxyl group, methylthio group, halogen, methyl or trifluoromethyl;
More preferably, each R 20Be independently
(1) is selected from the C that following substituting group replaces arbitrarily by 1-3 1-C 6Alkyl: amino, methylamino-, dimethylamino, t-butoxycarbonyl amino, N-((tert.-butoxy) carbonyl)-N-(methyl) amino, amino carbonyl amino, hydroxyl, butoxy, methoxyl group, butylthio, methylthio group, methylsulfinyl, methylsulfonyl, halogen or the C that is replaced arbitrarily by the individual group that is selected from amino, dimethylamino, kharophen, hydroxyl, methoxyl group, methylthio group, halogen, methyl or trifluoromethyl of 1-2 5-C 6Cycloalkyl, heterocyclic radical, phenyl or heteroaryl groups;
(2) heterocyclic radical; Perhaps
(3) by 1-2 any aryl or the heteroaryl that replaces of group that is selected from amino, dimethylamino, hydroxyl, methoxyl group, methylthio group, halogen, methyl or trifluoromethyl;
Most preferably, each R 20Be independently
(1) is selected from the C that following substituting group replaces arbitrarily by 1-3 1-C 6Alkyl: amino, methylamino-, dimethylamino, hydroxyl or the phenyl or the heteroaryl groups that are replaced arbitrarily by the individual group that is selected from amino, dimethylamino, hydroxyl, methoxyl group, methylthio group, halogen, methyl or trifluoromethyl of 1-2;
(2) heterocyclic radical; Perhaps
(3) by 1-2 any aryl or the heteroaryl that replaces of group that is selected from amino, dimethylamino, hydroxyl, methoxyl group, methylthio group, halogen, methyl or trifluoromethyl;
Each R 21Be hydrogen or R independently 20
Each R 22Be independently
(1) hydrogen;
(2) alkyl that is replaced arbitrarily by heterocyclic radical, aryl or heteroaryl groups, described substituting group can be replaced arbitrarily by 1-3 group that is selected from amino, alkylamino, dialkylamino, alkanoyl amido, alkoxycarbonyl amido, alkyl sulfonyl amino, hydroxyl, alkoxyl group, alkylthio, alkyl sulphinyl, alkyl sulphonyl, cyano group, halogen, alkyl or haloalkyl; Perhaps
(3) by 1-3 any heterocyclic radical, aryl or the heteroaryl that replaces of group that is selected from amino, alkylamino, dialkylamino, alkanoyl amido, alkoxycarbonyl amido, alkyl sulfonyl amino, hydroxyl, alkoxyl group, alkylthio, alkyl sulphinyl, alkyl sulphonyl, cyano group, halogen, alkyl or haloalkyl; Condition is, when Z is that chemical bond and Y are-NR 22-C (O)-NH 2The time, R 22It or not the aryl that is optionally substituted;
Preferably, each R 22Be independently
(1) hydrogen;
(2) C that is replaced arbitrarily by heterocyclic radical, aryl or heteroaryl groups 1-C 4Alkyl, described substituting group can be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, C 1-C 4Alkyl sulphinyl, C 1-C 4Alkyl sulphonyl, cyano group, halogen, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4The group of haloalkyl replaces arbitrarily; Perhaps
(3) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, C 1-C 4Alkyl sulphinyl, C 1-C 4Alkyl sulphonyl, cyano group, halogen, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4Heterocyclic radical, aryl or heteroaryl that the group of haloalkyl replaces arbitrarily; Condition is, when Z is that chemical bond and Y are-NR 22-C (O)-NH 2The time, R 22It or not the aryl that is optionally substituted;
More preferably, each R 22Be independently
(1) hydrogen; Perhaps
(2) by phenyl or any C that replaces of heteroaryl groups 1-C 4Alkyl, described substituting group can be selected from amino, two-(C by 1-3 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 2The group of haloalkyl replaces arbitrarily;
More preferably, each R 22Be hydrogen or C independently 1-C 4Alkyl; And most preferably, each R 22Be hydrogen or methyl independently;
R 11And R 12Be selected from aryl and the heteroaryl that following group replaces arbitrarily by 1-3 independently of one another:
(1)R 30；
(2) halogen or cyano group;
(1)R 30；
(2) halogen or cyano group;
(3)-C (O)-R 30,-C (O)-OR 29,-C (O)-NR 31R 32Or-C (NR 31)-NR 31R 32Group;
(4)-OR 29,-O-C (O)-R 29,-O-C (O)-NR 31R 32Or-O-C (O)-NR 33-S (O) 2-R 30Group;
(5)-SR 29,-S (O)-R 30,-S (O) 2-R 30,-S (O) 2-NR 31R 32,-S (O) 2-NR 33-C (O)-R 30,-S (O) 2-NR 33-C (O)-OR 30Or-S (O) 2-NR 33-C (O)-NR 31R 32Group;
Or
(6)-NR 31R 32,-NR 33-C (O)-R 29,-NR 33-C (O)-OR 30,-NR 33-C (O)-NR 31R 32,-NR 33-C (NR 31)-NR 31R 32,-NR 33-S (O) 2-R 30Or-NR 33-S (O) 2-NR 31R 32Group;
Condition is (1) R 11Not by any 4-pyridyl, 4-pyrimidyl, 4-quinolyl or the 6-isoquinolyl that replaces of 1-2 substituting group; (2) at each R 11And R 12The aryl of last replacement, heteroaryl, cycloalkyl and heterocyclic radical add up to 0-1;
Preferably, R 11And R 12Be selected from aryl and the heteroaryl that following group replaces arbitrarily by 1-2 independently of one another
(1)R 30；
(2) halogen or cyano group;
(3)-C (O)-R 30,-C (O)-OR 29,-C (O)-NR 31R 32Or-C (NR 31)-NR 31R 32Group;
(4)-OR 29,-O-C (O)-R 29,-O-C (O)-NR 31R 32Or-O-C (O)-NR 33-S (O) 2-R 30Group;
(5)-SR 29,-S (O)-R 30,-S (O) 2-R 30,-S (O) 2-NR 31R 32,-S (O) 2-NR 33-C (O)-R 30,-S (O) 2-NR 33-C (O)-OR 30Or-S (O) 2-NR 33-C (O)-NR 31R 32Group;
Or
(6)-NR 31R 32,-NR 33-C (O)-R 29,-NR 33-C (O)-OR 30,-NR 33-C (O)-NR 31R 32,-NR 33-C (NR 31)-NR 31R 32,-NR 33-S (O) 2-R 30Or-NR 33-S (O) 2-NR 31R 32Group;
Condition is (1) R 11Not by any 4-pyridyl, 4-pyrimidyl, 4-quinolyl or the 6-isoquinolyl that replaces of 1-2 substituting group; (2) at each R 11And R 12The aryl of last replacement, heteroaryl, cycloalkyl and heterocyclic radical add up to 0-1;
More preferably, R 11And R 12Be selected from aryl and the heteroaryl that following group replaces arbitrarily by 1-2 independently of one another:
(1)R 30；
(2) halogen or cyano group;
(3)-C (O)-R 30,-C (O)-OR 29,-C (O)-NR 31R 32Or-C (NR 31)-NR 31R 32Group;
(4)-OR 29,-SR 29,-S (O)-R 30,-S (O) 2-R 30,-S (O) 2-NR 31R 32,-NR 31R 32,-NR 33-C (O)-R 29Or-NR 33-C (O)-OR 30Group;
More preferably, R 11Be aryl and R 12Be heteroaryl, wherein said aryl and heteroaryl can be selected from following group by 1-2 and replace arbitrarily:
(1)R 30；
(2) halogen or cyano group;
(3)-C (O)-R 30,-C (O)-OR 29,-C (O)-NR 31R 32Or-C (NR 31)-NR 31R 32Group; Or
(4)-OR 29,-SR 29,-S (O)-R 30,-S (O) 2-R 30,-S (O) 2-NR 31R 32,-NR 31R 32Or-NR 33-C (O)-R 29Group;
More preferably, R 11Be aryl and R 12Be heteroaryl, wherein said aryl and heteroaryl can be selected from following group by 1-2 and replace arbitrarily:
(1)R 30；
(2) halogen or cyano group;
(3)-C (O)-NR 31R 32,-OR 29,-SR 29,-S (O)-R 30,-S (O) 2-R 30,-S (O) 2-NR 31R 32,-NR 31R 32Or-NR 33-C (O)-R 29Group;
More preferably, R 11Be can be by 1-2 aryl that is selected from any replacement of following group, described group be (1) R 30(2) halogen or cyano group; Perhaps (3)-C (O)-NR 31R 32,-OR 29,-SR 29,-S (O)-R 30,-S (O) 2-R 30,-S (O) 2-NR 31R 32,-NR 31R 32Or-NR 33-C (O)-R 29Group; More preferably, R 11Be can be by 1-2 aryl that is selected from any replacement of following group, described group be amino, dimethylamino, kharophen, hydroxyl, halogen, cyano group, methoxyl group, methylthio group, methylsulfinyl, methyl sulphonyl, aminocarboxyl, methyl or trifluoromethyl group; More preferably, R 11Be unsubstituted phenyl or naphthyl or can be selected from the phenyl that following group replaces arbitrarily that described group is amino, dimethylamino, kharophen, hydroxyl, halogen, cyano group, methoxyl group, methylthio group, methylsulfinyl, methyl sulphonyl, aminocarboxyl, methyl or trifluoromethyl group by 1-2; And most preferably, R 11Be unsubstituted phenyl or be selected from the phenyl that the group of amino, dimethylamino, kharophen, hydroxyl, halogen, cyano group, methoxyl group, methylthio group, methyl sulphonyl, methyl or trifluoromethyl group replaces arbitrarily by 1-2;
More preferably, R 12Be can be by 1-2 heteroaryl that is selected from any replacement of following group, described group be (1) R 30(2) halogen or cyano group; Perhaps (3)-C (O)-NR 31R 32,-OR 29,-SR 29,-NR 31R 32Or-NR 33-C (O)-R 29Group; More preferably, R 12Be can be by 1-2 heteroaryl that is selected from any replacement of following group, described group be amino, dimethylamino, kharophen, hydroxyl, halogen, cyano group, methoxyl group, methyl or trifluoromethyl group; More preferably, R 12Be can be by any 4-pyridyl, 4-quinolyl, 4-imidazolyl or the 4-pyrimidyl that replaces of following groups, described group be amino, dimethylamino, kharophen, hydroxyl, halogen, cyano group, methoxyl group, methyl or trifluoromethyl group; And most preferably, R 12By any 4-pyridyl that replaces of the group of amino, dimethylamino, kharophen, hydroxyl, halogen, cyano group, methoxyl group, methyl or trifluoromethyl group;
Each R wherein 30Be independently
(1) is selected from alkyl, the alkenyl or alkynyl that following substituting group replaces arbitrarily :-NR by 1-3 31R 31,-CO 2R 23, hydroxyl, alkoxyl group, alkylthio, alkyl sulphinyl, alkyl sulphonyl, cyano group, halogen or aralkoxy, aromatic alkylthio, aralkyl alkylsulfonyl, heterocyclic radical, aryl or heteroaryl groups, it can be replaced arbitrarily by 1-3 group that is selected from amino, alkylamino, dialkylamino, alkanoyl amido, alkoxycarbonyl amido, alkyl sulfonyl amino, hydroxyl, alkoxyl group, alkylthio, alkyl sulphinyl, alkyl sulphonyl, cyano group, halogen, alkyl or haloalkyl;
(2) by 1-3 any heterocyclic radical that replaces of group that is selected from amino, alkylamino, dialkylamino, alkanoyl amido, alkoxycarbonyl amido, alkyl sulfonyl amino, hydroxyl, alkoxyl group, alkylthio, cyano group, alkyl or haloalkyl; Perhaps
(3) by 1-3 any aryl or the heteroaryl that replaces of group that is selected from amino, alkylamino, dialkylamino, alkanoyl amido, alkoxycarbonyl amido, alkyl sulfonyl amino, hydroxyl, alkoxyl group, alkylthio, cyano group, halogen, alkyl or haloalkyl;
Preferably, each R 30Be independently
(1) is selected from the C that following substituting group replaces arbitrarily by 1-3 1-C 4Alkyl, C 2-C 4Thiazolinyl or C 2-C 4Alkynyl :-NR 31R 31,-CO 2R 23, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, C 1-C 4Alkyl sulphinyl, C 1-C 4Alkyl sulphonyl, cyano group, halogen or aryl-C 1-C 4-alkoxyl group, aryl-C 1-C 4-alkylthio, aryl-C 1-C 4-alkyl sulphonyl, heterocyclic radical, aryl or heteroaryl groups, it can be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, C 1-C 4Alkyl sulphinyl, C 1-C 4Alkyl sulphonyl, cyano group, halogen, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4The group of haloalkyl replaces arbitrarily;
(2) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4The heterocyclic radical that the group of haloalkyl replaces arbitrarily; Perhaps
(3) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4Aryl or heteroaryl that the group of haloalkyl replaces arbitrarily;
More preferably, each R 30Be independently
(1) is selected from the C that following group replaces arbitrarily by 1-3 1-C 4Alkyl:
(a)-NR 31R 31；
(b) C 1-C 4-alkoxy carbonyl or carbobenzoxy or phenyl methoxycarbonyl, it can be selected from amino, alkylamino, two-(C by 1-3 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, C 1-C 4The group of alkyl or trifluoromethyl replaces arbitrarily; Perhaps
(c) hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, or phenyl-C 1-C 4-alkoxyl group, phenyl-C 1-C 4-alkylthio, heterocyclic radical, phenyl or heteroaryl, it can be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4The group of haloalkyl replaces arbitrarily;
(2) contain the C of 1-3 halogen 1-C 4Haloalkyl; Perhaps
(3) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, C 1-C 4Aryl or heteroaryl that the group of alkyl or trifluoromethyl replaces arbitrarily;
More preferably, each R 30Be independently
(1) C that is replaced arbitrarily by following groups 1-C 4Alkyl:
(a) amino, C 1-C 4Alkylamino or two-(C 1-C 4Alkyl) amino; Perhaps
(b) hydroxyl, C 1-C 4Alkoxyl group, heterocyclic radical, phenyl or heteroaryl, it can be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, C 1-C 4The group of alkyl or trifluoromethyl replaces arbitrarily;
(2) contain the C of 1-3 halogen 1-C 2Haloalkyl; Perhaps
(3) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, C 1-C 4Aryl or heteroaryl that the group of alkyl or trifluoromethyl replaces arbitrarily;
More preferably, each R 30Be independently
(1) by phenyl or any C that replaces of heteroaryl 1-C 4Alkyl, described substituting group can be selected from amino, two-(C by 1-3 1-C 2Alkyl) amino, kharophen, hydroxyl, C 1-C 2Alkoxyl group, halogen, C 1-C 4The group of alkyl or trifluoromethyl replaces arbitrarily;
(2) trifluoromethyl; Perhaps
(3) be selected from amino, two-(C by 1-3 1-C 2Alkyl) amino, kharophen, hydroxyl, C 1-C 2Alkoxyl group, halogen, C 1-C 4Aryl or heteroaryl that the group of alkyl or trifluoromethyl replaces arbitrarily;
More preferably, each R 30Be independently
(1) by phenyl or any C that replaces of heteroaryl 1-C 4Alkyl, described substituting group can be replaced arbitrarily by 1-3 group that is selected from amino, dimethylamino, kharophen, hydroxyl, halogen, methoxyl group, methyl or trifluoromethyl;
(2) trifluoromethyl; Perhaps
(3) by 1-3 any aryl or the heteroaryl that replaces of group that is selected from amino, dimethylamino, kharophen, hydroxyl, halogen, methoxyl group, methyl or trifluoromethyl;
Most preferably, each R 30Be independently
(1) by phenyl or any C that replaces of heteroaryl 1-C 4Alkyl, described substituting group can be replaced arbitrarily by 1-2 group that is selected from amino, dimethylamino, kharophen, hydroxyl, halogen, methoxyl group, methyl or trifluoromethyl;
(2) trifluoromethyl; Perhaps
(3) by 1-3 any aryl or the heteroaryl that replaces of group that is selected from amino, dimethylamino, kharophen, hydroxyl, halogen, methoxyl group, methyl or trifluoromethyl;
Each R 29Be hydrogen or R independently 30And preferably, R 29By 1-2 any aryl or the heteroaryl that replaces of group that is selected from amino, dimethylamino, kharophen, hydroxyl, halogen, methoxyl group, methyl or trifluoromethyl;
Each R 31Be independently
(1) hydrogen;
(2) alkyl that is replaced arbitrarily by cycloalkyl, aryl, heterocyclic radical or heteroaryl groups, described substituting group can be replaced arbitrarily by 1-3 group that is selected from amino, alkylamino, dialkylamino, alkanoyl amido, alkoxycarbonyl amido, alkyl sulfonyl amino, hydroxyl, alkoxyl group, alkylthio, cyano group, alkyl or haloalkyl; Perhaps
(3) by 1-3 any aryl, heteroaryl, heterocyclic radical or the cycloalkyl that replaces of group that is selected from amino, alkylamino, dialkylamino, alkanoyl amido, alkoxycarbonyl amido, alkyl sulfonyl amino, hydroxyl, alkoxyl group, alkylthio, cyano group, alkyl or haloalkyl;
Preferably, each R 31Be independently
(1) hydrogen;
(2) by C 3-C 8The C that cycloalkyl, aryl, heterocyclic radical or heteroaryl groups replace arbitrarily 1-C 4Alkyl, described substituting group can be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4The group of haloalkyl replaces arbitrarily; Perhaps
(3) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4Aryl, heteroaryl, heterocyclic radical or C that the group of haloalkyl replaces arbitrarily 3-C 8Cycloalkyl;
More preferably, each R 31Be independently
(1) hydrogen; Perhaps
(2) by phenyl or any C that replaces of heteroaryl groups 1-C 4Alkyl, described substituting group can be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, C 1-C 4The group of alkyl or trifluoromethyl replaces arbitrarily;
More preferably, each R 31Be hydrogen or C independently 1-C 4Alkyl; And most preferably, each R 31Be hydrogen, methyl or ethyl independently;
Each R 32Be independently
(1) hydrogen;
(2) alkyl that is replaced arbitrarily by cycloalkyl, aryl, heterocyclic radical or heteroaryl groups, described substituting group can be replaced arbitrarily by 1-3 group that is selected from amino, alkylamino, dialkylamino, alkanoyl amido, alkoxycarbonyl amido, alkyl sulfonyl amino, hydroxyl, alkoxyl group, alkylthio, cyano group, alkyl or haloalkyl; Perhaps
(3) by 1-3 any aryl, heteroaryl, heterocyclic radical or the cycloalkyl that replaces of group that is selected from amino, alkylamino, dialkylamino, alkanoyl amido, alkoxycarbonyl amido, alkyl sulfonyl amino, hydroxyl, alkoxyl group, alkylthio, cyano group, alkyl or haloalkyl;
Preferably, each R 32Be independently
(1) hydrogen;
(2) by C 3-C 8The C that cycloalkyl, aryl, heterocyclic radical or heteroaryl groups replace arbitrarily 1-C 4Alkyl, described substituting group can be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4The group of haloalkyl replaces arbitrarily; Perhaps
(3) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4Aryl, heteroaryl, heterocyclic radical or C that the group of haloalkyl replaces arbitrarily 3-C 8Cycloalkyl;
More preferably, each R 32Be independently
(1) hydrogen;
(2) by C 3-C 6The C that cycloalkyl, aryl, heterocyclic radical or heteroaryl groups replace arbitrarily 1-C 4Alkyl, described substituting group can be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4The group of haloalkyl replaces arbitrarily; Perhaps
(3) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4Aryl, heteroaryl, heterocyclic radical or C that the group of haloalkyl replaces arbitrarily 3-C 6Cycloalkyl;
More preferably, each R 32Be independently
(1) hydrogen;
(2) by phenyl or any C that replaces of heteroaryl groups 1-C 4Alkyl, described substituting group can be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4The group of alkyl or trifluoromethyl replaces arbitrarily; Perhaps
(3) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Phenyl or heteroaryl that the group of alkyl or trifluoromethyl replaces arbitrarily;
More preferably, each R 32Be independently
(1) hydrogen;
(2) C 1-C 4Alkyl or the C that is replaced arbitrarily by phenyl or heteroaryl groups 1-C 2Alkyl, described substituting group can be replaced arbitrarily by 1-3 group that is selected from amino, dimethylamino, kharophen, hydroxyl, methoxyl group, methyl or trifluoromethyl; Perhaps
(3) by 1-3 any phenyl or the heteroaryl that replaces of group that is selected from amino, dimethylamino, kharophen, hydroxyl, methoxyl group, methyl or trifluoromethyl;
Most preferably, each R 32Be independently
(1) hydrogen or C 1-C 4Alkyl; Perhaps
(2) by 1-2 any phenyl or the heteroaryl groups that replaces of group that is selected from amino, dimethylamino, kharophen, hydroxyl, methoxyl group, methyl or trifluoromethyl;
With
Each R wherein 33Be independently
(1) hydrogen; Perhaps
(2) alkyl that is replaced arbitrarily by heterocyclic radical, aryl or heteroaryl groups, described substituting group can be replaced arbitrarily by 1-3 group that is selected from amino, alkylamino, dialkylamino, alkanoyl amido, alkoxycarbonyl amido, alkyl sulfonyl amino, hydroxyl, alkoxyl group, alkylthio, cyano group, alkyl or haloalkyl;
Preferably, each R 33Be independently
(1) hydrogen; Perhaps
(2) C that is replaced arbitrarily by heterocyclic radical, aryl or heteroaryl groups 1-C 4Alkyl, described substituting group can be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 4The group of haloalkyl replaces arbitrarily;
More preferably, each R 33Be hydrogen or C independently 1-C 4Alkyl; And most preferably, each R 33Be hydrogen or methyl independently.
Compound of the present invention generally can contain several asymmetric centers and represent with the racemic mixture form typically.The present invention includes racemic mixture, partial racemic compound and single enantiomorph and diastereomer.
Interesting compound comprises following compounds:
R wherein 11, R 12And R 1Be one of listed combination in the following table:
R 11 R 12 R 1
Phenyl The 4-pyridyl The 1-piperazinyl
The 4-fluorophenyl The 4-pyridyl The 1-piperazinyl
The 3-fluorophenyl The 4-pyridyl The 1-piperazinyl
The 2-fluorophenyl The 4-pyridyl The 1-piperazinyl
The 4-chloro-phenyl- The 4-pyridyl The 1-piperazinyl
The 3-chloro-phenyl- The 4-pyridyl The 1-piperazinyl
The 2-chloro-phenyl- The 4-pyridyl The 1-piperazinyl
The 4-tolyl The 4-pyridyl The 1-piperazinyl
The 3-tolyl The 4-pyridyl The 1-piperazinyl
The 2-tolyl The 4-pyridyl The 1-piperazinyl
The 4-trifluoromethyl The 4-pyridyl The 1-piperazinyl
The 3-trifluoromethyl The 4-pyridyl The 1-piperazinyl
2, the 6-dichlorophenyl The 4-pyridyl The 1-piperazinyl
2, the 6-3,5-dimethylphenyl The 4-pyridyl The 1-piperazinyl
3, the 4-dichlorophenyl The 4-pyridyl The 1-piperazinyl
3, the 4-3,5-dimethylphenyl The 4-pyridyl The 1-piperazinyl
The 2,4 dichloro benzene base The 4-pyridyl The 1-piperazinyl
2, the 4-3,5-dimethylphenyl The 4-pyridyl The 1-piperazinyl
Phenyl 2-amino-4-pyridyl The 1-piperazinyl
The 4-fluorophenyl 2-amino-4-pyridyl The 1-piperazinyl
The 3-fluorophenyl 2-amino-4-pyridyl The 1-piperazinyl
The 2-fluorophenyl 2-amino-4-pyridyl The 1-piperazinyl
The 4-chloro-phenyl- 2-amino-4-pyridyl The 1-piperazinyl
The 3-chloro-phenyl- 2-amino-4-pyridyl The 1-piperazinyl
The 2-chloro-phenyl- 2-amino-4-pyridyl The 1-piperazinyl
The 4-tolyl 2-amino-4-pyridyl The 1-piperazinyl
The 3-tolyl 2-amino-4-pyridyl The 1-piperazinyl
The 2-tolyl 2-amino-4-pyridyl The 1-piperazinyl
The 4-trifluoromethyl 2-amino-4-pyridyl The 1-piperazinyl
The 3-trifluoromethyl 2-amino-4-pyridyl The 1-piperazinyl
2, the 6-dichlorophenyl 2-amino-4-pyridyl The 1-piperazinyl
2, the 6-3,5-dimethylphenyl 2-amino-4-pyridyl The 1-piperazinyl
3, the 4-dichlorophenyl 2-amino-4-pyridyl The 1-piperazinyl
3, the 4-3,5-dimethylphenyl 2-amino-4-pyridyl The 1-piperazinyl
The 2,4 dichloro benzene base 2-amino-4-pyridyl The 1-piperazinyl
2, the 4-3,5-dimethylphenyl 2-amino-4-pyridyl The 1-piperazinyl
Phenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 1-piperazinyl
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 1-piperazinyl
The 3-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 1-piperazinyl
The 2-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 1-piperazinyl
The 4-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 1-piperazinyl
The 3-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 1-piperazinyl
The 2-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 1-piperazinyl
The 4-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 1-piperazinyl
The 3-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 1-piperazinyl
The 2-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 1-piperazinyl
The 4-trifluoromethyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 1-piperazinyl
The 3-trifluoromethyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 1-piperazinyl
2, the 6-dichlorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 1-piperazinyl
2, the 6-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 1-piperazinyl
3, the 4-dichlorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 1-piperazinyl
3, the 4-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 1-piperazinyl
The 2,4 dichloro benzene base 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 1-piperazinyl
2, the 4-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 1-piperazinyl
Phenyl 2-amino-4-pyrimidyl The 1-piperazinyl
The 4-fluorophenyl 2-amino-4-pyrimidyl The 1-piperazinyl
The 3-fluorophenyl 2-amino-4-pyrimidyl The 1-piperazinyl
The 2-fluorophenyl 2-amino-4-pyrimidyl The 1-piperazinyl
The 4-chloro-phenyl- 2-amino-4-pyrimidyl The 1-piperazinyl
The 3-chloro-phenyl- 2-amino-4-pyrimidyl The 1-piperazinyl
The 2-chloro-phenyl- 2-amino-4-pyrimidyl The 1-piperazinyl
The 4-tolyl 2-amino-4-pyrimidyl The 1-piperazinyl
The 3-tolyl 2-amino-4-pyrimidyl The 1-piperazinyl
The 2-tolyl 2-amino-4-pyrimidyl The 1-piperazinyl
The 4-trifluoromethyl 2-amino-4-pyrimidyl The 1-piperazinyl
The 3-trifluoromethyl 2-amino-4-pyrimidyl The 1-piperazinyl
2, the 6-dichlorophenyl 2-amino-4-pyrimidyl The 1-piperazinyl
2, the 6-3,5-dimethylphenyl 2-amino-4-pyrimidyl The 1-piperazinyl
3, the 4-dichlorophenyl 2-amino-4-pyrimidyl The 1-piperazinyl
3, the 4-3,5-dimethylphenyl 2-amino-4-pyrimidyl The 1-piperazinyl
The 2,4 dichloro benzene base 2-amino-4-pyrimidyl The 1-piperazinyl
2, the 4-3,5-dimethylphenyl 2-amino-4-pyrimidyl The 1-piperazinyl
Phenyl The 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 4-fluorophenyl The 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 3-fluorophenyl The 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 2-fluorophenyl The 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 4-chloro-phenyl- The 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 3-chloro-phenyl- The 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 2-chloro-phenyl- The 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 4-tolyl The 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 3-tolyl The 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 2-tolyl The 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 4-trifluoromethyl The 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 3-trifluoromethyl The 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
2, the 6-dichlorophenyl The 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
2, the 6-3,5-dimethylphenyl The 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
3, the 4-dichlorophenyl The 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
3, the 4-3,5-dimethylphenyl The 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 2,4 dichloro benzene base The 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
2, the 4-3,5-dimethylphenyl The 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 4-fluorophenyl The 4-pyridyl 3-(3-fluorophenyl) third amino
The 4-fluorophenyl 2-amino-4-pyrimidyl 3-(3-fluorophenyl) third amino
Benzyl The 4-pyridyl 3-phenyl third amino
Benzyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 2-thienyl The 4-pyridyl 3-phenyl third amino
The 2-thienyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
Cyclohexyl The 4-pyridyl 3-phenyl third amino
Cyclohexyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
The tertiary butyl The 4-pyridyl 3-phenyl third amino
The tertiary butyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 4-fluorophenyl The 4-piperidyl 3-phenyl third amino
The 4-fluorophenyl The 4-piperidyl 2-(4-fluorophenyl) ethylamino
The 4-fluorophenyl The 4-pyranyl 3-phenyl third amino
The 4-fluorophenyl The 4-pyranyl 2-(4-fluorophenyl) ethylamino
Phenyl 2-amino-4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 4-fluorophenyl 2-amino-4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 3-fluorophenyl 2-amino-4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 2-fluorophenyl 2-amino-4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 4-chloro-phenyl- 2-amino-4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 3-chloro-phenyl- 2-amino-4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 2-chloro-phenyl- 2-amino-4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 4-tolyl 2-amino-4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 3-tolyl 2-amino-4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 2-tolyl 2-amino-4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 4-trifluoromethyl 2-amino-4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 3-trifluoromethyl 2-amino-4-pyridyl 2-(2-chloro-phenyl-) ethylamino
2, the 6-dichlorophenyl 2-amino-4-pyridyl 2-(2-chloro-phenyl-) ethylamino
2, the 6-3,5-dimethylphenyl 2-amino-4-pyridyl 2-(2-chloro-phenyl-) ethylamino
3, the 4-dichlorophenyl 2-amino-4-pyridyl 2-(2-chloro-phenyl-) ethylamino
3, the 4-3,5-dimethylphenyl 2-amino-4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 2,4 dichloro benzene base 2-amino-4-pyridyl 2-(2-chloro-phenyl-) ethylamino
2, the 4-3,5-dimethylphenyl 2-amino-4-pyridyl 2-(2-chloro-phenyl-) ethylamino
Phenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 3-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 2-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 4-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 3-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 2-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 4-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 3-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 2-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 4-trifluoromethyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 3-trifluoromethyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
2, the 6-dichlorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
2, the 6-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
3, the 4-dichlorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
3, the 4-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
The 2,4 dichloro benzene base 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
2, the 4-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(2-chloro-phenyl-) ethylamino
Phenyl 2-amino-4-pyrimidyl 2-(2-chloro-phenyl-) ethylamino
The 4-fluorophenyl 2-amino-4-pyrimidyl 2-(2-chloro-phenyl-) ethylamino
The 3-fluorophenyl 2-amino-4-pyrimidyl 2-(2-chloro-phenyl-) ethylamino
The 2-fluorophenyl 2-amino-4-pyrimidyl 2-(2-chloro-phenyl-) ethylamino
The 4-chloro-phenyl- 2-amino-4-pyrimidine base 2-(2-chloro-phenyl-) ethylamino
The 3-chloro-phenyl- 2-amino-4-pyrimidyl 2-(2-chloro-phenyl-) ethylamino
The 2-chloro-phenyl- 2-amino-4-pyrimidyl 2-(2-chloro-phenyl-) ethylamino
The 4-tolyl 2-amino-4-pyrimidyl 2-(2-chloro-phenyl-) ethylamino
The 3-tolyl 2-amino-4-pyrimidyl 2-(2-chloro-phenyl-) ethylamino
The 2-tolyl 2-amino-4-pyrimidyl 2-(2-chloro-phenyl-) ethylamino
The 4-trifluoromethyl 2-amino-4-pyrimidyl 2-(2-chloro-phenyl-) ethylamino
The 3-trifluoromethyl 2-amino-4-pyrimidyl 2-(2-chloro-phenyl-) ethylamino
2, the 6-dichlorophenyl 2-amino-4-pyrimidyl 2-(2-chloro-phenyl-) ethylamino
2, the 6-3,5-dimethylphenyl 2-amino-4-pyrimidyl 2-(2-chloro-phenyl-) ethylamino
3, the 4-dichlorophenyl 2-amino-4-pyrimidyl 2-(2-chloro-phenyl-) ethylamino
3, the 4-3,5-dimethylphenyl 2-amino-4-pyrimidyl 2-(2-chloro-phenyl-) ethylamino
The 2,4 dichloro benzene base 2-amino-4-pyrimidyl 2-(2-chloro-phenyl-) ethylamino
2, the 4-3,5-dimethylphenyl 2-amino-4-pyrimidyl 2-(2-chloro-phenyl-) ethylamino
Phenyl The 4-pyridyl 3-imidazolyl third amino
The 4-fluorophenyl The 4-pyridyl 3-imidazolyl third amino
The 3-fluorophenyl The 4-pyridyl 3-imidazolyl third amino
The 2-fluorophenyl The 4-pyridyl 3-imidazolyl third amino
The 4-chloro-phenyl- The 4-pyridyl 3-imidazolyl third amino
The 3-chloro-phenyl- The 4-pyridyl 3-imidazolyl third amino
The 2-chloro-phenyl- The 4-pyridyl 3-imidazolyl third amino
The 4-tolyl The 4-pyridyl 3-imidazolyl third amino
The 3-tolyl The 4-pyridyl 3-imidazolyl third amino
The 2-tolyl The 4-pyridyl 3-imidazolyl third amino
The 4-trifluoromethyl The 4-pyridyl 3-imidazolyl third amino
The 3-trifluoromethyl The 4-pyridyl 3-imidazolyl third amino
The 2-6-dichlorophenyl The 4-pyridyl 3-imidazolyl third amino
2, the 6-3,5-dimethylphenyl The 4-pyridyl 3-imidazolyl third amino
3, the 4-dichlorophenyl The 4-pyridyl 3-imidazolyl third amino
3, the 4-3,5-dimethylphenyl The 4-pyridyl 3-imidazolyl third amino
The 2,4 dichloro benzene base The 4-pyridyl 3-imidazolyl third amino
2, the 4-3,5-dimethylphenyl The 4-pyridyl 3-imidazolyl third amino
Phenyl 2-amino-4-pyridyl 3-imidazolyl third amino
The 4-fluorophenyl 2-amino-4-pyridyl 3-imidazolyl third amino
The 3-fluorophenyl 2-amino-4-pyridyl 3-imidazolyl third amino
The 2-fluorophenyl 2-amino-4-pyridyl 3-imidazolyl third amino
The 4-chloro-phenyl- 2-amino-4-pyridyl 3-imidazolyl third amino
The 3-chloro-phenyl- 2-amino-4-pyridyl 3-imidazolyl third amino
The 2-chloro-phenyl- 2-amino-4-pyridyl 3-imidazolyl third amino
The 4-tolyl 2-amino-4-pyridyl 3-imidazolyl third amino
The 3-tolyl 2-amino-4-pyridyl 3-imidazolyl third amino
The 2-tolyl 2-amino-4-pyridyl 3-imidazolyl third amino
The 4-trifluoromethyl 2-amino-4-pyridyl 3-imidazolyl third amino
The 3-trifluoromethyl 2-amino-4-pyridyl 3-imidazolyl third amino
2, the 6-dichlorophenyl 2-amino-4-pyridyl 3-imidazolyl third amino
2, the 6-3,5-dimethylphenyl 2-amino-4-pyridyl 3-imidazolyl third amino
3, the 4-dichlorophenyl 2-amino-4-pyridyl 3-imidazolyl third amino
3, the 4-3,5-dimethylphenyl 2-amino-4-pyridyl 3-imidazolyl third amino
The 2,4 dichloro benzene base 2-amino-4-pyridyl 3-imidazolyl third amino
2, the 4-3,5-dimethylphenyl 2-amino-4-pyridyl 3-imidazolyl third amino
Phenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-imidazolyl third amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-imidazolyl third amino
The 3-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-imidazolyl third amino
The 2-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-imidazolyl third amino
The 4-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-imidazolyl third amino
The 3-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-imidazolyl third amino
The 2-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-imidazolyl third amino
The 4-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-imidazolyl third amino
The 3-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-imidazolyl third amino
The 2-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-imidazolyl third amino
The 4-trifluoromethyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-imidazolyl third amino
The 3-trifluoromethyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-imidazolyl third amino
2, the 6-dichlorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-imidazolyl third amino
2, the 6-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-imidazolyl third amino
3, the 4-dichlorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-imidazolyl third amino
3, the 4-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-imidazolyl third amino
The 2,4 dichloro benzene base 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-imidazolyl third amino
2, the 4-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-imidazolyl third amino
Phenyl 2-amino-4-pyrimidyl 3-imidazolyl third amino
The 4-fluorophenyl 2-amino-4-pyrimidyl 3-imidazolyl third amino
The 3-fluorophenyl 2-amino-4-pyrimidyl 3-imidazolyl third amino
The 2-fluorophenyl 2-amino-4-pyrimidyl 3-imidazolyl third amino
The 4-chloro-phenyl- 2-amino-4-pyrimidyl 3-imidazolyl third amino
The 3-chloro-phenyl- 2-amino-4-pyrimidyl 3-imidazolyl third amino
The 2-chloro-phenyl- 2-amino-4-pyrimidyl 3-imidazolyl third amino
The 4-tolyl 2-amino-4-pyrimidyl 3-imidazolyl third amino
The 3-tolyl 2-amino-4-pyrimidyl 3-imidazolyl third amino
The 2-tolyl 2-amino-4-pyrimidyl 3-imidazolyl third amino
The 4-trifluoromethyl 2-amino-4-pyrimidyl 3-imidazolyl third amino
The 3-trifluoromethyl 2-amino-4-pyrimidyl 3-imidazolyl third amino
2, the 6-dichlorophenyl 2-amino-4-pyrimidyl 3-imidazolyl third amino
2, the 6-3,5-dimethylphenyl 2-amino-4-pyrimidyl 3-imidazolyl third amino
The 3-4-dichlorophenyl 2-amino-4-pyrimidyl 3-imidazolyl third amino
3, the 4-3,5-dimethylphenyl 2-amino-4-pyrimidyl 3-imidazolyl third amino
The 2,4 dichloro benzene base 2-amino-4-pyrimidyl 3-imidazolyl third amino
2, the 4-3,5-dimethylphenyl 2-amino-4-pyrimidyl 3-imidazolyl third amino
The 4-fluorophenyl The 4-pyridyl 2-(2-chloro-phenyl--1-methyl) ethyl) amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(2-chloro-phenyl--1-methyl) ethyl) amino
The 4-fluorophenyl 2-amino-4-pyrimidyl 2-(2-chloro-phenyl--1-methyl) ethyl) amino
The 3-fluorophenyl The 4-pyridyl (S)-tetrahydroisoquinoline-3-base methylamino-
The 2-fluorophenyl 2-amino-4-pyridyl (S)-3-benzyl diethylenediamine base
The 3-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (S)-2-N-isopropylamino-3-phenyl third amino
The 2-chloro-phenyl- 2-amino-4-pyrimidyl (S)-2-N-glycyl amino-3-phenyl third amino
The 4-tolyl The 4-pyridyl (S)-2-amino-3-phenyl third amino
The 3-tolyl 2-amino-4-pyridyl (R)-2-amino-3-phenyl third amino
The 2-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-amino-3-phenyl third amino
The 4-trifluoromethyl 2-amino-4-pyrimidyl (S)-2-amino-3-(2-fluorophenyl) third amino
The 3-trifluoromethyl The 4-pyridyl (S)-2-amino-3-(2-aminomethyl phenyl) third amino
2, the 6-dichlorophenyl 2-amino-4-pyridyl 3-amino-3-(2-fluorophenyl) third amino
2, the 6-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-amino-3-(2-aminomethyl phenyl) third amino
3, the 4-dichlorophenyl 2-amino-4-pyrimidyl 2-amino-2-methyl-3-phenyl third amino
3, the 4-3,5-dimethylphenyl The 4-pyridyl 3-amino-2-methyl-3-phenyl third amino
The 3-fluorophenyl 2-amino-4-pyridyl (S)-2-amino-3-phenyl third amino
The 2-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (S)-2-amino-3-(2-fluorophenyl) third amino
The 3-chloro-phenyl- 2-amino-4-pyrimidyl (S)-2-amino-3-(2-aminomethyl phenyl) third amino
The 2-chloro-phenyl- The 4-pyridyl (S)-2-N-isopropylamino-3-phenyl third amino
The 4-tolyl 2-amino-4-pyridyl (S)-2-N-glycyl amino-3-phenyl third amino
The 3-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-amino-2-methyl-3-phenyl third amino
The 2-tolyl 2-amino-4-pyrimidyl (R)-2-amino-3-phenyl third amino
The 4-trifluoromethyl The 4-pyridyl 3-amino-3-phenyl third amino
The 3-trifluoromethyl 2-amino-4-pyridyl 3-amino-3-(2-fluorophenyl) third amino
2, the 6-dichlorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-amino-3-(2-aminomethyl phenyl) third amino
2, the 6-3,5-dimethylphenyl 2-amino-4-pyrimidyl 2-amino-2-methyl-3-phenyl third amino
3, the 4-dichlorophenyl The 4-pyridyl (S)-tetrahydroisoquinoline-3-base methylamino-
3, the 4-3,5-dimethylphenyl The 4-pyridyl (S)-3-benzyl diethylenediamine base
With
Figure C9718155800641
R wherein 11, R 12And R 1Be one of listed combination in the following table:
R 11 R 12 R 1
Phenyl The 4-pyridyl The 4-pyridyl
The 4-fluorophenyl The 4-pyridyl The 4-pyridyl
The 3-fluorophenyl The 4-pyridyl The 4-pyridyl
The 2-fluorophenyl The 4-pyridyl The 4-pyridyl
The 4-chloro-phenyl- The 4-pyridyl The 4-pyridyl
The 3-chloro-phenyl- The 4-pyridyl The 4-pyridyl
The 2-chloro-phenyl- The 4-pyridyl The 4-pyridyl
The 4-tolyl The 4-pyridyl The 4-pyridyl
The 3-tolyl The 4-pyridyl The 4-pyridyl
The 2-tolyl The 4-pyridyl The 4-pyridyl
The 4-trifluoromethyl The 4-pyridyl The 4-pyridyl
The 3-trifluoromethyl The 4-pyridyl The 4-pyridyl
2, the 6-dichlorophenyl The 4-pyridyl The 4-pyridyl
2, the 6-3,5-dimethylphenyl The 4-pyridyl The 4-pyridyl
3, the 4-dichlorophenyl The 4-pyridyl The 4-pyridyl
3, the 4-3,5-dimethylphenyl The 4-pyridyl The 4-pyridyl
The 2,4 dichloro benzene base The 4-pyridyl The 4-pyridyl
2, the 4-3,5-dimethylphenyl The 4-pyridyl The 4-pyridyl
Phenyl 2-amino-4-pyridyl The 4-pyridyl
The 4-fluorophenyl 2-amino-4-pyridyl The 4-pyridyl
The 3-fluorophenyl 2-amino-4-pyridyl The 4-pyridyl
The 2-fluorophenyl 2-amino-4-pyridyl The 4-pyridyl
The 4-chloro-phenyl- 2-amino-4-pyridyl The 4-pyridyl
The 3-chloro-phenyl- 2-amino-4-pyridyl The 4-pyridyl
The 2-chloro-phenyl- 2-amino-4-pyridyl The 4-pyridyl
The 4-tolyl 2-amino-4-pyridyl The 4-pyridyl
The 3-tolyl 2-amino-4-pyridyl The 4-pyridyl
The 2-tolyl 2-amino-4-pyridyl The 4-pyridyl
The 4-trifluoromethyl 2-amino-4-pyridyl The 4-pyridyl
The 3-trifluoromethyl 2-amino-4-pyridyl The 4-pyridyl
2, the 6-dichlorophenyl 2-amino-4-pyridyl The 4-pyridyl
2, the 6-3,5-dimethylphenyl 2-amino-4-pyridyl The 4-pyridyl
3, the 4-dichlorophenyl 2-amino-4-pyridyl The 4-pyridyl
3, the 4-3,5-dimethylphenyl 2-amino-4-pyridyl The 4-pyridyl
The 2,4 dichloro benzene base 2-amino-4-pyridyl The 4-pyridyl
2, the 4-3,5-dimethylphenyl 2-amino-4-pyridyl The 4-pyridyl
Phenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 4-pyridyl
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 4-pyridyl
The 3-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 4-pyridyl
The 2-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 4-pyridyl
The 4-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 4-pyridyl
The 3-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 4-pyridyl
The 2-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 4-pyridyl
The 4-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 4-pyridyl
The 3-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 4-pyridyl
The 2-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 4-pyridyl
The 4-trifluoromethyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 4-pyridyl
The 3-trifluoromethyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 4-pyridyl
2, the 6-dichlorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 4-pyridyl
2, the 6-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 4-pyridyl
3, the 4-dichlorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 4-pyridyl
3, the 4-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 4-pyridyl
The 2,4 dichloro benzene base 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 4-pyridyl
2, the 4-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl The 4-pyridyl
Phenyl 2-amino-4-pyrimidyl The 4-pyridyl
The 4-fluorophenyl 2-amino-4-pyrimidyl The 4-pyridyl
The 3-fluorophenyl 2-amino-4-pyrimidyl The 4-pyridyl
The 2-fluorophenyl 2-amino-4-pyrimidyl The 4-pyridyl
The 4-chloro-phenyl- 2-amino-4-pyrimidyl The 4-pyridyl
The 3-chloro-phenyl- 2-amino-4-pyrimidyl The 4-pyridyl
The 2-chloro-phenyl- 2-amino-4-pyrimidyl The 4-pyridyl
The 4-tolyl 2-amino-4-pyrimidyl The 4-pyridyl
The 3-tolyl 2-amino-4-pyrimidyl The 4-pyridyl
The 2-tolyl 2-amino-4-pyrimidyl The 4-pyridyl
The 4-trifluoromethyl 2-amino-4-pyrimidyl The 4-pyridyl
The 3-trifluoromethyl 2-amino-4-pyrimidyl The 4-pyridyl
2, the 6-dichlorophenyl 2-amino-4-pyrimidyl The 4-pyridyl
2, the 6-3,5-dimethylphenyl 2-amino-4-pyrimidyl The 4-pyridyl
3, the 4-dichlorophenyl 2-amino-4-pyrimidyl The 4-pyridyl
3, the 4-3,5-dimethylphenyl 2-amino-4-pyrimidyl The 4-pyridyl
The 2,4 dichloro benzene base 2-amino-4-pyrimidyl The 4-pyridyl
2, the 4-3,5-dimethylphenyl 2-amino-4-pyrimidyl The 4-pyridyl
Phenyl The 4-pyridyl 4-methylsulfinyl phenyl
The 4-fluorophenyl The 4-pyridyl 4-methylsulfinyl phenyl
The 3-fluorophenyl The 4-pyridyl 4-methylsulfinyl phenyl
The 2-fluorophenyl The 4-pyridyl 4-methylsulfinyl phenyl
The 4-chloro-phenyl- The 4-pyridyl 4-methylsulfinyl phenyl
The 3-chloro-phenyl- The 4-pyridyl 4-methylsulfinyl phenyl
The 2-chloro-phenyl- The 4-pyridyl 4-methylsulfinyl phenyl
The 4-tolyl The 4-pyridyl 4-methylsulfinyl phenyl
The 3-tolyl The 4-pyridyl 4-methylsulfinyl phenyl
The 2-tolyl The 4-pyridyl 4-methylsulfinyl phenyl
The 4-trifluoromethyl The 4-pyridyl 4-methylsulfinyl phenyl
The 3-trifluoromethyl The 4-pyridyl 4-methylsulfinyl phenyl
The 2-6-dichlorophenyl The 4-pyridyl 4-methylsulfinyl phenyl
2, the 6-3,5-dimethylphenyl The 4-pyridyl 4-methylsulfinyl phenyl
3, the 4-dichlorophenyl The 4-pyridyl 4-methylsulfinyl phenyl
3, the 4-3,5-dimethylphenyl The 4-pyridyl 4-methylsulfinyl phenyl
The 2,4 dichloro benzene base The 4-pyridyl 4-methylsulfinyl phenyl
2, the 4-3,5-dimethylphenyl The 4-pyridyl 4-methylsulfinyl phenyl
Phenyl 2-amino-4-pyridyl 4-methylsulfinyl phenyl
The 4-fluorophenyl 2-amino-4-pyridyl 4-methylsulfinyl phenyl
The 3-fluorophenyl 2-amino-4-pyridyl 4-methylsulfinyl phenyl
The 2-fluorophenyl 2-amino-4-pyridyl 4-methylsulfinyl phenyl
The 4-chloro-phenyl- 2-amino-4-pyridyl 4-methylsulfinyl phenyl
The 3-chloro-phenyl- 2-amino-4-pyridyl 4-methylsulfinyl phenyl
The 2-chloro-phenyl- 2-amino-4-pyridyl 4-methylsulfinyl phenyl
The 4-tolyl 2-amino-4-pyridyl 4-methylsulfinyl phenyl
The 3-tolyl 2-amino-4-pyridyl 4-methylsulfinyl phenyl
The 2-tolyl 2-amino-4-pyridyl 4-methylsulfinyl phenyl
The 4-trifluoromethyl 2-amino-4-pyridyl 4-methylsulfinyl phenyl
The 3-trifluoromethyl 2-amino-4-pyridyl 4-methylsulfinyl phenyl
2, the 6-dichlorophenyl 2-amino-4-pyridyl 4-methylsulfinyl phenyl
2, the 6-3,5-dimethylphenyl 2-amino-4-pyridyl 4-methylsulfinyl phenyl
3, the 4-dichlorophenyl 2-amino-4-pyridyl 4-methylsulfinyl phenyl
3, the 4-3,5-dimethylphenyl 2-amino-4-pyridyl 4-methylsulfinyl phenyl
The 2,4 dichloro benzene base 2-amino-4-pyridyl 4-methylsulfinyl phenyl
2, the 4-3,5-dimethylphenyl 2-amino-4-pyridyl 4-methylsulfinyl phenyl
Phenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 4-methylsulfinyl phenyl
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 4-methylsulfinyl phenyl
The 3-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 4-methylsulfinyl phenyl
The 2-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 4-methylsulfinyl phenyl
The 4-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 4-methylsulfinyl phenyl
The 3-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 4-methylsulfinyl phenyl
The 2-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 4-methylsulfinyl phenyl
The 4-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 4-methylsulfinyl phenyl
The 3-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 4-methylsulfinyl phenyl
The 2-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 4-methylsulfinyl phenyl
The 4-trifluoromethyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 4-methylsulfinyl phenyl
The 3-trifluoromethyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 4-methylsulfinyl phenyl
2, the 6-dichlorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 4-methylsulfinyl phenyl
2, the 6-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 4-methylsulfinyl phenyl
3, the 4-dichlorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 4-methylsulfinyl phenyl
3, the 4-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 4-methylsulfinyl phenyl
The 2,4 dichloro benzene base 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 4-methylsulfinyl phenyl
2, the 4-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 4-methylsulfinyl phenyl
Phenyl 2-amino-4-pyrimidyl 4-methylsulfinyl phenyl
The 4-fluorophenyl 2-amino-4-pyrimidyl 4-methylsulfinyl phenyl
The 3-fluorophenyl 2-amino-4-pyrimidyl 4-methylsulfinyl phenyl
The 2-fluorophenyl 2-amino-4-pyrimidyl 4-methylsulfinyl phenyl
The 4-chloro-phenyl- 2-amino-4-pyrimidyl 4-methylsulfinyl phenyl
The 3-chloro-phenyl- 2-amino-4-pyrimidyl 4-methylsulfinyl phenyl
The 2-chloro-phenyl- 2-amino-4-pyrimidyl 4-methylsulfinyl phenyl
The 4-tolyl 2-amino-4-pyrimidyl 4-methylsulfinyl phenyl
The 3-tolyl 2-amino-4-pyrimidyl 4-methylsulfinyl phenyl
The 2-tolyl 2-amino-4-pyrimidyl 4-methylsulfinyl phenyl
The 4-trifluoromethyl 2-amino-4-pyrimidyl 4-methylsulfinyl phenyl
The 3-trifluoromethyl 2-amino-4-pyrimidyl 4-methylsulfinyl phenyl
2, the 6-dichlorophenyl 2-amino-4-pyrimidyl 4-methylsulfinyl phenyl
2, the 6-3,5-dimethylphenyl 2-amino-4-pyrimidyl 4-methylsulfinyl phenyl
3, the 4-dichlorophenyl 2-amino-4-pyrimidyl 4-methylsulfinyl phenyl
3, the 4-3,5-dimethylphenyl 2-amino-4-pyrimidyl 4-methylsulfinyl phenyl
The 2,4 dichloro benzene base 2-amino-4-pyrimidyl 4-methylsulfinyl phenyl
2, the 4-3,5-dimethylphenyl 2-amino-4-pyrimidyl 4-methylsulfinyl phenyl
Phenyl The 4-pyridyl 2, the 6-dichloro benzyl
The 4-fluorophenyl The 4-pyridyl 2, the 6-dichloro benzyl
The 3-fluorophenyl The 4-pyridyl 2, the 6-dichloro benzyl
The 2-fluorophenyl The 4-pyridyl 2, the 6-dichloro benzyl
The 4-chloro-phenyl- The 4-pyridyl 2, the 6-dichloro benzyl
The 3-chloro-phenyl- The 4-pyridyl 2, the 6-dichloro benzyl
The 2-chloro-phenyl- The 4-pyridyl 2, the 6-dichloro benzyl
The 4-tolyl The 4-pyridyl 2, the 6-dichloro benzyl
The 3-tolyl The 4-pyridyl 2, the 6-dichloro benzyl
The 2-tolyl The 4-pyridyl 2, the 6-dichloro benzyl
The 4-trifluoromethyl The 4-pyridyl 2, the 6-dichloro benzyl
The 3-trifluoromethyl The 4-pyridyl 2, the 6-dichloro benzyl
2, the 6-dichlorophenyl The 4-pyridyl 2, the 6-dichloro benzyl
2, the 6-3,5-dimethylphenyl The 4-pyridyl 2, the 6-dichloro benzyl
3, the 4-dichlorophenyl The 4-pyridyl 2, the 6-dichloro benzyl
3, the 4-3,5-dimethylphenyl The 4-pyridyl 2, the 6-dichloro benzyl
The 2,4 dichloro benzene base The 4-pyridyl 2, the 6-dichloro benzyl
2, the 4-3,5-dimethylphenyl The 4-pyridyl 2, the 6-dichloro benzyl
Phenyl 2-amino-4-pyridyl 2, the 6-dichloro benzyl
The 4-fluorophenyl 2-amino-4-pyridyl 2, the 6-dichloro benzyl
The 3-fluorophenyl 2-amino-4-pyridyl 2, the 6-dichloro benzyl
The 2-fluorophenyl 2-amino-4-pyridyl 2, the 6-dichloro benzyl
The 4-chloro-phenyl- 2-amino-4-pyridyl 2, the 6-dichloro benzyl
The 3-chloro-phenyl- 2-amino-4-pyridyl 2, the 6-dichloro benzyl
The 2-chloro-phenyl- 2-amino-4-pyridyl 2, the 6-dichloro benzyl
The 4-tolyl 2-amino-4-pyridyl 2, the 6-dichloro benzyl
The 3-tolyl 2-amino-4-pyridyl 2, the 6-dichloro benzyl
The 2-tolyl 2-amino-4-pyridyl 2, the 6-dichloro benzyl
The 4-trifluoromethyl 2-amino-4-pyridyl 2, the 6-dichloro benzyl
The 3-trifluoromethyl 2-amino-4-pyridyl 2, the 6-dichloro benzyl
2, the 6-dichlorophenyl 2-amino-4-pyridyl 2, the 6-dichloro benzyl
2, the 6-3,5-dimethylphenyl 2-amino-4-pyridyl 2, the 6-dichloro benzyl
3, the 4-dichlorophenyl 2-amino-4-pyridyl 2, the 6-dichloro benzyl
3, the 4-3,5-dimethylphenyl 2-amino-4-pyridyl 2, the 6-dichloro benzyl
The 2,4 dichloro benzene base 2-amino-4-pyridyl 2, the 6-dichloro benzyl
2, the 4-3,5-dimethylphenyl 2-amino-4-pyridyl 2, the 6-dichloro benzyl
Phenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2, the 6-dichloro benzyl
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2, the 6-dichloro benzyl
The 3-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2, the 6-dichloro benzyl
The 2-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2, the 6-dichloro benzyl
The 4-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2, the 6-dichloro benzyl
The 3-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2, the 6-dichloro benzyl
The 2-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2, the 6-dichloro benzyl
The 4-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2, the 6-dichloro benzyl
The 3-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2, the 6-dichloro benzyl
The 2-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2, the 6-dichloro benzyl
The 4-trifluoromethyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2, the 6-dichloro benzyl
The 3-trifluoromethyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2, the 6-dichloro benzyl
2, the 6-dichlorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2, the 6-dichloro benzyl
2, the 6-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2, the 6-dichloro benzyl
3, the 4-dichlorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2, the 6-dichloro benzyl
3, the 4-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2, the 6-dichloro benzyl
The 2,4 dichloro benzene base 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2, the 6-dichloro benzyl
2, the 4-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2, the 6-dichloro benzyl
Phenyl 2-amino-4-pyrimidyl 2, the 6-dichloro benzyl
The 4-fluorophenyl 2-amino-4-pyrimidyl 2, the 6-dichloro benzyl
The 3-fluorophenyl 2-amino-4-pyrimidyl 2, the 6-dichloro benzyl
The 2-fluorophenyl 2-amino-4-pyrimidyl 2, the 6-dichloro benzyl
The 4-chloro-phenyl- 2-amino-4-pyrimidyl 2, the 6-dichloro benzyl
The 3-chloro-phenyl- 2-amino-4-pyrimidyl 2, the 6-dichloro benzyl
The 2-chloro-phenyl- 2-amino-4-pyrimidyl 2, the 6-dichloro benzyl
The 4-tolyl 2-amino-4-pyrimidyl 2, the 6-dichloro benzyl
The 3-tolyl 2-amino-4-pyrimidyl 2, the 6-dichloro benzyl
The 2-tolyl 2-amino-4-pyrimidyl 2, the 6-dichloro benzyl
The 4-trifluoromethyl 2-amino-4-pyrimidyl 2, the 6-dichloro benzyl
The 3-trifluoromethyl 2-amino-4-pyrimidyl 2, the 6-dichloro benzyl
2, the 6-dichlorophenyl 2-amino-4-pyrimidyl 2, the 6-dichloro benzyl
2, the 6-3,5-dimethylphenyl 2-amino-4-pyrimidyl 2, the 6-dichloro benzyl
3, the 4-dichlorophenyl 2-amino-4-pyrimidyl 2, the 6-dichloro benzyl
3, the 4-3,5-dimethylphenyl 2-amino-4-pyrimidyl 2, the 6-dichloro benzyl
The 2,4 dichloro benzene base 2-amino-4-pyrimidyl 2, the 6-dichloro benzyl
2, the 4-3,5-dimethylphenyl 2-amino-4-pyrimidyl 2, the 6-dichloro benzyl
Phenyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 4-fluorophenyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 3-fluorophenyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 2-fluorophenyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 4-chloro-phenyl- The 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 3-chloro-phenyl- The 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 2-chloro-phenyl- The 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 4-tolyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 3-tolyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 2-tolyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 4-trifluoromethyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 3-trifluoromethyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
2, the 6-dichlorophenyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
2, the 6-3,5-dimethylphenyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
3, the 4-dichlorophenyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
3, the 4-3,5-dimethylphenyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 2,4 dichloro benzene base The 4-pyridyl 2-(4-fluorophenyl) ethylamino
2, the 4-3,5-dimethylphenyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
Phenyl 2-amino-4-pyridyl 2-(4-fluorophenyl) ethylamino
The 4-fluorophenyl 2-amino-4-pyridyl 2-(4-fluorophenyl) ethylamino
The 3-fluorophenyl 2-amino-4-pyridyl 2-(4-fluorophenyl) ethylamino
The 2-fluorophenyl 2-amino-4-pyridyl 2-(4-fluorophenyl) ethylamino
The 4-chloro-phenyl- 2-amino-4-pyridyl 2-(4-fluorophenyl) ethylamino
The 3-chloro-phenyl- 2-amino-4-pyridyl 2-(4-fluorophenyl) ethylamino
The 2-chloro-phenyl- 2-amino-4-pyridyl 2-(4-fluorophenyl) ethylamino
The 4-tolyl 2-amino-4-pyridyl 2-(4-fluorophenyl) ethylamino
The 3-tolyl 2-amino-4-pyridyl 2-(4-fluorophenyl) ethylamino
The 2-tolyl 2-amino-4-pyridyl 2-(4-fluorophenyl) ethylamino
The 4-trifluoromethyl 2-amino-4-pyridyl 2-(4-fluorophenyl) ethylamino
The 3-trifluoromethyl 2-amino-4-pyridyl 2-(4-fluorophenyl) ethylamino
2, the 6-dichlorophenyl 2-amino-4-pyridyl 2-(4-fluorophenyl) ethylamino
2, the 6-3,5-dimethylphenyl 2-amino-4-pyridyl 2-(4-fluorophenyl) ethylamino
3, the 4-dichlorophenyl 2-amino-4-pyridyl 2-(4-fluorophenyl) ethylamino
3, the 4-3,5-dimethylphenyl 2-amino-4-pyridyl 2-(4-fluorophenyl) ethylamino
The 2,4 dichloro benzene base 2-amino-4-pyridyl 2-(4-fluorophenyl) ethylamino
2, the 4-3,5-dimethylphenyl 2-amino-4-pyridyl 2-(4-fluorophenyl) ethylamino
Phenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 3-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 2-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 4-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 3-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 2-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 4-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 3-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 2-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 4-trifluoromethyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 3-trifluoromethyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(4-fluorophenyl) ethylamino
2, the 6-dichlorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(4-fluorophenyl) ethylamino
2, the 6-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(4-fluorophenyl) ethylamino
3, the 4-dichlorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(4-fluorophenyl) ethylamino
3, the 4-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 2,4 dichloro benzene base 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(4-fluorophenyl) ethylamino
2, the 4-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(4-fluorophenyl) ethylamino
Phenyl 2-amino-4-pyrimidyl 2-(4-fluorophenyl) ethylamino
The 4-fluorophenyl 2-amino-4-pyrimidyl 2-(4-fluorophenyl) ethylamino
The 3-fluorophenyl 2-amino-4-pyrimidyl 2-(4-fluorophenyl) ethylamino
The 2-fluorophenyl 2-amino-4-pyrimidyl 2-(4-fluorophenyl) ethylamino
The 4-chloro-phenyl- 2-amino-4-pyrimidyl 2-(4-fluorophenyl) ethylamino
The 3-chloro-phenyl- 2-amino-4-pyrimidyl 2-(4-fluorophenyl) ethylamino
The 2-chloro-phenyl- 2-amino-4-pyrimidyl 2-(4-fluorophenyl) ethylamino
The 4-tolyl 2-amino-4-pyrimidyl 2-(4-fluorophenyl) ethylamino
The 3-tolyl 2-amino-4-pyrimidyl 2-(4-fluorophenyl) ethylamino
The 2-tolyl 2-amino-4-pyrimidyl 2-(4-fluorophenyl) ethylamino
The 4-trifluoromethyl 2-amino-4-pyrimidyl 2-(4-fluorophenyl) ethylamino
The 3-trifluoromethyl 2-amino-4-pyrimidyl 2-(4-fluorophenyl) ethylamino
2, the 6-dichlorophenyl 2-amino-4-pyrimidyl 2-(4-fluorophenyl) ethylamino
2, the 6-3,5-dimethylphenyl 2-amino-4-pyrimidyl 2-(4-fluorophenyl) ethylamino
3, the 4-dichlorophenyl 2-amino-4-pyrimidyl 2-(4-fluorophenyl) ethylamino
3, the 4-3,5-dimethylphenyl 2-amino-4-pyrimidyl 2-(4-fluorophenyl) ethylamino
The 2,4 dichloro benzene base 2-amino-4-pyrimidyl 2-(4-fluorophenyl) ethylamino
2, the 4-3,5-dimethylphenyl 2-amino-4-pyrimidyl 2-(4-fluorophenyl) ethylamino
Phenyl The 4-pyridyl 3-phenyl third amino
The 4-fluorophenyl The 4-pyridyl 3-phenyl third amino
The 3-fluorophenyl The 4-pyridyl 3-phenyl third amino
The 2-fluorophenyl The 4-pyridyl 3-phenyl third amino
The 4-chloro-phenyl- The 4-pyridyl 3-phenyl third amino
The 3-chloro-phenyl- The 4-pyridyl 3-phenyl third amino
The 2-chloro-phenyl- The 4-pyridyl 3-phenyl third amino
The 4-tolyl The 4-pyridyl 3-phenyl third amino
The 3-tolyl The 4-pyridyl 3-phenyl third amino
The 2-tolyl The 4-pyridyl 3-phenyl third amino
The 4-trifluoromethyl The 4-pyridyl 3-phenyl third amino
The 3-trifluoromethyl The 4-pyridyl 3-phenyl third amino
2, the 6-dichlorophenyl The 4-pyridyl 3-phenyl third amino
2, the 6-3,5-dimethylphenyl The 4-pyridyl 3-phenyl third amino
3, the 4-dichlorophenyl The 4-pyridyl 3-phenyl third amino
3, the 4-3,5-dimethylphenyl The 4-pyridyl 3-phenyl third amino
The 2,4 dichloro benzene base The 4-pyridyl 3-phenyl third amino
2, the 4-3,5-dimethylphenyl The 4-pyridyl 3-phenyl third amino
Phenyl 2-amino-4-pyridyl 3-phenyl third amino
The 4-fluorophenyl 2-amino-4-pyridyl 3-phenyl third amino
The 3-fluorophenyl 2-amino-4-pyridyl 3-phenyl third amino
The 2-fluorophenyl 2-amino-4-pyridyl 3-phenyl third amino
The 4-chloro-phenyl- 2-amino-4-pyridyl 3-phenyl third amino
The 3-chloro-phenyl- 2-amino-4-pyridyl 3-phenyl third amino
The 2-chloro-phenyl- 2-amino-4-pyridyl 3-phenyl third amino
The 4-tolyl 2-amino-4-pyridyl 3-phenyl third amino
The 3-tolyl 2-amino-4-pyridyl 3-phenyl third amino
The 2-tolyl 2-amino-4-pyridyl 3-phenyl third amino
The 4-trifluoromethyl 2-amino-4-pyridyl 3-phenyl third amino
The 3-trifluoromethyl 2-amino-4-pyridyl 3-phenyl third amino
2, the 6-dichlorophenyl 2-amino-4-pyridyl 3-phenyl third amino
2, the 6-3,5-dimethylphenyl 2-amino-4-pyridyl 3-phenyl third amino
3, the 4-dichlorophenyl 2-amino-4-pyridyl 3-phenyl third amino
3, the 4-3,5-dimethylphenyl 2-amino-4-pyridyl 3-phenyl third amino
The 2,4 difluorobenzene base 2-amino-4-pyridyl 3-phenyl third amino
2, the 4-3,5-dimethylphenyl 2-amino-4-pyridyl 3-phenyl third amino
Phenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-phenyl third amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-phenyl third amino
The 3-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-phenyl third amino
The 2-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-phenyl third amino
The 4-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-phenyl third amino
The 3-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-phenyl third amino
The 2-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-phenyl third amino
The 4-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-phenyl third amino
The 3-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-phenyl third amino
The 2-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-phenyl third amino
The 4-trifluoromethyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-phenyl third amino
The 3-trifluoromethyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-phenyl third amino
2, the 6-dichlorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-phenyl third amino
2, the 6-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-phenyl third amino
3, the 4-dichlorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-phenyl third amino
3, the 4-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-phenyl third amino
The 2,4 dichloro benzene base 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-phenyl third amino
2, the 4-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-phenyl third amino
Phenyl 2-amino-4-pyrimidyl 3-phenyl third amino
The 4-fluorophenyl 2-amino-4-pyrimidyl 3-phenyl third amino
The 3-fluorophenyl 2-amino-4-pyrimidyl 3-phenyl third amino
The 2-fluorophenyl 2-amino-4-pyrimidyl 3-phenyl third amino
The 4-chloro-phenyl- 2-amino-4-pyrimidyl 3-phenyl third amino
The 3-chloro-phenyl- 2-amino-4-pyrimidyl 3-phenyl third amino
The 2-chloro-phenyl- 2-amino-4-pyrimidyl 3-phenyl third amino
The 4-tolyl 2-amino-4-pyrimidyl 3-phenyl third amino
The 3-tolyl 2-amino-4-pyrimidyl 3-phenyl third amino
The 2-tolyl 2-amino-4-pyrimidyl 3-phenyl third amino
The 4-trifluoromethyl 2-amino-4-pyrimidyl 3-phenyl third amino
The 3-trifluoromethyl 2-amino-4-pyrimidyl 3-phenyl third amino
2, the 6-dichlorophenyl 2-amino-4-pyrimidyl 3-phenyl third amino
2, the 6-3,5-dimethylphenyl 2-amino-4-pyrimidyl 3-phenyl third amino
3, the 4-dichlorophenyl 2-amino-4-pyrimidyl 3-phenyl third amino
3, the 4-3,5-dimethylphenyl 2-amino-4-pyrimidyl 3-phenyl third amino
The 2,4 dichloro benzene base 2-amino-4-pyrimidyl 3-phenyl third amino
2, the 4-3,5-dimethylphenyl 2-amino-4-pyrimidyl 3-phenyl third amino
Phenyl The 4-pyridyl (1-methyl-3-phenyl) third amino
The 4-fluorophenyl The 4-pyridyl (1-methyl-3-phenyl) third amino
The 3-fluorophenyl The 4-pyridyl (1-methyl-3-phenyl) third amino
The 2-fluorophenyl The 4-pyridyl (1-methyl-3-phenyl) third amino
The 4-chloro-phenyl- The 4-pyridyl (1-methyl-3-phenyl) third amino
The 3-chloro-phenyl- The 4-pyridyl (1-methyl-3-phenyl) third amino
The 2-chloro-phenyl- The 4-pyridyl (1-methyl-3-phenyl) third amino
The 4-tolyl The 4-pyridyl (1-methyl-3-phenyl) third amino
The 3-tolyl The 4-pyridyl (1-methyl-3-phenyl) third amino
The 2-tolyl The 4-pyridyl (1-methyl-3-phenyl) third amino
The 4-trifluoromethyl The 4-pyridyl (1-methyl-3-phenyl) third amino
The 3-trifluoromethyl The 4-pyridyl (1-methyl-3-phenyl) third amino
2, the 6-dichlorophenyl The 4-pyridyl (1-methyl-3-phenyl) third amino
2, the 6-3,5-dimethylphenyl The 4-pyridyl (1-methyl-3-phenyl) third amino
3, the 4-dichlorophenyl The 4-pyridyl (1-methyl-3-phenyl) third amino
3, the 4-3,5-dimethylphenyl The 4-pyridyl (1-methyl-3-phenyl) third amino
The 2,4 dichloro benzene base The 4-pyridyl (1-methyl-3-phenyl) third amino
2, the 4-3,5-dimethylphenyl The 4-pyridyl (1-methyl-3-phenyl) third amino
Phenyl 2-amino-4-pyridyl (1-methyl-3-phenyl) third amino
The 4-fluorophenyl 2-amino-4-pyridyl (1-methyl-3-phenyl) third amino
The 3-fluorophenyl 2-amino-4-pyridyl (1-methyl-3-phenyl) third amino
The 2-fluorophenyl 2-amino-4-pyridyl (1-methyl-3-phenyl) third amino
The 4-chloro-phenyl- 2-amino-4-pyridyl (1-methyl-3-phenyl) third amino
The 3-chloro-phenyl- 2-amino-4-pyridyl (1-methyl-3-phenyl) third amino
The 2-chloro-phenyl- 2-amino-4-pyridyl (1-methyl-3-phenyl) third amino
The 4-tolyl 2-amino-4-pyridyl (1-methyl-3-phenyl) third amino
The 3-tolyl 2-amino-4-pyridyl (1-methyl-3-phenyl) third amino
The 2-tolyl The amino 4-pyridyl of 2- (1-methyl-3-phenyl) third amino
The 4-trifluoromethyl 2-amino-4-pyridyl (1-methyl-3-phenyl) third amino
The 3-trifluoromethyl 2-amino-4-pyridyl (1-methyl-3-phenyl) third amino
2, the 6-dichlorophenyl 2-amino-4-pyridyl (1-methyl-3-phenyl) third amino
2, the 6-3,5-dimethylphenyl 2-amino-4-pyridyl (1-methyl-3-phenyl) third amino
3, the 4-dichlorophenyl 2-amino-4-pyridyl (1-methyl-3-phenyl) third amino
3, the 4-3,5-dimethylphenyl 2-amino-4-pyridyl (1-methyl-3-phenyl) third amino
The 2,4 dichloro benzene base 2-amino-4-pyridyl (1-methyl-3-phenyl) third amino
2, the 4-3,5-dimethylphenyl 2-amino-4-pyridyl (1-methyl-3-phenyl) third amino
Phenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (1-methyl-3-phenyl) third amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (1-methyl-3-phenyl) third amino
The 3-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (1-methyl-3-phenyl) third amino
The 2-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (1-methyl-3-phenyl) third amino
The 4-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (1-methyl-3-phenyl) third amino
The 3-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (1-methyl-3-phenyl) third amino
The 2-chloro-phenyl- 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (1-methyl-3-phenyl) third amino
The 4-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (1-methyl-3-phenyl) third amino
The 3-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (1-methyl-3-phenyl) third amino
The 2-tolyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (1-methyl-3-phenyl) third amino
The 4-trifluoromethyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (1-methyl-3-phenyl) third amino
The 3-trifluoromethyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (1-methyl-3-phenyl) third amino
2, the 6-dichlorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (1-methyl-3-phenyl) third amino
2, the 6-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (1-methyl-3-phenyl) third amino
3, the 4-dichlorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (1-methyl-3-phenyl) third amino
3, the 4-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (1-methyl-3-phenyl) third amino
The 2,4 dichloro benzene base 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (1-methyl-3-phenyl) third amino
2, the 4-3,5-dimethylphenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (1-methyl-3-phenyl) third amino
Phenyl 2-amino-4-pyrimidyl (1-methyl-3-phenyl) third amino
The 4-fluorophenyl 2-amino-4-pyrimidyl (1-methyl-3-phenyl) third amino
The 3-fluorophenyl 2-amino-4-pyrimidyl (1-methyl-3-phenyl) third amino
The 2-fluorophenyl 2-amino-4-pyrimidyl (1-methyl-3-phenyl) third amino
The 4-chloro-phenyl- 2-amino-4-pyrimidyl (1-methyl-3-phenyl) third amino
The 3-chloro-phenyl- 2-amino-4-pyrimidyl (1-methyl-3-phenyl) third amino
The 2-chloro-phenyl- 2-amino-4-pyrimidyl (1-methyl-3-phenyl) third amino
The 4-tolyl 2-amino-4-pyrimidyl (1-methyl-3-phenyl) third amino
The 3-tolyl 2-amino-4-pyrimidyl (1-methyl-3-phenyl) third amino
The 2-tolyl 2-amino-4-pyrimidyl (1-methyl-3-phenyl) third amino
The 4-trifluoromethyl 2-amino-4-pyrimidyl (1-methyl-3-phenyl) third amino
The 3-trifluoromethyl 2-amino-4-pyrimidyl (1-methyl-3-phenyl) third amino
2, the 6-dichlorophenyl 2-amino-4-pyrimidyl (1-methyl-3-phenyl) third amino
2, the 6-3,5-dimethylphenyl 2-amino-4-pyrimidyl (1-methyl-3-phenyl) third amino
3, the 4-dichlorophenyl 2-amino-4-pyrimidyl (1-methyl-3-phenyl) third amino
3, the 4-3,5-dimethylphenyl 2-amino-4-pyrimidyl (1-methyl-3-phenyl) third amino
The 2,4 dichloro benzene base 2-amino-4-pyrimidyl (1-methyl-3-phenyl) third amino
2, the 4-3,5-dimethylphenyl 2-amino-4-pyrimidyl (1-methyl-3-phenyl) third amino
The 4-fluorophenyl The 4-pyridyl 4-luorobenzyl amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 4-luorobenzyl amino
The 4-fluorophenyl 2-amino-4-pyrimidyl 4-luorobenzyl amino
The 4-fluorophenyl The 4-pyridyl (2-(4-fluorophenyl)-1-methyl-ethyl) amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (2-(4-fluorophenyl)-1-methyl-ethyl) amino
The 4-fluorophenyl 2-amino-4-pyrimidyl (2-(4-fluorophenyl)-1-methyl-ethyl) amino
The 4-fluorophenyl The 4-pyridyl (1,1-dimethyl-2-(4-fluorophenyl) ethyl) amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (1,1-dimethyl-2-(4-fluorophenyl) ethyl) amino
The 4-fluorophenyl 2-amino-4-pyrimidyl (1,1-dimethyl-2-(4-fluorophenyl) ethyl) amino
The 4-fluorophenyl The 4-pyridyl 2-(4-fluorophenyl)-2-methyl-ethylamino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(4-fluorophenyl)-2-methyl-ethylamino
The 4-fluorophenyl 2-amino-4-pyrimidyl 2-(4-fluorophenyl)-2-methyl-ethylamino
The 4-fluorophenyl The 4-pyridyl (2-methyl-2-phenylethyl) amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (2-methyl-2-phenylethyl) amino
The 4-fluorophenyl 2-amino-4-pyrimidyl (2-methyl-2-phenylethyl) amino
The 4-fluorophenyl The 4-pyridyl Methyl-(2-styroyl) amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl Methyl-(2-styroyl) amino
The 4-fluorophenyl 2-amino-4-pyrimidyl Methyl-(2-styroyl) amino
The 4-fluorophenyl The 4-pyridyl (2-(4-trifluoromethyl) ethylamino)
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (2-(4-trifluoromethyl) ethylamino)
The 4-fluorophenyl 2-amino-4-pyrimidyl (2-(4-trifluoromethyl) ethylamino)
The 4-fluorophenyl The 4-pyridyl 2-(4-tolyl) ethylamino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 2-(4-tolyl) ethylamino
The 4-fluorophenyl 2-amino-4-pyrimidyl 2-(4-tolyl) ethylamino
The 4-fluorophenyl The 4-pyridyl (2-(3-fluorophenyl) ethyl) amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (2-(3-fluorophenyl) ethyl) amino
The 4-fluorophenyl 2-amino-4-pyrimidyl (2-(3-fluorophenyl) ethyl) amino
The 4-fluorophenyl The 4-pyridyl (2-(2-fluorophenyl) ethyl) amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (2-(2-fluorophenyl) ethyl) amino
The 4-fluorophenyl 2-amino-4-pyrimidyl (2-(2-fluorophenyl) ethyl) amino
The 4-fluorophenyl The 4-pyridyl Methyl-(2-(2-pyridyl) ethyl) amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl Methyl-(2-(2-pyridyl) ethyl) amino
The 4-fluorophenyl 2-amino-4-pyrimidyl Methyl-(2-(2-pyridyl) ethyl) amino
The 4-fluorophenyl The 4-pyridyl (1,1-dimethyl-3-phenyl propyl) amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (1,1-dimethyl-3-phenyl propyl) amino
The 4-fluorophenyl 2-amino-4-pyrimidyl (1,1-dimethyl-3-phenyl propyl) amino
The 4-fluorophenyl The 4-pyridyl (3-(4-fluorophenyl) propyl group) amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (3-(4-fluorophenyl) propyl group) amino
The 4-fluorophenyl 2-amino-4-pyrimidyl (3-(4-fluorophenyl) propyl group) amino
The 4-fluorophenyl The 4-pyridyl (3-(4-fluorophenyl)-1-methyl-propyl) amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (3-(4-fluorophenyl)-1-methyl-propyl) amino
The 4-fluorophenyl 2-amino-4-pyrimidyl (3-(4-fluorophenyl)-1-methyl-propyl) amino
The 4-fluorophenyl The 4-pyridyl (1,1-dimethyl-3-(4-fluorophenyl) propyl group) amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (1,1-dimethyl-3-(4-fluorophenyl) propyl group) amino
The 4-fluorophenyl 2-amino-4-pyrimidyl (1,1-dimethyl-3-(4-fluorophenyl) propyl group) amino
The 4-fluorophenyl The 4-pyridyl (3-(2-fluorophenyl) propyl group) amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (3-(2-fluorophenyl) propyl group) amino
The 4-fluorophenyl 2-amino-4-pyrimidyl (3-(2-fluorophenyl) propyl group) amino
The 4-fluorophenyl The 4-pyridyl (3-methyl-3-phenyl propyl) amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (3-methyl-3-phenyl propyl) amino
The 4-fluorophenyl 2-amino-4-pyrimidyl (3-methyl-3-phenyl propyl) amino
The 4-fluorophenyl The 4-pyridyl (2-methyl-3-phenyl propyl) amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (2-methyl-3-phenyl propyl) amino
The 4-fluorophenyl 2-amino-4-pyrimidyl (2-methyl-3-phenyl propyl) amino
The 4-fluorophenyl The 4-pyridyl (3, the 3-dimethylbutyl) amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridine (3, the 3-dimethylbutyl) amino
The 4-fluorophenyl 2-amino-4-pyrimidine base (3, the 3-dimethylbutyl) amino
The 4-fluorophenyl The 4-pyridyl Isoamylamino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl Isoamylamino
The 4-fluorophenyl 2-amino-4-pyrimidyl Isoamylamino
The 4-fluorophenyl The 4-pyridyl Penta amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl Penta amino
The 4-fluorophenyl 2-amino-4-pyrimidyl Penta amino
The 4-fluorophenyl The 4-pyridyl (2, the 5-dimethyl) penta amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (2, the 5-dimethyl) penta amino
The 4-fluorophenyl 2-amino-4-pyrimidyl (2, the 5-dimethyl) penta amino
The 4-fluorophenyl The 4-pyridyl Piperazinyl
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl Piperazinyl
The 4-fluorophenyl 2-amino-4-pyrimidyl Piperazinyl
The 4-fluorophenyl The 4-pyridyl (3-(3-fluorophenyl) propyl group) amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (3-(3-fluorophenyl) propyl group) amino
The 4-fluorophenyl 2-amino-4-pyrimidyl (3-(3-fluorophenyl) propyl group) amino
Benzyl The 4-pyridyl 3-phenyl third amino
Benzyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 2-thienyl The 4-pyridyl 3-phenyl third amino
The 2-thienyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
Cyclohexyl The 4-pyridyl 3-phenyl third amino
Cyclohexyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
The tertiary butyl The 4-pyridyl 3-phenyl third amino
The tertiary butyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 4-fluorophenyl The 4-piperidyl 3-phenyl third amino
The 4-fluorophenyl The 4-piperidyl 2-(4-fluorophenyl) ethylamino
The 4-fluorophenyl The 4-pyranyl 3-phenyl third amino
The 4-fluorophenyl The 4-pyranyl 2-(4-fluorophenyl) ethylamino
Phenyl The 4-pyridyl Amino third amino of 3-phenyl-2-
The 4-fluorophenyl The 4-pyridyl Amino third amino of 3-phenyl-2-
The 3-fluorophenyl The 4-pyridyl Amino third amino of 3-phenyl-2-
The 2-fluorophenyl The 4-pyridyl Amino third amino of 3-phenyl-2-
The 4-chloro-phenyl- The 4-pyridyl Amino third amino of 3-phenyl-2-
The 3-chloro-phenyl- The 4-pyridyl Amino third amino of 3-phenyl-2-
The 2-fluorophenyl The 4-pyridyl Amino third amino of 3-phenyl-2-
The 4-tolyl The 4-pyridyl Amino third amino of 3-phenyl-2-
The 3-tolyl The 4-pyridyl Amino third amino of 3-phenyl-2-
The 2-tolyl The 4-pyridyl Amino third amino of 3-phenyl-2-
The 4-trifluoromethyl The 4-pyridyl Amino third amino of 3-phenyl-2-
The 3-trifluoromethyl The 4-pyridyl Amino third amino of 3-phenyl-2-
2, the 6-dichlorophenyl The 4-pyridyl Amino third amino of 3-phenyl-2-
2, the 6-3,5-dimethylphenyl The 4-pyridyl Amino third amino of 3-phenyl-2-
3, the 4-dichlorophenyl The 4-pyridyl Amino third amino of 3-phenyl-2-
3, the 4-3,5-dimethylphenyl The 4-pyridyl Amino third amino of 3-phenyl-2-
The 2,4 dichloro benzene base The 4-pyridyl Amino third amino of 3-phenyl-2-
2, the 4-3,5-dimethylphenyl The 4-pyridyl Amino third amino of 3-phenyl-2-
Phenyl The 4-pyridyl Amino third amino of 3-phenyl-3-
The 4-fluorophenyl The 4-pyridyl Amino third amino of 3-phenyl-3-
The 3-fluorophenyl The 4-pyridyl Amino third amino of 3-phenyl-3-
The 2-fluorophenyl The 4-pyridyl Amino third amino of 3-phenyl-3-
The 4-chloro-phenyl- The 4-pyridyl Amino third amino of 3-phenyl-3-
The 3-chloro-phenyl- The 4-pyridyl Amino third amino of 3-phenyl-3-
The 2-chloro-phenyl- The 4-pyridyl Amino third amino of 3-phenyl-3-
The 4-tolyl The 4-pyridyl Amino third amino of 3-phenyl-3-
The 3-tolyl The 4-pyridyl Amino third amino of 3-phenyl-3-
The 2-tolyl The 4-pyridyl Amino third amino of 3-phenyl-3-
The 4-trifluoromethyl The 4-pyridyl Amino third amino of 3-phenyl-3-
The 3-trifluoromethyl The 4-pyridyl Amino third amino of 3-phenyl-3-
2, the 6-dichlorophenyl The 4-pyridyl Amino third amino of 3-phenyl-3-
2, the 6-3,5-dimethylphenyl The 4-pyridyl Amino third amino of 3-phenyl-3-
3, the 4-dichlorophenyl The 4-pyridyl Amino third amino of 3-phenyl-3-
3, the 4-3,5-dimethylphenyl The 4-pyridyl Amino third amino of 3-phenyl-3-
The 2,4 dichloro benzene base The 4-pyridyl Amino third amino of 3-phenyl-3-
2, the 4-3,5-dimethylphenyl The 4-pyridyl Amino third amino of 3-phenyl-3-
With
R wherein 11, R 12And R 1Be one of listed combination in the following table:
R 11 R 12 R 1
The 4-fluorophenyl The 4-pyridyl (2-(4-fluorophenyl) ethyl) amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (2-(4-fluorophenyl) ethyl) amino
The 4-fluorophenyl 2-amino-4-pyrimidyl (2-(4-fluorophenyl) ethyl) amino
The 4-fluorophenyl The 4-pyridyl (3-hydrocinnamyl) amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (3-hydrocinnamyl) amino
The 4-fluorophenyl 2-amino-4-pyrimidyl (3-hydrocinnamyl) amino
The 4-fluorophenyl The 4-pyridyl (S)-2-amino-3-phenyl third amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (S)-2-amino-3-phenyl third amino
The 4-fluorophenyl 2-amino-4-pyrimidyl (S)-2-amino-3-phenyl third amino
The 4-fluorophenyl The 4-pyridyl 3-amino-3-phenyl third amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-amino-3-phenyl third amino
The 4-fluorophenyl 2-amino-4-pyrimidyl 3-amino-3-phenyl third amino
The 4-fluorophenyl The 4-pyridyl 3-amino-2-methyl-3-phenyl third amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl 3-amino-2-methyl-3-phenyl third amino
The 4-fluorophenyl 2-amino-4-pyrimidyl 3-amino-2-methyl-3-phenyl third amino
The 4-fluorophenyl The 4-pyridyl (S)-tetrahydroisoquinoline-3-base methylamino-
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (S)-tetrahydroisoquinoline-3-base methylamino-
The 4-fluorophenyl 2-amino-4-pyrimidyl (S)-tetrahydroisoquinoline-3-base methylamino-
The 4-fluorophenyl The 4-pyrrole, the pyridine base (S)-3-benzyl diethylenediamine base
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl (S)-3-benzyl diethylenediamine base
The 4-fluorophenyl 2-amino-4-pyrimidyl (S)-3-benzyl diethylenediamine base
With
R wherein 2Be H, methyl or benzyl, and R 11, R 12And R 1Be one of listed combination in the following table:
R 11 R 12 R 1
Phenyl The 4-pyridyl Phenyl
The 4-fluorophenyl The 4-pyridyl Phenyl
Phenyl 2-acetylaminohydroxyphenylarsonic acid pyridyl Phenyl
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid pyridyl Phenyl
Phenyl The 4-pyridyl The 4-ethylphenyl
The 4-fluorophenyl The 4-pyridyl The 4-ethylphenyl
Phenyl 2-acetylaminohydroxyphenylarsonic acid pyridyl The 4-ethylphenyl
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid pyridyl The 4-ethylphenyl
Phenyl The 4-pyridyl 2, the 4-3,5-dimethylphenyl
The 4-fluorophenyl The 4-pyridyl 2, the 4-3,5-dimethylphenyl
Phenyl 2-acetylaminohydroxyphenylarsonic acid pyridyl 2, the 4-3,5-dimethylphenyl
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid pyridyl 2, the 4-3,5-dimethylphenyl
Phenyl The 4-pyridyl 2, the 6-dichloro benzyl
The 4-fluorophenyl The 4-pyridyl 2, the 6-dichloro benzyl
Phenyl 2-acetylaminohydroxyphenylarsonic acid pyridyl 2, the 6-dichloro benzyl
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid pyridyl 2, the 6-dichloro benzyl
Phenyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 4-fluorophenyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
Phenyl 2-acetylaminohydroxyphenylarsonic acid pyridyl 2-(4-fluorophenyl) ethylamino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid pyridyl 2-(4-fluorophenyl) ethylamino
Phenyl The 4-pyridyl 3-phenyl third amino
The 4-fluorophenyl The 4-pyridyl 3-phenyl third amino
Phenyl 2-acetylaminohydroxyphenylarsonic acid pyridyl 3-phenyl third amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid pyridyl 3-phenyl third amino
Phenyl The 4-pyridyl The 1-piperazinyl
The 4-fluorophenyl The 4-pyridyl The 1-piperazinyl
Phenyl 2-acetylaminohydroxyphenylarsonic acid pyridyl The 1-piperazinyl
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid pyridyl The 1-piperazinyl
Benzyl The 4-pyridyl 3-phenyl third amino
Benzyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 2-thienyl The 4-pyridyl 3-phenyl third amino
The 2-thienyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
Cyclohexyl The 4-pyridyl 3-phenyl third amino
Cyclohexyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
The tertiary butyl The 4-pyridyl 3-phenyl third amino
The tertiary butyl The 4-pyridyl 2-(4-fluorophenyl) ethylamino
The 4-fluorophenyl The 4-piperazinyl 3-phenyl third amino
The 4-fluorophenyl The 4-piperazinyl 2-(4-fluorophenyl) ethylamino
The 4-fluorophenyl The 4-pyranyl 3-phenyl third amino
The 4-fluorophenyl The 4-pyranyl 2-(4-fluorophenyl) ethylamino
Phenyl The 4-pyridyl (S)-2-amino-3-phenyl third amino
The 4-fluorophenyl The 4-pyridyl (S)-2-amino-3-phenyl third amino
Phenyl 2-acetylaminohydroxyphenylarsonic acid pyridyl (S)-2-amino-3-phenyl third amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid pyridyl (S)-2-amino-3-phenyl third amino
Phenyl The 4-pyridyl 3-amino-3-phenyl third amino
The 4-fluorophenyl The 4-pyridyl 3-amino-3-phenyl third amino
Phenyl 2-acetylaminohydroxyphenylarsonic acid pyridyl 3-amino-3-phenyl third amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid pyridyl 3-amino-3-phenyl third amino
Phenyl The 4-pyridyl 3-amino-2-methyl-3-phenyl third amino
The 4-fluorophenyl The 4-pyridyl 3-amino-2-methyl-3-phenyl third amino
Phenyl 2-acetylaminohydroxyphenylarsonic acid pyridyl 3-amino-2-methyl-3-phenyl third amino
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid pyridyl 3-amino-2-methyl-3-phenyl third amino
Phenyl The 4-pyridyl (S)-tetrahydroisoquinoline-3-base methylamino-
The 4-fluorophenyl The 4-pyridyl (S)-tetrahydroisoquinoline-3-base methylamino-
Phenyl 2-acetylaminohydroxyphenylarsonic acid pyridyl (S)-tetrahydroisoquinoline-3-base methylamino-
The 4-fluorophenyl 2-kharophen pyridyl (S)-tetrahydroisoquinoline-3-base methylamino-
Phenyl The 4-pyridyl (S)-3-benzyl diethylenediamine base
The 4-fluorophenyl The 4-pyridyl (S)-3-benzyl diethylenediamine base
Phenyl 2-acetylaminohydroxyphenylarsonic acid pyridyl (S)-3-benzyl diethylenediamine base
The 4-fluorophenyl 2-acetylaminohydroxyphenylarsonic acid pyridyl (S)-3-benzyl diethylenediamine base
Preferred in addition compound is the compound of hereinafter enumerating especially among the embodiment.
Following term used herein has following implication:
Independent or " alkyl " that be used in combination is meant and contains preferred 1-15 carbon atom (C 1-C 15), more preferably 1-8 carbon atom (C 1-C 8), further preferred 1-6 carbon atom (C 1-C 6), preferred 1-4 carbon atom (C also 1-C 4), more preferably 1-3 carbon atom (C 1-C 3) and 1-2 carbon atom (C most preferably 1-C 2) the straight or branched alkyl.This type of examples of groups comprises methyl, ethyl, n-propyl, sec.-propyl, normal-butyl, isobutyl-, sec-butyl, the tertiary butyl, amyl group, isopentyl, hexyl, octyl group etc.
Separately or " hydroxyalkyl " that be used in combination be meant that wherein at least one hydrogen is replaced by hydroxyl, preferred 1-3 hydrogen is replaced by hydroxyl, more preferably 1-2 hydrogen is replaced by hydroxyl and 1 alkyl as defined above that hydrogen is replaced by hydroxyl most preferably.This type of examples of groups comprises methylol, 1-, 2-hydroxyethyl, 1-, 2-, 3-hydroxypropyl, 1,3-dihydroxyl-2-propyl group, 1,3-dihydroxyl butyl, 1,2,3,4,5,6-hexahydroxy--2-hexyl etc.
Separately or " thiazolinyl " that be used in combination be meant to have one or more pairs of keys, preferred 1-2 two keys, more preferably 1 two key, and contain 2-15 carbon atom (C 2-C 15), more preferably 2-8 carbon atom (C 2-C 8), further preferred 2-6 carbon atom (C 2-C 6), preferred 2-4 carbon atom (C also 2-C 4) and still can further preferred 2-3 carbon atom (C 2-C 3) the straight or branched alkyl.The example of this type of thiazolinyl comprises vinyl, propenyl, 2-methylpropenyl, 1,4-butadienyl etc.
Independent or " alkoxyl group " that be used in combination typically is meant " R-O-" group, and wherein " R " is that alkyl is the N atom with " O " as defined above.The example of this type of alkoxyl group comprises methoxyl group, oxyethyl group, positive propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert.-butoxy etc.
Independent or " carbalkoxy " that be used in combination typically is meant " R-O-C (O)-" group, and wherein " R-O-" is that alkoxyl group is a carbonyl with " C (O) " as defined above.
Independent or " alkoxycarbonyl amido " that be used in combination typically is meant " R-O-C (O)-NH-" group, wherein " R-O-C (O) " is carbalkoxy as defined above, and wherein said amino can be replaced arbitrarily by for example alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl etc.
Independent or " alkylthio " that be used in combination typically is meant " R-S-" group, and wherein " R " is that alkyl is a sulphur atom with " S " as defined above.The example of this type of alkylthio comprises methylthio group, ethylmercapto group, positive rosickyite base, iprotiazem base, positive butylthio, isobutyl sulfenyl, secondary butylthio, uncle's butylthio etc.
Separately or " alkyl sulphinyl " that be used in combination typically be meant " R-S (O)-" group, wherein " R " is alkyl and " S (O) is " by the sulphur atom of an oxidation as defined above.The example of this type of alkyl sulphinyl comprises methylsulfinyl, ethyl sulfinyl, n-propyl sulfinyl, sec.-propyl sulfinyl, normal-butyl sulfinyl, isobutyl-sulfinyl, sec-butyl sulfinyl, tertiary butyl sulfinyl etc.
Independent or " alkyl sulphonyl " that be used in combination typically is meant " R-S (O) 2-" group, wherein " R " is alkyl and " S (O) as defined above 2" by the sulphur atom of titanium dioxide.The example of this type of alkyl sulphonyl comprises methylsulfonyl, ethylsulfonyl, n-propyl alkylsulfonyl, sec.-propyl alkylsulfonyl, normal-butyl alkylsulfonyl, isobutyl-alkylsulfonyl, sec-butyl alkylsulfonyl, tertiary butyl alkylsulfonyl etc.
Independent or " aryl " that be used in combination is meant phenyl or xenyl; it can at random condense with phenyl ring or with heterocyclic fused and can be selected from following group and replace arbitrarily by one or more; described group is selected from alkyl; alkoxyl group; halogen; hydroxyl; amino; azido-; nitro; cyano group; haloalkyl; carboxyl; carbalkoxy; cycloalkyl; alkanoyl amino; amido; amidino groups; alkoxycarbonyl amido; the N-alkyl amidine; alkylamino; dialkylamino; aminoalkyl group; alkyl amino alkyl; dialkylaminoalkyl; the N-alkyl amido; N, N-dialkyl group amido; aralkoxycarbonyl amino; alkylthio; alkyl sulphinyl; alkyl sulphonyl; oxo etc.The example of aryl has phenyl, neighbour-tolyl, 4-p-methoxy-phenyl, 2-(tert.-butoxy) phenyl, 3-methyl-4-p-methoxy-phenyl, 2-CF 3-phenyl, the 2-fluorophenyl, the 2-chloro-phenyl-, the 3-nitrophenyl, the 3-aminophenyl, the 3-acetylamino phenyl, 2-amino-3-(amino methyl) phenyl, 6-methyl-3-acetylamino phenyl, 6-methyl-2-aminophenyl, 6-methyl-2, the 3-diamino-phenyl, 2-amino-3-aminomethyl phenyl, 4,6-dimethyl-2-aminophenyl, the 4-hydroxy phenyl, 3-alkyl-4-hydroxy phenyl, 4-(2-p-methoxy-phenyl) phenyl, 2-amino-1-naphthyl, the 2-naphthyl, 3-amino-2-naphthyl, 1-methyl-3-amino-2-naphthyl, 2,3-diaminostilbene-naphthyl, 4,8-dimethoxy-2-naphthyl etc.
Separately or " aralkyl " and " arylalkyl " that be used in combination be meant wherein at least one, preferred 1-2 the abovementioned alkyl group that hydrogen atom is replaced by above-mentioned aryl, for example benzyl, 1-, 2-styroyl, dibenzyl methyl, hydroxyphenyl methyl, tolyl methyl, diphenyl methyl, dichlorophenylmethyl, 4-anisole ylmethyl etc.
Separately or " aralkoxy " that be used in combination be meant wherein at least one, preferred 1-2 the above-mentioned alkoxy base that hydrogen atom is replaced by above-mentioned aryl, for example benzyloxy, 1-, 2-phenyl ethoxy, dibenzyl methoxyl group, hydroxyphenyl methoxyl group, tolyl methoxyl group, dichlorophenyl methoxyl group, 4-anisole ylmethoxy etc.
Separately or " aromatic alkoxy carbonyl " that be used in combination typically be meant " R-O-C (O)-" group, wherein " R-O-" is aralkoxy as defined above, and " C (O)-" is carbonyl.
Separately or " alkanoyl " that be used in combination typically be meant " R-C (O)-", wherein " R " is alkyl as defined above, and " C (O)-" is carbonyl.The example of this type of alkanoyl comprises ethanoyl, trifluoroacetyl group, hydroxyacetyl, propionyl, butyryl radicals, pentanoyl, 4-methylpent acyl group etc.
Independent or " alkanoyl amino " that be used in combination typically is meant " R-C (O)-NH-"; wherein " R-C (O)-" is alkanoyl as defined above, and wherein said amino can be replaced arbitrarily by for example alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl etc.
Separately or " aminocarboxyl " that be used in combination be meant the amino carbonyl (formamyl) that replaces, wherein said amino can be at random by for example alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, alkanoyl, carbalkoxy, aromatic alkoxy carbonyl etc.-or two-replace.
Independent or " amino-sulfonyl " that be used in combination is meant the amino alkylsulfonyl that replaces.
Independent or " benzo " that be used in combination is meant phenyl ring deutero-divalent group C 6H 4=." benzo-fused " is that wherein benzene and cycloalkyl or aryl have the ring system of two shared carbon atoms, for example naphthane etc.
" dicyclo " used herein means ring system for example naphthyl and the β-Ka Lin base that comprises two fused rings, and the ring system that replaces for example xenyl, phenylpyridyl and phenylbenzene piperazinyl.
Independent or " cycloalkyl " that be used in combination is meant and preferably contains 5-12 carbon atom (C 5-C 12), more preferably 5-10 carbon atom (C 5-C 10), further preferred 5-7 carbon atom (C 5-C 7), saturated or fractional saturation, preferably contain monocycle, dicyclo or the three ring carbocyclic ring alkyl of two keys, preferred monocycle, it can at random condense with phenyl ring or with heterocyclic fused and can be optionally substituted described in the aryl definition.The example of this type of cycloalkyl comprises cyclopentyl, cyclohexyl, dihydroxyl cyclohexyl, methylene-dioxy cyclohexyl, suberyl, octahydro naphthyl, tetralyl, octahydro quinolyl, dimethoxy tetralyl, 2,3-dihydro-1H-indenyl, azabicyclo [3.2.1] octyl group etc.
" heteroatoms " is meant nitrogen, oxygen and sulfur heteroatom.
" heterocyclic fused " is that wherein 5-6 unit heterocyclic radical or heteroaryl and cycloalkyl or aryl have the ring system of two shared carbon atoms, for example indoles, isoquinoline 99.9, tetrahydroquinoline, methylenedioxybenzenes etc.
" heterocyclic radical " is meant and contains at least one, preferred 1-4, more preferably 1-3, further preferred 1-2 nitrogen, oxygen or sulphur annular atoms and each ring are preferably 3-8 unit ring, each encircles 5-8 unit ring more preferably and each and encircles that 5-6 unit more preferably encircles, saturated or fractional saturation, the monocycle or the dicyclo that preferably contain two keys, preferred monocyclic heterocycles group." heterocyclic radical " means the sulfone that comprises the sulphur annular atoms and the N-oxide compound of sulfoxide derivant and uncle's azo-cycle atom, and with a preferred 3-6 ring carbon atom and more preferably 5-6 ring carbon atom carbocyclic fused and with phenyl ring condensed ring system." heterocyclic radical " can be by any replacement as described below; and at least one; preferred 1-4; more preferably 1-3; on further preferred 1-2 the carbon atom by replacements such as halogen, alkyl, alkoxyl group, hydroxyl, oxo, sulfo-, aryl, aralkyl, heteroaryl, heteroaralkyl, amidino groups, N-alkyl amidine, alkoxycarbonyl amido, alkyl sulfonyl amino, and/or on second nitrogen-atoms by hydroxyl, alkyl, aromatic alkoxy carbonyl, alkanoyl, carbalkoxy, heteroaralkyl, aryl or aralkyl replacement.More preferably, independent or " heterocyclic radical " that be used in combination is that wherein 1-3 annular atoms is oxygen, sulphur or nitrogen heteroatom, can be that at random part is undersaturated or with the phenyl ring condensed and at random replaced by 1-2 oxo or thio group, each ring is monocycle or dicyclo saturated heterocyclic system of 5-8 unit ring.The example of this type of heterocyclic radical comprises pyrrolidyl, piperidyl, piperazinyl, morpholinyl, thio-morpholinyl, 4-benzyl-piperazine-1-base, pyrimidyl, tetrahydrofuran base, pyrazolidine ketone group, pyrazolinyl, pyridazine ketone group, pyrrolidone-base, tetrahydro-thienyl and sulfoxide and sulfone derivatives, 2,3-indolinyl, tetrahydric quinoline group, 1,2,3,4-tetrahydro isoquinolyl, 1,2,3,4-tetrahydrochysene-1-oxo-isoquinolyl, 2,3-dihydro benzo furyl, benzopyranyl, methylenedioxyphenyl, ethylenedioxy phenyl etc.
" heteroaryl " is meant and contains at least one, preferred 1-4, more preferably 1-3, that further preferred 1-2 nitrogen, oxygen or thia annular atoms and each are encircled is that preferred 5-6 unit encircles, monocycle or dicyclo, preferred monocyclic aromatic heterocyclic radical, it can be at random and preferred 3-4 carbon atom (C 3-C 4) saturated carbon ring condense and form 5-6 unit ring and can described in above-mentioned aryl definition, be optionally substituted.The example of this type of heteroaryl comprises imidazolyl, 1-carbobenzoxy-(Cbz) imidazol-4 yl, pyrryl, pyrazolyl, pyridyl, 3-(2-methyl) pyridyl, 3-(4-trifluoromethyl) pyridyl, pyrimidyl, 5-(4-trifluoromethyl) pyrimidyl, pyrazinyl, triazolyl, furyl, thienyl,  azoles base, thiazolyl, indyl, quinolyl, 5,6,7,8-tetrahydric quinoline group, 5,6,7,8-tetrahydro isoquinolyl, quinoxalinyl, benzothiazolyl, benzofuryl, benzimidazolyl-, benzoxazol base etc.
Separately or " heteroaralkyl " and " heteroarylalkyl " that be used in combination be meant wherein at least one, preferred 1-2 hydrogen atom quilt is the abovementioned alkyl group of heteroaryl replacement, for example 3-furyl propyl group, 2-pyrryl propyl group, chloroquinoline ylmethyl, 2-thienyl ethyl, pyridylmethyl, 1-imidazolyl ethyl etc. as defined above.
Independent or " halogen " and " halo " that be used in combination is meant fluorine, chlorine, bromine or iodine.
Separately or " haloalkyl " that be used in combination be meant wherein at least one, preferred 1-3 hydrogen atom be by halogen, more preferably the abovementioned alkyl group of fluorine or chlorine replacement.The example of this type of haloalkyl comprises 1,1,1-trifluoroethyl, chloromethyl, 1-brooethyl, methyl fluoride, difluoromethyl, trifluoromethyl, two (trifluoromethyl) methyl etc.
" pharmaceutically acceptable salt " be meant through the preparation of conventional method and be to well known to a person skilled in the art salt.Described " pharmaceutically acceptable salt " comprises inorganic and the organic acid basic salt, comprise, but be not limited only to hydrochloric acid, Hydrogen bromide, sulfuric acid, phosphoric acid, methylsulfonic acid, ethyl sulfonic acid, oxysuccinic acid, acetate, oxalic acid, tartrate, citric acid, lactic acid, fumaric acid, succsinic acid, toxilic acid, Whitfield's ointment, phenylformic acid, toluylic acid, amygdalic acid etc.When compound of the present invention contains the acid function base for example during carboxyl, joining on the paired appropriate drug acceptable positively charged ion with described carboxyl is to well known to a person skilled in the art and comprise basic metal, alkaline-earth metal, ammonium, quaternary ammonium cation etc.The example of other " pharmaceutically acceptable salt " can vide infra and people's such as Berge J.Pharm.Sci.66, and 1 (1977).
" cytokine " is a kind of secretory protein that influences other cell functions, particularly it with the immune system cell interphase interaction or with inflammatory response relevant cell regulate relevant.The example of cytokine include but not limited to, interleukin 1 (IL-1), preferred IL-1 β, interleukin 6 (IL-6), interleukin 8 (IL-8) and TNF, preferred TNF-α (tumor necrosis factor-alpha).
The disease that " disease or the illness of TNF, IL-1, IL-6 and/or IL-8 mediation " is meant all these the wherein effect of TNF, IL-1, IL-6 and/or IL-8 is with the performance of TNF, IL-1, IL-6 and/or IL-8 self form, perhaps induces the release of another kind of cytokine to bring into play by TNF, IL-1, IL-6 and/or IL-8.For example, wherein IL-1 plays a major role, but wherein the generation of IL-1 or effect are the illnesss that the result's of TNF effect this illness is considered to the THF mediation.
" leavings group " is often referred to easily by nucleophilic reagent for example amine, mercaptan or pure nucleophilic reagent metathetical group.This type of leavings group is well known in the art.The example of this class leavings group include but not limited to, N-hydroxy-succinamide, N-hydroxybenzotriazole, halogenide, triflate, tosylate etc.Preferred leavings group is a suitable group described herein.
" protecting group " is often referred to and is used to protect selected active group for example carboxyl, amino, hydroxyl, sulfydryl etc. are avoided for example groups well known in the art such as nucleophilic reaction, electrophilic reaction, oxidizing reaction, reduction reaction of undesirable reaction.Preferred protecting group is a suitable protecting group as herein described.The example of amino protecting group include but not limited to, the allyl group of the cycloalkenyl alkyl of the aralkyl of aralkyl, replacement, cycloalkenyl alkyl and replacement, allyl group, replacement, acyl group, carbalkoxy, aromatic alkoxy carbonyl, silyl etc.The example of aralkyl include but not limited to, and benzyl, neighbour-methyl-benzyl, trityl and diphenyl-methyl that can be replaced arbitrarily by halogen, alkyl, alkoxyl group, hydroxyl, nitro, amido, acyl group etc. and salt is  and ammonium salt for example.The example of aryl comprises phenyl, naphthyl, 2,3-indanyl, anthryl, 9-(9-phenyl fluorenyl), phenanthryl, durol base etc.The example of the cycloalkenyl alkyl of cycloalkenyl alkyl or replacement is preferably 6-10 carbon atom, include but not limited to cyclohexenyl methyl etc.Suitable acyl group, carbalkoxy and aromatic alkoxy carbonyl comprises the benzoyl, butyryl radicals, ethanoyl, trifluoroacetyl group, tribromo-acetyl base, phthaloyl of carbobenzoxy-(Cbz), tertbutyloxycarbonyl, isobutyl boc, benzoyl, replacement etc.The mixture of protecting group can be used for protecting same amino group, and for example primary amino can be used aralkyl and two kinds of protections of aromatic alkoxy carbonyl.Amino protecting group also can form heterocycle with the nitrogen-atoms that they connected, and for example 1,2-two (methylene radical) benzene, phthaloyl imino, succinimido, maleimide amino etc., and this heterocycle can further wrap the aryl of adjacency and cycloalkyl etc.In addition, described heterocyclic radical can this one-, two-or three-replace nitro phthaloyl imino for example.Amino can also be protected to avoid for example oxidizing reaction of undesirable reaction by forming additive salt, and described additive salt for example is hydrochloride, tosylate, trifluoroacetate etc.Many amino protecting groups also are suitable for protecting carboxyl, hydroxyl and sulfydryl, for example aralkyl.The alkyl for example tertiary butyl also is the suitable protecting group of hydroxyl and sulfydryl.
The Siliciumatom that the silyl protecting group is replaced arbitrarily by one or more alkyl, aryl and aralkyl.Suitable silyl protecting group comprises; but be not limited only to; trimethyl silyl, triethylsilyl, triisopropyl silyl, t-butyldimethylsilyl, 3,5-dimethylphenyl silyl, 1; 2-two (dimetylsilyl) benzene, 1,2-two (dimetylsilyl) ethane and diphenyl methyl silyl.Amino silyl cycloalkyl can form one-or two-silyl amino group.The silylanizing of amino alcohol compound can obtain N, N, O-three-silyl derivative.By removing the silyl functional group in the silyl ether functional group by removing at an easy rate with for example metal hydroxides or Neutral ammonium fluoride agent treated, its both can be in the reactions steps of separating or with the alcohol radical reaction process in remove on the spot.Suitable sillylation reagent is the product that combines of trimethylsilyl chloride, tert-butyldimethylsilyl chloride thing, phenyl dimetylsilyl muriate, diphenyl methyl silyl chlorination thing or they and imidazoles or DMF for example.Removing of the silylanizing method of amine and silyl protecting group is well known to a person skilled in the art.The method that is prepared this class sulfonamide derivatives by corresponding amino acid, amino acid amide or amino acid ester also is an organic chemistry filed, comprises that amino acid/amino acid ester or amino alcohol chemical field technician are known.
Removing under the condition of other parts that do not influence described molecule of protecting group carried out.These methods are well known in the art and comprise acid-hydrolysis method, hydrogenolysis method etc.The preferred method that removes protecting group for example for example in alcohol, acetate etc. or their mixture, removes carbobenzoxy-(Cbz) by carrying out hydrogenolysis with palladium-carbon in the suitable solvent system.In the The suitable solvent system for example in two  alkane or the methylene dichloride, can for example HCl or trifluoroacetic acid remove with inorganic or organic acid.The gained amide is neutralized at an easy rate, generates unhindered amina.Carboxyl-protecting group for example methyl, ethyl, benzyl, the tertiary butyl, 4-anisole ylmethyl etc. can remove well known to a person skilled in the art under hydrolysis and the hydrogenolysis condition.
Above used symbol has following meanings:
The prodrug of compound of the present invention is also included among the present invention.Prodrug is a kind of activity or non-active compound through chemically modified, and it is after using to the patient, and for example hydrolysis, metabolism etc. are transformed into The compounds of this invention through the body physiological effect.The adaptability and the method for prodrug preparation and application facet are well known to a person skilled in the art.The generality discussion that comprises the relevant prodrug of ester can be referring to Svensson and Tunek Drug Metabolism Reviews 165 (1988) and Bundgaard Design of Prodrugs, Elsevier (1985).The example of covering up the carboxylate anion comprises various esters, for example alkyl (for example methyl, ethyl), cycloalkyl (for example cyclohexyl), aralkyl (for example benzyl, to methoxy-benzyl) and alkane carbonyl oxygen base alkyl (for example oxy acid methyl neopentyl) ester.Amine is covered up into the methyl substituted derivative of aryl-carbonyl oxygen, and it can discharge free drug and formaldehyde (Bungaard J.Med.Chem.2503 (1989)) in vivo by the esterase cracking.In addition, contain acid NH group for example the medicine of imidazoles, imide, indoles etc. can cover up (Bundgaard Design of Prodrugs, Elsevier (1985) with N-acyloxy methyl.Hydroxyl can be covered up into ester and ether.EP 039,051 (Sloan and Little, 4/11/81) discloses mannich base hydroxamic acid prodrug, their preparation and application.
The compounds of this invention can be synthetic according to following one or more methods.Be understandable that described general method relates to the method for preparing nonspecific stereochemistry compound.But this method is usually applicable to specific stereochemistry compound, and it is (S) or (R) that for example described stereochemistry relates to group.In addition, with known method conversion method for example, a certain compound (for example (R)) with stereochemistry characteristic can be used to prepare the compound (i.e. (S)) with opposite stereochemistry characteristic usually.4 (3H)-pyrimidinones:
For synthetic 4 (3H)-pyrimidinones II (or its tautomer, 4-hydroxyl-pyrimidines).According to reaction scheme 1 described method carry out (relevant synthetic method can referring to (D.J.Brown, Heterocyclic Compounds:the Pyrimidines, supra).This method comprises between acrylate XII and the amidine V carries out ring-closure reaction, with gained dihydropyrimidinonesand XIII oxidation, obtains formula II compound subsequently.
Reaction scheme 1
Synthetic (reaction scheme) of 5-(4-fluorophenyl)-6-(4-the pyridyl)-4-hydroxyl-pyrimidines II that replaces for 2-, by with Pyridine-4-Carboxaldehyde and the condensation of 4-fluorophenyl acetate, esterification subsequently can prepare dibasic acrylate XII.Formula XII compound and various amidine compound V can be reacted under elevated temperature.Be transformed into dehydrogenating agent in the Compound I I reaction as compounds X III, suitable is Sodium Nitrite/acetate.
Reaction scheme 2
In addition, by raw material being done suitable the selection, can further obtain wherein R 12Be R 12The formula II compound of other heteroaryl rings in the definition.This type of raw material comprises, but be not limited only to, 2-picoline-4-formaldehyde, 2,6-lutidine-4-formaldehyde (Mathes and Sauermilch, Chem.Ber.88,1276-1283 (1955)), quinoline-4-formaldehyde, pyrimidine-4-formaldehyde, 6-methylpyrimidine-4-formaldehyde, 2-methylpyrimidine-4-formaldehyde, 2,6-dimethyl pyrimidine-4-formaldehyde (people such as Bredereck, Chem.Ber.97,3407-3417 (1964)).Can obtain R with 2-nitropyridine-4-formaldehyde 12The formula II derivative of expression 2-nitro-4-pyridyl group.Described nitro is catalysed and reduced into amino, can obtains 2-amino-4-pyridinyl derivatives of formula II.In method shown in the reaction scheme 2, use other Arylacetic acids can obtain R 11It is the formula II compound of different aryl.
At suitable alkali for example in the presence of the salt of wormwood etc., by with for example alkyl halide such as methyl iodide or the reaction of ethyl bromide, can be at pyrimidone II (R 1=H) the N-3 position replaces.
Reaction scheme 3
Figure C9718155800971
Another kind of preparation 5, the method for 6-diaryl-4-hydroxyl-pyrimidines (reaction scheme 3) comprise, with b-ketone ester XIV and thiocarbamide cyclization, form sulfur uracil derivative XV.Compounds X V can be generated compounds X VI by the S-monomethylation.Compounds X VI and primary amine and secondary amine reaction can prepare the amino 4-hydroxyl-pyrimidines i I that replaces of 2-.For example, with compounds X V alkylation, can further obtain R with alkyl halide 1=SR 212-sulfide derivative II.With compounds X V or XVI Raney nickel and H 2Handle, can prepare wherein R 1It is the formula II compound of H.
Although reaction scheme 3 is illustrated is R wherein 12Be the synthetic method of 4-pyridyl, but by selecting suitable raw material, this method is equally applicable to R 12Any other heteroaryl ring in the definition.This type of raw material comprises, but be not limited only to 2-methyl iso ethyl nicotinate (Efimovsky and Rumpf, Bull.Soc.Chim.FR.648-649 (1954)), pyrimidine-4-carboxylate methyl ester, 2-methylpyrimidine-4-carboxylate methyl ester, 6-methylpyrimidine-4-carboxylate methyl ester and 2,6-dimethyl pyrimidine-4-carboxylate methyl ester (people such as Sakasi, Heterocycles 13,235 (1978)).Equally, 2-nitro iso methyl nicotinate (Stanonis, J.Org.Chem.22,475 (1957)) can react with aryl acetate, subsequently according to reaction scheme 3 similarity methods, with the thiocarbamide cyclization of gained b-ketone ester.Then, described nitro is catalysed and reduced into amino, will obtains wherein R 12The pyrimidone II (reaction scheme 4) of expression 2-amino-4-pyridyl.
Reaction scheme 4
In addition, with (P such as t-butyldimethylsilyloxy ylmethyl group for example people such as (, Acta Chem.Scand.B.42 384-389 (1988)) Benneche, t-butyldimethylsilyl, benzyloxymethyl, benzyls 1) nitrogen-atoms of described acid amides is suited 2-kharophen iso methyl nicotinate (reaction scheme 5) to be similar to the reaction of reaction scheme 3 after the protection.
Reaction scheme 5
Figure C9718155800991
With suitable reagent (for example, at P 1Be under tertiary butyl dimethyl-siloxy-methyl situation, use tetrabutyl ammonium fluoride) remove protecting group P 1, can obtain R 12The pyrimidone II of expression 2-acetylaminohydroxyphenylarsonic acid 4-pyridyl.Beyond all doubt, in reaction scheme 3 described methods, can replace with any Arylacetic acids alkyl ester the fluorophenyl ethyl acetate, thereby obtain having different R 11The formula II compound of aryl substituent.
In another kind of method, XVIII derivative that formula II pyrimidone can be by will be suitable (L is a leavings group, for example halogen etc.) and suitable aryl equivalent coupling preparation.
This type of aryl/hetaryl coupled reaction is to well known to a person skilled in the art and relate in the presence of catalyzer and the reactive derivative of the second kind of compound organic-metallic composition of halo derivatives reaction for example.Described metal-organic component both can be provided by described pyrimidone under described aryl component provides the situation of described reactive halogen equivalent, perhaps described pyrimidone can be can with the organic aryl compound reactive activity of metal 5-halo derivatives form.Therefore, at inert solvent for example in the tetrahydrofuran (THF), at palladium catalyst for example in the presence of two (triphenyl phosphine) palladium (II) dichloride, the 5-bromine of XVIII and the available arylalkyl tin compound of 5-iodine derivative (L=Br, I) for example trimethylammonium stannyl benzene are handled (people such as Peters, J.Heterocyclic Chem.27,2165-2173 (1990)).In addition, by reacting, carry out lithium saltsization and can in the presence of catalyzer,, the halogen derivative of XVIII can be transformed into trialkyltin derivative (L=Bu with butyllithium subsequently with the aryl halide reaction with for example tributyl stannyl muriate 3Sn) (Sandosham and Undheim, Acta Chem.Scand.43,684-689 (1989)).Two kinds of methods all can obtain wherein R 11The pyrimidines II of expression aryl and heteroaryl.
(Kabbe, Lieb.Ann.Chem.704,144 (1967) described in document; German Patent 1271116 (1968)) and shown in the reaction scheme 6, in the presence of sodium methylate,, can prepare 5-aryl-2 with one-step synthesis, 6-bipyridyl-4 (3H)-pyrimidone II by with cyanopyridine and for example phenylacetic acid ethyl ester reaction of aryl acetate.
Reaction scheme 6
Figure C9718155801001
In reaction scheme 7, formula XXX compound of the present invention can pass through methylthio group intermediate X XXI and described amine NHR 5R 21Reaction for example preferably is being higher than under the l00 ℃ of temperature, more preferably heats described mixture down at l50-2l0 ℃, can make at an easy rate.In addition, formula XXX compound can pass through methylsulfonyl intermediate X XXII and described amine NHR 5R 21Reaction for example preferably is being higher than under 40 ℃ of temperature, more preferably heats described mixture down at 50-21O ℃, can make at an easy rate.
Reaction scheme 7
Figure C9718155801002
Formula NHR 5R 21Amine can be prepared by the raw material of commercially available acquisition at an easy rate by commercially available acquisition or those skilled in the art.For example, under reductive condition, as in the presence of reductive agent such as lithium aluminium hydride etc., can be with acid amides, nitro or cyano reduction, to form corresponding amine.Amino alkylation and acylation reaction are well known to a person skilled in the art.Use method well known in the art, can make the amine of chirality and achirality replacement by chiral amino acid and amino acid amide (for example glycine of replacements such as alkyl, aryl, heteroaryl, cycloalkyl, aralkyl, heteroaralkyl, cycloalkylalkyl, Beta-alanine etc.), H.Brunner for example, P.Hankofer, U.Holzinger, B.Treittingerand H.Schoenenberger, Eur.J.Med.Chem.25,35-44,1990; M.Freiberger and R.B.Hasbrouck, J.Am.Chem.Soc.82,696-698,1960; Dornow and Fust, Chem.Ber.87,984,1954; M.Kojima and J.Fujita, Bull.Chem.Soc.Jpn.55,1454-1459,1982; W.Wheeler and D.O ' Bannon, Journal of Labelled Compounds and RadiopharmaceuticalsXXXI, 306,1992; And S.Davies, N.Garrido, O.Ichihara and I.Walters, J.Chem.Soc., Chem.Commun.1153,1993.
Pyridine compounds:
Shown in reaction scheme 8, the proper method of preparation 2 (1H)-pyridine compounds III is included in alkali and exists down, at a, b-beta-unsaturated ketone XXII and have between the ethanamide enough reactive behavioies, that replace and carry out ring-closure reaction (El-Rayyes and Al-Hajjar, J.Heterocycl.Chem.21,1473 (1984)) and carry out dehydrogenation subsequently.
Reaction scheme 8
Reaction scheme 9
Therefore (as reaction scheme 9); Pyridine-4-Carboxaldehyde or other heteroaromatic formaldehydes pyrimidine-4-formaldehyde or quinoline-4-benzaldehyde compound can be under elevated temperatures; in the presence of piperidines/acetate, react (Bayerand Hartmann with ethanoyl aryl, ethanoyl heteroaryl or ethanoyl cycloalkyl derivatives; Arch.Pharm. (Weinheim) 324,815 (1991)) and in the presence of sodium hydroxide with Pinacolone (CH 3-CO-C (CH 3) 3) reaction, obtain undersaturated ketone XXII (or by corresponding heteroaromatic-similar ketone of 4-formaldehyde gained).Then, in the presence of sodium ethylate, with the reaction of XXII compound and phenyl-acetamides, through 3,4-dihydropyridine ketone obtains 3-phenyl-4-(heteroaryl)-2 (1H)-pyridone that the 6-of formula III replaces.
In reaction scheme 10, illustrated a kind of preparation 6-chloro-2 (1H)-pyridone XXIV, modified the facilitated method of making further various intermediates in the 6-position.This method is transformed into XXIV compound (G.Simchen, Chem.Ber.103,389-397 (1970)) based in the presence of hydrogenchloride with unsaturated g-cyano group acyl chlorides XXIII
Reaction scheme 10
Figure C9718155801031
With XXIV compound and ammonia (Katritzky and Rachwal, J.Heterocylic Chem.32,1007 (1995)), primary amine and secondary amine reaction, the amino pyridone III that replaces of 2-will be obtained.In addition, in palladium or the catalytic cross-coupling reaction of Raney nickel, the XXIV compound can with alkyl or aryl boric acid or alkyl or aryl zinc halide reaction, can obtain wherein R 3Be the pyridone III of alkyl or aryl or heteroaryl.
In addition,,, can replace for example in the presence of the salt of wormwood at suitable alkali in the N-1 position of pyridone III by reacting with for example alkyl halide.
Reaction scheme 11 has been illustrated the method that can prepare the general formula III pyrimidone.
Reaction scheme 11
According to this method (Shaw and Warrener, J.Chem.Soc.153-156 (1958); Hronowski and Szarek, Can.J.Chem.63,2787 (1985); Agathocleous and Shaw; J.Chem.Soc.Perkin Trans.I.2555 (1993)); can be with ethoxy-c enoyl-lsothiocyanates XXVI and primary amine reaction; obtain adduct acylthioureas XXVII; with its cyclization under alkalescence or acidic conditions, obtain thiouracil compounds X XVIII.The XXVIII compound can be methylated, and obtains methylthio group derivative XXIX, a kind of further ten minutes useful as intermediates of transformation of doing in the 2-position.
Condensed 4 (3H)-pyrimidinones:
Shown in reaction scheme 12 and 13,, introduce suitable R through the XXXIII alkylation 4Group obtains wherein R 1The intermediate of 5, the 6 or 7 yuan of ring systems of formula I condensed that link to each other with V or W.Described synthetic method is utilized haloalkyl amine; wherein warp is with 1; two (Chlorodimethyl silyl) ethane reactions of 2-; described amino is protected; obtain stable derivative (referring to Basha and Debernardis Tetrahedron Lett 5271; 1984), its (sodium hydride is protected described amine in DMF) at subsequently alkylation step.
Reaction scheme 12
Figure C9718155801041
Reaction scheme 13
Figure C9718155801051
The deprotection of described amine can be by finishing dealing with acid treatment (tosic acid) or tetrabutyl ammonium fluoride.By being warmed to comparatively high temps, described unhindered amina can be with the cyclization of intramolecularly mode.Described bromo alkylamine can obtain by trinitride being reduced into amine is synthetic by corresponding haloalkyl trinitride by commercially available acquisition (for example 3-propantheline bromide hydrobromide, 2-bromine ethylamine hydrobromide) or they (referring to: people Tetrahedron Lett 4597 (1987) such as Handry).As long as allow at functional group described in the conversion reaction shown in the reaction scheme 12, can use the haloalkyl amine of greater functionality baseization, comprise (Synlett.51-53 as people such as Baldwin, 1993) and people (Tetrahedron Lett.4485 such as Leanna, 1993) described, obtain described bromo derivative by amino acid precursor.
In addition, shown in reaction scheme 14, also can prepare and condense ring system by adding hydroxyalkyl amine.At first,, obtain compounds X XXVII, subsequently described alcohol is transformed into suitable leavings group (for example methanesulfonates or triflate) with the alternative 2-methylthio group of the amine moiety of described hydroxyalkyl amine.In DMF,, can realize the closed loop of described ring by handling with excessive sodium hydride.
Reaction scheme 14
Figure C9718155801061
Shown in reaction scheme 15, can obtain 6,5 condensed ring systems.With the alkylation of N-3 nitrogen-atoms, with suitable amine for example but be not limited only to phenylalkyl amine and substitute the 2-methylthio group, under reaction conditions, the amino cyclization of 2-removes trimethyl silyl simultaneously to acetylene subsequently with 3-bromo-1-trimethyl silyl propine.This conversion reaction has obtained illustrating in the following example, wherein with 3-phenyl-1-propylamine and benzyl amine and 3-(3-trimethyl silyl-2-propynyl)-5-(4-fluorophenyl)-2-methylthio group-6-(4-pyridyl)-4 (3H)-pyrimidones reaction, obtain corresponding 6,5 condensed ring systems.
Reaction scheme 15
Reaction scheme 16
Can prepare U according to above-mentioned reaction scheme 2 is CHR 21The compounds of this invention, wherein R1 contains the group (L that leavings group maybe can be transformed into leavings group *), it can react with the nitrogen-atoms of pyrimidine, forms fused rings (referring to reaction scheme 16).
The following example only is used for illustration purpose, and is not intended to, and also should not constitute any restriction to the present invention.It will be appreciated by persons skilled in the art that in spirit and scope of the invention, can make modification and change compound described herein.
Embodiment
Embodiment 1
The general method of 5-(4-fluorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidinones that preparation 2-replaces
Figure C9718155801081
A.2-(4-fluorophenyl)-3-(4-pyridyl)-propionic acid: with 4-fluorophenyl acetate (9g, 58.4mmol), the 4-pyridylaldehyde (5.6ml, 58.6mmol), the mixture of pyridine (6ml) and diacetyl oxide (6ml) is in 150 ℃ of heating 1 hour down, evaporation subsequently and with the water condistillation.Make the products therefrom crystallization after adding ethanol, cross filter solid and, obtain described title compound with ethanol and ethyl acetate washing.MS (m/z): 244.0 (M+H) +C 14H 10FNO 2Theoretical value 243.2 1H-NMR (DMSO-d 6): d8.43,6.98 (2d, each 2H, pyridines .), 7.73 (s, 1H, CH=), 7.21 (d, 4H, PhF).
B.2-(4-fluorophenyl)-3-(4-pyridyl)-ethyl propenoate: the vitriol oil (2.2ml) is joined 2-(4-fluorophenyl)-3-(4-pyridyl)-vinylformic acid carefully, and (6.7g heated 24 hours down in refluxing in ethanol 27.5mmol) (120ml) suspension and with mixture.Steaming desolventizes, and resistates is dissolved in methylene dichloride, and organic solution is also evaporated with sodium bicarbonate aqueous solution and water washing, subsequent drying.On silica gel, carry out flash column chromatography (hexane-acetone=2: 1), obtain pure described title compound.MS (m/z): 271.8 (M+H) +C 16H 14FNO 2Theoretical value 271.3 1H-NMR (CDCl 3): 8.44,6.88 (2m, each 2H, pyridines .), 7.72 (s, 1H, CH=), 7.16,7.06 (2m, each 2H, PhF), 4.28 (q, 2H, CH 2), 1.28 (t, 3H, CH 3).
C. general method: in the test tube of a sealing, under 120 ℃, with 2-(4-fluorophenyl)-3-(4-the pyridyl)-ethyl propenoate under stirring (357mg, 1.38mmol), (250mg, 4.62mmol) mixture heating up in ethanol (5ml) is 3 hours for amidine hydrochloride (2.61mmol) and sodium methylate.Before evaporation, it is neutralized with 2N hydrochloric acid, resistates is dissolved in acetate (25ml) and (670mg 9.71mmol) handled 20 minutes with Sodium Nitrite down in 44 ℃.After the evaporation, products therefrom is dissolved in methylene dichloride, solution sodium bicarbonate aqueous solution and water washing, dry afterwards and evaporation.Product is by recrystallization purifying in methyl alcohol.If the crude product of nitrite-oxidizing reaction is water miscible, 5-(4-fluorophenyl)-2-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones for example, then do not carry out water treatment, but will before recrystallization, will evaporate the back products therefrom and place (5% ethanol/methylene) on the silicagel column.
Therefore, can prepare following compounds with suitable amidine hydrochloride:
1-1 5-(4-fluorophenyl)-2-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones:
MS (m/z): 282.2 (M+H) +C 16H 12FN 3O theoretical value 281.3 1H-NMR (DMSO-d 6): d8.46 (m 2H, pyridine), 7.2-7.03 (m, 6H, PhF, pyridine .) .2.38 (s, 3H, CH 3).
R1＝CH-
1-2 5-(4-fluorophenyl)-2-sec.-propyl-6-(4-pyridyl)-4 (3H)-pyrimidines Ketone: MS (m/z): 310.0 (M+H) +C 18H 16FN 3O theoretical value 309.4 1H-NMR (DMSO-d 6): 8.45 (m, 2H, pyridines .), 7.21-7.03 (m, 6H, PhF, pyridine .), 2.90 (m, 1H, CH (CH 3) 2) 1.26,1.24 (2s, each 3H, 2CH 3).
R1＝(CH 2) 2CH-
1-3 2-(2, the 6-dichloro benzyl)-5-(4-fluorophenyl)-6-(4-pyridyl)-4 (3H) -pyrimidone: MS (m/z): 426.0 (M) +
C 22H 14Cl 3FN 2O theoretical value 426.3 1H-NMR (DMSO-d 6): d8.37 (m, 2H, pyridine .), 7.50 (d, 2H, PhCl 2), 7.35 (t, 1H, PhCl 2), 7.18-7.08 (m, 4H, PhF), 6.96 (m, 2H, pyridines .), 4.36 (s, 2H, CH 2).
Figure C9718155801101
1-4 5-(4-fluorophenyl)-2-phenyl-6-(4-pyridyl)-4 (3H)-pyrimidones:
MS (m/z): 344.2 (M+H) +C 21H 14FN 3O theoretical value 343.4 1H-NMR (DMSO-d 6): d8.49 (d, 2H, pyridine .), 8,20 (d, 2H, Ph), 7.66-7.50 (m, 3H, pyridine., Ph), 7.32-7.11 (m, 6H, PhF, Ph).
Figure C9718155801102
Embodiment 2
The general method of 2-amino-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidinones that preparation 2-N replaces:
Steps A .5-(4-fluorophenyl)-3-methyl-2-methylthio group-6-(4-pyridyl)-4 (3H) -pyrimidone:
Under room temperature, with methyl iodide (418ml, 6.67mmol) be added to 5-(4-fluorophenyl)-6-(4-pyridyl)-2-thiouracil under stirring (1.0g, 3.34mmol) and salt of wormwood (923mg, 6.68mmol) in N, in the mixture in the dinethylformamide (30ml).Continue to stir evaporation subsequently and 3 hours in silicagel column (hexane-acetone=3: 1,2: 1,1: 1) or Iatrobeads R(chloroform-methanol=90: 7; Chloroform-methanol-triethylamine=90: 7: 3) goes up through flash chromatography method purifying, by obtaining the described title compound of solid state in second main flow part.MS (m/z): 328.0 (M+H) +C 17H 14FN 3OS theoretical value 327.4. 1H-NMR (DMSO-d 6): d8.50,7.26 (2m, each 2H, pyridines .), 7.18,7.14 (2m, each 2H, PhF), 3.52 (s, 3H, NCH 3), 2.65 (s, 3H, SCH 3).
Step B. general method:
(103mg is 0.32mmol) with amine HNR with 5-(4-fluorophenyl)-3-methyl-2-methylthio group-6-(4-pyridyl)-4 (3H)-pyrimidones 5R 21Mixture (1.2-3.2mmol) heated 2-48 hour down in 190-200 ℃.Products therefrom through flash chromatography method purifying (hexane-acetone or methyl alcohol-methylene dichloride or methyl alcohol-methylene fluoride-dense ammonium hydroxide), obtains described purpose compound on silicagel column.
Can prepare following compounds with above-mentioned general method and suitable amine:
2-1 2-(2-normal-butyl amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridine Base)-4 (3H)-pyrimidones: be reflected in the airtight test tube and under 190 ℃, carried out 5 hours.
MS (m/z): 353.0 (M+H) +C 20H 21FN 4O theoretical value 352.4.
R 1＝CH 3(CH 2) 3NH-。
2-2 5-(4-fluorophenyl)-3-methyl-2-(penta amino)-6-(4-pyridyl)- 4 (3H)-pyrimidones: be reflected in the airtight test tube and under 190 ℃, carried out 2.5 hours.
MS (m/z): 366.8 (M+H) +C 21H 23FN 4O theoretical value 366.4.
R 1＝CH 3(CH 2) 3NH-。
2-3 2-(3,3-dimethyl butyrate amino)-5-(4-fluorophenyl)-3-methyl-6-(4- Pyridyl)-4 (3H)-pyrimidone: be reflected in the airtight test tube and under 190 ℃, carried out 5 hours.
MS (m/z): 381.2 (M+H) +C 22H 25FN 4O theoretical value: 380.5.
R 1＝(CH 3) 3C(CH 2) 2NH-。
2-4 2-(benzyl amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)- 4 (3H)-pyrimidones: react on and carried out under 185 ℃ 6 hours.
MS (m/z): 387.2 (M+H) +C 23H 19FN 4O theoretical value 386.4.
2-5 2-(4-fluorine benzyl amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl) -4 (3H)-pyrimidones: react on and carried out under 190 ℃ 24 hours.
MS (m/z): 405.2 (M+H) +C 23H 18F 2N 4O theoretical value 404.4.
Figure C9718155801122
2-6 2-(3-fluorine benzyl amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl) -4 (3H)-pyrimidones: be reflected at and carried out under 195 ℃ 40 hours.
MS (m/z): 405.0 (M+H) +C 23H 18F 2N 4O theoretical value 404.4.
2-7 5-(4-fluorophenyl)-3-methyl-((R-1-styroyl) amino)-(4-pyridyl)-4 (3H)-pyrimidones: be reflected at and carried out under 180 ℃ 4 days.
MS (m/z): 401.0 (M+H) +C 24H 21FN 4O theoretical value 400.5.
2-8 2-(2-(2-chloro-phenyl--ethylamino)-5-(4-fluorophenyl)-3-methyl-6- (4-pyridyl)-4 (3H)-pyrimidones: be reflected at and carried out under 190 ℃ 5 hours.
MS (m/z): 435.2 (M+H) +C 24H 20ClFN 4O theoretical value 434.9.
Figure C9718155801131
2-9 5-(4-fluorophenyl)-2-(2-(4-fluorophenyl)-ethylamino)-3-methyl-6- (4-pyridyl)-4 (3H)-pyrimidones: be reflected at and carried out under 190 ℃ 5 hours.
MS (m/z): 419.2 (M+H) +C 24H 20F 2N 4O theoretical value 418.5.
Figure C9718155801132
2-10 5-(2-fluorophenyl)-2-(2-(3-fluorophenyl)-ethylamino)-3-methyl-6- (4-pyridyl)-4 (3H)-pyrimidones: be reflected at and carried out under 190 ℃ 24 hours.
MS (m/z): 419.2 (M+H) +C 24H 20F 2N 4O theoretical value 418.5.
2-11 5-(2-fluorophenyl)-2-(2-(2-fluorophenyl)-ethylamino)-3-methyl-6- (4-pyridyl)-4 (3H)-pyrimidones: be reflected at and carried out under 190 ℃ 12 hours.
MS (m/z): 419.0 (M+H) +C 24H 20F 2N 4O theoretical value 418.5.
Figure C9718155801134
2-12 5-(2-fluorophenyl)-2-((2-hydroxyl-2-phenyl)-ethylamino)-3-methyl -6-(4-pyridyl)-4 (3H)-pyrimidones: be reflected at and carried out under 190 ℃ 1.5 hours.
MS (m/z): 417.0 (M+H) +C 24H 21FN 4O 2Theoretical value 416.5.
Figure C9718155801141
2-13 5-(4-fluorophenyl)-3-methyl-2-((3-hydrocinnamyl) amino)-6-(4-pyridyl)- 4 (3H)-pyrimidones: be reflected at and carried out under 190 ℃ 6 hours.MS (m/z): 415.0 (M+H) +C 25H 23FN 4O theoretical value: 414.5. 1H-NMR (CDCl 3): d8.49,7.20 (2m, each 2H, pyridines .), 7.35 (t, 2H, Ph), 7.30-7.25 (m, 3H, Ph), 7.12,6.97 (2m, each 2H, PhF), 4.61 (t, 1H, NH), 3.67 (q, 2H, CH 2N), 3.28 (s, 3H, CH 3), 2.82 (t, 2H, CH 2Ph), 2.12 (m, 2H, CH 2).
Figure C9718155801142
2-14 5-(4-fluorophenyl)-3-methyl-2-((1-methyl-3-hydrocinnamyl) amino)-6 -(4-pyridyl)-4 (3H)-pyrimidones: be reflected at and carried out under 200 ℃ 48 hours.
MS (m/z): 429.0 (M+H) +C 26H 25FN 4O theoretical value 428.5.
2-15 5-(4-fluorophenyl)-3-methyl-2-((R-1-methyl-3-hydrocinnamyl) amino) -6-(4-pyridyl)-4 (3H)-pyrimidones: be reflected at and carried out under 200 ℃ 48 hours.
MS (m/z): 429.0 (M+H) +C 26H 25FN 4O theoretical value 428.5.
Figure C9718155801144
2-16 2-((3, the 3-diphenyl propyl) amino)-5-(4-fluorophenyl)-3-methyl-6-(4 -pyridyl)-4 (3H)-pyrimidone: be reflected at and carried out under 190 ℃ 6 hours.
MS (m/z): 490.8 (M+H) +C 31H 27FN 4O theoretical value 490.6.
Figure C9718155801151
2-17 5-(4-fluorophenyl)-3-methyl-2-((2-phenylamino ethyl) amino)-6-(4- Pyridyl)-4 (3H)-pyrimidone: be reflected at and carried out under 190 ℃ 4 hours.
MS (m/z): 416.2 (M+H) +C 24H 22FN 5O theoretical value 415.5.
Figure C9718155801152
2-18 5-(4-fluorophenyl)-2-((3-imidazolyl propyl group) amino)-3-methyl-6-(4- Pyridyl)-4 (3H)-pyrimidone: be reflected at and carried out under 190 ℃ 2 hours.
MS (m/z): 405.0 (M+H) +C 22H 21FN 6O theoretical value 404.5.
2-19 5-(4-fluorophenyl)-3-methyl-2 (2-(piperazine-1-yl) ethylamino)-6- (4-pyridyl)-4 (3H)-pyrimidones: be reflected at and carried out under 190 ℃ 30 minutes.
MS (m/z): 409.2 (M+H) +C 22H 25FN 6O theoretical value 408.5.
Figure C9718155801154
2-20 5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-2-(the 3-tetramethyleneimine- The 1-yl)-4 (3H)-pyrimidones third amino): be reflected at and carried out under 190 ℃ 2 hours.
MS (m/z): 408.2 (M+H) +C 23H 26FN 5O theoretical value 407.5.
2-21 2-(((S)-2-amino-3-hydrocinnamyl) amino)-5-(4-fluorophenyl)-3-first Base-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides: be reflected at and carried out under 190 ℃ 2.5 hours.
MS (m/z): 430.1 (M+H) +C 25H 24FN 5O theoretical value 429.5 (free alkali).
Figure C9718155801162
2-22 2-(((S)-2-N-ethyl-3-hydrocinnamyl) amino)-5-(4-fluorophenyl)-3- Methyl-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides: be reflected at and carried out under 190 ℃ 4 hours.
MS (m/z): 458.3 (M+H) +C 27H 28FN 5O theoretical value 457.6 (free alkali).
2-23 2-((2-amino-2-methyl-3-hydrocinnamyl) amino)-5-(4-fluorophenyl)-3 -methyl-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides: be reflected at and carried out under 190 ℃ 4 hours.
MS (m/z): 444.0 (M+H) +C 26H 26FN 5O theoretical value 443.5 (free alkali).
2-24 2-((2-aminomethyl-3-hydrocinnamyl) amino)-5-(4-fluorophenyl)-3-methyl -6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides: be reflected at and carried out under 190 ℃ 1 hour.
MS (m/z): 444.0 (M+H) +C 26H 26FN 4O theoretical value 443.5 (free alkali).
Figure C9718155801171
2-25 2-((3-amino-3-hydrocinnamyl) amino)-5-(4-fluorophenyl)-3-methyl-6 -(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides: be reflected at and carried out under 190 ℃ 2.5 hours.
MS (m/z): 430.0 (M+H) +C 25H 24FN 5O theoretical value 429.5 (free alkali).
2-26 5-(4-fluorophenyl)-3-methyl-2 (3 (2-tolyl) propyl group) amino)-6- (4-pyridyl)-4 (3H)-pyrimidones: be reflected at and carried out under 190 ℃ 4 hours.
MS (m/z): 429.5 (M+H) +C 26H 25FN 4O theoretical value 428.5.
2-27 5-(4-fluorophenyl)-3-methyl-2-(((R, S)-2-amino-3-(2-fluorobenzene Base) third amino)-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides: be reflected at and carried out under 190 ℃ 7 hours.MS(m/z)：448(M+H) +。
Figure C9718155801174
2-28 2-(((R)-2-amino-3-hydrocinnamyl) amino)-5-(4-fluorophenyl)-3-first Base-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides: be reflected at and carried out under 190 ℃ 2 hours.
MS (m/z): 430.2 (M+H) +C 25H 24FN 5O theoretical value 429.5 (free alkali).
2-29 2-(((S)-2-N-methyl-3-hydrocinnamyl) amino)-5-(4-fluorophenyl)-3- Methyl-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides: be reflected at and carried out under 190 ℃ 4 hours.
MS (m/z): 444.0 (M+H) +C 26H 26FN 5O theoretical value 443.5 (free alkali).
Figure C9718155801182
2-30 2-((2-thiophenyl ethyl) amino)-5-(4-fluorophenyl)-3-methyl-6-(4 -pyridyl)-4 (3H)-pyrimidone: be reflected at and carried out under 190 ℃ 16 hours.
MS(m/z)：433(M+H) +。
2-31 2-((2-hydroxyethyl) amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyrrole The pyridine base)-4 (3H)-pyrimidone: be reflected at and carried out under 190 ℃ 16 hours.
MS(m/z)：341(M+H) +。
2-32 2-((2,2-dimethyl-3-hydroxypropyl) amino)-5-(4-fluorophenyl)-3-first Base-6-(4-pyridyl)-4 (3H)-pyrimidones: be reflected at and carried out under 190 ℃ 16 hours.
MS(m/z)：383(M+H) +。
2-33 2-((2,2-dimethyl-3-thiophenyl propyl group) amino)-5-(4-fluorophenyl)-3- Methyl-6-(4-pyridyl)-4 (3H)-pyrimidones: under 0 ℃, to triphenyl phosphine (262mg, add in (2ml) tetrahydrofuran solution 0.29mmol) azoformic acid diisopropyl ester (DIAD) (56ml, 0.29mmol).In 0 ℃ after 30 minutes, be incorporated in 2-((2,2-dimethyl-3-hydroxypropyl) amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones in the tetrahydrofuran (THF) (2ml) (50mg, 0.14mmol) and 2,6-dichloro thiophenol.After 16 hours, will react under the nitrogen gas stream and concentrate, reaction mixture will directly be carried out flash chromatography method purifying (gradient elution, ethyl acetate: CHCl 31: 3,1: 2 then, 1: 1,2: 1,3: 1), obtain described title compound.MS(m/z)：544(M+H) +。
2-34 2-((3-amino-3-(2-fluorophenyl) propyl group) amino)-5-(4-fluorophenyl)-3 -methyl-6-(4-pyridyl)-4 (3H)-pyrimidones: according to described general method, by 5-(4-fluorophenyl)-3-methyl-2-methylthio group-6-(4-pyridyl)-4 (3H)-pyrimidones and 1-(2-fluorophenyl)-1, the preparation of 3-propylene diamine.Be reflected at and carried out under 190 ℃ 3 hours.
MS (m/z): 448.1 (M+H) +C 25H 23F 2N 5O theoretical value 447.5 (free alkali).
2-35 2-((3-amino-3-(2-aminomethyl phenyl) propyl group) amino)-5-(4-fluorophenyl)- 3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides: according to described general method, by 5-(4-fluorophenyl)-3-methyl-2-methylthio group-6-(4-pyridyl)-4 (3H)-pyrimidones and 1-(2-aminomethyl phenyl)-1, the preparation of 3-propylene diamine.Be reflected at and carried out under 185 ℃ 4 hours.
MS (m/z): 444.5 (M+H) +C 26H 26FN 5O theoretical value 443.5 (free alkali).
Figure C9718155801201
2-36 2-(((S)-3-amino-3-phenyl propyl) amino)-5-(4-fluorophenyl)-3- Methyl-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides: according to described general method, by 5-(4-fluorophenyl)-3-methyl-2-methylthio group-6-(4-pyridyl)-4 (3H)-pyrimidones and (S)-1-phenyl-1, the preparation of 3-propylene diamine.Be reflected at and carried out under 190 ℃ 2.5 hours.
MS (m/z): 430.2 (M+H) +C 25H 24FN 5O theoretical value 429.5 (free alkali).
2-37 2-(((R)-3-amino-3-phenyl propyl) amino)-5-(4-fluorophenyl)-3- Methyl-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides: according to described general method, by 5-(4-fluorophenyl)-3-methyl-2-methylthio group-6-(4-pyridyl)-4 (3H)-pyrimidones and (R)-1-phenyl-1, the preparation of 3-propylene diamine.Be reflected at and carried out under 190 ℃ 3.5 hours.
MS (m/z): 430.7 (M+H) +C 25H 24FN 5O theoretical value 429.5 (free alkali).
Figure C9718155801203
2-38 2-(((2R, 3R)-3-amino-2-methyl-3-phenyl propyl) amino)-5-(4- Fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides: according to described general method, by 5-(4-fluorophenyl)-3-methyl-2-methylthio group-6-(4-pyridyl)-4 (3H)-pyrimidones and (2R, 3R)-2-methyl-3-phenyl-1, the preparation of 3-propylene diamine.Be reflected at and carried out under 190 ℃ 3 hours.
MS (m/z): 444.5 (M+H) +C 26H 26FN 5O theoretical value 443.5 (free alkali).
2-39 2-(((2S, 3S)-3-amino-2-methyl-3-phenyl propyl) amino)-5-(4- Fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides: according to described general method, by 5-(4-fluorophenyl)-3-methyl-2-methylthio group-6-(4-pyridyl)-4 (3H)-pyrimidones and (2S, 3S)-2-methyl-3-phenyl-1, the preparation of 3-propylene diamine.Be reflected at and carried out under 190 ℃ 2 hours.
MS (m/z): 444.4 (M+H) +C 26H 26FN 5O theoretical value 443.5 (free alkali).
Figure C9718155801212
Similarly, can prepare isomer 2-(((2S by corresponding diamine, 3R)-and 3-amino-2-methyl-3-phenyl propyl) amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones and 2-(((2R, 3S)-3-amino-2-methyl-3-phenyl propyl) amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones.2-40 5-(4-fluorophenyl)-2-((3-hydroxyl-3-phenyl propyl) amino)-3-methyl -6-(4-pyridyl)-4 (3H)-pyrimidones: be reflected at and carried out under 190 ℃ 3 hours.
MS (m/z): 431.2 (M+H) +C 25H 23FN 4O 2Theoretical value 430.5.
Figure C9718155801213
Embodiment 3
The general method of the pyrimidinones that preparation N-replaces:
2-(2, the 6-dichloro benzyl)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)- 4 (3H)-pyrimidones: with methyl iodide (41ml, 0.65mmol) be added to 2-(2, the 6-dichloro benzyl)-5-(4-fluorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones under stirring (280mg, 0.61mmol) and salt of wormwood (181mg, 1.30mmol) in N, in the mixture in the dinethylformamide (2ml).Continue to stir 2 hours, evaporation subsequently, products therefrom is gone up through flash chromatography method purifying in silicagel column (hexane-acetone=3: 1), obtains the described title compound of white solid.
MS (m/z): 440.2 (M+H) +C 23H 16Cl 2FN 3O theoretical value: 440.3.
Embodiment 4
The general method of preparation 2-N and 2 '-2-amino-5-(4-fluorophenyl)-3-methyl-6-(4-(2-amino) pyridyl)-4 (3H)-pyrimidinones that N replaces:
Steps A .5-(4-fluorophenyl)-3-methyl-2-methylthio group-6-(4-(2-kharophen) Pyridyl)-4 (3H)-pyrimidone: in 23 ℃ in following 1 minute, to 5-(4-fluorophenyl)-6-(4-(2-kharophen) pyridyl)-2-thiouracil (600mg, add in DMF 1.68mmol) (35ml) solution powdery sodium hydride (60% oily dispersion liquid, 221mg, 5.56mmol).After 45 minutes, and the dropping methyl iodide (210ml, 3.37mmol).After 45 minutes, will react vacuum concentration (rotary evaporation that links to each other with high vacuum only, bath temperature is no more than 40 ℃), resistates carries out flash chromatography purifying (gradient elution, hexane: acetone 4: 1 immediately; 3: 1 then, 2: 1; 1: 1), obtain required product.
Step is (4-fluorophenyl)-3-methyl-2-((3-phenyl propyl) amino)-6-(4-B.5- (2-amino) pyridyl)-4 (3H)-pyrimidones: only with 5-(4-fluorophenyl)-3-methyl-2-methylthio group-6-(4-(2-kharophen) pyridyl)-4 (3H)-pyrimidones (50mg, 0.13mmol) and 3-phenyl-1-propylamine (88mg, mixture 0.65mmol) be warmed to 190 ℃ 17 hours.After being cooled to 23 ℃, reaction mixture is directly carried out flash chromatography purifying (gradient elution, 1%MeOH:CHCl 3, use 2% then; 3%; 4%; 5%), obtains required product: MS (m/z): 430 (M+H) +
Figure C9718155801231
R 31＝H
R 32＝H
Can prepare following compounds with aforesaid method and suitable amine:
4-1 ((3-phenyl propyl) amino)-(4-(2 for 6-for 5-(4-fluorophenyl)-3-methyl-2- -kharophen) (3H)-pyrimidone pyridyl)-4: under 23 ℃, (11mg adds (5 μ l, 0.064mmol) Acetyl Chloride 98Min.s in 600 μ l pyridine solutions 0.026mmol) to 5-(4-fluorophenyl)-3-methyl-2-((3-hydrocinnamyl) amino)-6-(4-(2-amino) pyridyl)-4 (3H)-pyrimidones.After 2 hours, reaction water (5 μ l) is ended and will be reacted under the nitrogen gas stream and concentrates.Reaction mixture is directly carried out flash chromatography purifying (gradient elution, 1%MeOH:CHCl 3, use 2% then; 3%), obtains described title compound: MS (m/z): 472 (M+H) +
Figure C9718155801232
R 32＝H
R 31＝Ac
4-2 5-(4-fluorophenyl)-3-methyl-2-((3-phenyl propyl) amino)-6-(4-(2-first Oxygen base kharophen)-4 (3H)-pyrimidones pyridyl): under 23 ℃, to 5-(4-fluorophenyl)-3-methyl-2-((3-hydrocinnamyl) amino)-6-(4-(2-amino) pyridyl)-4 (3H)-pyrimidone (11mg, 0.026mmol) 600 μ l pyridine solutions in add (5 μ l, 0.064mmol) methoxyacetyl chlorides.After 2 hours, reaction water (5 μ l) is ended and will be reacted under the nitrogen gas stream and concentrates.Reaction mixture is directly carried out flash chromatography purifying (gradient elution, 1%MeOH:CHCl 3, use 2% then; 3%), obtains described title compound: MS (m/z): 502 (M+H) +
Figure C9718155801241
R 32＝H
R 31＝C(O)CH 2OMe
4-3 ((3-phenyl propyl) amino)-(4-(2 for 6-for 5-(4-fluorophenyl)-3-methyl-2- -acetoxyl group kharophen)-4 (3H)-pyrimidones pyridyl): use the alpha-Acetoxyacetyl chloride replacing acetyl chloride, react according to the method described above, behind chromatogram purification, obtain described title compound: MS (m/z): 530 (M+H) +
R 32＝H
R 31＝C(O)CH 2OAc
4-4 ((3-phenyl propyl) amino)-(4-(2 for 6-for 5-(4-fluorophenyl)-3-methyl-2- -glycoloyl amino)-4 (3H)-pyrimidones pyridyl): under 23 ℃, to 5-(4-fluorophenyl)-3-methyl-2-((3-hydrocinnamyl) amino)-6-(4-(2-acetoxyl group kharophen) pyridyl)-4 (3H)-pyrimidone (2mg, 0.003mmol) 900 μ l methyl alcohol: add in the 100 μ l aqueous solution solid carbonic acid potassium (4mg, 0.032mmol).After 3 hours, react under the nitrogen gas stream and to concentrate, with reaction mixture with chloroform (20ml) dilution, dry (Na 2SO 4) and concentrate, obtain described title compound: MS (m/z): 488 (M+H) +
R 32＝H
R 31＝C(O)CH 2OH
4-5 ((3-phenyl propyl) amino)-(4-(2 for 6-for 5-(4-fluorophenyl)-3-methyl-2- -methanesulfonamido) (3H)-pyrimidone pyridyl))-4: under 23 ℃, to 5-(4-fluorophenyl)-3-methyl-2-((3-hydrocinnamyl) amino)-6-(4-(2-amino) pyridyl)-4 (3H)-pyrimidones (11mg, add in 600 μ l pyridine solutions 0.026mmol) methylsulfonyl chloride (4 μ l, 0.051mmol).After 2 hours, reaction water (5 μ l) is ended and will be reacted under the nitrogen gas stream and concentrates.Reaction mixture is directly carried out flash chromatography purifying (gradient elution, 1%MeOH:CHCl 3, use 2% then), obtain described title compound: MS (m/z): 508 (M+H) +
R 32＝H
R 31＝SO 2Me
4-6 ((3-phenyl propyl) amino)-(4-(2 for 6-for 5-(4-fluorophenyl)-3-methyl-2- -benzyl amino)-4 (3H)-pyrimidones pyridyl): under 23 ℃, to 5-(4-fluorophenyl)-3-methyl-2-((3-hydrocinnamyl) amino)-6-(4-(2-amino) pyridyl)-4 (3H)-pyrimidone (11mg, 0.026mmol) 600 μ l 1, add phenyl aldehyde (8.9mg in the 2-dichloroethane solution, 0.084mmol) and and sodium triacetoxy borohydride (14.8mg, 0.070mmol).After 16 hours, reaction water (15 μ l) is ended and will be reacted under the nitrogen gas stream and concentrates.Reaction mixture is directly carried out flash chromatography purifying (gradient elution, 1%MeOH:CHCl 3, use 2% then; 3%; 4%; 5%), obtains described title compound: MS (m/z): 458 (M+H) +
Figure C9718155801252
R 32＝H
R 31＝CH 2Ph
4-7 ((3-phenyl propyl) amino)-(4-(2 for 6-for 5-(4-fluorophenyl)-3-methyl-2- -(2-p-methoxy-phenyl) methylamino-)-4 (3H)-pyrimidones pyridyl): replace phenyl aldehyde with the 2-methoxybenzaldehyde, react according to the method described above, behind chromatogram purification, obtain described title compound: MS (m/z): 550 (M+H) +
Figure C9718155801261
R 32＝H
Figure C9718155801262
4-8 ((3-phenyl propyl) amino)-(4-(2 for 6-for 5-(4-fluorophenyl)-3-methyl-2- -ethylamino) (3H)-pyrimidone pyridyl)-4: replace phenyl aldehyde with acetaldehyde, react according to the method described above, behind chromatogram purification, obtain described title compound: MS (m/z): 458 (M+H) +
R 32＝H
R 31＝Et
4-9 ((3-phenyl propyl) amino)-(4-(2 for 6-for 5-(4-fluorophenyl)-3-methyl-2- -(two-(3-methyl butyl) amino) pyridyl))-4 (3H)-pyrimidones: replace phenyl aldehyde with pivalyl aldehyde, react according to the method described above, behind chromatogram purification, obtain described title compound: MS (m/z): 570 (M+H) +
R 32＝CH 2CH 2CH(CH 3) 2
R 31＝CH 2CH 2CH(CH 3) 2
4-10 5-(4-fluorophenyl)-3-methyl-2-((3-phenyl propyl) amino)-6-(4- (2-diethylin) pyridyl)-4 (3H)-pyrimidones: replace phenyl aldehyde with acetaldehyde, react according to the method described above, behind chromatogram purification, obtain described title compound:
MS(m/z)：486(M+H) +。
Figure C9718155801271
R 32＝Et
R 31＝Et
4-11 5-(4-fluorophenyl)-3-methyl-2-((3-phenyl propyl) amino)-6-(4- (2-phenylamino carbonyl-amino) pyridyl))-4 (3H)-pyrimidones: under 23 ℃, to 5-(4-fluorophenyl)-3-methyl-2-((3-hydrocinnamyl) amino)-6-(4-(2-amino) pyridyl)-4 (3H)-pyrimidone (11mg, 0.026mmol) 600 μ l, two  alkane solution in add phenylcarbimide (3.3ml, 0.03mmol).After 16 hours, reaction water (15 μ l) is ended and will be reacted under the nitrogen gas stream and concentrates.Reaction mixture is directly carried out flash chromatography purifying (gradient elution, 1%MeOH:CHCl 3, use 2% then; 3%; 4%; 5%), obtains described title compound: MS (m/z): 549 (M+H) +
Figure C9718155801272
R 32＝H
R 31＝NH(CO)NHPh
4-12 5-(4-fluorophenyl)-3-methyl-2-((3-phenyl propyl) amino)-6-(4- (2-amino-carbonyl-amino) pyridyl))-4 (3H)-pyrimidones: replace phenylcarbimide with methyl isocyanate, react according to the method described above, behind chromatogram purification, obtain described title compound: MS (m/z): 487 (M+H) +
R 32＝H
R 31＝NH(CO)NHMe
4-13 5-(4-fluorophenyl)-3-methyl-2-((3-phenyl propyl) amino)-6-(4- (2-(2 '-amino-1 '-oxo-ethylamino) pyridyl))-4 (3H)-pyrimidones: the general method of mixed acid anhydride coupling-(32ml is added drop-wise to 0.24mmol)-20-30 ℃ N-a-t-Boc-glycine that (5.6mg is 0.05mmol) and in pyridine (0.6ml) solution with the chloroformic acid isobutyl.In-20-30 ℃ after following 20 minutes, once adding 5-(4-fluorophenyl)-3-methyl-2-((3-hydrocinnamyl)-amino)-6-(4-(2-amino)) pyridyl) (11mg, 0.026mmol) and pyridine (0.6ml), the order reaction is warmed to 23 ℃ to-4 (3H)-pyrimidones.In 23 ℃ after following 16 hours, will react in the impouring saturated bicarbonate solution (20ml), (2 * 50ml) extractions are with salt solution (1 * 50ml) washing and dry (Na with ethyl acetate 2SO 4).Reaction mixture is directly carried out flash chromatography purifying (gradient elution, 1%MeOH:CHCl 3, use 2% then; 3%; 4%; 5%), obtains the described title compound of N-Boc protection.Use 50% trifluoroacetic acid: chloroform (1ml) was handled after 16 hours, obtained the crude product of described title compound.After concentrating under the nitrogen gas stream, reaction mixture is directly carried out flash chromatography purifying (gradient elution, 1%MeOH:CHCl 3, use 2% then; 3%; 4%; 5%), obtains described title compound: MS (m/z): 487 (M+H) +
R 32＝H
R 31＝NH(CO)CH 2NH 2
4-14 5-(4-fluorophenyl)-3-methyl-2-((3-phenyl propyl) amino)-6-(4- (2-(4 '-amino-1 '-oxo-Ding amino) pyridyl))-4 (3H)-pyrimidones: replace N-α-t-Boc-glycine with the N-t-Boc-g-aminobutyric acid, react according to the method described above, behind deprotection as mentioned above, obtain described title compound: MS (m/z): 515 (M+H) +
Figure C9718155801282
R 32＝H
R 31＝NH(CO)CH 2CH 2CH 2NH 2
4-15 5-(4-fluorophenyl)-3-methyl-2-((3-phenyl propyl) amino)-6-(4- (2-(3 '-amino-1 ' oxo-third amino) pyridyl))-4 (3H)-pyrimidones: replace N-α-t-Boc-glycine with the N-t-Boc-Beta-alanine, react according to the method described above, behind deprotection as mentioned above, obtain described title compound:
MS(m/z)：501(M+H) +.
Figure C9718155801291
R 32＝H
R 31＝NH(CO)CH 2CH 2NH 2
4-16 2-(((S)-2-amino-3-phenyl propyl) amino)-5-(4-fluorophenyl)-3 -methyl-6-(4-(2-aminopyridine base))-4 (3H)-pyrimidone hydrochlorides: with (S)-1,2-diamino-3-phenyl-propane replaces 3-phenyl-1-propylamine, reacts 6 hours down in 190 ℃ according to the method described above: MS (m/z): 445 (M+H) +
Figure C9718155801292
R 31-＝H
R 32＝H
4-17 2-(((S)-2-dimethylamino-3-phenyl propyl) amino)-5-(4-fluorophenyl) -3-methyl-6-(4-(2-aminopyridine base))-4 (3H)-pyrimidone hydrochlorides: replace 3-phenyl-1-propylamine with 1-amino-2 (S)-dimethylamino-3-phenyl-propane, reacted 6 hours down in 190 ℃ according to the method described above: MS (m/z): 473 (M+H) +
Figure C9718155801293
R 32＝H
R 31＝H
4-18 2-(((S)-2-amino-3-phenyl propyl) amino)-5-(4-fluorophenyl)-3 -methyl-6-(4-(2-kharophen pyridyl))-4 (3H)-pyrimidone hydrochlorides: replace 5-(4-fluorophenyl)-3-methyl-2-((3-phenyl propyl) amino)-6-(4-(2-aminopyridine base))-4 (3H)-pyrimidones with 2-(((S)-2-dimethylamino-3-phenyl propyl) amino)-5-(4-fluorophenyl)-3-methyl-6-(4-(2-aminopyridine base))-4 (3H)-pyrimidone hydrochlorides, react according to the described method of embodiment XX, obtain described title compound: MS (m/z): 515 (M+H) +
Figure C9718155801301
R 32＝H
R 31＝Ac
4-19 2-(((R, S)-3-amino-3-phenyl propyl) amino)-5-(4-fluorophenyl)-3 -methyl-6-(4-(2-aminopyridine base))-4 (3H)-pyrimidone hydrochlorides: with (3R, S)-1,3-diamino-3-phenyl-propane replaces 3-phenyl-1-propylamine, reacts 12 hours down in 190 ℃ according to the method described above: MS (m/z): 445 (M+H) +
R 32＝H
R 31＝H
4-20 5-(4-fluorophenyl)-3-methyl-2-(phenyl methyl amino)-6-(4-(2-(3 ' -phenyl-1 '-oxo-third amino) pyridyl))-(4-(2-amino) pyridyl))-4-(3H) -pyrimidone: only with 5-(4-fluorophenyl)-3-methyl-2-methylthio group-6-(4-(2-kharophen) pyridyl))-4 (3H)-pyrimidones (260mg, 0.13mmol) and benzylamine (88mg, mixture 2.71mmol) are warmed to 190 ℃ and kept 17 hours.After being cooled to 23 ℃, reaction mixture is directly carried out flash chromatography purifying (gradient elution, 1%MeOH:CHCl 3, use 2% then; 3%; 4%; 5%), obtain 5-(4-fluorophenyl)-3-methyl-2-(phenmethyl amino)-6-(4-(2-amino) pyridyl))-4 (3H)-pyrimidones.With the hydrocinnamoyl chloride replacing acetyl chloride and with 5-(4-fluorophenyl)-3-methyl-2-(phenmethyl amino)-6-(4-(2-amino) pyridyl))-4 (3H)-pyrimidones replace 5-(4-fluorophenyl)-3-methyl-2-((3-hydrocinnamyl) amino)-6-(4-(2-amino) pyridyl))-4 (3H)-pyrimidones, according to the method described above with 5-(4-fluorophenyl)-3-methyl-2-(phenmethyl amino) base-6-(4-(2-amino) pyridyl))-4 (3H)-pyrimidones transform, behind the chromatogram purification, obtain described title compound: MS (m/z): 534 (M+H) +
R 1＝NHCH 2Ph
R 32＝H
R 31＝(CO)CH 2CH 2Ph。
Embodiment 5
The general method of preparation 5-(4-fluorophenyl)-6-(4-pyridyl)-2-alkylthio-4 (3H)-pyrimidinones
Steps A .2-(4-fluorophenyl)-3 oxos-3-(4-pyridyl) ethyl propionate:
(according to: Legrand and Lozac ' h, Bull.Soc.Chim.Fr., 79-81 (1955)).
Under the argon atmospher, with 4-fluorophenyl ethyl acetate (13g, 71.35mmol), iso ethyl nicotinate (10.7ml, 71.4mmol) and the sodium particle (1.64g, mixture 71.34mmol) are in 90-95 ℃ of down heating, and mixture begins to reflux and become solid gradually.2.5 after hour, cooling neutralizes mixture down with acetic acid,diluted, use dichloromethane extraction subsequently.Organic solution washes with water, dry and evaporation.On silicagel column, carry out flash chromatography (hexane-acetone=4: 1,3: 1,2: 1), obtain the described title compound of oily.MS (m/z): 287.8 (M+H) +C 16H 14FNO 3Theoretical value 287.3 1H-NMR (CDCl 3), (ketone: enol=1: 0.33): d13.50 (s, 0.3H, OH-E), and 8.81 (m, 2H, pyridine .-K), 8.48 (m, 0.66H, pyridine .-E), 7.72 (m, 2H, pyridine .-K), 7.38 (m, 2H, PhF-K), 7.14-7.04 (m, 2H, PhF-K;～0.65H, pyridine .-E;-0.65H, PhF-E), 6.96 (t, 0.64H, PhF-E), 5.51 (s, 1H, CH-K), 4.23-4.2-(m, CH 2-K, E), 1.26 (t, CH 3-K, E).
Step is (4-fluorophenyl)-6-(4-pyridyl)-2-thiouracil B.5-
Figure C9718155801312
Under the argon atmospher, with stir 2-(4-fluorophenyl)-3-oxo-3-(4-pyridyl) ethyl propionate down (22.3g, 77.6mmol) and thiocarbamide (5.9g, mixture 77.6mmol) reacted 40 minutes in 190 ℃ times.Make reaction mixture be cooled to room temperature, be dissolved in acetone and, obtain described title compound sedimentation and filtration.
MS (m/z): 300.2 (M+H) +C 15H 10FN 3OS theoretical value 299.3 1H-NMR (DMSO-d 6): d12.74,12.65 (2s, 2H), 8.51 (m, 2H, pyridines .), 7.26 (m, 2H, pyridines .), 7.09 and 7.03 (2m, each 2H, PhF).
In addition, under agitation condition fully, with 2-(4-fluorophenyl)-3-oxo-3-(4-pyridyl) ethyl propionate (2.87g, 10mmol) and thiocarbamide (2.28g, 30mmol) be suspended in the p-Xylol (50ml), in described mixture, add pyridine  tosilate (100mg) and with Dean and Stark apparatus under the condition that removes water (0.2ml) continuously backflow 12-16 hour.With the reaction mixture cooling, the chocolate solid is filtered with B.The solid suspension of collecting is also filtered in acetone (25ml).Product with washing with acetone still contains the trace thiocarbamide, and its hot water (20-30ml) development is removed.Product is filtered and dry air.
Step C. general method:
With aralkyl bromide (0.36mmol) be added drop-wise to 5-(4-fluorophenyl)-6-(4-pyridyl)-2-thiouracil under stirring (100mg, 0.33mmol) and salt of wormwood (46mg is 0.33mmol) at N, in the mixture in the dinethylformamide (4.6ml).Continue to stir 3 hours, subsequently evaporation.On silicagel column, carry out flash chromatography (hexane-acetone=3: 1,2: 1,1: 1) and in hot methanol recrystallization, obtain the purpose compound.
According to the method described above, can obtain following compounds: 5-1 with suitable aralkyl bromide 5-(4-fluorophenyl)-2-(2-styroyl) sulfenyl-6-(4-pyridyl)-4 (3H) -pyrimidone: MS (m/z): 404.2 (M+H) +
C 23H 18FN 3OS theoretical value 403.4. 1H-NMR (DMSO-d 6): d13.08 (bs, 0.7H), 8.49 (m, 2H, pyridines .), 7.30-7.06 (m, 11H, pyridine., Ph, PbF), 3.41 (dd, 2H, CH 2S), 3.00 (t, 2H, CH 2).
5-2 5-(4-fluorophenyl)-2-(3-hydrocinnamyl) sulfenyl-6-(4-pyridyl)-4 (3H) -pyrimidone: MS (m/z): 418.0 (M+H) +C 24H 20FN 3OS theoretical value 417.5. 1H-NMR (DMSO-d 6): d13.10 (bs, 0.7H), 8.47 (m, 2H, pyridines .), 7.29-7.06 (m, 11H, pyridine., Ph, PhF), 3.18 (t, 2H, CH 2S), 2.71 (t, 2H, CH 2Ph), 2.03 (m, 2H, CH 2).
Figure C9718155801331
5-3 5-(4-fluorophenyl)-2-(2-benzene oxygen ethyl) sulfenyl-6-(4-pyridyl)- 4 (3H)-pyrimidones: MS (m/z): 420.0 (M+H) +C 23H 18FN 3O 2S theoretical value 419.5. 1H-NMR (DMSO-d 6): d13.20 (bs, 0.7H), 8.46 (m, 2H, pyridines .), 7.24-7.07 (m, 8H, pyridine, PhF, Ph), 6.95 (d, 2H, Ph), 6.92 (t, overlapping, 1H, Ph), 4.30 (t, 2H, CH 2O), 3.58 (t, 2H, CH 2S).
Figure C9718155801332
5-4 5-(4-fluorophenyl)-2-(2-phenylamino ethyl) sulfenyl-6-(4-pyridyl)- 4 (3H)-pyrimidones: MS (m/z): 419.0 (M+H) +C 23H 19FN 4OS theoretical value 418.5. 1H-NMR (DMSO-d 6): d13.20 (bs, 0.8H), 8.48,7.22 (2m, each 2H, pyridines .), 7.16,7.10 (2m, each 2H, PhF), 6.89 (t, 2H, Ph), 6.54 (d, 2H, Ph), 6.48 (t, 1H, Ph), 5.90 (bs, 0.6H, NH), 3.43-3.25 (m, 2CH 2).
Figure C9718155801333
Embodiment 6
The general method of 2-amino-5-(4-fluorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidinones that preparation 2-N replaces:
Steps A .5-(4-fluorophenyl)-2-methylthio group-6-(4-pyridyl)-4 (3H)-pyrimidines Ketone:
Figure C9718155801341
Under the ice bath temperature, with methyl iodide (90ml, 1.44mmol) be added drop-wise to 5-(4-fluorophenyl)-6-(4-pyridyl)-2-thiouracil under stirring (430mg, 1.44mmol) and salt of wormwood (198mg, 1.43mmol) in N, in the mixture in the dinethylformamide (13ml).After 40 minutes, with its evaporation, crude product through flash chromatography method purifying (hexane-acetone=2: 1,1: 1,1: 2), obtains the described title compound of solid state on silicagel column.
MS (m/z): 314.2 (M+H) +C 16H 12FN 3OS theoretical value 313.3. 1H-NMR (DMSO-d 6): d13.10 (bs), 8.47,7.22 (2m, each 2H, pyridines .), 7.16,7.10 (2m, each 2H, PhF), 2.56 (s, 3H, CH 3).
Step B. general method:
Figure C9718155801342
(100mg is 0.32mmol) with amine HNR with 5-(4-fluorophenyl)-2-methylthio group-6-(4-pyridyl)-4 (3H)-pyrimidones 5R 21Mixture (1mmol) heated 2 hours down in 180 ℃.Products therefrom through flash chromatography method purifying (hexane-acetone or methyl alcohol-methylene dichloride or methylene chloride-methanol-dense ammonium hydroxide), obtains described purpose compound on silicagel column.
Can prepare following compounds with above-mentioned general method and suitable amine:
6-1 2-(2-(2-chloro-phenyl-) ethyl-amino)-5-(4-fluorophenyl)-6-(4-pyrrole The pyridine base)-4 (3H)-pyrimidone:
MS (m/z): 421.2 (M+H) +C 23H 18ClFN 4O theoretical value 420.9. 1H NMR (DMSO-d 6): d11.24 (bs), 8.44,7.16 (2m, each 2H, pyridines .), 7.43,7.38 (2dd, each 1H, PhCl), and 7.30,7.26  2dt, each 1H, PhCl), 7.10-7.00 (m, 2H, PhF), 6.74 (bs, 1H, NH); 3.60 (q, 2H, CH 2N), 3.03 (t, 2H, CH 2).
6-2 5-(4-fluorophenyl)-2-((3-phenyl propyl)-amino)-6-(4-pyridyl)- 4 (3H)-pyrimidones: MS (m/z): 401.2 (M+H) +C 24H 21FN 4O theoretical value 400.5. 1H-NMR (DMSO-d 6): d11.16 (bs), 8.44,7.14 (2m, each 2H, pyridines .), 7.32-7.01 (m, 9H, Ph, PhF), 6.78 (bs, NH), 3.36 (q, 2H, CH 2N), 2.67 (t, 2H, CH 2Ph), 1.89 (m, 2H, CH 2).
Figure C9718155801352
6-3 5-(4-fluorophenyl)-2-((1-methyl-3-phenyl propyl)-amino)-6-(4 -pyridyl)-4 (3H)-pyrimidone: MS (m/z): 415.0
(M+H) +C 25H 23FN 4O theoretical value 414.5. 1H-NMR (CDCl 3): d8.48 (m, 2H, pyridine .), 7.28-7.08 (m, 9H, pyridine, Ph, PhF), 6.94 (m, 2H, PhF), 5.67 (bs, 1H, NH), 4.08 (m, 1H, CHCH 3), 2.61 (t, 2H, CH 2Ph), 1.67 (m, 2H, CH 2), 1.08 (d, 3H, CH 3).
6-4 5-(4-fluorophenyl)-2-((3-imidazolyl propyl group)-amino)-6-(4-pyridyl) -4 (3H)-pyrimidones: MS (m/z): 391.0
(M+H) +C 21H 19FN 6O theoretical value 390.4. 1H-NMR (DMSO-d 6): d11.24 (bs), 8.42,7.12 (2m, each 2H, pyridines .), 7.62,7.18 (2s, each 1H, imidazoles .), 7.08-6.99 (m, 4H, PhF), 6.88 (s, 1H, imidazoles .), 4.02 (t, 2H, CH 2N), 3.28 (are covered CH by the water signal 2NH), 2.00 (m, 2H, CH 2).
Figure C9718155801361
6-5 2-(((S)-2-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-6 -(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides:
MS (m/z): 416.1 (M+H) +C 26H 22FN 5O theoretical value 415.5.
Figure C9718155801362
Embodiment 7
5-(4-fluorophenyl)-2-diazanyl-6-(4-pyridyl)-4 (3H)-pyrimidones
With 5-(4-fluorophenyl)-6-(4-pyridyl)-2-thiouracil (500mg, 1.66mmol) and hydrazine hydrate (800ml ,～14mmol) mixture is in 120 ℃ of heating 60 minutes down.With its evaporation, reaction product obtains described title compound in recrystallization from hot methanol.
MS (m/z): 298.0 (M+H) +C 15H 12FN 5O theoretical value 297.3. 1H-NMR (DMSO-d 6): d8.41,7.12 (2m, each 2H, pyridines), 7.05,7.00 (2m, each 2H, PhF).
R 1＝NH-NH 2
Embodiment 8
Preparation 5-aryl-2, the general method of 6-bipyridyl-3 (H)-pyrimidinones
According to the described document (article of Kabbe mentioned above; German Patent 1271116 (1968)), this compounds of preparation as described below:
Phenylacetic acid ethyl ester (3.13mmol), cyanopyridine (6.24mmol) and the mixture of sodium methylate (3.5mmol) in propyl carbinol (1.2ml) under stirring were heated 2 hours down in 110 ℃.Reaction mixture is concentrated and water-soluble (4ml), add saturated aqueous ammonium chloride (2ml) subsequently.With sedimentation and filtration and in hot methanol recrystallization.
According to this method, can prepare following compounds with suitable raw material:
8-1 5-phenyl-2,6-two-(4-pyridyl)-4 (3H)-pyrimidones:
MS (m/z): 327.2 (M+H) +C 20H 14N 4O theoretical value 326.4. 1H-NMR (DMSO-d 6): d8.78,8.47,8.13 (3m, each 2H, pyridines), 7.40-7.14 (m, 7H, Ph, pyridine).
8-2 5-(4-fluorophenyl)-2,6-two-(4-pyridyl)-4 (3H)-pyrimidones:
MS (m/z): 345.2 (M+H) +C 20H 13FN 4O theoretical value 344.4. 1H-NMR (DMSO-d 6): d8.80,8.49,8.13 (3m, each 2H, pyridines), 7.40-7.08 (m, 6H, PhF, pyridine).
8-3 2, 5,6-three-(4-pyridyl)-4 (3H)-pyrimidones: according to described general method, in the presence of sodium methylate, by with 4-pyridyl ethyl acetate and 4-cyanopyridine prepared in reaction.
MS (m/z): 328.2 (M+H) +C 19H 13N 5O theoretical value 327.4. 1H-NMR (DMSO-d 6): d8.65,8.45,8.35,8.18,7.25,7.13 (6m, each 2H, pyridines).8-4 5-(4-fluorophenyl)-2,6-two-(3-pyridyl)-4 (3H)-pyrimidones:
MS (m/z): 345.2 (M+H) +C 20H 13FN 4O theoretical value: 344.4. 1H-NMR (DMSO-d 6): d9.34,8.77,8.54,8.48,7.78,7.60,7.34 (7m, 3 * 1H, 2H, 3 * 1H, pyridines), 7.26,7.15 (2m, each 2H, PhF).
Embodiment 9
3-(3-trimethyl silyl-2-propynyl)-5-(4-fluorophenyl)-2-methylthio group-6-(4-pyridyl)-4 (3H)-pyrimidones
According to the same procedure of preparation 3-ethyl-5-(4-fluorophenyl)-2-methylthio group-6-(4-pyridyl)-4 (3H)-pyrimidones, replace monobromethane to react with 3-bromo-1-(trimethyl silyl)-1-propine, prepare described title compound.
Embodiment 10
6-(4-fluorophenyl)-2-methyl isophthalic acid-(3-hydrocinnamyl)-7-pyridin-4-yl-1H-imidazo (1,2-a) pyrimidine-5-ketone
With 3-(3-trimethyl silyl-2-propynyl)-5-(4-fluorophenyl)-2-methylthio group-6-(4-pyridyl)-4 (3H)-pyrimidone (50mg, 0.12mmol) and 3-phenyl-1-propylamine (67mg, mixture 0.47mmol) are warmed to 190 ℃ and kept 17 hours.After being cooled to 23 ℃, reaction mixture is directly carried out flash chromatography purifying (gradient elution, 1MeOH:CHCl 3, use 2% then; 3%), obtain required product: MS (m/z) 439 (M+H)+.
Embodiment 11
6-(4-fluorophenyl)-2-methyl isophthalic acid-benzyl-7-pyridin-4-yl-1H-imidazo (1,2-a) pyrimidine-5-ketone
Figure C9718155801391
(1, the 2-a) same procedure of pyrimidine-5-ketone replaces 3-phenyl-1-propylamine to react with benzylamine, can prepare described title compound according to preparation 6-(4-fluorophenyl)-2-methyl isophthalic acid-(3-hydrocinnamyl)-7-pyridin-4-yl-1H-imidazo; MS (m/z): 411 (M+H) +
Embodiment 12
The general method of 3-phenyl-4-(4-pyridyl)-2 (1H)-pyridones that preparation 6-replaces Steps A. the general side of preparation 1-aryl-3-(4-pyridyl)-2-propylene-1-ketone Method:
Under the ice bath temperature, (1.6ml 16.6mmol) mixes, and adds methyl phenyl ketone (12.0mmol) then and mixture is descended heating 1.5 hours in 130 ℃ under room temperature with piperidines (206ml), acetate (206ml) and 4-pyridylaldehyde.Reaction mixture dilutes with methylene dichloride, with sodium bicarbonate aqueous solution and water washing, and subsequent drying and evaporation.Crude product on silica gel through column chromatography purifying (hexane-acetone=3: 1).
According to this method, can prepare following compounds with suitable acetophenone derivs:
1-phenyl-3-(4-pyridyl)-2-propylene-1-ketone: MS (m/z): 210.1 (M+H) +C 14H 11NO theoretical value 209.3.
1-(4-tolyl)-3-(4-pyridyl)-2-propylene-1-ketone: MS (m/z): 224.2 (M+H) +C 15H 13NO theoretical value 223.3.
1-(4-ethylphenyl)-3-(4-pyridyl)-2-propylene-1-ketone: MS (m/z): 237.8 (M+H) +C 16H 15NO theoretical value 237.3.
1-(4-isopropyl phenyl)-3-(4-pyridyl)-2-propylene-1-ketone: MS (m/z): 252.0 (M+H) +C 17H 17NO theoretical value 251.3.
1-(2-tolyl)-3-(4-pyridyl)-2-propylene-1-ketone: MS (m/z): 223.8 (M+H) +C 15H 13The NO theoretical value.223.3。
1-(2, the 4-xylyl)-3-(4-pyridyl)-2-propylene-1-ketone: MS (m/z): 238.0 (M+H) +C 16H 15The NO theoretical value.237.3。
1-(2-p-methoxy-phenyl)-3-(4-pyridyl)-2-propylene-1-ketone: MS (m/z): 240.0 (M+H) +C 15H 13NO 2Theoretical value 239.3.
1-(4-chloro-phenyl-)-3-(4-pyridyl)-2-propylene-1-ketone: MS (m/z): 244.0 (M+H) +C 14H 10ClNO theoretical value 243.7.
1-(4-cyano-phenyl)-3-(4-pyridyl)-2-propylene-1-ketone: (MS (m/z): 235.1 (M+H) +C 15H 10N 2O theoretical value 234.3.
1-(a-naphthyl)-3-(4-pyridyl)-2-propylene-1-ketone: MS (m/z): 260.0 (M+H) +C 18H 13NO theoretical value 259.3.
1,3-two-(4-pyridyl)-2-propylene-1-ketone: MS (m/z): 211.0 (M+H) +C 13H 10N 2O theoretical value 210.2.
3-(4-pyridyl-1-(2-thienyl)-2-propylene-1-ketone: MS (m/z): 216.0 (M+H) +C 12H 9NOS theoretical value 215.3.
1-(2-furyl-3-(4-pyridyl)-2-propylene-1-ketone: MS (m/z): 200.0 (M+H) +C 12H 9NO 2Theoretical value 199.2.
1-cyclohexyl-3-(4-pyridyl)-2-propylene-1-ketone prepares according to identical method with acetyl cyclohexane: MS (m/z): 216.2 (M+H) +C 14H 17NO theoretical value 215.3.
The 1-tertiary butyl-3-(4-pyridyl)-2-propylene-1-ketone: with 3,3-dimethyl-2-butanone (2.5ml, 20.0mmol), the 4-pyridylaldehyde (2.15ml, 22.3mmol), the mixture of ethanol (7.6ml) and 4.5% aqueous sodium hydroxide solution (4.6ml) kept under room temperature 12 hours.It is diluted with methylene dichloride, with aqueous hydrochloric acid and water washing, dry and evaporation.Carry out column chromatography purifying (hexane-ethyl acetate=3: 1) subsequently, obtain described title compound MS (m/z): 190.4 (M+H) +C 12H 15NO theoretical value 189.3.
Step B. prepares 3-phenyl-4-(4-pyridyl)-2 (1H)-pyridinones that 6-replaces The general method of compound
Figure C9718155801411
(40mg, (880mg is 6.51mmol) and in the mixture of ethanol (5ml) 1.74mmol) to be dissolved in phenyl-acetamides under stirring with sodium.If solvability allows, 3-(4-the pyridyl)-2-propylene-1-ketone (5.4mmol) that 1-can be replaced is added drop-wise in the phenyl-acetamides solution under refluxing with the form of ethanolic soln or under room temperature it is added with solid form.Mixture was kept 1.5 hours down in refluxing, make it reach room temperature then.Add 2N hydrochloric acid, make pH reach 5, add several ml waters subsequently.To filter by the product that crystallization in this mixture goes out, use ethanol, water, washing with alcohol and recrystallization in methyl alcohol successively.If after adding hydrochloric acid, described product is by crystallization not in the reaction mixture, and then with the mixture evaporation, resistates is dissolved in methylene dichloride.Organic solution washes with water, dry and evaporation.Products therefrom crystallization and in recrystallizing methanol in hot acetone.
With 2-(4-pyridyl)-2-propylene-1-ketone derivatives, can prepare following compounds according to the described method of embodiment 12.a:
12-1 3,6-phenylbenzene-4-(4-pyridyl)-2 (1H)-pyridones: MS (m/z): 325.4 (M+H) +C 22H 26N 2O theoretical value 324.4. 1H-NMR (DMSO-d6): d8.63 (m, 2H, pyridine .), 7.86 (m, 2H), 7.58-7.45,7.29-7.08 (2m).
Figure C9718155801412
12-2 6-(4-aminomethyl phenyl)-3-phenyl-4-(4-pyridyl)-2 (1H)-pyridines Ketone: MS (m/z): 339.2 (M+H) +C 23H 18N 2O theoretical value 338.4. 1H-NMR (DMSO-d 6): d8.44 (m, 2H, pyridine), 7.79 (d, 2H), 7.32 (d, 2H), 7.26-7.01 (m, 7H, Ph, pyridine .), 6.67 (bs, 1H).
Figure C9718155801421
12-3 6-(4-ethylphenyl)-3-phenyl-4-(4-pyridyl)-2 (1H)-pyridines Ketone: MS (m/z): 353.0 (M+H) +C 24H 20N 2O theoretical value 352.4. 1H-NMR (DMSO-d 6): d8.42 (m, 2H, pyridine .), 7.79 (d, 2H), 7.33 (d, 2H)-, 7.24-7.06 (m, 7H, Ph, pyridine .), 6.65 (bs, 1H, CH=), 2.66 (q, 2H, CH 2), 1.21 (t, 3H, CH 3).
12-4 6-(4-isopropyl phenyl)-3-phenyl-4-(4-pyridyl)-2 (1H)-pyridines Ketone: MS (m/z): 367.0 (M+H) +C 25H 22N 2O theoretical value 366.5. 1H-NMR (DMSO-d 6): d8.45 (m, 2H, pyridine .), 7.82 (d, 2H), 7.39 (d, 2H), 7.28-7.10 (m, 7H, Ph, pyridine .), 6.67 (bs, 1H, CH=), 2.98 (m, 1H, CH (CH 3) 2), 1.27,1.25 (2s, each 3H, 2CH 3).
Figure C9718155801423
12-5 6-(2-aminomethyl phenyl)-3-phenyl-4-(4-pyridyl)-2 (1H)-pyridines Ketone: MS (m/z): 339.2 (M+H) +C 23H 18N 2O theoretical value 338.4. 1H-NMR (DMSO-d 6): d8.40 (m, 2H, pyridine .), 7.45-7.09 (m, 11H, Ph, pyridine .), 6.21 (bs, 1H, CH=), 2.39 (s, 3H, CH 3).
Figure C9718155801424
12-6 6-(2, the 4-3,5-dimethylphenyl)-3-phenyl-4-(4-pyridyl)-2 (1H)-pyrroles Pyridine ketone: MS (m/z): 353.0 (M+H) +C 24H 20N 2O theoretical value 352.4. 1H-NMR (DMSO-d 6): d8.42 (m, 2H, pyridine .), 7.29 (d, 1H), 7.23-7.06 (m, 9H, Ph, pyridine .), 6.17 (bs, 1H, CH=), 2.34,2.31 (2s, each 3H, 2CH 3).
Figure C9718155801431
12-7 6-(2-p-methoxy-phenyl)-3-phenyl-4-(4-pyridyl)-2 (1H)-pyridines Ketone: MS (m/z): 355.0 (M+H) +C 23H 18N 2O 2Theoretical value 354.4. 1H-NMR (DMSO-d 6): d8.41 (m, 2H, pyridine .), 7.49 (bd, 1H), 7.44 (m, 1H), 7.24-7.06 (m, 8H, Ph, pyridine .), 7.02 (dt, 1H), 6.32 (bs, 1H, CH=), 3.82 (s, 3H, CH 3).
12-8 6-(4-chloro-phenyl-)-3-phenyl-4-(4-pyridyl)-2 (1H)-pyridones: MS (m/z): 359.2 (M+H) +C 22H 15ClN 2O theoretical value 358.8. 1H-NMR (DMSO-d 6): d8.42 (m, 2H, pyridine .), 7.93 (bd, 2H), 7.54 (m, 2H), 7.26-7.08 (m, 7H, Ph, pyridine .), 6.80 (bs, 1H, CH=).
Figure C9718155801433
12-9 6-(4-cyano-phenyl)-3-phenyl-4-(4-pyridyl)-2 (1H)-pyridines Ketone: MS (m/z): 350.2 (M+H) +C 23H 15N 3O theoretical value 349.4. 1H-NMR (DMSO-d 6): d8.45 (m, 2H, pyridine .), 8.16 (bd, 2H), 7.98 (d, 2H), 7.32-7.00 (m, 8H, Ph, pyridine., CH=).
Figure C9718155801434
12-10 6-(a-naphthyl)-3-phenyl-4-(4-pyridyl)-2 (1H)-pyridones: MS (m/z): 375.0 (M+H) +C 26H 18N 2O theoretical value 374.5. 1H-NMR (DMSO-d 6): d8.38 (m, 2H, pyridine .), 8.06-7.98 (m, 3H), 7.67 (dd, 1H), 7.62-7.54 (m, 3H), 7.25-7.11 (m, 7H, Ph, pyridine .), 6.38 (bs, 1H, CH=).
Figure C9718155801441
12-11 3-phenyl-4,6-two-(4-pyridyl)-2 (1H)-pyridones: MS (m/z): 326.0 (M+H) +C 21H 15N 3O theoretical value 325.4. 1H-NMR (DMSO-d 6: d8.69,8.43 (2m, each 2H, pyridines .), 7.92 (bs, 2H), 7.28-7.05 (m, 8H).
12-12 3-phenyl-4-(4-pyridyl)-6-(2-thienyl)-2 (1H)-pyridines Ketone: MS (m/z): 331.0 (M+H) +C 20H 14N 2OS theoretical value 330.4. 1H-NMR (DMSO-d 6): d8.44 (m, 2H, pyridine .), 7.90,7.70 (2bd, each 1H), 7.28-7.08 (m, 9H).
Figure C9718155801443
12-13 6-(2-furyl)-3-phenyl-4-(4-pyridyl)-2 (1H)-pyridines Ketone: MS (m/z): 315.0 (M+H) +C 20H 14N 2O 2Theoretical value: 314.4. 1H-NMR (DMSO-d 6): d8.44 (m, 2H, pyridine .), 7.90 (s, 1H), 7.43 (bs, 1H), 7.27-7.08 (m, 7H, Ph, pyridine .), 6.71 (m, 2H).
Figure C9718155801444
12-14 6-cyclohexyl-3-phenyl-4-(4-pyridyl)-2 (1H)-pyridones: MS (m/z): 331.2 (M+H) +C 22H 22N 2O theoretical value: 330.4. 1H-NMR (DMSO-d 6): d8.40 (m, 2H, pyridine .), 7.22-7.13,7.10-7.03 (2m, 7H, Ph, pyridine .), 6.04 (bs, 1H, CH=), 1.95-1.15 (m, 11H, hexanaphthene .).
Figure C9718155801451
The 12-15 6-tertiary butyl-3-phenyl-4-(4-pyridyl)-2 (1H)-pyridone: MS (m/z): 305.0 (M+H) +C 20H 20N 2The O theoretical value.304.4。 1H-NMR (DMSO-d 6): d8.39 (m, 2H, pyridine .), 7.20-7.12,7.10-7.02 (2m, 7H, Ph, pyridine .), 6.02 (bs, 1H, CH=), 1.31 (s, 9H, 3CH 3).
R 1＝(CH 3) 3C-
Embodiment 13
(S)-1, the preparation method of 2-benzyl quadrol
Figure C9718155801452
(S)-1,2-benzyl quadrol: according to described document (H.Brunner, P.Hankofer, U.Holzinger, B.Treittinger and H.Schoenenberger, Eur.J.Med.Chem.25,35-44, (1990)), by preparing described diamines with lithium aluminium hydride reduction L-DL-Phenylalanine amide.According to identical method, by D-DL-Phenylalanine amide preparation (R)-enantiomorph.
Embodiment 14
The preparation method of 2-(((S)-2-acetylaminohydroxyphenylarsonic acid 3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-acetylaminohydroxyphenylarsonic acid 3-phenyl propyl)-amino)-5-(4-fluorine Phenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones: with 2-(((S)-2-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones (25mg, 0.058mmol) and methyl alcohol (2ml) solution of diacetyl oxide (200ml) under room temperature, kept 1 hour.Evaporation composes products therefrom to purifying (10% ethanol/methylene) in the enterprising circumstances in which people get things ready for a trip of silicagel column subsequently, obtains described title compound.MS (m/z): 472.3 (M+H) +C 27H 26FN 5O 2Theoretical value: 471.5.
Embodiment 15
The preparation method of 5-(4-fluorophenyl)-2-(((S)-2-N-sec.-propyl amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides
5-(4-fluorophenyl)-2-(((S)-2-N-sec.-propyl amino-3-phenyl propyl) -amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides: sodium triacetoxy borohydride (23mg, 0.109mmol) join 2-(((S)-2-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (the 3H)-pyrimidone hydrochloride (50mg under stirring, 0.107mmol), triethylamine (15ml, 0.108mmol) and acetone (7.9ml, 0.108mmol) in 1, in the mixture in the 2-ethylene dichloride (0.8ml), after 4 hours, make the stopping of reaction by adding saturated sodium bicarbonate aqueous solution, use dichloromethane extraction subsequently, dry and evaporation with organic solution.In the enterprising circumstances in which people get things ready for a trip spectrum of silicagel column purifying (10% methyl alcohol/chloroform), obtain the described title compound of free alkali form, (21mml 0.08mmol) and subsequently evaporates, and is converted into a hydrochloride by add 4N hydrogenchloride/two  alkane in its methanol solution (1ml).MS (m/z): 472.1 (M+H) +C 28H 30FN 5O theoretical value 471.6 (free alkali).
Embodiment 16
The preparation method of 5-(4-fluorophenyl)-2-(((S)-2-N-cyclohexyl amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides
Figure C9718155801471
5-(4-fluorobenzene)-2-(((S)-2-N-cyclohexyl amino-3-phenyl propyl)-amino) -3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides: the same procedure according to preparation 5-(4-fluorophenyl)-2-(((S)-2-N-sec.-propyl amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones makes 5-(4-fluorophenyl)-2-(((S)-2-N-cyclohexyl amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidone: MS (m/z): 511.6 (M) with pimelinketone +C 31H 34FN 5O theoretical value 511.6 (free alkali).
Embodiment 17
The preparation method of 2-(((S)-2-N-normal-butyl amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides
2-(((S)-2-N-normal-butyl amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl) -3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides: sodium triacetoxy borohydride (28mg, 0.13mmol) join 2-(((S)-2-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidone (41mg under stirring, 0.095mmol) and butyraldehyde (8.5ml, 0.094mmol) in 1, in the mixture in the 2-ethylene dichloride (0.8ml), after 2 hours, make the stopping of reaction by adding saturated sodium bicarbonate aqueous solution, use dichloromethane extraction subsequently, dry and evaporation with organic solution.In the enterprising circumstances in which people get things ready for a trip spectrum of silicagel column purifying (5% methyl alcohol/chloroform), obtain the described title compound of free alkali form, (12mml 0.048mmol) and subsequently evaporates, and is converted into a hydrochloride by add 4N hydrogenchloride/two  alkane in its methanol solution (1ml).MS (m/z): 486.2 (M+H) +C 29H 32FN 5O theoretical value: 485.6 (free alkalis).
Embodiment 18
(S)-and 2-N, the preparation method of N-dimethylamino-3-phenylpropylamine
Figure C9718155801481
(S)-and 2-N, N-dimethylamino-3-phenylpropylamine: (13.0g, (3.6g, 21.9mmol) (4.4ml is 58.7mmol) in 1, in the mixture in the 2-ethylene dichloride (77ml) with 37% formaldehyde solution 61.3mmol) to join DL-Phenylalanine amide under stirring with triacetyl oxygen base sodium hydride.Stir after 2 hours, make the stopping of reaction, add the potassium hydroxide particle then, use dichloromethane extraction subsequently, dry and evaporation organic solution by adding saturated sodium bicarbonate aqueous solution.Method (H.Brunner according to described document, P.Hankofer, U.Holzinger, B.Treittinger and H.Schoenenberger, Eur.J.Med.Chem.25,35-44, (1990)), with gained (S)-2-N, N-dimethylamino-3-hydrocinnamamide reduces with lithium aluminium hydride, obtains described title compound.
Embodiment 19
The preparation method of 2-(((S)-2-N, N-dimethylamino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides
Steps A .5-(4-fluorophenyl)-3-methyl-2-methylsulfonyl-6-(4-pyridyl)- 4 (3H)-pyrimidones: with 5-(4-fluorophenyl)-3-methyl-2-methylthio group-6-(4-pyridyl)-4 (3H)-pyrimidones (400mg, 1.22mmol) and Oxone R(3.74mmol) mixture in methyl alcohol (100ml) and water (45ml) stirred 13 hours for permonosulphuric acid potassium, 2.3g.Solvent is concentrated into about 50ml, uses dichloromethane extraction subsequently.Dry and the evaporation with organic solution.Need not purifying, the gained white solid is directly used in next step.
Step is (((S)-2-N, N-dimethylamino-3-phenyl propyl)-amino)-5-(4-B.2- Fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides: with 5-(4-fluorophenyl)-3-methyl-2-methylsulfonyl-6-(4-pyridyl)-4 (3H)-pyrimidone crude product (430mg; 1.19mmol) and (S)-2-N; N-dimethylamino-3-phenylpropylamine (600mg;～3.4mmol) mixture stirred under room temperature 1 hour, and is of short duration warm down in 50 ℃ then.Carry out column chromatography (3-5% methyl alcohol/chloroform) on silica gel, obtain the described title compound of free alkali form, (160mml 0.64mmol) and subsequently evaporates, and is converted into a hydrochloride by add 4N hydrogenchloride/two  alkane in its methanol solution (4ml).MS (m/z): 458.0 (M+H) +C 27H 28FN 5O theoretical value 457.5 (free alkali).
Embodiment 20
5-(4-fluorophenyl)-6-(4-(2-kharophen)-pyridyl)-2-alkylthio-4 (3H)-pyrimidinones
Steps A .2-(4-fluorophenyl)-3-oxo-3-(4-(2-kharophen)-pyridyl)- Ethyl propionate:
In a steel bomb, (25.0g, 65ml ammonium hydroxide solution,stronger 0.16mmol) are warmed to 205 ℃ and kept 72 hours with the 2-chloroisonicotinic acid.After being cooled to 23 ℃, with 6N HCl described solution is acidified to pH1, subsequent filtration is to remove unreacting material.With 1/4th (the about 200mls) of solution for vacuum concentration, transfer to pH6 carefully with 1N NaOH to original volume.Turbid solution after placing 20 hours under 0 ℃, is leached the amino Yi Yansuan of required 2-.The two  alkane solution that in ethanol (600ml) suspension of the amino Yi Yansuan of 2-, add the anhydrous HCl of 47.1ml 4N.Be warmed to backflow after 20 hours, add the two  alkane solution of the anhydrous HCl of 47.1ml 4N again and again reaction is warmed to and refluxed 20 hours.In stink cupboard, concentrate with nitrogen gas stream, further subsequently vacuum concentration, residual solid is with saturated bicarbonate solution (200ml) dilution, with ethyl acetate (2 * 200ml) extractions, drying (Na 2SO 4).Behind the vacuum concentration, obtain the amino iso ethyl nicotinate of required 2-.Under 0 ℃ of argon atmospher, in 5 minutes, dripping acetyl chloride in pyridine (45ml) solution of the amino iso ethyl nicotinate of 2-, in 0 ℃ after 2 hours, with reactant impouring 300g on ice, (2 * 300ml) extractions, (salt solution (2 * 100ml) washings and dry (Na are used in 2 * 100ml) washings to water subsequently with ethyl acetate 2SO 4).Behind the vacuum concentration, and resistates flash chromatography method purifying (gradient elution, ethyl acetate: hexane 1: 4, use ethyl acetate then: hexane 1: 1), obtain 2-kharophen iso ethyl nicotinate.
In-78 ℃ in 5 minutes, to Isopropylamine (14.15ml, 101mmol) and drip in THF (40ml) solution n-Butyl Lithium (38.1ml, 95mmol).After 10 minutes, add 4-fluorophenyl ethyl acetate (17.3g, 40ml anhydrous THF solution 95mmol).After 10 minutes, (6.0g, 20ml anhydrous THF solution 29mmol) are warmed to 23 ℃ with reaction and spend the night, a collection of then adding acetate (95mmol) to add 2-kharophen iso ethyl nicotinate.To react vacuum concentration, partition repeatedly between saturated bicarbonate solution (200ml) and ether (300ml) neutralizes the hydrogen-carbonate salt deposit that merges with 10% citric acid then, and (2 * 300ml) extract the diacetyl oxide ethyl acetate.With organic layer drying (Na 2SO 4), vacuum concentration obtains 2-(4-fluorophenyl)-3-oxo-3-(4-(2-kharophen)-pyridyl)-ethyl propionate.
Step is (4-fluorophenyl)-6-(4-(2-kharophen) pyridyl) B.5-)-2-sulphur urine is phonetic Pyridine:
Under abundant stirring, with 2-(4-fluorophenyl)-3-oxo-3-(4-(2-kharophen)-pyridyl)-ethyl propionate (1.3g, 3.78mmol) and thiocarbamide (863mg 11.3mmol) is suspended in the anhydrous p-Xylol (15ml).In described mixture, add pyridine  tosilate (38mg) and, remove water (0.1ml) simultaneously continuously with Dean and Stark apparatus backflow 12-16 hour.With the reaction mixture cooling, the chocolate solid is filtered with B.The solid suspension of collecting is also filtered in acetone (25ml).Product through washing with acetone still contains the trace thiocarbamide, and it is removed with hot water (20-30ml) development.Product is filtered and dry air, subsequently with methylbenzene azeotropic.
Embodiment 21
(S)-preparation method of 2-N-ethylamino-3-phenylpropylamine
(S)-2-N-ethylamino-3-phenylpropylamine: (1.2ml, (1.0g is in methyl alcohol 6.10mmol) (25ml) solution 12.7mmol) to join L-DL-Phenylalanine amide under stirring with diacetyl oxide.After following 1.5 hours of the room temperature,, vacuumize down dry subsequently in oil pump with its evaporation.Under 55 ℃, (570mg is 15.0mmol) in tetrahydrofuran (THF) (65ml) reduction 4 hours with lithium aluminium hydride with gained L-N-ethylbenzene ala amide (6.1mmol).In reaction mixture impouring saturated sodium bicarbonate aqueous solution, use dichloromethane extraction subsequently, dry and evaporation.On silica gel, carry out column chromatography (chloroform: methyl alcohol: triethylamine=90: 7: 3), obtain yellow oily amine.MS (m/z): 179.1 (M+H) +C 11H 18N 2Theoretical value 178.3.
Embodiment 22
The preparation method of 2-amino-2-methyl-3-phenylpropylamine
Figure C9718155801511
2-amino-2-methyl-3-phenylpropylamine: with the D of commercially available acquisition, L-Alpha-Methyl phenylalanine methyl ester (5.0g, placed 3 days under room temperature by 28% ammonium hydroxide aqueous solution (50ml) 25.7mmol).With gained D, the white precipitate of L-Alpha-Methyl DL-Phenylalanine amide filters and dry (2.5g).(2.0g, 11.22mmol) (1.3g, 34.26mmol) reductase 12 is 4 hours with lithium aluminium hydride in the ebullient tetrahydrofuran (THF) with this product.Under the ice bath temperature, make the stopping of reaction by adding the sodium sulfate decahydrate.Described salt is filtered, and evaporation obtains the described title compound of oily subsequently.MS (m/z): 165.1 (M+H) +C 10H 16N 2Theoretical value 164.2.M.Freiberger and R.B.Hasbrouck, J.Am.Chem.Soc.82,696-698 (1960) discloses another kind of preparation method.
Embodiment 23
The preparation method of 2-methyl-3-phenylpropylamine
2-methyl-3-phenylpropylamine: with the 2-methyl-3-hydrocinnamamide of commercially available acquisition (4.32g, 26.5mmol) and lithium aluminium hydride (1.3g, 34.3mmol) mixture in tetrahydrofuran (THF) (184ml) stirred under room temperature 5 hours.To also use dichloromethane extraction in its impouring saturated aqueous sodium sulfate, the dry and evaporation with organic solution subsequently obtains the described amine of oily.For example Dornow and Fust, Chem.Ber.87 discloses other synthetic methods in 984 (1954).
Embodiment 24
The preparation method of 5-(4-fluorophenyl)-3-methyl-2-((2-methyl-3-phenyl propyl) amino)-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides
Figure C9718155801521
5-(4-fluorophenyl)-3-methyl-2-((2-methyl-3-phenyl propyl) amino)-6-(4 -pyridyl)-4 (3H)-pyrimidone hydrochloride: (520mg, 1.45mmol) (1.5g, mixture 10.1mmol) heated 30 minutes down in 50 ℃ with 2-methyl-3-amphetamine with 5-(4-fluorophenyl)-3-methyl-2-methylsulfonyl-6-(4-pyridyl)-4 (3H)-pyrimidone crude products.On silica gel, carry out column chromatography (2-5% ethanol/methylene; Hexane-acetone=2: 1), obtain described title compound.MS (m/z): 429.4 (M+H) +C 26H 25FN 4O theoretical value 428.5 (free alkali).
Embodiment 25
1-phenyl-1, the preparation method of 3-propylene diamine
1-phenyl-1, the 3-propylene diamine: document (S.G.Cohen and S.Y.Weinstein, J.Am.Chem.Soc.86,725-728 as described, 1964) described in, with 3-phenyl-3-alanine (M.Kojima and J.Fujita, Bull.Chem.Soc.Jpn.55,1454-1459 (1982)) is transformed into 1-phenyl-1,3-propylene diamine.
Be, to have prepared 1-(2-fluorophenyl)-1,3-propylene diamine, 1-(2-aminomethyl phenyl)-1,3-propylene diamine and 1-(2-chloro-phenyl-)-1,3-propylene diamine similarly with aforesaid method and suitable raw material.
Embodiment 26
The preparation method of 3-ethyl-5-(4-fluorophenyl)-2-methylthio group-6-(4-pyridyl)-4 (3H)-pyrimidones
Figure C9718155801531
3-ethyl-5-(4-fluorophenyl)-2-methylthio group-6-(4-pyridyl)-4 (3H)-pyrimidines Ketone: under the room temperature, with monobromoethane (600ml, 8.03mmol) join 5-(4-fluorophenyl)-2-methylthio group-6-(4-pyridyl)-4 (3H)-pyrimidone (1.8g under stirring, 5.97mmol) and sodium hydride (60% oil suspension, 320mg, 8mmol) in N, in the mixture of dinethylformamide (60ml).After 2 hours and 3.5 hours, add monobromoethane (2 * 600ml, 2 * 8.03mmol) again.After 8 hours, reaction mixture neutralizes and evaporation with acetate, and resistates is dissolved in methylene dichloride, and organic solution washes with water, dry and evaporation.On silicagel column, carry out flash chromatography (hexane-acetone=3: 1,2: 1), in second main flow part, obtain the described title compound of solid state.
Embodiment 27
The preparation method of 3-ethyl-5-(4-fluorophenyl)-2-methylsulfonyl-6-(4-pyridyl)-4 (3H)-pyrimidones
3-ethyl-5-(4-fluorophenyl)-2-methylsulfonyl-6-(4-pyridyl)-4 (3H) -pyrimidone: with 3-ethyl-5-(4-fluorophenyl)-2-methylthio group-6-(4-pyridyl)-4 (3H)-pyrimidones (300mg, 0.88mmol) and Oxone R(4.14mmol) mixture in methyl alcohol (71ml) and water (33ml) stirred 14 hours for permonosulphuric acid potassium, 2.54g.Solvent is concentrated into about 35ml, uses dichloromethane extraction subsequently, dry and evaporation need not purifying, and the gained white solid can be directly used in next step.
Embodiment 28
The preparation method of 2-(((S)-2-amino-3-phenyl propyl)-amino)-3-ethyl-5-(4-fluorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides
Figure C9718155801541
2-(((S)-2-amino-3-phenyl propyl)-amino)-3-ethyl-5-(4-fluorophenyl) -6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides: (150mg, 0.44mmol) and (S)-1, (200ml ,～1.3mmol) mixture is in 190 ℃ of heating 4.5 hours down for 2-benzyl quadrol with 3-ethyl-5-(4-fluorophenyl)-2-methylthio group-6-(4-pyridyl)-4 (3H)-pyrimidones.In Iatrobeads ROn carry out column chromatography (chloroform: methyl alcohol: triethylamine=90: 7: 3), obtain the described title compound of free alkali form, by add 2N hydrochloric acid (165ml, 0.33mmol) and methyl alcohol (1.5ml) be converted into a hydrochloride, filter, obtain described title compound.MS (m/z): 444.0 (M+H) +C 265H 27FN 5O theoretical value 443.5 (free alkali).
Embodiment 29
The preparation method of 3-ethyl-5-(4-fluorophenyl)-2-((2-methyl-3-phenyl propyl) amino)-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides
Figure C9718155801542
3-ethyl-5-(4-fluorophenyl)-2-((2-methyl-3-phenyl propyl) amino)-6-(4 -pyridyl)-4 (3H)-pyrimidone hydrochloride: with 3-ethyl-5-(4-fluorophenyl)-2-methylsulfonyl-6-(4-pyridyl)-4 (3H)-pyrimidone crude products (320mg, 0.89mmol) and 2-methyl-3-phenylpropylamine (600ml ,～4mmol) mixture is in 60 ℃ of heating 2 hours down.On silica gel, carry out column chromatography (hexane-acetone=2: 1; The 2-5% ethanol/methylene), obtain described title compound.MS (m/z): 443.2 (M+H) +C 27H 27FN 4O theoretical value 442.5.
Embodiment 30
The preparation method of 3-(2-tolyl) propylamine
3-(2-tolyl) propylamine: under the argon atmospher, (5.0ml, (60% oil suspension, 1.24g is in the suspension of tetrahydrofuran (THF) 31mmol) (50ml) 30.9mmol) to join sodium hydride under stirring with diethyl cyano methyl phosphoric acid ester.After 30 minutes, (3.6ml 31.1mmol) also continues to stir 1 hour to add the 2-tolyl aldehyde.Dichloromethane extraction is ended and used to reaction by adding entry, the dry and evaporation with organic solution subsequently.Carry out column chromatography (hexane; Hexane: ethyl acetate=3: 1), obtain oily 2-(2-tolyl) vinyl cyanide.(11.8ml, 142mmol) normal pressure is used hydrogen hydrogenation 2 days down in methyl alcohol (125ml) with this product (3.8g), 10% palladium/carbon (3.8g) and 12N hydrochloric acid.Filtration catalizer is with solvent evaporation.Products therefrom is partition between methylene dichloride and water, and water layer transfers to alkalescence with 10N sodium hydroxide, uses dichloromethane extraction, subsequent drying and evaporation.Products therefrom is purifying (chloroform: methyl alcohol: triethylamine=85: 10: 5), obtain the described title compound of oily on silicagel column.
Embodiment 31
The preparation method of 1-amino-3-(2-fluorophenyl)-propylamine
Figure C9718155801552
Steps A .2-amino-3-(2-fluorophenyl) methyl propionate: (D, L)-(2-fluorophenyl) L-Ala is suspended in the 50ml HCl methanol solution and stirred 3 days under room temperature with 5g (27.3mmol).With reaction mixture vacuum concentration and dry, obtain a yellow oil.MS (m/z): 198 (M+H) +C 10H 12FNO 2Theoretical value: 197.2.
Step is amino-3-(2-fluorophenyl) propionic acid amide B.2-: be suspended in 2-amino-3-(2-fluorophenyl) methyl propionate in 50ml 30% ammonium hydroxide and under room temperature, stirred 18 hours.Mixture is filtered, with cold water washing and collect white solid 2-amino-3-(2-fluorophenyl) propionic acid amide.MS (m/z): 183.1 (M+H) +C 9H 11FN 2O theoretical value: 182.2.
Step is amino-3-(2-fluorophenyl) propylamine C.2-: under argon atmospher, 2-amino-3-(2-fluorophenyl) propionic acid amide is joined the LAH of cooling (5 ℃) carefully, and (1.0g 26.3mmol) and in the mixture of 20ml THF, will react on the heating down 10 hours that refluxes then.Reaction is cooled to 5 ℃ also uses Na carefully 2SO 410H 2O handles, and the gained mixture is stirred 18 hours, then solids removed by filtration.With the filtrate vacuum concentration, obtain an amber oily thing.MS (m/z): 169 (M+H) +C 9H 13FN 2Theoretical value 168.19.
Embodiment 32
The preparation method of 5-(4-fluorophenyl)-2-(((S)-2-N-glycyl amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides
5-(4-fluorophenyl)-2-(((S)-2-N-glycyl amino-3-phenyl propyl)-ammonia Base)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides: under the ice bath temperature, (56.8 μ l, (104mg, 0.59mmol) (65.3 μ l are 0.59mmol) in the mixture in tetrahydrofuran (THF) (9ml) with the 4-methylmorpholine 0.59mmol) to join N-(tertbutyloxycarbonyl) glycine under stirring with Vinyl chloroformate.After 50 minutes, under the ice bath temperature, add 2-(((S)-2-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones (250mg, tetrahydrofuran (THF) 0.58mmol) (9ml) solution, in 2 hours, make mixture be cooled to room temperature.It is diluted with methylene dichloride, with the sodium bicarbonate aqueous solution washing, the dry and evaporation with organic solution subsequently.Products therefrom is dissolved in methyl alcohol (1.2ml) and adds 4N hydrogenchloride/two  alkane (1.2ml).After following 1 hour of the room temperature, be dissolved in methylene dichloride with its evaporation and with resistates, subsequently with the sodium bicarbonate aqueous solution washing, the dry and evaporation with organic solution.Purifying on silicagel column (methylene chloride-methanol-dense ammonium hydroxide=93: 7: 0.7), obtain the described title compound of free alkali form, by in its methanol solution (3ml), add 4N hydrogenchloride/two  alkane (112 μ l, 0.45mmol), evaporation is converted into hydrochloride subsequently.MS (m/z): 487.1 (M+H) +C 27H 27FN 6O 2Theoretical value 486.6 (free alkali).
Similarly, by 2-(((S)-2-amino-3-phenyl propyl)-amino)-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones preparation 2-(((S)- 2-N-glycyl amino-3-phenyl propyl)-amino)-3-methyl-5-(3-methyl Phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides
Embodiment 33
The preparation method of 5-(4-fluorophenyl)-2-(((S)-2-glycoloyl amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides
5-(4-fluorophenyl)-2-(((S)-2-glycoloyl amino-3-phenyl propyl)-amino)- 3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones: under the ice bath temperature, with alpha-Acetoxyacetyl chloride (55 μ l, 0.51mmol) join 2-(((S)-2-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidone (200mg under stirring, 0.466mmol) and triethylamine (130 μ l are 0.93mmol) in methylene dichloride (4ml) solution.After 50 minutes, make the stopping of reaction, subsequently evaporation by adding a methyl alcohol.Be dissolved in products therefrom in 1: 1: 1 methanol/triethylamine (3ml) and make its placement spend the night.Column chromatography (3-7% methyl alcohol/chloroform) is carried out in evaporation subsequently, obtains described title compound: MS (m/z): 488.3 (M+H) +C 27H 26FN 5O 3Theoretical value 487.5.
Embodiment 34
The preparation method of 5-(4-fluorophenyl)-2-(2-((3-N-methyl urea groups)-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-2-(2-((3-N-methyl urea groups)-3-phenyl propyl)-amino)- 3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones: under 15 ℃, with methyl isocyanate (6 μ l, 0.102mmol) (43.6mg is in two  alkane (1.5ml) solution 0.102mmol) to join 2-(((S)-2-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones under stirring.After 15 minutes, steaming desolventizes, and reaction product is applied directly to (5-7% methyl alcohol/chloroform) on the silicagel column, obtains described title compound.MS (m/z): 486.6 (M+H) +C 27H 27FN 6O 2Theoretical value 486.6.
Embodiment 35
The preparation method of 5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-2-((2-pyrrolidyl-3-phenyl propyl)-amino)-4 (3H)-pyrimidone hydrochlorides
Figure C9718155801582
5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-2-(((S)-2-pyrrolidyl- The 3-phenyl propyl)-and amino)-4 (3H)-pyrimidone hydrochlorides: under the ice bath temperature, with sodium hydride (60% oil suspension, 84mg, 2.1mmol) add the 2-that falls in lines (((S)-2-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidone (300mg, 0.70mmol) N, in dinethylformamide (8ml) solution.After 30 minutes, add 1, (108 μ l 0.91mmol), continue to stir following 20 hours of room temperature 30 minutes under the ice bath temperature 4-dibromobutane.It is neutralized with acetate, subsequently evaporation.With crude product purifying (methylene chloride-methanol=93: 7 on silicagel column; Methylene chloride-methanol-dense ammonium hydroxide=93: 7: 0.7).By add 4N hydrogenchloride/two  alkane (37 μ l) in its methanol solution (2ml), evaporation is transformed into hydrochloride with products therefrom subsequently.MS (m/z): 484.6 (M+H) +C 29H 30FN 5O theoretical value 483.6 (free alkali).
Embodiment 36
The preparation method of 5-(4-fluorophenyl)-2-(((S)-3-N-sec.-propyl amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides
5-(4-fluorophenyl)-2-(((S)-3-N-sec.-propyl amino-3-phenyl propyl)-amino) -3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides: triacetyl oxygen base sodium borohydride (12.9mg, 0.061mmol) join 2-(((S)-2-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidone (21.8mg under stirring, 0.051mmol) and acetone (4.5 μ l, 0.061mmol) in 1, in the mixture in the 2-ethylene dichloride (0.4ml), 2.5 after hour, make the stopping of reaction by adding saturated sodium bicarbonate aqueous solution, use dichloromethane extraction subsequently, dry and evaporation with organic solution.In the enterprising circumstances in which people get things ready for a trip spectrum of silicagel column purifying (10% methyl alcohol/chloroform), obtain the described title compound of free alkali form, by in its methanol solution (1ml), adding 4N hydrogenchloride/two  alkane (12.2 μ l) and evaporation subsequently, be converted into a hydrochloride.MS (m/z): 472.0 (M+H) +C 28H 30FN 5O theoretical value 471.6 (free alkali).
Embodiment 37
The preparation method of 5-(4-fluorophenyl)-2-(((R)-3-N-sec.-propyl amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides
5-(4-fluorophenyl)-2-(((R)-3-N-sec.-propyl amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides, as the preparation method of above-mentioned its S-enantiomorph, by 5-(4-fluorophenyl)-2-(((R)-3-N-sec.-propyl amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones preparation.MS (m/z): 472.1 (M+H) +C 28H 30FN 5O theoretical value: 471.6 (free alkalis).
Embodiment 38
The preparation method of 2-(((S)-3-acetylaminohydroxyphenylarsonic acid 3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
Figure C9718155801601
2-(((S)-3-acetylaminohydroxyphenylarsonic acid 3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones: with 2-(((S)-3-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidone (23.8mg, 0.055mmol) and Glacial acetic acid (20 μ l, methyl alcohol 0.21mmol) (1ml) solution kept under room temperature 30 minutes.Column chromatography purifying (methylene chloride-methanol-ammonium hydroxide=93: 7: 0.7) is carried out in evaporation subsequently, obtains described title compound.MS (m/z): 472.2 (M+H) +C 27H 26FN 5O 2Theoretical value 471.5.
Embodiment 39
(S)-and 1-phenyl-1, the preparation method of 3-propylene diamine
Figure C9718155801602
(S)-and 1-phenyl-1, the 3-propylene diamine: according to document described (W.J.Wheeler and D.D.O ' Bannon, J.Label.Compds.Radiopharm.XXXI (4), 305-315,1992), prepare S-3-N-tertiary butyloxycarbonyl amino-3-phenyl propionitrile by D-(-)-α-phenyl glycinol.For reduction reaction (D.Mitchell and T.M.Koenig, Synth.Comm.25 (8), 1231-1238,1995), to described nitrile (1g, drip in tetrahydrofuran (THF) 4.06mmol) (6ml) solution borine-dimethyl sulfide mixture (2N, 3ml, 6g, 6mmol).Steam except that dimethyl sulfide and with gained solution and refluxed 2.5 hours.Under the cooling, and the methanol solution of adding hydrogenchloride (1N, 3ml), evaporation subsequently.Resistates is dissolved in methyl alcohol (10ml) and adds 4N hydrogenchloride/two  alkane (10ml).After following 1 hour of the room temperature, with its evaporation, the aqueous solution washed with dichloromethane of products therefrom.Add solid potassium hydroxide, make the aqueous solution be alkalescence, use dichloromethane extraction subsequently again.Dry and evaporation obtains oily diamines crude product with dichloromethane solution.MS (m/z): 150.8 (M+H) +C 9H 14N 2Theoretical value: 150.2.
Similarly, can prepare enantiomer by L-(+)-α-phenyl glycinol (R)-1 -phenyl-1, the 3-propylene diamineMS (m/z): 150.9 (M+H) +C 9H 14N 2Theoretical value 150.2.
Embodiment 40
(2R, 3R)-2-methyl-3-phenyl-1, the preparation method of 3-propylene diamine
Steps A: (2S, 3R, α S)-3-(N-benzyl-N-alpha-methyl benzyl amino)-2-first Base-3-phenylpropionic acid methyl esters, as S.G.Davies and I.A.S.Walters, preparation 2R among the J.Chem.Soc.Perkin Trahs.I, 1129-1139 (1994), 3S, the described method preparation of α R-enantiomorph.
Step B:(2S, 3R)-3-amino-2-methyl-3-phenylpropionic acid methyl esters: with (2S, 3R, α S)-3-(N-benzyl-N-alpha-methyl benzyl amino)-2-methyl-3-phenylpropionic acid methyl esters (13.0g, 33.55mmol) and the hydrogenation 24 hours under hydrogen-pressure of the mixture of 10% palladium-carbon (13.0g) in Glacial acetic acid (260ml).Remove by filter crystallization, subsequently the evaporation and with the toluene condistillation, obtain the described title compound of white solid.MS (m/z): 194.2 (M+H) +C 11H 15NO 2Theoretical value 193.3.
Step C:(2S, 3R)-3-amino-2-methyl-3-Phenylpropionamide: will (2S, 3R)-(6.3g, (28-30%, 40ml) solution stirs under room temperature 3-amino-2-methyl-3-phenylpropionic acid methyl esters for 2N ammonia methyl alcohol (20ml) 33mmol) and ammonium hydroxide.After 4 days,, separate (methylene chloride-methanol-dense ammonium hydroxide=93: 7: 0.7 in the enterprising circumstances in which people get things ready for a trip spectrum of silica gel short column subsequently with its evaporation; 90: 10: 0.8), obtain the described acid amides of white solid.MS (m/z): 179.2 (M+H) +C 10H 14N 2O theoretical value 178.2.
Step D:(2R, 3R)-2-methyl-3-phenyl-1, the 3-propylene diamine: under the ice bath temperature, with lithium aluminium hydride (2.3g, 60.60mmol) join in batches under stirring (2S, 3R)-(2.6g is in tetrahydrofuran (THF) 14.59mmol) (54ml) solution for 3-amino-2-methyl-3-Phenylpropionamide.After 45 minutes, the mixture backflow was heated 16 hours down.The ice bath cooling is reacted by adding sodium sulfate decahydrate and some methyl alcohol and is ended, until there not being hydrogen to emit down.Solid filtering is also used washed with dichloromethane, and the filtrate evaporation with merging obtains described title compound.MS (m/z): 165.2 (M+H) +C 10H 16N 2Theoretical value.164.3。
Correspondingly, can prepare enantiomorph by (2R, 3S, α R)-3-(N-benzyl-N-alpha-methyl benzyl amino)-2-methyl-3-phenylpropionic acid methyl esters (2S, 3S)-the 2-methyl -3-phenyl-1, the 3-propylene diamineMS (m/z): 165.3 (M+H) +C 10H 16N 2Theoretical value 164.3.
Similarly, by (2S, 3S, α R)-and (2R, 3R, α S)-3-(N-benzyl-N-alpha-methyl benzyl amino)-2-methyl-3-phenylpropionic acid tertiary butyl ester people such as (, J.Chem.Soc.Chem.Commun.1153-1155,1993) S.Davies preparation enantiomorph (2R, 3S)- 2-methyl-3-phenyl-1, the 3-propylene diamine and (2S, 3R)-2-methyl-3-phenyl-1,3 -propylene diamine
Embodiment 41
The preparation method of 2-((S)-3-benzyl diethylenediamine base)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides
Figure C9718155801621
Steps A: (S)-the 2-benzyl diethylenediamine: under the ice bath temperature, (1.6g 42.16mmol) joins (S)-2-benzyl diethylenediamine-3 under stirring in batches, and (3.0g is 14.70mmol) in (commercially available acquisition) and tetrahydrofuran (THF) (80ml) mixture for the 6-diketone with lithium aluminium hydride.After following 30 minutes, mixture is stirred backflow down 4 hours in the ice bath temperature.Make the stopping of reaction by add sodium sulfate decahydrate and some methyl alcohol in batches, until there not being hydrogen to emit.With its filtration, solid with washed with dichloromethane for several times.Filtrate evaporation with merging obtains a white solid.MS (m/z): 177.1 (M+H) +C 11H 16N 2Theoretical value: 176.3.
Step B:2-((S)-3-benzyl diethylenediamine base)-5-(4-fluorophenyl)-3-methyl-6-(4 -pyridyl)-4 (3H)-pyrimidone hydrochloride: with 5-(4-fluorophenyl)-3-methyl-2-methylsulfonyl-6-(4-pyridyl)-4 (3H)-pyrimidone crude products (434mg, 1.21mmol) and (S)-(426mg, mixture 2.42mmol) is in 105 ℃ of heating 1 hour down for the 2-benzyl diethylenediamine.With crude reaction product on silica gel through column chromatography purifying (methylene dichloride-methane=93: 7; Methylene chloride-methanol-dense ammonium hydroxide=93: 7: 0.7).By in its methanol solution (3ml), adding 4N hydrogenchloride/two  alkane (75 μ l) products therefrom is transformed into its hydrochloride.MS (m/z): 456.5 (M+H) +C 27H 26FN 5O theoretical value: 455.5 (free alkalis).
Embodiment 42
The preparation method of 5-(4-fluorophenyl)-3-methyl-2-(3-phenyl propoxy-)-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-3-methyl-2-(3-phenyl propoxy-)-6-(4-pyridyl)- 4 (3H)-pyrimidones: ((387mg is in tetrahydrofuran (THF) 2.85mmol) (1ml) solution 2.79mmol) to join 3-phenyl propanol under stirring for 60% oil suspension, 111mg with sodium hydride.After gas stopped to emit, (100mg 0.279mmol) and with mixture heated 30 minutes down in 60 ℃ to add 5-(4-fluorophenyl)-3-methyl-2-methylsulfonyl-6-(4-pyridyl)-4 (3H)-pyrimidones.With reaction mixture partition between methylene dichloride and water, organic solution salt water washing, dry and evaporation.On silica gel, carry out column chromatography (hexane-ethyl acetate=2: 1), obtain described title compound.MS (m/z): 416.1 (M+H) +C 25H 22FN 3O 2Theoretical value 415.5.
Embodiment 43
The preparation method of 5-(4-fluorophenyl)-3-methyl-2-(4-phenyl butyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
Steps A: 5-(4-fluorophenyl)-2-(4-phenyl butyl)-6-(4-pyridyl)-4 (3H) -pyrimidone: with 2-(4-fluorophenyl)-3-oxo-3-(4-pyridyl)-ethyl propionate (293mg, 1.02mmol), 4-phenyl butane carbonamidine (315mg, 1.79mmol) and pyridine  tosilate (10mg) be suspended in the p-Xylol (10ml).Fully stir down, mixture heating up is refluxed, simultaneously continuously dehydrating with Dean and Stark apparatus.After 16 hours, steaming desolventizes, product on silica gel through column chromatography purifying (3% ethanol/methylene), recrystallization in acetone subsequently.MS (m/z): 400.3 (M+H) +C 25H 22FN 3The O theoretical value.399.5。
Step B:5-(4-fluorophenyl)-3-methyl-2-(4-phenyl butyl)-6-(4-pyridine Base)-4 (3H)-pyrimidones: methyl iodide (22 μ l, 0.351) is joined 5-(4-fluorophenyl)-2-(4-phenyl butyl)-6-(4-pyridyl)-4 (3H)-pyrimidones under stirring, and (140mg is 0.351mmol) in N, in the mixture in the dinethylformamide (5ml).After 75 minutes, with its evaporation and with products therefrom purifying (hexane-acetone=3: 1 on silicagel column; 2: 1), obtain described title compound.MS (m/z): 414.3 (M+H) +C 26H 24FN 3O theoretical value 413.5.
Embodiment 44
Can prepare compound shown in the following Table I with the described method of embodiment 1-43.
Table I
MS(m/z)：464.0(M) +； MS(m/z)：479.7(M) +；
C 25H 23FN 5O theoretical value: 463.9 C 29H 26FN 5O theoretical value 479.6
Figure C9718155801652
MS(m/z)：498.0(M) +； MS(m/z)：416.1(M+H) +；
C 25H 22FN 5O theoretical value 498.4 C 24H 22FN 5O theoretical value 415
MS(m/z)：464.1(M) +；. MS(m/z)：414.0(M+H) +；
C 25H 23ClFN 5O theoretical value 463.9 C 21H 24FN 5OS theoretical value 413.5
Figure C9718155801654
MS(m/z)：448.3(M+H) +； MS(m/z)：436.2(M+H) +；
C 25H 23F 2N 5O 2Theoretical value 447.5 C 25H 30FN 5O theoretical value 435.6
MS(m/z)：448.2(M+H) +； MS(m/z)：428.1(M+H) +；
C 25H 22F 2N 5O theoretical value 447.3 C 25H 22FN 5O theoretical value: 427.5
Figure C9718155801656
MS(m/z)：486.1(M+H) +； MS(m/z)：442.1(M+H) +；
C 27H 24FN 5OS theoretical value 485.4 C 26H 24FN 5O theoretical value 413.5
Embodiment 45
Can prepare compound shown in the following Table II, wherein R with the described method of embodiment 1-43 11Expression 3-aminomethyl phenyl, 3-chloro-phenyl-, 3-trifluoromethyl, 4-fluorophenyl, 4-aminomethyl phenyl, 4-chloro-phenyl-and 3, the 4-3,5-dimethylphenyl.
Table II
Figure C9718155801661
Figure C9718155801671
Embodiment 46
The preparation method of 3-methyl-2-(2 (S)-amino-3-phenyl third amino)-5-(3-trifluoromethyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
Figure C9718155801672
Steps A .6-(4-pyridyl)-2-thiouracil: under the vigorous stirring, with different nicotinoyl ethyl acetate (5g, 25.89mmol) and thiocarbamide (5.94g 77.64mmol) is suspended in the anhydrous p-Xylol (100ml).In described mixture, add pyridine  tosilate (150mg) and with Dean and Stark apparatus backflow 12-16 hour, continuously dehydrating (0.5ml) simultaneously.With the reaction mixture cooling and with the Vandyke brown solid filtering, the solid suspension of collecting is also filtered in acetone (25ml).The product that washing with acetone is crossed still contains the trace thiocarbamide, by being removed with hot water (20-30ml) development, separates obtaining described title compound after filtration.
MS (m/z): 206.2C 9H 7N 3OS theoretical value 205.3. 1H-NMR (DMSO-d 6): d12.65 (bm, 2H, NH and SH), 8.71 (m, 2H, pyridines .), 7.66 (m, 2H, pyridines .), 6.25 (s, 1H, H-5).
Step is methyl-6-(4-pyridyl)-2-methylthio group-4 (3H)-pyrimidone B.3-: (1.5g 7.299mmol) is dissolved in DMF (50ml) and mixture is cooled to 0 ℃, and (0.437g, 0.730g 60% oil suspension 18.2mmol) and with reaction mixture stirred 30 minutes to add sodium hydride with 6-(4-pyridyl)-2-thiouracil.(1.2ml, 2.6g 18.25mmol), monitor the formation of dimethyl compound with TLC to drip methyl iodide in 15 minutes.Reaction mixture is concentrated and resistates is used hexane on silicagel column: acetone (9: 1,4: 1 and 2: 1) carries out chromatogram purification, obtains the described title compound of solid state.
MS (m/z): 234.1 C 11H 11N 3OS theoretical value: 233.2; 1H-NMR (CDCl 3): d8.75 (m, 2H, pyridyl), 7.8 (m, 2H, pyridyl), 6.75 (s, 1H), 3.58 (s, 3H, N-CH 3), 2.72 (s, 3H, S-CH 3).
Step is methyl-5-bromo-6-(4-pyridyl)-2-methylthio group-4 (3H)-pyrimidine C.3- Ketone: with 3-methyl-6-(4-pyridyl)-2-methylthio group-4 (3H)-pyrimidone (1.00g, 4.29mmol) be suspended in acetate (24ml) and in described settled solution, add bromine (0.5ml, 1.5g, 9.38mmol).Reaction mixture was stirred under room temperature 24 hours, mixture is concentrated, resistates and methylbenzene azeotropic are until removing all bromines.Crude product is used for next step.MS (m/z): 312 and 314.C 11H 10BrN 3OS theoretical value 311and313.1H-NMR (DMSO-d6): d8.75 (m, 2H, pyridyl) 8.19 (m, 2H, pyridyl), 3.67 (s, 3H, N-CH 3), 2.80 (s, 3H, s-CH 3).
Step is methyl-5-(3-trifluoromethyl)-6-(4-pyridyl)-2-first sulphur D.3- Base-4 (3H)-pyrimidones: (1.2g 3.8mmol) is suspended in the 2M sodium carbonate solution (30ml), and the light yellow bromine of viscosity is scattered in the described reaction mixture, obtains colourless precipitation with 3-methyl-5-bromo-6-(4-pyridyl)-2-methylthio group-4 (3H)-pyrimidone.In said mixture, add 3-trifluoromethyl phenylo boric acid (1.00g, 5.27mmol) and toluene (30ml) and reaction mixture outgased.Add four-triphenyl phosphine Pd (0) (350mg), with reaction mixture refluxed 8-12 hour, with the formation of TCL monitoring product.With mixture cooling, dilute and wash with water with toluene (20ml), the organic layer dried over sodium sulfate, concentrated and through the silica gel chromatography separated product, obtain described title compound.MS (m/z): 378.4 C 18H 14F 3N 3OS theoretical value 377.39; 1H-NMR (CDCl 3): d8.5 (m, 2H, pyridyl), 7.45 (s, 1H), 7.17-7.25 (m, 3H, pyridyl and Ph-CF 3), 6.95 (d, 1H, Ph-CF 3), 3.67 (N-CH 3), 2.8 (S-CH 3).
Step e .3-methyl-2-(2 (S)-amino-3-phenyl third amino)-5-(3-trifluoromethyl Phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones: in round-bottomed flask, with 3-methyl-5-(3-trifluoromethyl)-6-(4-pyridyl)-2-methylthio group-4 (3H)-pyrimidone (0.7g, 1.85mmol) and (S)-2-amino-3-phenyl-1-propylamine (0.9ml, 6.00mmol) mixed 185 ℃ of following heating 3 hours that are incorporated in.Mixture is separated (methylene dichloride: methyl alcohol: ammonium hydroxide=92: 7: 1), obtain described title compound on silica gel.MS (m/z): 480, C 26H 24F 3N 5O theoretical value 479.51; 1H-NMR (CDCl 3): d8.49 (m, 2H, pyridyl), 7.51-7.17 (m, 11H, Ph and pyridyl), 5.81 (bm, 1H, NH), 3.91 (m, 1H, CH), 3.53 (s, 3H, N-CH 3), 3.35 (m, 2H, CH 2), 2.94 (dd, 1H, CH 2), 2.82 (dd, 1H, CH 2).
Embodiment 47
Use corresponding raw material, the method with preparing 3-methyl-2-(2 (S)-amino-3-phenyl third amino)-5-(3-trifluoromethyl)-6-(4-pyridyl)-4 (3H)-pyrimidones can prepare compound shown in the following Table III.
Table III
R 30 R 31 MS(m/z)
The 4-tolyl 2 (S)-amino-3-phenyl propyl 426
The 4-trifluoromethyl 2 (S)-amino-3-phenyl propyl 480
The 3-isopropyl phenyl 2 (S)-amino-3-phenyl propyl 454
3-chloro-4-fluorophenyl 2 (S)-amino-3-phenyl propyl 464
3,5-two (trifluoromethyl) phenyl 2 (S)-amino-3-phenyl propyl 548
3, the 4-dichlorophenyl 2 (S)-amino-3-phenyl propyl 482
The 1-naphthyl 2 (S)-amino-3-phenyl propyl 462
The 3-fluorophenyl 2 (S)-amino-3-phenyl propyl 430
The 3-chloro-phenyl- 2 (S)-amino-3-phenyl propyl
The 3-aminomethyl phenyl 2 (S)-amino-3-phenyl propyl
The 4-chloro-phenyl- 2 (S)-amino-3-phenyl propyl
The 2-chloro-phenyl- 2 (S)-amino-3-phenyl propyl
The 2-thienyl 2 (S)-amino-3-phenyl propyl
3, the 4-3,5-dimethylphenyl 2 (S)-amino-3-phenyl propyl 440.6
3, the 5-dichlorophenyl The 3-phenyl propyl 467
The 4-tolyl The 3-phenyl propyl 411
The 3-trifluoromethyl The 3-phenyl propyl 465
The 4-p-methoxy-phenyl The 3-phenyl propyl 427
The 4-trifluoromethyl The 3-phenyl propyl 465
The 3-chloro-phenyl- The 3-phenyl propyl
The 3-aminomethyl phenyl The 3-phenyl propyl
The 4-chloro-phenyl- The 3-phenyl propyl
The 2-chloro-phenyl- The 3-phenyl propyl
The 3-nitrophenyl The 3-phenyl propyl
The 3-p-methoxy-phenyl The 3-phenyl propyl
The 2-fluorophenyl The 3-phenyl propyl
Benzothienyl The 3-phenyl propyl
The 3-fluorophenyl 2-methyl-3-phenyl propyl 429
The 1-naphthyl 2-methyl-3-phenyl propyl 461
The 3-trifluoromethyl 2 (S)-dimethylamino-3-phenyl propyl
The 3-aminomethyl phenyl 2 (S)-dimethylamino-3-phenyl propyl
The 3-chloro-phenyl- 2 (S)-N, N-dimethylamino-3-phenyl propyl
The 3-nitrophenyl 2 (S)-N, N-dimethylamino-3-phenyl propyl
The 3-p-methoxy-phenyl 2 (S)-N, N-dimethylamino-3-phenyl propyl
The 2-fluorophenyl 2 (S)-N, N-dimethylamino-3-phenyl propyl
The 3-trifluoromethyl (S)-tetrahydroisoquinoline-3-base methylamino- 492.1
The 3-aminomethyl phenyl (S)-tetrahydroisoquinoline-3-base methylamino- 438
3, the 4-3,5-dimethylphenyl 3-amino-3-phenylpropylamine 440.6
The 3-aminomethyl phenyl 3-amino-3-phenylpropylamine
Benzothienyl 3-amino-3-phenylpropylamine
Benzofuryl 3-amino-3-phenylpropylamine
Embodiment 48
3-methyl-5-(4-methanesulfinyl phenyl)-6-(4-pyridyl)-2-methylthio group-4 (3H)-pyrimidone: replace 3-trifluoromethyl phenylo boric acid with 4-methanesulfinyl phenylo boric acid, prepare described title compound according to the described method of embodiment 34-D.
Embodiment 49
3-methyl-2-(3 (S)-(1; 2; 3; the 4-tetrahydro isoquinolyl) methylamino-)-and 5-(4-methylthio group phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones: replace 3-methyl-5-(3-trifluoromethyl)-6-(4-pyridyl)-2-methylthio group-4 (3H)-pyrimidone also with 3 (S)-(1 with 3-methyl-5-(4-methanesulfinyl phenyl)-6-(4-pyridyl)-2-methylthio group-4 (3H)-pyrimidone; 2; 3; the 4-tetrahydro isoquinolyl) methylamine replaces (S)-2-amino-3-phenyl-1-propylamine, according to the described method of embodiment 34 step D prepare described title compound: MS (m/z) 470 (M+H)+.
Embodiment 50
3-methyl-2-(3 (S)-(1; 2; 3; the 4-tetrahydro isoquinolyl) methylamino-)-5-(4-methylsulfonyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones: under 23 ℃, to 3-methyl-2-(3 (S)-(1,2; 3; the 4-tetrahydro isoquinolyl) methylamino-)-5-(4-methylthio group phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones (50mg, methyl alcohol 0.11mmol): water (15ml: 10ml) once add in the solution oxone solid (127mg, 0.21mmol).After 16 hours, will react under the nitrogen gas stream and concentrate, reaction mixture directly is prepared thin-layer chromatography purifying (3 silica gel 2mm slabs; The dichloromethane solution of 5% methyl alcohol), obtain described title compound: MS (m/z): 502 (M+H) +
Embodiment 51
2-(((S)-3-amino-3-phenyl propyl) amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidone hydrochlorides, according to general method, by 3-methyl-2-methylthio group-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidones and (S)-1-phenyl-1, the 3-propylene diamine makes.React on and carried out under 190 ℃ 1 hour.MS (m/z): 480.0 (M+H) +C 26H 24F 3N 5The O theoretical value.(479.5 free alkali).
Embodiment 52
2-(((R)-3-amino-3-phenyl propyl) amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidone hydrochlorides, according to general method, by 3-methyl-2-methylthio group-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidones and (R)-1-phenyl-1, the 3-propylene diamine makes.React on and carried out under 190 ℃ 3.5 hours.MS (m/z): 480.4 (M+H) +C 26H 24F 3N 5O theoretical value: 479.5 (free alkalis).
Embodiment 53
The preparation method of 2-chloro-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
Steps A: 3-methyl-5 (3-aminomethyl phenyl)-6-(4-pyridyl)-2,4 (1H, 3H) -pyrimidine dione: 10N sodium hydroxide (25ml) and water (50ml) are joined 3-methyl-5-(3-aminomethyl phenyl)-2-methylthio group-6-(4-pyridyl)-4 (3H)-pyrimidine diones, and (16.17g is in two  alkane (65ml) solution 0.05mol).Under argon atmospher, mixture was heated 16 hours down in 80 ℃, make mixture be cooled to room temperature, the pH value is transferred to 9 with 1N hydrochloric acid.Filtering-depositing washes with water and drying, obtains described title compound.MS (m/z): 292 (M-H) +C 17H 15N 3O 2Theoretical value: 293.3.
Step B:2-chloro-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H) -pyrimidone: with 3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-2,4 (1H, 3H)-pyrimidine dione (12.5g, 0.043mol) and the mixture of phosphoryl chloride (65ml) refluxed 16 hours.Steam and remove excessive phosphoryl chloride, subsequently with methylbenzene azeotropic.Resistates is partition between methylene dichloride and sodium bicarbonate aqueous solution carefully, and organic solution washes with water, and dry and evaporation obtains described title compound.MS (m/z): 312 (M) +C 17H 14ClN 3O theoretical value 311.8.
Can prepare by the same way 2-chloro-3-methyl-6-(4-pyridyl)-5-(3- Trifluoromethyl)-4 (3H)-pyrimidone
Embodiment 54
The preparation method of 2-(((S)-2-amino-3-phenyl propyl) amino)-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides
2-(((S)-2-amino-3-phenyl propyl) amino)-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides: with 2-chloro-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidone (3.34g, 10.71mmol) and (S)-1-benzyl-1, (2.3g, ethanol 15.31mmol) (50ml) solution stirred under room temperature 16 hours the 2-quadrol.Steaming desolventizes, and crude product is recrystallization in methyl alcohol.MS (m/z): 426 (M+H) +C 26H 27N 5O theoretical value 425.5 (free alkali).
Embodiment 55
The preparation method of 2-((3-amino-2,2-dimethyl-3-phenyl propyl) amino)-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides
2-((3-amino-2,2-dimethyl-3-phenyl propyl) amino)-3-methyl-5-(3- Aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidone hydrochlorides: with 2-fluoro-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidone (228mg, 0.73mmol) and 3-phenyl-2,2-dimethyl-1,3-propylene diamine (178mg, 1mmol) (according to W.Ten Hoeve and H.Wynberg, Synth.Commun.24 (15), 2215-2221, the preparation of 1994 described methods) ethanol (4ml) solution under room temperature, stirred 16 hours.Steaming desolventizes, and crude product carries out the column chromatography purifying on silica gel.MS (m/z): 454 (M+H) +C 28H 31N 5The O theoretical value.(453.6 free alkali).
Correspondingly, 2-((3-amino-2,2-dimethyl-3-phenyl propyl) amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidone hydrochlorides have been prepared.MS (m/z): 508 (M+H) +C 28H 28F 3N 5O theoretical value 507.6 (free alkali).
Embodiment 56
The preparation method of 2-(((S)-3-amino-3-phenyl propyl) amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidone hydrochlorides
Figure C9718155801741
2-(((S)-3-amino-3-phenyl propyl) amino)-3-methyl-6-(4-pyridyl)-5 -(3-trifluoromethyl)-4 (3H)-pyrimidone hydrochlorides: saturated aqueous sodium carbonate (2ml) is joined 2-chloro-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidone (730mg, 2mmol) and (S)-1-phenyl-1,3-propylene diamine (360mg, 2.4mmol) ethanol (10ml) solution in, mixture stirred under room temperature 4 hours.With its evaporation, resistates is partition between methylene dichloride and water, and column chromatography (methylene dichloride: methyl alcohol: dense ammonium hydroxide=93: 7: 0.7) is carried out in dry and evaporation subsequently on silica gel with organic solution.MS (m/z): 480 (M+H) +C 26H 24F 3N 5O theoretical value 479.5 (free alkali).
Embodiment 57
The preparation method of 3-methyl-2-methylthio group-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
Figure C9718155801742
3-methyl-2-methylthio group-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones: with potassium tert.-butoxide solution (1M t-butanol solution, 1l, (178g, N 1mol) is in dinethylformamide (21) solution 1mol) to be added drop-wise to 3-aminomethyl phenyl ethyl acetate under stirring.In about 4.5 hours, with 4-cyanopyridine (104.11g, N 1mol), dinethylformamide (11) solution pumps in the described reaction mixture, then reaction mixture was stirred under room temperature 3 hours, in 10 minutes, drip methylthiocyanide methylthiocyanate (68.4ml, N 1mol), dinethylformamide (50ml) solution afterwards.After stirring 1 hour under the room temperature, reaction mixture is cooled to 3 ℃ and dripped methyl iodide in 10 minutes (62.3ml 1mol), continues to stir to spend the night under room temperature.Mixture is cooled to 3 ℃, in 6 hours, in reaction mixture, pumps into water (41).Filtration leaches precipitation, washes with water and dry in vacuum drying oven, obtains described title compound.MS (m/z): 324 (M+H) +C 18H 17N 3OS theoretical value 323.4.
Embodiment 58
Use corresponding raw material, (1, the 2-a) preparation method of pyrimidine-5-ketone can prepare following Table IV compound according to 6-(4-fluorophenyl)-2-methyl isophthalic acid-(3-hydrocinnamyl)-7-pyridin-4-yl-1H-imidazo.Have different R 11Substituent required pyrimidinone compound can be according to above-mentioned general method preparation.
Table IV
Figure C9718155801751
R 11 R 21
3, the 5-dichlorophenyl 2 (S)-amino-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2 (S)-amino-3-phenyl-propyl group
The 3-tolyl 2 (S)-amino-3-phenyl-propyl group
The 3-chloro-phenyl- 2 (S)-amino-3-phenyl-propyl group
The 4-fluorophenyl 2 (S)-amino-3-phenyl-propyl group
The 2-naphthyl 2 (S)-amino-3-phenyl-propyl group
Normal-butyl 2 (S)-amino-3-phenyl-propyl group
The 2-thiophene 2 (S)-amino-3-phenyl-propyl group
The 3-thiophene 2 (S)-amino-3-phenyl-propyl group
The 3-aminophenyl 2 (S)-amino-3-phenyl-propyl group
2-(5-chlorothiophene) 2 (S)-amino-3-phenyl-propyl group
The 3-isopropyl phenyl The 3-hydrocinnamyl
The 3-tolyl The 3-hydrocinnamyl
The 3-chloro-phenyl- The 3-hydrocinnamyl
3-chloro-4-fluorophenyl The 3-hydrocinnamyl
3,5-two trifluoromethyls The 3-hydrocinnamyl
The 4-fluorophenyl The 3-hydrocinnamyl
3, the 4-dichlorophenyl The 3-hydrocinnamyl
The 1-naphthyl The 3-hydrocinnamyl
The 3-fluorophenyl The 3-hydrocinnamyl
The 2-naphthyl The 3-hydrocinnamyl
Normal-butyl The 3-hydrocinnamyl
The 2-thiophene The 3-hydrocinnamyl
The 3-thiophene The 3-hydrocinnamyl
The 3-aminophenyl The 3-hydrocinnamyl
2-(5-chlorothiophene) The 3-hydrocinnamyl
3, the 5-dichlorophenyl 3-methyl-3-phenyl-propyl group
The 4-tolyl 3-methyl-3-phenyl-propyl group
The 3-trifluoromethyl 3-methyl-3-phenyl-propyl group
The 4-p-methoxy-phenyl 3-methyl-3-phenyl-propyl group
The 4-trifluoromethyl 3-methyl-3-phenyl-propyl group
The 3-isopropyl phenyl 3-methyl-3-phenyl-propyl group
The 3-tolyl 3-methyl-3-phenyl-propyl group
The 3-chloro-phenyl- 3-methyl-3-phenyl-propyl group
3-chloro-4-fluorophenyl 3-methyl-3-phenyl-propyl group
3,5-two trifluoromethyls 3-methyl-3-phenyl-propyl group
The 4-fluorophenyl 3-methyl-3-phenyl-propyl group
3, the 4-dichlorophenyl 3-methyl-3-phenyl-propyl group
The 2-naphthyl 3-methyl-3-phenyl-propyl group
Normal-butyl 3-methyl-3-phenyl-propyl group
The 2-thiophene 3-methyl-3-phenyl-propyl group
The 3-thiophene 3-methyl-3-phenyl-propyl group
The 3-aminophenyl 3-methyl-3-phenyl-propyl group
2-(5-chlorothiophene) 3-methyl-3-phenyl-propyl group
3, the 5-dichlorophenyl 3-amino-3-phenyl-propyl group
The 4-tolyl 3-amino-3-phenyl-propyl group
The 3-trifluoromethyl 3-amino-3-phenyl-propyl group
The 4-p-methoxy-phenyl 3-amino-3-phenyl-propyl group
The 4-trifluoromethyl 3-amino-3-phenyl-propyl group
The 3-isopropyl phenyl 3-amino-3-phenyl-propyl group
The 3-tolyl 3-amino-3-phenyl-propyl group
The 3-chloro-phenyl- 3-amino-3-phenyl-propyl group
3-chloro-4-fluorophenyl 3-amino-3-phenyl-propyl group
3,5-two trifluoromethyls 3-amino-3-phenyl-propyl group
The 4-fluorophenyl 3-amino-3-phenyl-propyl group
3, the 4-dichlorophenyl 3-amino-3-phenyl-propyl group
The 1-naphthyl 3-amino-3-phenyl-propyl group
The 3-fluorophenyl 3-amino-3-phenyl-propyl group
The 2-naphthyl 3-amino-3-phenyl-propyl group
Normal-butyl 3-amino-3-phenyl-propyl group
The 2-thiophene 3-amino-3-phenyl-propyl group
The 3-thiophene 3-amino-3-phenyl-propyl group
The 3-aminophenyl 3-amino-3-phenyl-propyl group
2-(5-chlorothiophene) 3-amino-3-phenyl-propyl group
3, the 5-dichlorophenyl 2 (R)-3-amino-3-phenyl-propyl group
The 4-tolyl 2 (R)-3-amino-3-phenyl-propyl group
The 3-trifluoromethyl 2 (R)-3-amino-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2 (R)-3-amino-3-phenyl-propyl group
The 4-trifluoromethyl 2 (R)-3-amino-3-phenyl-propyl group
The 3-isopropyl phenyl 2 (R)-3-amino-3-phenyl-propyl group
The 3-tolyl 2 (R)-3-amino-3-phenyl-propyl group
The 3-chloro-phenyl- 2 (R)-3-amino-3-phenyl-propyl group
3-chloro-4-fluorophenyl 2 (R)-3-amino-3-phenyl-propyl group
3,5-two trifluoromethyls 2 (R)-3-amino-3-phenyl-propyl group
The 4-fluorophenyl 2 (R)-3-amino-3-phenyl-propyl group
3, the 4-dichlorophenyl 2 (R)-3-amino-3-phenyl-propyl group
The 1-naphthyl 2 (R)-3-amino-3-phenyl-propyl group
The 3-fluorophenyl 2 (R)-3-amino-3-phenyl-propyl group
The 2-naphthyl 2 (R)-3-amino-3-phenyl-propyl group
Normal-butyl 2 (R)-3-amino-3-phenyl-propyl group
The 2-thiophene 2 (R)-3-amino-3-phenyl-propyl group
The 3-thiophene 2 (R)-3-amino-3-phenyl-propyl group
The 3-aminophenyl 2 (R)-3-amino-3-phenyl-propyl group
2-(5-chlorothiophene) 2 (R)-3-amino-3-phenyl-propyl group
3, the 5-dichlorophenyl 2-methyl-2-amino-3-phenyl-propyl group
The 4-tolyl 2-methyl-2-amino-3-phenyl-propyl group
The 3-trifluoromethyl 2-methyl-2-amino-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2-methyl-2-amino-3-phenyl-propyl group
The 4-trifluoromethyl 2-methyl-2-amino-3-phenyl-propyl group
The 3-isopropyl phenyl 2-methyl-2-amino-3-phenyl-propyl group
The 3-tolyl 2-methyl-2-amino-3-phenyl-propyl group
The 3-chloro-phenyl- 2-methyl-2-amino-3-phenyl-propyl group
3-chloro-4-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl group
3,5-two trifluoromethyls 2-methyl-2-amino-3-phenyl-propyl group
The 4-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl group
3, the 4-dichlorophenyl 2-methyl-2-amino-3-phenyl-propyl group
The 1-naphthyl 2-methyl-2-amino-3-phenyl-propyl group
The 3-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl group
The 2-naphthyl 2-methyl-2-amino-3-phenyl-propyl group
Normal-butyl 2-methyl-2-amino-3-phenyl-propyl group
The 2-thiophene 2-methyl-2-amino-3-phenyl-propyl group
The 3-thiophene 2-methyl-2-amino-3-phenyl-propyl group
The 3-aminophenyl 2-methyl-2-amino-3-phenyl-propyl group
2-(5-chlorothiophene) 2-methyl-2-amino-3-phenyl-propyl group
3, the 5-dichlorophenyl 2-methyl-3-phenyl-propyl group
The 4-tolyl 2-methyl-3-phenyl-propyl group
The 3-trifluoromethyl 2-methyl-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2-methyl-3-phenyl-propyl group
The 4-trifluoromethyl 2-methyl-3-phenyl-propyl group
The 3-isopropyl phenyl 2-methyl-3-phenyl-propyl group
The 3-tolyl 2-methyl-3-phenyl-propyl group
The 3-fluorophenyl 2-methyl-3-phenyl-propyl group
3-chloro-4-fluorophenyl 2-methyl-3-phenyl-propyl group
3,5-two trifluoromethyls 2-methyl-3-phenyl-propyl group
The 4-fluorophenyl 2-methyl-3-phenyl-propyl group
3, the 4-dichlorophenyl 2-methyl-3-phenyl-propyl group
The 1-naphthyl 2-methyl-3-phenyl-propyl group
The 3-fluorophenyl 2-methyl-3-phenyl-propyl group
The 2-naphthyl 2-methyl-3-phenyl-propyl group
Normal-butyl 2-methyl-3-phenyl-propyl group
The 2-thiophene 2-methyl-3-phenyl-propyl group
The 3-thiophene 2-methyl-3-phenyl-propyl group
The 3-aminophenyl 2-methyl-3-phenyl-propyl group
2-(5-chlorothiophene) 2-methyl-3-phenyl-propyl group
3, the 5-dichlorophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 4-tolyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-trifluoromethyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 4-trifluoromethyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-isopropyl phenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-tolyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-chloro-phenyl- 2-(N, N-dimethylamino)-3-phenyl-propyl group
3-chloro-4-fluorophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
3,5-two trifluoromethyls 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 4-fluorophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
3, the 4-dichlorophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 1-naphthyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-fluorophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 2-naphthyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
Normal-butyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 2-thiophene 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-thiophene 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-aminophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
2-(5-chlorothiophene) 2-(N, N-dimethylamino)-3-phenyl-propyl group
3, the 5-dichlorophenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 4-tolyl 2-(N-methylamino-)-3-phenyl-propyl group
The 3-trifluoromethyl 2-(N-methylamino-)-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 4-trifluoromethyl 2-(N-methylamino-)-3-phenyl-propyl group
The 3-isopropyl phenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 3-tolyl 2-(N-methylamino-)-3-phenyl-propyl group
The 3-chloro-phenyl- 2-(N-methylamino-)-3-phenyl-propyl group
3-chloro-4-fluorophenyl 2-(N-methylamino-)-3-phenyl-propyl group
3,5-two trifluoromethyls 2-(N-methylamino-)-3-phenyl-propyl group
3, the 4-dichlorophenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 4-fluorophenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 1-naphthyl 2-(N-methylamino-)-3-phenyl-propyl group
The 3-fluorophenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 2-naphthyl 2-(N-methylamino-)-3-phenyl-propyl group
Normal-butyl 2-(N-methylamino-)-3-phenyl-propyl group
The 2-thiophene 2-(N-methylamino-)-3-phenyl-propyl group
The 3-thiophene 2-(N-methylamino-)-3-phenyl-propyl group
The 3-aminophenyl 2-(N-methylamino-)-3-phenyl-propyl group
2-(5-chlorothiophene) 2-(N-methylamino-)-3-phenyl-propyl group
Embodiment 59
Can prepare the described compound of Table V with suitable raw material and following method: can prepare with above-mentioned general method and have different R 11Substituent required pyrimidinone compound.Can prepare R as mentioned above 21Be condensed 6,5 ring systems of hydrogen.With suitable amino protecting group (Boc group), utilize corresponding aldehyde can introduce other R through the reductive amination reaction 21Group.For example, described in document (Konieczny and Cushman Tetrahedron Lett 6939,1992).Can prepare N-Boc-phenylpropyl alcohol amino-aldehyde by corresponding Weinreb acid amides through reducing with lithium aluminium hydride.Then, described N-Boc-phenylpropyl alcohol amino-aldehyde can react with amino with triacetyl oxygen base borohydride.In addition, the alcohol of N-Boc-phenylpropyl alcohol amino alcohol can (triphenyl phosphine, azoformic acid diisopropyl ester) activate and react with 6,5 amino that condense ring system under the Mitsunobu condition, removes Boc group (trifluoroacetic acid) subsequently.
Table V
R 11 R 21
3, the 5-dichlorophenyl 2 (S)-amino-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2 (S)-amino-3-phenyl-propyl group
The 3-tolyl 2 (S)-amino-3-phenyl-propyl group
The 3-chloro-phenyl- 2 (S)-amino-3-phenyl-propyl group
The 4-fluorophenyl 2 (S)-amino-3-phenyl-propyl group
The 2-naphthyl 2 (S)-amino-3-phenyl-propyl group
Normal-butyl 2 (S)-amino-3-phenyl-propyl group
The 2-thiophene 2 (S)-amino-3-phenyl-propyl group
The 3-thiophene 2 (S)-amino-3-phenyl-propyl group
The 3-aminophenyl 2 (S)-amino-3-phenyl-propyl group
2-(5-chlorothiophene) 2 (S)-amino-3-phenyl-propyl group
The 3-isopropyl phenyl The 3-hydrocinnamyl
The 3-tolyl The 3-hydrocinnamyl
The 3-chloro-phenyl- The 3-hydrocinnamyl
3-chloro-4-fluorophenyl The 3-hydrocinnamyl
3,5-two trifluoromethyls The 3-hydrocinnamyl
The 4-fluorophenyl The 3-hydrocinnamyl
3, the 4-dichlorophenyl The 3-hydrocinnamyl
The 1-naphthyl The 3-hydrocinnamyl
The 3-fluorophenyl The 3-hydrocinnamyl
The 2-naphthyl The 3-hydrocinnamyl
Normal-butyl The 3-hydrocinnamyl
The 2-thiophene The 3-hydrocinnamyl
The 3-thiophene The 3-hydrocinnamyl
The 3-aminophenyl The 3-hydrocinnamyl
2-(5-chlorothiophene) The 3-hydrocinnamyl
3, the 5-dichlorophenyl 3-methyl-3-phenyl-propyl group
The 4-tolyl 3-methyl-3-phenyl-propyl group
The 3-trifluoromethyl 3-methyl-3-phenyl-propyl group
The 4-p-methoxy-phenyl 3-methyl-3-phenyl-propyl group
The 4-trifluoromethyl 3-methyl-3-phenyl-propyl group
The 3-isopropyl phenyl 3-methyl-3-phenyl-propyl group
The 3-tolyl 3-methyl-3-phenyl-propyl group
The 3-chloro-phenyl- 3-methyl-3-phenyl-propyl group
3-chloro-4-fluorophenyl 3-methyl-3-phenyl-propyl group
3,5-two trifluoromethyls 3-methyl-3-phenyl-propyl group
The 4-fluorophenyl 3-methyl-3-phenyl-propyl group
3, the 4-dichlorophenyl 3-methyl-3-phenyl-propyl group
The 2-naphthyl 3-methyl-3-phenyl-propyl group
Normal-butyl 3-methyl-3-phenyl-propyl group
The 2-thiophene 3-methyl-3-phenyl-propyl group
The 3-thiophene 3-methyl-3-phenyl-propyl group
The 3-aminophenyl 3-methyl-3-phenyl-propyl group
2-(5-chlorothiophene) 3-methyl-3-phenyl-propyl group
3, the 5-dichlorophenyl 3-amino-3-phenyl-propyl group
The 4-tolyl 3-amino-3-phenyl-propyl group
The 3-trifluoromethyl 3-amino-3-phenyl-propyl group
The 4-p-methoxy-phenyl 3-amino-3-phenyl-propyl group
The 4-trifluoromethyl 3-amino-3-phenyl-propyl group
The 3-isopropyl phenyl 3-amino-3-phenyl-propyl group
The 3-tolyl 3-amino-3-phenyl-propyl group
The 3-chloro-phenyl- 3-amino-3-phenyl-propyl group
3-chloro-4-fluorophenyl 3-amino-3-phenyl-propyl group
3,5-two trifluoromethyls 3-amino-3-phenyl-propyl group
The 4-fluorophenyl 3-amino-3-phenyl-propyl group
3, the 4-dichlorophenyl 3-amino-3-phenyl-propyl group
The 1-naphthyl 3-amino-3-phenyl-propyl group
The 3-fluorophenyl 3-amino-3-phenyl-propyl group
The 2-naphthyl 3-amino-3-phenyl-propyl group
Normal-butyl 3-amino-3-phenyl-propyl group
The 2-thiophene 3-amino-3-phenyl-propyl group
The 3-thiophene 3-amino-3-phenyl-propyl group
The 3-aminophenyl 3-amino-3-phenyl-propyl group
2-(5-chlorothiophene) 3-amino-3-phenyl-propyl group
3, the 5-dichlorophenyl 2 (R)-3-amino-3-phenyl-propyl group
The 4-tolyl 2 (R)-3-amino-3-phenyl-propyl group
The 3-trifluoromethyl 2 (R)-3-amino-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2 (R)-3-amino-3-phenyl-propyl group
The 4-trifluoromethyl 2 (R)-3-amino-3-phenyl-propyl group
The 3-isopropyl phenyl 2 (R)-3-amino-3-phenyl-propyl group
The 3-tolyl 2 (R)-3-amino-3-phenyl-propyl group
The 3-chloro-phenyl- 2 (R)-3-amino-3-phenyl-propyl group
3-chloro-4-fluorophenyl 2 (R)-3-amino-3-phenyl-propyl group
3,5-two trifluoromethyls 2 (R)-3-amino-3-phenyl-propyl group
The 4-fluorophenyl 2 (R)-3-amino-3-phenyl-propyl group
3, the 4-dichlorophenyl 2 (R)-3-amino-3-phenyl-propyl group
The 1-naphthyl 2 (R)-3-amino-3-phenyl-propyl group
The 3-fluorophenyl 2 (R)-3-amino-3-phenyl-propyl group
The 2-naphthyl 2 (R)-3-amino-3-phenyl-propyl group
Normal-butyl 2 (R)-3-amino-3-phenyl-propyl group
The 2-thiophene 2 (R)-3-amino-3-phenyl-propyl group
The 3-thiophene 2 (R)-3-amino-3-phenyl-propyl group
The 3-aminophenyl 2 (R)-3-amino-3-phenyl-propyl group
2-(5-chlorothiophene) 2 (R)-3-amino-3-phenyl-propyl group
3, the 5-dichlorophenyl 2-methyl-2-amino-3-phenyl-propyl group
The 4-tolyl 2-methyl-2-amino-3-phenyl-propyl group
The 3-trifluoromethyl 2-methyl-2-amino-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2-methyl-2-amino-3-phenyl-propyl group
The 4-trifluoromethyl 2-methyl-2-amino-3-phenyl-propyl group
The 3-isopropyl phenyl 2-methyl-2-amino-3-phenyl-propyl group
The 3-tolyl 2-methyl-2-amino-3-phenyl-propyl group
The 3-chloro-phenyl- 2-methyl-2-amino-3-phenyl-propyl group
3-chloro-4-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl group
3,5-two trifluoromethyls 2-methyl-2-amino-3-phenyl-propyl group
The 4-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl group
3, the 4-dichlorophenyl 2-methyl-2-amino-3-phenyl-propyl group
The 1-naphthyl 2-methyl-2-amino-3-phenyl-propyl group
The 3-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl group
The 2-naphthyl 2-methyl-2-amino-3-phenyl-propyl group
Normal-butyl 2-methyl-2-amino-3-phenyl-propyl group
The 2-thiophene 2-methyl-2-amino-3-phenyl-propyl group
The 3-thiophene 2-methyl-2-amino-3-phenyl-propyl group
The 3-aminophenyl 2-methyl-2-amino-3-phenyl-propyl group
2-(5-chlorothiophene) 2-methyl-2-amino-3-phenyl-propyl group
3, the 5-dichlorophenyl 2-methyl-3-phenyl-propyl group
The 4-tolyl 2-methyl-3-phenyl-propyl group
The 3-trifluoromethyl 2-methyl-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2-methyl-3-phenyl-propyl group
The 4-trifluoromethyl 2-methyl-3-phenyl-propyl group
The 3-isopropyl phenyl 2-methyl-3-phenyl-propyl group
The 3-tolyl 2-methyl-3-phenyl-propyl group
The 3-chloro-phenyl- 2-methyl-3-phenyl-propyl group
3-chloro-4-fluorophenyl 2-methyl-3-phenyl-propyl group
3,5-two trifluoromethyls 2-methyl-3-phenyl-propyl group
The 4-fluorophenyl 2-methyl-3-phenyl-propyl group
3, the 4-dichlorophenyl 2-methyl-3-phenyl-propyl group
The 1-naphthyl 2-methyl-3-phenyl-propyl group
The 3-fluorophenyl 2-methyl-3-phenyl-propyl group
The 2-naphthyl 2-methyl-3-phenyl-propyl group
Normal-butyl 2-methyl-3-phenyl-propyl group
The 2-thiophene 2-methyl-3-phenyl-propyl group
The 3-thiophene 2-methyl-3-phenyl-propyl group
The 3-aminophenyl 2-methyl-3-phenyl-propyl group
2-(5-chlorothiophene) 2-methyl-3-phenyl-propyl group
3, the 5-dichlorophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 4-tolyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-trifluoromethyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 4-trifluoromethyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-isopropyl phenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-tolyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-chloro-phenyl- 2-(N, N-dimethylamino)-3-phenyl-propyl group
3-chloro-4-fluorophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
3,5-two trifluoromethyls 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 4-fluorophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
3, the 4-dichlorophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 1-naphthyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-fluorophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 2-naphthyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
Normal-butyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 2-thiophene 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-thiophene 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-aminophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
2-(5-chlorothiophene) 2-(N, N-dimethylamino)-3-phenyl-propyl group
3, the 5-dichlorophenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 4-tolyl 2-(N-methylamino-)-3-phenyl-propyl group
The 3-trifluoromethyl 2-(N-methylamino-)-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 4-trifluoromethyl 2-(N-methylamino-)-3-phenyl-propyl group
The 3-isopropyl phenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 3-tolyl 2-(N-methylamino-)-3-phenyl-propyl group
The 3-chloro-phenyl- 2-(N-methylamino-)-3-phenyl-propyl group
3-chloro-4-fluorophenyl 2-(N-methylamino-)-3-phenyl-propyl group
3,5-two trifluoromethyls 2-(N-methylamino-)-3-phenyl-propyl group
3, the 4-dichlorophenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 4-fluorophenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 1-naphthyl 2-(N-methylamino-)-3-phenyl-propyl group
The 3-fluorophenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 2-naphthyl 2-(N-methylamino-)-3-phenyl-propyl group
Normal-butyl 2-(N-methylamino-)-3-phenyl-propyl group
The 2-thiophene 2-(N-methylamino-)-3-phenyl-propyl group
The 3-thiophene 2-(N-methylamino-)-3-phenyl-propyl group
The 3-aminophenyl 2-(N-methylamino-)-3-phenyl-propyl group
2-(5-chlorothiophene) 2-(N-methylamino-)-3-phenyl-propyl group
Embodiment 60
Can prepare the described compound of Table VI with suitable raw material and aforesaid method.
Table VI
R 11 R 21
3, the 5-dichlorophenyl 2 (S)-amino-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2 (S)-amino-3-phenyl-propyl group
The 3-tolyl 2 (S)-amino-3-phenyl-propyl group
The 3-chloro-phenyl- 2 (S)-amino-3-phenyl-propyl group
The 4-fluorophenyl 2 (S)-amino-3-phenyl-propyl group
The 2-naphthyl 2 (S)-amino-3-phenyl-propyl group
Normal-butyl 2 (S)-amino-3-phenyl-propyl group
The 2-thiophene 2 (S)-amino-3-phenyl-propyl group
The 3-thiophene 2 (S)-amino-3-phenyl-propyl group
The 3-aminophenyl 2 (S)-amino-3-phenyl-propyl group
2-(5-chlorothiophene) 2 (S)-amino-3-phenyl-propyl group
The 3-isopropyl phenyl The 3-hydrocinnamyl
The 3-tolyl The 3-hydrocinnamyl
The 3-chloro-phenyl- The 3-hydrocinnamyl
3-chloro-4-fluorophenyl The 3-hydrocinnamyl
3,5-two trifluoromethyls The 3-hydrocinnamyl
The 4-fluorophenyl The 3-hydrocinnamyl
3, the 4-dichlorophenyl The 3-hydrocinnamyl
The 1-naphthyl The 3-hydrocinnamyl
The 3-fluorophenyl The 3-hydrocinnamyl
The 2-naphthyl The 3-hydrocinnamyl
Normal-butyl The 3-hydrocinnamyl
The 2-thiophene The 3-hydrocinnamyl
The 3-thiophene The 3-hydrocinnamyl
The 3-aminophenyl The 3-hydrocinnamyl
2-(5-fluorine thiophene) The 3-hydrocinnamyl
3, the 5-dichlorophenyl 3-methyl-3-phenyl-propyl group
The 4-tolyl 3-methyl-3-phenyl-propyl group
The 3-trifluoromethyl 3-methyl-3-phenyl-propyl group
The 4-p-methoxy-phenyl 3-methyl-3-phenyl-propyl group
The 4-trifluoromethyl 3-methyl-3-phenyl-propyl group
The 3-isopropyl phenyl 3-methyl-3-phenyl-propyl group
The 3-tolyl 3-methyl-3-phenyl-propyl group
The 3-chloro-phenyl- 3-methyl-3-phenyl-propyl group
3-chloro-4-fluorophenyl 3-methyl-3-phenyl-propyl group
3,5-two trifluoromethyls 3-methyl-3-phenyl-propyl group
The 4-fluorophenyl 3-methyl-3-phenyl-propyl group
3, the 4-dichlorophenyl 3-methyl-3-phenyl-propyl group
The 2-naphthyl 3-methyl-3-phenyl-propyl group
Normal-butyl 3-methyl-3-phenyl-propyl group
The 2-thiophene 3-methyl-3-phenyl-propyl group
The 3-thiophene 3-methyl-3-phenyl-propyl group
The 3-aminophenyl 3-methyl-3-phenyl-propyl group
2-(5-chlorothiophene) 3-methyl-3-phenyl-propyl group
3, the 5-dichlorophenyl 3-amino-3-phenyl-propyl group
The 4-tolyl 3-amino-3-phenyl-propyl group
The 3-trifluoromethyl 3-amino-3-phenyl-propyl group
The 4-p-methoxy-phenyl 3-amino-3-phenyl-propyl group
The 4-trifluoromethyl 3-amino-3-phenyl-propyl group
The 3-isopropyl phenyl 3-amino-3-phenyl-propyl group
The 3-tolyl 3-amino-3-phenyl-propyl group
The 3-chloro-phenyl- 3-amino-3-phenyl-propyl group
3-chloro-4-fluorophenyl 3-amino-3-phenyl-propyl group
3,5-two trifluoromethyls 3-amino-3-phenyl-propyl group
The 4-fluorophenyl 3-amino-3-phenyl-propyl group
3, the 4-dichlorophenyl 3-amino-3-phenyl-propyl group
The 1-naphthyl 3-amino-3-phenyl-propyl group
The 3-fluorophenyl 3-amino-3-phenyl-propyl group
The 2-naphthyl 3-amino-3-phenyl-propyl group
Normal-butyl 3-amino-3-phenyl-propyl group
The 2-thiophene 3-amino-3-phenyl-propyl group
The 3-thiophene 3-amino-3-phenyl-propyl group
The 3-aminophenyl 3-amino-3-phenyl-propyl group
2-(5-chlorothiophene) 3-amino-3-phenyl-propyl group
3, the 5-dichlorophenyl 2 (R)-amino-3-phenyl-propyl group
The 4-tolyl 2 (R)-amino-3-phenyl-propyl group
The 3-trifluoromethyl 2 (R)-amino-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2 (R)-amino-3-phenyl-propyl group
The 4-trifluoromethyl 2 (R)-amino-3-phenyl-propyl group
The 3-isopropyl phenyl 2 (R)-amino-3-phenyl-propyl group
The 3-tolyl 2 (R)-amino-3-phenyl-propyl group
The 3-chloro-phenyl- 2 (R)-amino-3-phenyl-propyl group
3-chloro-4-fluorophenyl 2 (R)-amino-3-phenyl-propyl group
3,5-two trifluoromethyls 2 (R)-amino-3-phenyl-propyl group
The 4-fluorophenyl 2 (R)-amino-3-phenyl-propyl group
3, the 4-dichlorophenyl 2 (R)-amino-3-phenyl-propyl group
The 1-naphthyl 2 (R)-amino-3-phenyl-propyl group
The 3-fluorophenyl 2 (R)-amino-3-phenyl-propyl group
The 2-naphthyl 2 (R)-amino-3-phenyl-propyl group
Normal-butyl 2 (R)-amino-3-phenyl-propyl group
The 2-thiophene 2 (R)-amino-3-phenyl-propyl group
The 3-thiophene 2 (R)-amino-3-phenyl-propyl group
The 3-aminophenyl 2 (R)-amino-3-phenyl-propyl group
2-(5-chlorothiophene) 2 (R)-amino-3-phenyl-propyl group
3, the 5-dichlorophenyl 2-methyl-2-amino-3-phenyl-propyl group
The 4-tolyl 2-methyl-2-amino-3-phenyl-propyl group
The 3-trifluoromethyl 2-methyl-2-amino-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2-methyl-2-amino-3-phenyl-propyl group
The 4-trifluoromethyl 2-methyl-2-amino-3-phenyl-propyl group
The 3-isopropyl phenyl 2-methyl-2-amino-3-phenyl-propyl group
The 3-tolyl 2-methyl-2-amino-3-phenyl-propyl group
The 3-chloro-phenyl- 2-methyl-2-amino-3-phenyl-propyl group
3-chloro-4-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl group
3,5-two trifluoromethyls 2-methyl-2-amino-3-phenyl-propyl group
The 4-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl group
3, the 4-dichlorophenyl 2-methyl-2-amino-3-phenyl-propyl group
The 1-naphthyl 2-methyl-2-amino-3-phenyl-propyl group
The 3-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl group
The 2-naphthyl 2-methyl-2-amino-3-phenyl-propyl group
Normal-butyl 2-methyl-2-amino-3-phenyl-propyl group
The 2-thiophene 2-methyl-2-amino-3-phenyl-propyl group
The 3-thiophene 2-methyl-2-amino-3-phenyl-propyl group
The 3-aminophenyl 2-methyl-2-amino-3-phenyl-propyl group
2-(5-chlorothiophene) 2-methyl-2-amino-3-phenyl-propyl group
3, the 5-dichlorophenyl 2-methyl-3-phenyl-propyl group
The 4-tolyl 2-methyl-3-phenyl-propyl group
The 3-trifluoromethyl 2-methyl-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2-methyl-3-phenyl-propyl group
The 4-trifluoromethyl 2-methyl-3-phenyl-propyl group
The 3-isopropyl phenyl 2-methyl-3-phenyl-propyl group
The 3-tolyl 2-methyl-3-phenyl-propyl group
The 3-chloro-phenyl- 2-methyl-3-phenyl-propyl group
3-chloro-4-fluorophenyl 2-methyl-3-phenyl-propyl group
3,5-two trifluoromethyls 2-methyl-3-phenyl-propyl group
The 4-fluorophenyl 2-methyl-3-phenyl-propyl group
3, the 4-dichlorophenyl 2-methyl-3-phenyl-propyl group
The 1-naphthyl 2-methyl-3-phenyl-propyl group
The 3-fluorophenyl 2-methyl-3-phenyl-propyl group
The 2-naphthyl 2-methyl-3-phenyl-propyl group
Normal-butyl 2-methyl-3-phenyl-propyl group
The 2-thiophene 2-methyl-3-phenyl-propyl group
The 3-thiophene 2-methyl-3-phenyl-propyl group
The 3-aminophenyl 2-methyl-3-phenyl-propyl group
2-(5-chlorothiophene) 2-methyl-3-phenyl-propyl group
3, the 5-dichlorophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 4-tolyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-trifluoromethyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 4-trifluoromethyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-isopropyl phenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-tolyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-chloro-phenyl- 2-(N, N-dimethylamino)-3-phenyl-propyl group
3-chloro-4-fluorophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
3,5-two trifluoromethyls 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 4-fluorophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
3, the 4-dichlorophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 1-naphthyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-fluorophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 2-naphthyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
Normal-butyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 2-thiophene 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-thiophene 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-aminophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
2-(5-chlorothiophene) 2-(N, N-dimethylamino)-3-phenyl-propyl group
3, the 5-dichlorophenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 4-tolyl 2-(N-methylamino-)-3-phenyl-propyl group
The 3-trifluoromethyl 2-(N-methylamino-)-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 4-trifluoromethyl 2-(N-methylamino-)-3-phenyl-propyl group
The 3-isopropyl phenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 3-tolyl 2-(N-methylamino-)-3-phenyl-propyl group
The 3-chloro-phenyl- 2-(N-methylamino-)-3-phenyl-propyl group
3-chloro-4-fluorophenyl 2-(N-methylamino-)-3-phenyl-propyl group
3,5-two trifluoromethyls 2-(N-methylamino-)-3-phenyl-propyl group
3, the 4-dichlorophenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 4-fluorophenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 1-naphthyl 2-(N-methylamino-)-3-phenyl-propyl group
The 3-fluorophenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 2-naphthyl 2-(N-methylamino-)-3-phenyl-propyl group
Normal-butyl 2-(N-methylamino-)-3-phenyl-propyl group
The 2-thiophene 2-(N-methylamino-)-3-phenyl-propyl group
The 3-thiophene 2-(N-methylamino-)-3-phenyl-propyl group
The 3-aminophenyl 2-(N-methylamino-)-3-phenyl-propyl group
2-(5-chlorothiophene) 2-(N-methylamino-)-3-phenyl-propyl group
Embodiment 61
Can prepare the described compound of Table VII with suitable raw material and aforesaid method.
Table VII
R 11 R 21
3, the 5-dichlorophenyl 2 (S)-amino-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2 (S)-amino-3-phenyl-propyl group
The 3-tolyl 2 (S)-amino-3-phenyl-propyl group
The 3-chloro-phenyl- 2 (S)-amino-3-phenyl-propyl group
The 4-fluorophenyl 2 (S)-amino-3-phenyl-propyl group
The 2-naphthyl 2 (S)-amino-3-phenyl-propyl group
Normal-butyl 2 (S)-amino-3-phenyl-propyl group
The 2-thiophene 2 (S)-amino-3-phenyl-propyl group
The 3-thiophene 2 (S)-amino-3-phenyl-propyl group
The 3-aminophenyl 2 (S)-amino-3-phenyl-propyl group
2-(5-chlorothiophene) 2 (S)-amino-3-phenyl-propyl group
The 3-isopropyl phenyl The 3-hydrocinnamyl
The 3-tolyl The 3-hydrocinnamyl
The 3-chloro-phenyl- The 3-hydrocinnamyl
3-chloro-4-fluorophenyl The 3-hydrocinnamyl
3,5-two trifluoromethyls The 3-hydrocinnamyl
The 4-fluorophenyl The 3-hydrocinnamyl
3, the 4-dichlorophenyl The 3-hydrocinnamyl
The 1-naphthyl The 3-hydrocinnamyl
The 3-fluorophenyl The 3-hydrocinnamyl
The 2-naphthyl The 3-hydrocinnamyl
Normal-butyl The 3-hydrocinnamyl
The 2-thiophene The 3-hydrocinnamyl
The 3-thiophene The 3-hydrocinnamyl
The 3-aminophenyl The 3-hydrocinnamyl
2-(5-chlorothiophene) The 3-hydrocinnamyl
3, the 5-dichlorophenyl 3-methyl-3-phenyl-propyl group
The 4-tolyl 3-methyl-3-phenyl-propyl group
The 3-trifluoromethyl 3-methyl-3-phenyl-propyl group
The 4-p-methoxy-phenyl 3-methyl-3-phenyl-propyl group
The 4-trifluoromethyl 3-methyl-3-phenyl-propyl group
The 3-isopropyl phenyl 3-methyl-3-phenyl-propyl group
The 3-tolyl 3-methyl-3-phenyl-propyl group
The 3-chloro-phenyl- 3-methyl-3-phenyl-propyl group
3-chloro-4-fluorophenyl 3-methyl-3-phenyl-propyl group
3,5-two trifluoromethyls 3-methyl-3-phenyl-propyl group
The 4-fluorophenyl 3-methyl-3-phenyl-propyl group
3, the 4-dichlorophenyl 3-methyl-3-phenyl-propyl group
The 2-naphthyl 3-methyl-3-phenyl-propyl group
Normal-butyl 3-methyl-3-phenyl-propyl group
The 2-thiophene 3-methyl-3-phenyl-propyl group
The 3-thiophene 3-methyl-3-phenyl-propyl group
The 3-aminophenyl 3-methyl-3-phenyl-propyl group
2-(5-chlorothiophene) 3-methyl-3-phenyl-propyl group
3, the 5-dichlorophenyl 3-amino-3-phenyl-propyl group
The 4-tolyl 3-amino-3-phenyl-propyl group
The 3-trifluoromethyl 3-amino-3-phenyl-propyl group
The 4-p-methoxy-phenyl 3-amino-3-phenyl-propyl group
The 4-trifluoromethyl 3-amino-3-phenyl-propyl group
The 3-isopropyl phenyl 3-amino-3-phenyl-propyl group
The 3-tolyl 3-amino-3-phenyl-propyl group
The 3-chloro-phenyl- 3-amino-3-phenyl-propyl group
3-chloro-4-fluorophenyl 3-amino-3-phenyl-propyl group
3,5-two trifluoromethyls 3-amino-3-phenyl-propyl group
The 4-fluorophenyl 3-amino-3-phenyl-propyl group
3, the 4-dichlorophenyl 3-amino-3-phenyl-propyl group
The 1-naphthyl 3-amino-3-phenyl-propyl group
The 3-fluorophenyl 3-amino-3-phenyl-propyl group
The 2-naphthyl 3-amino-3-phenyl-propyl group
Normal-butyl 3-amino-3-phenyl-propyl group
The 2-thiophene 3-amino-3-phenyl-propyl group
The 3-thiophene 3-amino-3-phenyl-propyl group
The 3-aminophenyl 3-amino-3-phenyl-propyl group
2-(5-chlorothiophene) 3-amino-3-phenyl-propyl group
3, the 5-dichlorophenyl 2 (R)-amino-3-phenyl-propyl group
The 4-tolyl 2 (R)-amino-3-phenyl-propyl group
The 3-trifluoromethyl 2 (R)-amino-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2 (R)-amino-3-phenyl-propyl group
The 4-trifluoromethyl 2 (R)-amino-3-phenyl-propyl group
The 3-isopropyl phenyl 2 (R)-amino-3-phenyl-propyl group
The 3-tolyl 2 (R)-amino-3-phenyl-propyl group
The 3-chloro-phenyl- 2 (R)-amino-3-phenyl-propyl group
3-chloro-4-fluorophenyl 2 (R)-amino-3-phenyl-propyl group
3,5-two trifluoromethyls 2 (R)-amino-3-phenyl-propyl group
The 4-fluorophenyl 2 (R)-amino-3-phenyl-propyl group
3, the 4-dichlorophenyl 2 (R)-amino-3-phenyl-propyl group
The 1-naphthyl 2 (R)-amino-3-phenyl-propyl group
The 3-fluorophenyl 2 (R)-amino-3-phenyl-propyl group
The 2-naphthyl 2 (R)-amino-3-phenyl-propyl group
Normal-butyl 2 (R)-amino-3-phenyl-propyl group
The 2-thiophene 2 (R)-amino-3-phenyl-propyl group
The 3-thiophene 2 (R)-amino-3-phenyl-propyl group
The 3-aminophenyl 2 (R)-amino-3-phenyl-propyl group
2-(5-chlorothiophene) 2 (R)-amino-3-phenyl-propyl group
3, the 5-dichlorophenyl 2-methyl-2-amino-3-phenyl-propyl group
The 4-tolyl 2-methyl-2-amino-3-phenyl-propyl group
The 3-trifluoromethyl 2-methyl-2-amino-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2-methyl-2-amino-3-phenyl-propyl group
The 4-trifluoromethyl 2-methyl-2-amino-3-phenyl-propyl group
The 3-isopropyl phenyl 2-methyl-2-amino-3-phenyl-propyl group
The 3-tolyl 2-methyl-2-amino-3-phenyl-propyl group
The 3-chloro-phenyl- 2-methyl-2-amino-3-phenyl-propyl group
3-chloro-4-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl group
3,5-two trifluoromethyls 2-methyl-2-amino-3-phenyl-propyl group
The 4-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl group
3, the 4-dichlorophenyl 2-methyl-2-amino-3-phenyl-propyl group
The 1-naphthyl 2-methyl-2-amino-3-phenyl-propyl group
The 3-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl group
The 2-naphthyl 2-methyl-2-amino-3-phenyl-propyl group
Normal-butyl 2-methyl-2-amino-3-phenyl-propyl group
The 2-thiophene 2-methyl-2-amino-3-phenyl-propyl group
The 3-thiophene 2-methyl-2-amino-3-phenyl-propyl group
The 3-aminophenyl 2-methyl-2-amino-3-phenyl-propyl group
2-(5-chlorothiophene) 2-methyl-2-amino-3-phenyl-propyl group
3, the 5-dichlorophenyl 2-methyl-3-phenyl-propyl group
The 4-tolyl 2-methyl-3-phenyl-propyl group
The 3-trifluoromethyl 2-methyl-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2-methyl-3-phenyl-propyl group
The 4-trifluoromethyl 2-methyl-3-phenyl-propyl group
The 3-isopropyl phenyl 2-methyl-3-phenyl-propyl group
The 3-tolyl 2-methyl-3-phenyl-propyl group
The 3-chloro-phenyl- 2-methyl-3-phenyl-propyl group
3-chloro-4-fluorophenyl 2-methyl-3-phenyl-propyl group
3,5-two trifluoromethyls 2-methyl-3-phenyl-propyl group
The 4-fluorophenyl 2-methyl-3-phenyl-propyl group
3, the 4-dichlorophenyl 2-methyl-3-phenyl-propyl group
The 1-naphthyl 2-methyl-3-phenyl-propyl group
The 3-fluorophenyl 2-methyl-3-phenyl-propyl group
The 2-naphthyl 2-methyl-3-phenyl-propyl group
Normal-butyl 2-methyl-3-phenyl-propyl group
The 2-thiophene 2-methyl-3-phenyl-propyl group
The 3-thiophene 2-methyl-3-phenyl-propyl group
The 3-aminophenyl 2-methyl-3-phenyl-propyl group
2-(5-chlorothiophene) 2-methyl-3-phenyl-propyl group
3, the 5-dichlorophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 4-tolyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-trifluoromethyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 4-trifluoromethyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-isopropyl phenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-tolyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-chloro-phenyl- 2-(N, N-dimethylamino)-3-phenyl-propyl group
3-chloro-4-fluorophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
3,5-two trifluoromethyls 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 4-fluorophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
3, the 4-dichlorophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 1-naphthyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-fluorophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 2-naphthyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
Normal-butyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 2-thiophene 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-thiophene 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-aminophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
2-(5-chlorothiophene) 2-(N, N-dimethylamino)-3-phenyl-propyl group
3, the 5-dichlorophenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 4-tolyl 2-(N-methylamino-)-3-phenyl-propyl group
The 3-trifluoromethyl 2-(N-methylamino-)-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 4-trifluoromethyl 2-(N-methylamino-)-3-phenyl-propyl group
The 3-isopropyl phenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 3-tolyl 2-(N-methylamino-)-3-phenyl-propyl group
The 3-chloro-phenyl- 2-(N-methylamino-)-3-phenyl-propyl group
3-chloro-4-fluorophenyl 2-(N-methylamino-)-3-phenyl-propyl group
3,5-two trifluoromethyls 2-(N-methylamino-)-3-phenyl-propyl group
3, the 4-dichlorophenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 4-fluorophenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 1-naphthyl 2-(N-methylamino-)-3-phenyl-propyl group
The 3-fluorophenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 2-naphthyl 2-(N-methylamino-)-3-phenyl-propyl group
Normal-butyl 2-(N-methylamino-)-3-phenyl-propyl group
The 2-thiophene 2-(N-methylamino-)-3-phenyl-propyl group
The 3-thiophene 2-(N-methylamino-)-3-phenyl-propyl group
The 3-aminophenyl 2-(N-methylamino-)-3-phenyl-propyl group
2-(5-chlorothiophene) 2-(N-methylamino-)-3-phenyl-propyl group
Embodiment 62
With suitable raw material, utilize the preparation method of 3-methyl-2-(2 (S)-amino-3-phenyl third amino)-5-(3-trifluoromethyl)-6-(4-pyridyl)-4 (3H)-pyrimidones, can prepare the described compound of Table VIII.
Table VIII
Figure C9718155801981
R 11 R 21
3, the 5-dichlorophenyl 2 (S)-amino-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2 (S)-amino-3-phenyl-propyl group
The 3-tolyl 2 (S)-amino-3-phenyl-propyl group
The 3-chloro-phenyl- 2 (S)-amino-3-phenyl-propyl group
The 4-fluorophenyl 2 (S)-amino-3-phenyl-propyl group
The 2-naphthyl 2 (S)-amino-3-phenyl-propyl group
Normal-butyl 2 (S)-amino-3-phenyl-propyl group
The 2-thiophene 2 (S)-amino-3-phenyl-propyl group
The 3-thiophene 2 (S)-amino-3-phenyl-propyl group
The 3-aminophenyl 2 (S)-amino-3-phenyl-propyl group
2-(5-chlorothiophene) 2 (S)-amino-3-phenyl-propyl group
The 3-isopropyl phenyl The 3-hydrocinnamyl
The 3-tolyl The 3-hydrocinnamyl
The 3-chloro-phenyl- The 3-hydrocinnamyl
3-chloro-4-fluorophenyl The 3-hydrocinnamyl
3,5-two trifluoromethyls The 3-hydrocinnamyl
The 4-fluorophenyl The 3-hydrocinnamyl
3, the 4-dichlorophenyl The 3-hydrocinnamyl
The 1-naphthyl The 3-hydrocinnamyl
The 3-fluorophenyl The 3-hydrocinnamyl
The 2-naphthyl The 3-hydrocinnamyl
Normal-butyl The 3-hydrocinnamyl
The 2-thiophene The 3-hydrocinnamyl
The 3-thiophene The 3-hydrocinnamyl
The 3-aminophenyl The 3-hydrocinnamyl
2-(5-chlorothiophene) The 3-hydrocinnamyl
3, the 5-dichlorophenyl 3-methyl-3-phenyl-propyl group
The 4-tolyl 3-methyl-3-phenyl-propyl group
The 3-trifluoromethyl 3-methyl-3-phenyl-propyl group
The 4-p-methoxy-phenyl 3-methyl-3-phenyl-propyl group
The 4-trifluoromethyl 3-methyl-3-phenyl-propyl group
The 3-isopropyl phenyl 3-methyl-3-phenyl-propyl group
The 3-tolyl 3-methyl-3-phenyl-propyl group
The 3-chloro-phenyl- 3-methyl-3-phenyl-propyl group
3-chloro-4-fluorophenyl 3-methyl-3-phenyl-propyl group
3,5-two trifluoromethyls 3-methyl-3-phenyl-propyl group
The 4-fluorophenyl 3-methyl-3-phenyl-propyl group
3, the 4-dichlorophenyl 3-methyl-3-phenyl-propyl group
The 2-naphthyl 3-methyl-3-phenyl-propyl group
Normal-butyl 3-methyl-3-phenyl-propyl group
The 2-thiophene 3-methyl-3-phenyl-propyl group
The 3-thiophene 3-methyl-3-phenyl-propyl group
The 3-aminophenyl 3-methyl-3-phenyl-propyl group
2-(5-chlorothiophene) 3-methyl-3-phenyl-propyl group
3, the 5-dichlorophenyl 3-amino-3-phenyl-propyl group
The 4-tolyl 3-amino-3-phenyl-propyl group
The 3-trifluoromethyl 3-amino-3-phenyl-propyl group
The 4-p-methoxy-phenyl 3-amino-3-phenyl-propyl group
The 4-trifluoromethyl 3-amino-3-phenyl-propyl group
The 3-isopropyl phenyl 3-amino-3-phenyl-propyl group
The 3-tolyl 3-amino-3-phenyl-propyl group
The 3-chloro-phenyl- 3-amino-3-phenyl-propyl group
3-chloro-4-fluorophenyl 3-amino-3-phenyl-propyl group
3,5-two trifluoromethyls 3-amino-3-phenyl-propyl group
The 4-fluorophenyl 3-amino-3-phenyl-propyl group
3, the 4-dichlorophenyl 3-amino-3-phenyl-propyl group
The 1-naphthyl 3-amino-3-phenyl-propyl group
The 3-fluorophenyl 3-amino-3-phenyl-propyl group
The 2-naphthyl 3-amino-3-phenyl-propyl group
Normal-butyl 3-amino-3-phenyl-propyl group
The 2-thiophene 3-amino-3-phenyl-propyl group
The 3-thiophene 3-amino-3-phenyl-propyl group
The 3-aminophenyl 3-amino-3-phenyl-propyl group
2-(5-chlorothiophene) 3-amino-3-phenyl-propyl group
3, the 5-dichlorophenyl 2 (R)-amino-3-phenyl-propyl group
The 4-tolyl 2 (R)-amino-3-phenyl-propyl group
The 3-trifluoromethyl 2 (R)-amino-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2 (R)-amino-3-phenyl-propyl group
The 4-trifluoromethyl 2 (R)-amino-3-phenyl-propyl group
The 3-isopropyl phenyl 2 (R)-amino-3-phenyl-propyl group
The 3-tolyl 2 (R)-amino-3-phenyl-propyl group
The 3-chloro-phenyl- 2 (R)-amino-3-phenyl-propyl group
3-chloro-4-fluorophenyl 2 (R)-amino-3-phenyl-propyl group
3,5-two trifluoromethyls 2 (R)-amino-3-phenyl-propyl group
The 4-fluorophenyl 2 (R)-amino-3-phenyl-propyl group
3, the 4-dichlorophenyl 2 (R)-amino-3-phenyl-propyl group
The 1-naphthyl 2 (R)-amino-3-phenyl-propyl group
The 3-fluorophenyl 2 (R)-amino-3-phenyl-propyl group
The 2-naphthyl 2 (R)-amino-3-phenyl-propyl group
Normal-butyl 2 (R)-amino-3-phenyl-propyl group
The 2-thiophene 2 (R)-amino-3-phenyl-propyl group
The 3-thiophene 2 (R)-amino-3-phenyl-propyl group
The 3-aminophenyl 2 (R)-amino-3-phenyl-propyl group
2-(5-chlorothiophene) 2 (R)-amino-3-phenyl-propyl group
3, the 5-dichlorophenyl 2-methyl-2-amino-3-phenyl-propyl group
The 4-tolyl 2-methyl-2-amino-3-phenyl-propyl group
The 3-trifluoromethyl 2-methyl-2-amino-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2-methyl-2-amino-3-phenyl-propyl group
The 4-trifluoromethyl 2-methyl-2-amino-3-phenyl-propyl group
The 3-isopropyl phenyl 2-methyl-2-amino-3-phenyl-propyl group
The 3-tolyl 2-methyl-2-amino-3-phenyl-propyl group
The 3-chloro-phenyl- 2-methyl-2-amino-3-phenyl-propyl group
3-chloro-4-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl group
3,5-two trifluoromethyls 2-methyl-2-amino-3-phenyl-propyl group
The 4-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl group
3, the 4-dichlorophenyl 2-methyl-2-amino-3-phenyl-propyl group
The 1-naphthyl 2-methyl-2-amino-3-phenyl-propyl group
The 3-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl group
The 2-naphthyl 2-methyl-2-amino-3-phenyl-propyl group
Normal-butyl 2-methyl-2-amino-3-phenyl-propyl group
The 2-thiophene 2-methyl-2-amino-3-phenyl-propyl group
The 3-thiophene 2-methyl-2-amino-3-phenyl-propyl group
The 3-aminophenyl 2-methyl-2-amino-3-phenyl-propyl group
2-(5-chlorothiophene) 2-methyl-2-amino-3-phenyl-propyl group
3, the 5-dichlorophenyl 2-methyl-3-phenyl-propyl group
The 4-tolyl 2-methyl-3-phenyl-propyl group
The 3-trifluoromethyl 2-methyl-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2-methyl-3-phenyl-propyl group
The 4-trifluoromethyl 2-methyl-3-phenyl-propyl group
The 3-isopropyl phenyl 2-methyl-3-phenyl-propyl group
The 3-tolyl 2-methyl-3-phenyl-propyl group
The 3-chloro-phenyl- 2-methyl-3-phenyl-propyl group
3-chloro-4-fluorophenyl 2-methyl-3-phenyl-propyl group
3,5-two trifluoromethyls 2-methyl-3-phenyl-propyl group
The 4-fluorophenyl 2-methyl-3-phenyl-propyl group
3, the 4-dichlorophenyl 2-methyl-3-phenyl-propyl group
The 1-naphthyl 2-methyl-3-phenyl-propyl group
The 3-fluorophenyl 2-methyl-3-phenyl-propyl group
The 2-naphthyl 2-methyl-3-phenyl-propyl group
Normal-butyl 2-methyl-3-phenyl-propyl group
The 2-thiophene 2-methyl-3-phenyl-propyl group
The 3-thiophene 2-methyl-3-phenyl-propyl group
The 3-aminophenyl 2-methyl-3-phenyl-propyl group
2-(5-chlorothiophene) 2-methyl-3-phenyl-propyl group
3, the 5-dichlorophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 4-tolyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-trifluoromethyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 4-trifluoromethyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-isopropyl phenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-tolyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-chloro-phenyl- 2-(N, N-dimethylamino)-3-phenyl-propyl group
3-chloro-4-fluorophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
3,5-two trifluoromethyls 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 4-fluorophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
3, the 4-dichlorophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 1-naphthyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-fluorophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 2-naphthyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
Normal-butyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 2-thiophene 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-thiophene 2-(N, N-dimethylamino)-3-phenyl-propyl group
The 3-aminophenyl 2-(N, N-dimethylamino)-3-phenyl-propyl group
2-(5-chlorothiophene) 2-(N, N-dimethylamino)-3-phenyl-propyl group
3, the 5-dichlorophenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 4-tolyl 2-(N-methylamino-)-3-phenyl-propyl group
The 3-trifluoromethyl 2-(N-methylamino-)-3-phenyl-propyl group
The 4-p-methoxy-phenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 4-trifluoromethyl 2-(N-methylamino-)-3-phenyl-propyl group
The 3-isopropyl phenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 3-tolyl 2-(N-methylamino-)-3-phenyl-propyl group
The 3-chloro-phenyl- 2-(N-methylamino-)-3-phenyl-propyl group
3-chloro-4-fluorophenyl 2-(N-methylamino-)-3-phenyl-propyl group
3,5-two trifluoromethyls 2-(N-methylamino-)-3-phenyl-propyl group
3, the 4-dichlorophenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 4-fluorophenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 1-naphthyl 2-(N-methylamino-)-3-phenyl-propyl group
The 3-fluorophenyl 2-(N-methylamino-)-3-phenyl-propyl group
The 2-naphthyl 2-(N-methylamino-)-3-phenyl-propyl group
Normal-butyl 2-(N-methylamino-)-3-phenyl-propyl group
The 2-thiophene 2-(N-methylamino-)-3-phenyl-propyl group
The 3-thiophene 2-(N-methylamino-)-3-phenyl-propyl group
The 3-aminophenyl 2-(N-methylamino-)-3-phenyl-propyl group
2-(5-chlorothiophene) 2-(N-methylamino-)-3-phenyl-propyl group
Embodiment 63
The preparation method of 2-((2-(3-trifluoromethyl) phenmethyl) amino)-3-methyl-5-(4-fluorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
Figure C9718155802041
Steps A .2-((2-Brombenzyl) amino)-5-(4-fluorophenyl)-6-(4-pyridyl)-3 -methyl-4 (3H)-pyrimidone: with described compound 3-methyl-5-(4-fluorophenyl)-6-(4-pyridyl)-2-methylthio group-4 (3H)-pyrimidone (470mg, 1.44mmol) be dissolved in methyl alcohol: water mixture (1.8: 1,40ml and 22.5ml) in, add permonosulphuric acid potassium (OXONE Aldrich) in refrigerative (4 ℃) reaction mixture, reaction is at room temperature proceeded 16 hours then.Reaction mixture is concentrated, use dichloromethane extraction, organic layer washes with water, Na 2SO 4Dry and concentrated.Resistates (500mg) and neighbour-bromobenzyl amine mixes in the 4-two  alkane (20ml) in 1, and settled solution was heated 18 hours down in 85 ℃, and reaction is monitored with TLC in carrying out.Reaction mixture is concentrated and separate, obtain described title compound in the enterprising circumstances in which people get things ready for a trip spectrum of silicagel column.MS (m/z): 466.9C 23H 28BrFN 4O theoretical value: 465.33 1H-NMR (CDCl 3): d8.49 (dd, 2H, pyridyl), 7.67-6.81 (m, 12H, Ph and pyridyl), 5.44 (t, 1H, NH), 4.92 (d2H, CH 2-Ph), 3.6 (s, 3H, N-CH 3).
Step is ((2-(3-trifluoromethyl) phenmethyl) amino)-3-methyl-5-(4-B.2- Fluorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones: with 2-((2-Brombenzyl) amino)-5-(4-fluorophenyl)-6-(4-pyridyl)-3-methyl-4 (3H)-pyrimidone (175mg, 0.38mmol) be suspended in 2M sodium carbonate solution (12ml) and 3-trifluoromethylbenzene-boric acid (170mg, 0.89mmol) in, in said mixture, add toluene (12ml) and, add catalyzer four triphenyl phosphine Pd (0) (50mg) the reaction mixture degassing.With reaction mixture refluxed 16 hours, the forming process of product was monitored with TLC, then with its cooling, diluted and washed with water with toluene (12ml).The organic layer dried over sodium sulfate, concentrate and with product through the silica gel chromatography purifying, obtain described title compound.
MS (m/z): 531.1 C 30H 22F 4N 4O theoretical value 530.53; 1H-NMR (CDCl 3): d8.43 (m, 2H, pyridyl), 7.69-7.12 (m, 8H, Ph), 7.11-6.88 (m, 6H, pyridyl and Ph-CF 3), 4.85 (m, 3H, CH 2-Ph and NH), 3.32 (N-CH 3).
Embodiment 64
Use corresponding raw material, utilize the preparation method of 2-((2-(3-trifluoromethyl) phenmethyl) amino)-3-methyl-5-(4-fluorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones, can prepare the described compound of following Table I X.
Table I X
Figure C9718155802051
R 11 R 40
The 4-fluorophenyl 3, the 5-dichlorophenyl
The 4-fluorophenyl The 4-tolyl
The 4-fluorophenyl The 4-p-methoxy-phenyl
The 4-fluorophenyl The 4-trifluoromethyl
The 4-fluorophenyl The 3-isopropyl phenyl
The 4-fluorophenyl The 3-tolyl
The 4-fluorophenyl The 3-chloro-phenyl-
The 4-fluorophenyl 3-chloro-4-fluorophenyl
The 4-fluorophenyl 3,5-two trifluoromethyls
The 4-fluorophenyl The 4-fluorophenyl
The 4-fluorophenyl 3, the 4-dichlorophenyl
The 4-fluorophenyl The 1-naphthyl
The 4-fluorophenyl The 3-fluorophenyl
The 4-fluorophenyl The 2-naphthyl
The 4-fluorophenyl Normal-butyl
The 4-fluorophenyl The 2-thiophene
The 4-fluorophenyl The 3-thiophene
The 4-fluorophenyl The 3-aminophenyl
The 4-fluorophenyl 2-(5-chlorothiophene)
The 3-trifluoromethyl 3, the 5-dichlorophenyl
The 3-trifluoromethyl The 4-tolyl
The 3-trifluoromethyl The 3-trifluoromethyl
The 3-trifluoromethyl The 4-p-methoxy-phenyl
The 3-trifluoromethyl The 4-trifluoromethyl
The 3-trifluoromethyl The 3-isopropyl phenyl
The 3-trifluoromethyl The 3-tolyl
The 3-trifluoromethyl The 3-chloro-phenyl-
The 3-trifluoromethyl 3-chloro-4-fluorophenyl
The 3-trifluoromethyl 3,5-two trifluoromethyls
The 3-trifluoromethyl The 4-fluorophenyl
The 3-trifluoromethyl 3, the 4-dichlorophenyl
The 3-trifluoromethyl The 1-naphthyl
The 3-trifluoromethyl The 3-fluorophenyl
The 3-trifluoromethyl The 2-naphthyl
The 3-trifluoromethyl Normal-butyl
The 3-trifluoromethyl The 2-thiophene
The 3-trifluoromethyl The 3-thiophene
The 3-trifluoromethyl The 3-aminophenyl
The 3-trifluoromethyl 2-(5-chlorothiophene)
Embodiment 65
Use corresponding raw material, utilize the preparation method of 2-((2-(3-trifluoromethyl) phenmethyl) amino)-3-methyl-5-(4-fluorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones, can prepare the described compound of following Table X.
Table X
Figure C9718155802071
R 11 R 40
The 4-fluorophenyl 3, the 5-dichlorophenyl
The 4-fluorophenyl The 4-tolyl
The 4-fluorophenyl The 4-p-methoxy-phenyl
The 4-fluorophenyl The 4-trifluoromethyl
The 4-fluorophenyl The 3-isopropyl phenyl
The 4-fluorophenyl The 3-tolyl
The 4-fluorophenyl The 3-chloro-phenyl-
The 4-fluorophenyl 3-chloro-4-fluorophenyl
The 4-fluorophenyl 3,5-two trifluoromethyls
The 4-fluorophenyl The 4-fluorophenyl
The 4-fluorophenyl 3, the 4-difluorophenyl
The 4-fluorophenyl The 1-naphthyl
The 4-fluorophenyl The 3-fluorophenyl
The 4-fluorophenyl The 2-naphthyl
The 4-fluorophenyl Normal-butyl
The 4-fluorophenyl The 2-thiophene
The 4-fluorophenyl The 3-thiophene
The 4-fluorophenyl The 3-aminophenyl
The 4-fluorophenyl 2-(5-chlorothiophene)
The 3-trifluoromethyl 3, the 5-dichlorophenyl
The 3-trifluoromethyl The 4-tolyl
The 3-trifluoromethyl The 3-trifluoromethyl
The 3-trifluoromethyl The 4-p-methoxy-phenyl
The 3-trifluoromethyl The 4-trifluoromethyl
The 3-trifluoromethyl The 3-isopropyl phenyl
The 3-trifluoromethyl The 3-tolyl
The 3-trifluoromethyl The 3-chloro-phenyl-
The 3-trifluoromethyl 3-chloro-4-fluorophenyl
The 3-trifluoromethyl 3,5-two trifluoromethyls
The 3-trifluoromethyl The 4-fluorophenyl
The 3-trifluoromethyl 3, the 4-dichlorophenyl
The 3-trifluoromethyl The 1-naphthyl
The 3-trifluoromethyl The 3-fluorophenyl
The 3-trifluoromethyl The 2-naphthyl
The 3-trifluoromethyl Normal-butyl
The 3-trifluoromethyl The 2-thiophene
The 3-trifluoromethyl The 3-thiophene
The 3-trifluoromethyl The 3-aminophenyl
The 3-trifluoromethyl 2-(5-chlorothiophene)
Embodiment 66
Use corresponding raw material, utilize the preparation method of 2-((2-(3-trifluoromethyl) phenmethyl) amino)-3-methyl-5-(4-fluorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones, can prepare the described compound of following Table X I.
Table X I
Figure C9718155802081
R 11 R 40
The 4-fluorophenyl 3, the 5-dichlorophenyl
The 4-fluorophenyl The 4-tolyl
The 4-fluorophenyl The 4-p-methoxy-phenyl
The 4-fluorophenyl The 4-trifluoromethyl
The 4-fluorophenyl The 3-isopropyl phenyl
The 4-fluorophenyl The 3-tolyl
The 4-fluorophenyl The 3-chloro-phenyl-
The 4-fluorophenyl 3-chloro-4-fluorophenyl
The 4-fluorophenyl 3,5-two trifluoromethyls
The 4-fluorophenyl The 4-fluorophenyl
The 4-fluorophenyl 3, the 4-dichlorophenyl
The 4-fluorophenyl The 1-naphthyl
The 4-fluorophenyl The 3-fluorophenyl
The 4-fluorophenyl The 2-naphthyl
The 4-fluorophenyl Normal-butyl
The 4-fluorophenyl The 2-thiophene
The 4-fluorophenyl The 3-thiophene
The 4-fluorophenyl The 3-aminophenyl
The 4-fluorophenyl 2-(5-chlorothiophene)
The 3-trifluoromethyl 3, the 5-dichlorophenyl
The 3-trifluoromethyl The 4-tolyl
The 3-trifluoromethyl The 3-trifluoromethyl
The 3-trifluoromethyl The 4-p-methoxy-phenyl
The 3-trifluoromethyl The 4-trifluoromethyl
The 3-trifluoromethyl The 3-isopropyl phenyl
The 3-trifluoromethyl The 3-tolyl
The 3-trifluoromethyl The 3-chloro-phenyl-
The 3-trifluoromethyl 3-chloro-4-fluorophenyl
The 3-trifluoromethyl 3,5-two trifluoromethyls
The 3-trifluoromethyl The 4-fluorophenyl
The 3-trifluoromethyl 3, the 4-dichlorophenyl
The 3-trifluoromethyl The 1-naphthyl
The 3-trifluoromethyl The 3-fluorophenyl
The 3-trifluoromethyl The 2-naphthyl
The 3-trifluoromethyl Normal-butyl
The 3-trifluoromethyl The 2-thiophene
The 3-trifluoromethyl The 3-thiophene
The 3-trifluoromethyl The 3-aminophenyl
The 3-trifluoromethyl 2-(5-chlorothiophene)
Embodiment 67
Biological test
Following test is used to illustrate the ability that The compounds of this invention suppresses TNF-α and IL-1-β generation.Second test is behind oral described test compound, and the restraining effect of TNF-α in the mouse and/or IL-1-β is measured.The 3rd test is the in vitro tests of a hyperglycemic-glycogenolytic factor in conjunction with inhibition, can be used for illustrating The compounds of this invention glucagon suppression binding ability.The 4th test is that a cyclooxygenase (COX-1 and COX-2) suppresses active in vitro tests, can be used for illustrating The compounds of this invention and suppresses COX-1 and/or COX-2 ability.
Lipopolysaccharides activatory monocyte TNF produces test
Monocytic separation
By with bacteria lipopolysaccharide (LPS) activatory monocyte, test compound vitro inhibition TNF generation ability is estimated.The white corpuscle source (by product of platelet removal method) that obtains fresh remnants by local blood bank, and go up by density gradient centrifugation at Ficol-Paque Plus (Pharmacia), isolate peripheral blood lymphocytes (PBMC).With 2 * 10 6The concentration of/ml is suspended in PBMC and is supplemented with 2%FCS, 10mM, among the DMEM of 0.3mg/ml glutaminate, 100U/ml penicillin G and 100mg/ml Vetstrep (perfect medium).Cell placed the flat 96 hole culture dish of Falcon (200 μ l/ hole) and in 6% CO 2With 37 ℃ of following overnight incubation.Clean with 200 μ l/ hole fresh cultures, remove the cell of not adhesion.The hole that to contain AC (～70% monocyte) recharges with 100 μ l fresh cultures.
The preparation of test compound stock solution
Test compound is dissolved in DMZ.It is 10-50 μ M that the stock solution of compound is made initial concentration.At first, stock solution is diluted to 20-200 μ M with perfect medium, uses 9 twice serial dilutions of complete each compound of medium preparation then.
Handle cell and with the generation of lipopolysaccharides activation TNF with test compound
The diluent of every kind of test compound of 100 microlitres is joined in the microtitre hole of containing adhesion monocyte and 100 μ l perfect mediums.Monocyte was cultivated 60 minutes with test compound, at this moment, in every hole, added and contain the 25 μ l perfect mediums of 30ng/ml by intestinal bacteria K532 gained lipopolysaccharides.Each hole was cultivated 4 hours again, remove culture supernatants then, measure the quantity of the TNF that exists in the supernatant liquor with ELISA.
TNF ELISA
With flat 96 hole Corning High Binding ELISA culture dish with 150 μ l/ holes, 3 μ g/ml mouse-antis-humanTNF-MAb (R﹠amp; D Systems#MAB210) covers spend the night (4 ℃).Under room temperature, each hole is supplemented with 20mg/ml BSA (standard ELISA damping fluid: 20mM, 150mM NaCl, 2mM CaCl with 200 μ l/ holes then 2, 0.15mM Thiomersalate, no CaCl pH7.4) 2ELISA damping fluid blocking-up 1 hour.Cleaning culture dish also fills up with 100 μ l test supernatant liquor (diluting 1: 3) or reference liquid again.Reference liquid is by 11 1ng/ml recombinant human TNF stock solution (R﹠amp; D Systems) 1.5 times of serial dilutions constitute.On orbital shaker (300rpm), culture dish was hatched under room temperature 1 hour, clean and with 100 μ l/ holes with 4: 1 biotinylated 0.5 μ g/ml goat-anti-humanTNF-(R﹠amp of ratio; D systems%AB-210-NA) fills up again.Culture dish was hatched 40 minutes, clean and fill up again with 100 μ l/ holes, 0.02 μ g/ml alkaline phosphatase-conjugated streptavidins (Jackson Immuno Research#016-050-084).Culture dish was hatched 30 minutes, clean and fill up again with 200 μ l/ hole 1mg/ml p-nitrophenyl phosphoric acid ester.After 30 minutes, at V MaxUnder 405nm, read the culture dish data on the culture dish reader.
Data analysis
The typical curve data are adjusted into the secondary polynomial expression and determine unknown TNF-α concentration by separating this concentration equation formula by their OD value.Use the secondary polynomial expression, draw TNF concentration the test compound concentration map.The concentration of test compound when producing inhibition with this equation calculating causing 50%TNF then.
With well known to a person skilled in the art method,, show that The compounds of this invention also can suppress LPS-inductive monocyte and discharge IL-1 β, IL-6 and/or IL-8 by measuring the concentration of IL-1 β, IL-6 and/or IL-8.According to discharging the described similarity method of test of TNF-α with above-mentioned relevant LPS inductive monocyte, with well known to a person skilled in the art method, by measuring the concentration of IL-1 β, IL-6 and/or IL-8, show that The compounds of this invention also can suppress LPS inductive monocyte and discharge IL-1 β, IL-6 and/or IL-8.Like this, The compounds of this invention can reduce upborne TNF-α, IL-1 β, IL-6 and IL-8 concentration.The upborne level of this type of inflammatory cytokine is reduced to basal level or low again, is favourable for controlling, alleviating the course of disease and improve numerous disease.All compounds of the present invention can be used in the treatment of diseases method, and wherein in the whole range of definition of disease of TNF-α described herein-mediation, TNF-α, IL-1 β, IL-6 and IL-8 play an important role.
Restraining effect to mouse LPS-inductive TNF-α generation
(2mg/kg I.V.) before, uses vehicle or the test compound in vehicle (vehicle is made of 0.5% tragakanta in 0.03N HCl) for male DBA/1LACJ mouse at the injection lipopolysaccharides.Behind the injection LPS 90 minutes, gather blood and the TNF level in the blood plasma is analyzed with ELISA.
In monocyte test (LPS inductive TNF release), following compounds has activity, its IC 50Value is 20 μ M or lower:
2-(2, the 6-dichloro benzyl)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(fourth amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(benzyl amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-3-methyl-((R-1-styroyl) amino)-(4-pyridyl)-4 (3H)-pyrimidones
2-(2-(2-chloro-phenyl-)-ethylamino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-2-(2-(4-fluorophenyl)-ethylamino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-2-((2-hydroxyl-2-phenyl)-ethylamino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-3-methyl-2-((3-hydrocinnamyl)-amino)-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-3-methyl-2-((1-methyl-3-hydrocinnamyl)-amino)-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-3-methyl-2-((R-1-methyl-3-hydrocinnamyl)-amino)-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-3-methyl-2-((2-phenylamino ethyl)-amino)-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-2-((3-imidazolyl propyl group)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-2-(3-(tetramethyleneimine-1-yl)-third amino)-4 (3H)-pyrimidones
3,6-phenylbenzene-4-(4-pyridyl)-2 (1H)-pyridones
6-(4-aminomethyl phenyl)-3-phenyl-4-(4-pyridyl)-2 (1H)-pyridones
6-(4-ethylphenyl)-3-phenyl-4-(4-pyridyl)-2 (1H)-pyridones
6-(2, the 4-3,5-dimethylphenyl)-3-phenyl-4-(4-pyridyl)-2 (1H)-pyridones
3-phenyl-4-(4-pyridyl)-6-(2-thienyl)-2 (1H)-pyridones
6-(2-furyl)-3-phenyl-4-(4-pyridyl)-2 (1H)-pyridones
2-(((S)-2-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((R)-2-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-N-ethyl-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-((2-amino-2-methyl-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-((2-aminomethyl-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-((3-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-3-methyl-2-(3-(2-tolyl) propyl group)-amino)-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-3-methyl-2-((R, S)-2-amino-3-(2 '-fluorophenyl)-propyl group-amino)-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-acetylaminohydroxyphenylarsonic acid 3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-2-(((S)-2-N-isopropylamino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-N-n-butyl amine base-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-N, N-dimethylamino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-3-methyl-2-((2-methyl-3-phenyl propyl) amino)-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-amino-3-phenyl propyl)-amino)-3-ethyl-5-(4-fluorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-ethyl-5-(4-fluorophenyl)-2-((2-methyl-3-phenyl propyl) amino)-6-(4-pyridyl)-4 (3H)-pyrimidones
2-((2-(3-trifluoromethyl) phenmethyl) amino)-3-methyl-5-(4-fluorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(4-tolyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(4-trifluoromethyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(3-isopropyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(3-chloro-phenyl-)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(3,5-two (trifluoromethyl) phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(3, the 4-dichlorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(1-naphthyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(3-fluorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(3-trifluoromethyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(3-phenyl propyl amino)-5-(3, the 5-dichlorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(3-phenyl propyl amino)-5-(4-tolyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(3-phenyl propyl amino)-5-(3-trifluoromethyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(3-phenyl propyl amino)-5-(4-p-methoxy-phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(3-phenyl propyl amino)-5-(4-trifluoromethyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(2-methyl-3-phenyl propyl amino)-5-(3-fluorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(2-methyl-3-phenyl propyl amino)-5-(1-naphthyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-2-(((S)-2-N-glycyl amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-N-glycyl amino-3-phenyl propyl)-amino)-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-2-(((S)-2-glycoloyl amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-2-(((S)-2-pyrrolidyl-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-((S)-3-benzyl diethylenediamine base)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-((3-amino-3-(2-fluorophenyl) propyl group)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-((3-amino-3-(2-aminomethyl phenyl) propyl group)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-3-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((R)-3-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-3-amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidones
2-(((R)-3-amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidones
2-((3-amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidones
2-((3-amino-3-(2-tolyl) propyl group)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidones
2-((3-amino-3-(2-fluorophenyl) propyl group)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidones
2-((3-amino-3-phenyl propyl)-amino)-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
2-((3-amino-3-(2-fluorophenyl) propyl group)-amino)-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
2-((3-amino-3-(2-chloro-phenyl-) propyl group)-amino)-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-3-amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-5-(3, the 4-3,5-dimethylphenyl)-4 (3H)-pyrimidones
2-(((2R, 3R)-3-amino-2-methyl-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((2S, 3S)-3-amino-2-methyl-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-2-(((S)-3-N-isopropylamino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-2-(((R)-3-N-isopropylamino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-2-(the basic methylamino-of (S)-tetrahydroisoquinoline-3)-4 (3H)-pyrimidones
3-methyl-6-(4-pyridyl)-2-((S)-tetrahydroisoquinoline-3-base methylamino-)-5-(3-trifluoromethyl)-4 (3H)-pyrimidones
3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-2-((S)-tetrahydroisoquinoline-3-base methylamino-)-4 (3H)-pyrimidones
3-methyl-5-(4-methylthio group phenyl)-6-(4-pyridyl)-2-((S)-tetrahydroisoquinoline-3-base methylamino-)-4 (3H)-pyrimidones
2-(((S)-2-amino-3-phenyl propyl)-amino)-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-2-((3-hydroxyl-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-amino-3-(2-fluorophenyl) propyl group)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-amino-3-(4-fluorophenyl) propyl group)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-amino-3-(2-chloro-phenyl-) propyl group)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-N-isopropylamino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidones
2-(((S)-2-N-isopropylamino-3-phenyl propyl)-amino)-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(3-chloro-phenyl-)-2-(((S)-2-N-isopropylamino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-N, N-dimethylamino-3-phenyl propyl)-amino)-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-N, N-dimethylamino-3-phenyl propyl)-amino)-3-methyl-5-(3-chloro-phenyl-)-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-N, N-dimethylamino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-3-methyl-2-(((S)-2-N-methylamino--3-phenyl propyl)-amino)-6-(4-pyridyl)-4 (3H)-pyrimidones.
In monocyte test (LPS inductive TNF release), following compounds has activity, its IC 50Value is 5 μ M or lower:
2-(2, the 6-dichloro benzyl)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(benzyl amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-3-methyl-((R-1-styroyl) amino)-(4-pyridyl)-4 (3H)-pyrimidones
2-(2-(2-chloro-phenyl-)-ethylamino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-2-(2-(4-fluorophenyl)-ethylamino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-3-methyl-2-((3-hydrocinnamyl)-amino)-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-3-methyl-2-((1-methyl-3-hydrocinnamyl)-amino)-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-3-methyl-2-((R-1-methyl-3-hydrocinnamyl)-amino)-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-3-methyl-2-((2-phenylamino ethyl)-amino)-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-2-(3-(tetramethyleneimine-1-yl)-third amino)-4 (3H)-pyrimidones
6-(4-ethylphenyl)-3-phenyl-4-(4-pyridyl)-2 (1H)-pyridones
2-(((S)-2-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((R)-2-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-N-ethyl-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-((2-amino-2-methyl-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-((2-aminomethyl-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-((3-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-3-methyl-2-(3-(2-tolyl) propyl group)-amino)-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-3-methyl-2-((R, S)-2-amino-3-(2 '-fluorophenyl)-propyl group-amino)-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-acetylaminohydroxyphenylarsonic acid 3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-2-(((S)-2-N-isopropylamino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-N-n-butyl amine base-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-N, N-dimethylamino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-3-methyl-2-((2-methyl-3-phenyl propyl) amino)-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-amino-3-phenyl propyl)-amino)-3-ethyl-5-(4-fluorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-ethyl-5-(4-fluorophenyl)-2-((2-methyl-3-phenyl propyl) amino)-6-(4-pyridyl)-4 (3H)-pyrimidones
2-((2-(3-trifluoromethyl) phenmethyl) amino)-3-methyl-5-(4-fluorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(4-tolyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(4-trifluoromethyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(3-isopropyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(3-chloro-phenyl-)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(3,5-two (trifluoromethyl) phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(3, the 4-dichlorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(1-naphthyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(3-fluorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(3-trifluoromethyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(3-phenyl propyl amino)-5-(3, the 5-dichlorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(3-phenyl propyl amino)-5-(4-tolyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(3-phenyl propyl amino)-5-(3-trifluoromethyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(3-phenyl propyl amino)-5-(4-p-methoxy-phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(3-phenyl propyl amino)-5-(4-trifluoromethyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(2-methyl-3-phenyl propyl amino)-5-(3-fluorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
3-methyl-2-(2-methyl-3-phenyl propyl amino)-5-(1-naphthyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-2-(((S)-2-N-glycyl amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-N-glycyl amino-3-phenyl propyl)-amino)-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-2-(((S)-2-glycoloyl amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-2-(((S)-2-pyrrolidyl-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-((S) benzyl diethylenediamine base)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-((3-amino-3-(2-fluorophenyl) propyl group)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-((3-amino-3-(2-aminomethyl phenyl) propyl group)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-3-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((R)-3-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-3-amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidones
2-(((R)-3-amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidones
2-((3-amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidones
2-((3-amino-3-(2-tolyl) propyl group)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidones
2-((3-amino-3-(2-fluorophenyl) propyl group)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidones
2-((3-amino-3-phenyl propyl)-amino)-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
2-((3-amino-3-(2-fluorophenyl) propyl group)-amino)-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
2-((3-amino-3-(2-chloro-phenyl-) propyl group)-amino)-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-3-amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-5-(3, the 4-3,5-dimethylphenyl)-4 (3H)-pyrimidones
2-(((2R, 3R)-3-amino-2-methyl-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((2S, 3 S)-3-amino-2-methyl-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-2-(((S)-3-N-isopropylamino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-2-(((R)-3-N-isopropylamino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-2-((S)-tetrahydroisoquinoline-3-base methylamino-)-4 (3H)-pyrimidones
3-methyl-6-(4-pyridyl)-2-((S)-tetrahydroisoquinoline-3-base methylamino-)-5-(3-trifluoromethyl)-4 (3H)-pyrimidones
3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-2-((S)-tetrahydroisoquinoline-3-base methylamino-)-4 (3H)-pyrimidones
3-methyl-5-(4-methylthio group phenyl)-6-(4-pyridyl)-2-((S)-tetrahydroisoquinoline-3-base methylamino-)-4 (3H)-pyrimidones
2-(((S)-2-amino-3-phenyl propyl)-amino)-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-2-((3-hydroxyl-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-amino-3-(2-fluorophenyl) propyl group)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-amino-3-(4-fluorophenyl) propyl group)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-amino-3-(2-chloro-phenyl-) propyl group)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-N-isopropylamino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidones
2-(((S)-2-N-isopropylamino-3-phenyl propyl)-amino)-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
5-(3-chloro-phenyl-)-2-(((S)-2-N-isopropylamino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-N, N-dimethylamino-3-phenyl propyl)-amino)-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-N, N-dimethylamino-3-phenyl propyl)-amino)-3-methyl-5-(3-chloro-phenyl-)-6-(4-pyridyl)-4 (3H)-pyrimidones
2-(((S)-2-N, N-dimethylamino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidones
5-(4-fluorophenyl)-3-methyl-2-(((S)-2-N-methylamino--3-phenyl propyl)-amino)-6-(4-pyridyl)-4 (3H)-pyrimidones.
In inflammation, comprise in the animal model of carrageenin pawl oedema, collagen protein inductive sacroiliitis and adjuvant arthritis, for example carrageenin pawl edema model (people such as C.A.Winter, Proc.Soc.Exp.Biol.Med. (1962) vol111, p544; K.F.Swingle, in R.A.Scherrer and M.W.Whitehouse, Eds., Antiinflammatory Agents, Chemistry and Pharmacology, vol.13-II, Academic, New York, 1974, p.33) and collagen protein inductive sacroiliitis (people such as D.E.Trentham, J.Exp.Med. (1977) Vol.146, p.857; J.S.Courtenay, Nature (New Biol.) (1980), Vol283, p666) The compounds of this invention all can show anti-inflammatory property.
Carry out with the CHO/hGLUR cell 125The I-hyperglycemic-glycogenolytic factor is in conjunction with screening
This test is disclosed among the WO97/16442, and the document is incorporated this paper into as a reference in full.
Reagent
Described reagent can as described belowly prepare: (a) the fresh 1M phenanthrolene (Aldrich) (198.2mg/ml ethanol) of preparation; (b) the fresh 0.5M DTT (Sigma) of preparation; (c) protease inhibitor cocktail (1000X): every milliliter of DMSO contains 5mg leupeptin, 10mg benzamidine, 40mg bacitracin and 5mg Trypsin inhibitor SBTI and aliquots containig is descended storage in-20 ℃; (d) 250 μ M Porcine glucagons (Peninsula): the bottle of 0.5mg is dissolved in 575 μ l0.1N acetate (for nonspecific binding test, the ultimate density that 1 μ l produces is 1 μ M) and stores aliquots containig down in-20 ℃; (e) test damping fluid: 20mM Tris (pH7.8), 1mMDTT and 3mM phenanthrolene; (f) the test damping fluid that contains 0.1%BSA (only is used to dilute mark; Ultimate density is 0.01% in the test): 10 μ l 10%BSA (hot deactivation) and 990 μ l test damping fluid; (g) 125The I-hyperglycemic-glycogenolytic factor (NEN, the acceptor level, 2200Ci/mmol): be diluted to 50,000cpm/25 μ l (ultimate density is about 50pM in the test) with the test damping fluid that contains BSA.
The results of test CHO/hGLUR cell
1. remove substratum by merging in the flask, (Specialty Media, Inc.) each cleans once respectively to use PBS (Ca, no Mg) and Enzyme-free Dissociation Fluid then respectively.
2. add 10ml Enzyme-free Dissoc.Fluid and be incubated about 4 minutes down in 37 ℃.
3. make cellular segregation, development is got aliquots containig counting and with residuum under 1000rpm centrifugal 5 minutes.
With granular precipitation with 75000 cells/100 μ l resuspending in the test damping fluid in.
With identical tested number, replace full cell with the film preparation of CHO/hGLUR cell.Based on every batch, measure the final protein concentration of film preparation.
Test
In the presence of formula I compound, by measuring 125I-hyperglycemic-glycogenolytic factor bonded reduces can be determined hyperglycemic-glycogenolytic factor bonded restraining effect.The following combination of described reagent:
Compound/vehicle 250 μ M hyperglycemic-glycogenolytic factors 125 I-pancreas hyperglycemia system The CHO/hGLUR cell
Total binding+non-specific binding compound --/5μl 5μl/-- --/5μl -- -- 1μl 25μl 25μl 25μl 100μl 100μl 100μl
In on the jolting device under 22 ℃ of 275rpm, mixture was hatched 60 minutes.Mixture cleans four times with ice-cooled 20mM Tris damping fluid (pH7.8) through the GF/C strainer of wetting (0.5% polymine (PEI)) Innotech Harvester or Tomtec Harvester filtration in advance.Measure the radioactivity of strainer with γ-scintillometer.
So also show, but the combining of The compounds of this invention glucagon suppression and glucagon receptor.
The cyclooxygenase-2 activity test
By being the alienation of THP-1 contact phorbol ester with people's monocyte, only express COX-1; Human osteosarcoma cell line 143B mainly expresses COX-2.The THP-1 cell is carried out routine cultivate in being supplemented with the RPMI perfect medium of 10%FBS, and human osteosarcoma cell (HOSC) cultivates in being supplemented with 10% N of tire serum minimum essential medium (MEM-10%FBS); All cells is containing 5%CO 2Under 37 ℃, hatch under the wet condition.
The COX-1 test
Prepare the COX-1 test, the THP-1 cell is grown to fusion, split among the RPMI that contains 2%FBS and 10mM phorbol 12-myristinate 13-acetic ester (TPA) with 1: 3, and on the jolting device, hatched 48 hours, prevent that it from adhering to.Cell made granular precipitation and with 2.5 * 10 6The concentration resuspending of individual cell/ml is in Hank ' s Buffered Saline (HBS), with 5 * 10 5The density of individual cell/ml joins in the 96 hole culture dish.With HBS dilution test compound and join required ultimate density, cell was hatched 4 hours again.Add arachidonic acid, reaching ultimate density is 30mM, cell is hatched 20 minutes mensuration enzymic activity as described below under 37 ℃.
The COX-2 test
For COX-2 test, inferior fusion HOSC carried out tryptic digestion and with 3 * 10 6Individual cell/ml resuspending is in the MEM-FBS that contains 1ng people IL-1b/ml, with every hole 3 * 10 4The density of individual cell is added in the 96 hole tissue culture wares, hatches on the jolting device 1 hour, so that cell is evenly distributed, static more subsequently hatching 2 hours makes it adhere to.Substitute substratum with the MEM that contains 2%FBS (MEM-2%FBS) and 1ng people IL-1b/ml then, described cell was hatched 18-22 hour.Substitute substratum with 190ml MEM subsequently, add the test compound of 10ml, reach desired concn and cell was hatched 4 hours with the HBS dilution.Remove supernatant liquor, substitute, cell was hatched 20 minutes mensuration enzymic activity as described below under 37 ℃ with containing the arachidonic MEM of 30mM.
The determination of activity of COX
After arachidonic acid is hatched, by adding 1N HCl, make to react with 1N NaOH neutralization subsequently to stop, centrifugally go out granular cell debris.ELISA (Neogen#404110) with commercially available acquisition passes through to measure PGE 2Concentration is determined the activity of cyclooxygenase in HOSC and two kinds of cell conditioned medium liquid of THP-1.Use PGE 2Typical curve is calibrated, and makes standard control with the COX-1 and the cox 2 inhibitor of commercially available acquisition.
Therefore, compound of the present invention or pharmaceutical composition can be used for prevention and treatment rheumatoid arthritis; Paget's disease; Osteoporosis; Multiple myeloma; Uveitis; Acute and chronic lymphocytic leukemia; Pancreatic; Osteoarthritis; Rheumatoid osteomyelitis; Urarthritis; Enteritis; Adult respiratory distress syndrome (ARDS); Psoriasis; Crohn disease; Rhinallergosis; Ulcerative colitis; Irritated; Contact dermatitis; Asthma; Muscle deterioration; Emaciation; Reiter syndrome; I type and type ii diabetes; Bone resorption disease; Graft-vs-host reaction; The ischemia reperfusion damage; Atherosclerosis; Cerebral trauma; Presenile dementia; Apoplexy; Myocardial infarction; Multiple sclerosis; Cerebral malaria; Sepsis; Septic shock; Toxic shock syndrome; Because of the myopathy that infection causes, fever.To HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, simplexvirus (comprising HSV-1, HSV-2) and the zoster of restraining effect or the glucagon antagonist sensitivity of TNF-α and/or IL-1, Compounds and methods for of the present invention also has good action for all.
Compound of the present invention also has the pain relieving characteristic and can be used for treating pain disease, for example hyperpathia that causes because of IL-1 is excessive.Compound of the present invention also can comprise that cyclooxygenase (WO 96/03387, incorporates this paper into as a reference in full) stops the generation of prostaglandin(PG) by suppressing the enzyme in people's arachidonic acid/prostaglandin(PG) action path.
Because compound of the present invention can reduce combining of the concentration of TNF-α and IL-1 or glucagon suppression and its acceptor, so they also can be used in the test method of the physiological Study relevant with this class effect of blocking-up.
The method of the invention comprises, gives the curee that needs to reduce TNF-α, IL-1, IL-6 and/or IL-8 level and/or lowering blood glucose level (be animal, preferred mammal, optimum is chosen) and/or may suffer from rheumatoid arthritis; Paget's disease; Osteoporosis; Multiple myeloma; Uveitis; Acute and chronic lymphocytic leukemia; Pancreatic; Osteoarthritis; Rheumatoid osteomyelitis; Urarthritis; Enteritis; Adult respiratory distress syndrome (ARDS); Psoriasis; Crohn disease; Rhinallergosis; Ulcerative colitis; Irritated; Contact dermatitis; Asthma; Muscle deterioration; Emaciation; Reiter syndrome; I type and type ii diabetes; Bone resorption disease; Graft-vs-host reaction; Presenile dementia; Apoplexy; Myocardial infarction; The ischemia reperfusion damage; Atherosclerosis; Cerebral trauma; Multiple sclerosis; Cerebral malaria; Sepsis; Septic shock; Toxic shock syndrome; The myalgia that causes because of infection, curee with fever, perhaps the curee of infected by HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, simplexvirus (comprising HSV-1, HSV-2) and zoster uses The compounds of this invention, its pharmaceutically acceptable salt, perhaps pharmaceutical composition of significant quantity.
In addition, the present invention also comprises The compounds of this invention or its pharmaceutically acceptable salt disease in the acute or chronic TNF-α of preparation treatment, IL-1, IL-6 and/or IL-8 mediation, comprises the application in the medicine of above-mentioned disease.And compound of the present invention also can be used for preparing anodyne and for example sick feel of treatment pain disease medicine hypersensitive.Compound of the present invention also can be used for preparing by suppressing the medicine of enzyme to stop arachidonic acid to produce in people's arachidonic acid/prostaglandin(PG) action path.
In addition, the present invention also provides a kind of pharmaceutical composition, said composition comprises effective reduction TNF-α, IL-1, IL-6 and/or the amount of IL-8 and/or The compounds of this invention and the pharmaceutically acceptable carrier or the thinner of effective lowering blood glucose level amount, and also can contain other active ingredients if desired.Compound of the present invention can be used preferably in the suitable mode of pharmaceutical composition, and with dose therapeutically effective by any suitable mode.The dose therapeutically effective of compound of the present invention need stop advancing of disease or prevent and the tissue injury of described disease-related that this is that those of ordinary skills determine easily with ordinary method.
For TNF-α, IL-1, IL-6 and the disease of IL-8 mediation and/or the treatment of hyperglycemia, can be with the unit dosage that contains acceptable carrier on the conventional medicine, adjuvant and vehicle by oral, non-enteron aisle, by suction, rectum or the topical application compound of the present invention of spraying.That the non-enteron aisle of term used herein comprises is subcutaneous, in the intravenously, intramuscular, breastbone, infusion methods or intraperitoneal.
Dosage range with the disease of compound of the present invention and/or present composition treatment TNF-α, IL-1, IL-6 and IL-8 mediation and/or hyperglycemia can be based on various different factors, and these factors comprise type, patient's age, body weight, sex, the physical appearance of disease, severity, application method and the used specific compound of disease.Like this, described dosage range can change in wide range, but can determine with ordinary method usually.The dosage rule that can be used for all application methodes described herein is the about 0.01mg-30mg of per kilogram of body weight every day, preferably about 0.1mg-10mg/kg, more preferably from about 0.25mg-1mg/kg.
According to the pharmaceutics ordinary method, pharmaceutical active compounds of the present invention can be processed, make and be suitable for the pharmaceutical preparation that the patient comprises that people and other animals are used.
When Orally administered, described pharmaceutical composition can be for example capsule, tablet, suspension or liquor.Described pharmaceutical composition preferred preparation becomes to contain the unit dosage of given described active ingredient.For example, they can contain the 1-2000mg that has an appointment, preferably about 1-500mg, more preferably from about 5-150mg active ingredient.For people or other animals, suitable per daily dose can change according to patient's situation and other factors, but can determine with ordinary method once more.
Described active ingredient can also be used through injection to contain the composition forms that appropriate carrier comprises physiological saline, glucose or water.The per daily dose scope that non-enteron aisle is used is about 0.1-30mg/kg of TBW, preferably about 0.1-10mg/kg, and 0.25-1mg/kg more preferably from about.
Injection for example aseptic injection aqua or oiliness suspension agent can be prepared according to known method with suitable dispersion agent or wetting agent and suspension agent.Described aseptic injection can also be injection solution or the suspension that nontoxic non-enteron aisle is used acceptable diluent or solvent, for example 1,3 butylene glycol solution.The acceptable carrier that can Gong use and solvent are water, normal saline solution and isotonic sodium chlorrde solution.In addition, aseptic expressed oil can be used as solvent or suspension medium usually.For this reason, the expressed oil of any gentleness all can use, and comprises synthetic list-or two glyceryl ester.In addition, in injection, also can use for example oleic acid of lipid acid.
The suppository of rectal application can be by will described medicine being solid down with typical temperature, and be that for example theobroma oil and polyoxyethylene glycol are mixed with for liquid and the non-stimulated vehicle that suits that therefore fusion discharges described medicine simultaneously in rectum at internal rectum.
The dosage that is suitable for topical application of active ingredient of the present invention is 0.1mg-150mg, and use 1-4 every day, preferably once or twice.During topical application, the 0.001-10%w/w that described active ingredient accounts for described preparation is 1%-2% (weight ratio) for example, although its proportion can preferably be not more than 5%w/w greater than 10%w/w, and more preferably accounts for the 0.1%-01% of described preparation.
The preparation that is suitable for topical application comprises that the liquid or the semiliquid (for example liniment, lotion, ointment, emulsion or paste) that are suitable for transdermal flux are suitable for the drops that eye, ear or nose are used.
During medication, compound of the present invention mixes with the suitable adjuvant of described application method with one or more usually.Described compound can mix with lactose, sucrose, starch, paraffinic acid cellulose ester, stearic acid, talcum, Magnesium Stearate, magnesium dioxide, phosphoric acid and vitriolic sodium salt and calcium salt, gum arabic, gelatin, sodiun alginate, polyvinylpyrrolidone and/or polyvinyl alcohol, and can be made into tablet or the capsule that routine is used.In addition, The compounds of this invention dissolves in physiological saline, water, polyoxyethylene glycol, propylene glycol, ethanol, Semen Maydis oil, peanut oil, cotton seed oil, sesame oil, tragakanta and/or various damping fluid.Other adjuvants and application method are that pharmaceutical field is known.Described carrier or thinner can comprise slow-release material, for example separately or with wax blended glyceryl monostearate or stearic acid two glyceryl ester, other materials perhaps well known in the art.
Described pharmaceutical composition can be mixed with solid form (comprising granule, pulvis or suppository) or liquid form (for example solution, suspension or emulsion).Described pharmaceutical composition can carry out conventional medicine operational example as sterilizing and/or can containing conventional adjuvant, for example sanitas, stablizer, wetting agent, emulsifying agent, damping fluid etc.
Be suitable for oral solid dosage and can comprise capsule, tablet, pill, pulvis and granule.In this type of solid dosage, described active compound can for example sucrose, lactose or starch mix with at least a inert diluent.Under normal conditions, other materials except inert diluent, this type of acute for example lubricant such as Magnesium Stearate of also can containing.Under the situation of capsule, tablet and pill, described formulation also can contain buffer reagent.Tablet and pill also can be used enteric coating again.
Be suitable for oral liquid dosage form and can comprise that containing this area uses inert diluent for example pharmaceutically acceptable emulsion, solution, suspension, syrup and the elixir of water always.This based composition also can contain adjuvant for example wetting agent, sweeting agent, seasonings and spices.
The compounds of this invention can have one or more unsymmetrical carbons and can with the optical isomer form with and racemize or non-racemic mixture form exist.According to ordinary method, by resolving racemic mixtures, for example by forming diastereoisomeric salt, passing through to obtain described optical isomer with optics active acid or alkaline purification.The example of suitable acid is tartrate, diacetyl tartrate, dibenzoyl tartaric acid, dimethylbenzene acyl group tartrate and camphorsulfonic acid, then by the described non-enantiomer mixture of Crystallization Separation, subsequently by the described optical active alkali that dissociates in this salt.The another kind of method of separating optical isomeric body comprises, utilizes the chiral chromatographic column of optimal selection, with enantiomer separation to greatest extent.Another kind of operational method comprises, by with The compounds of this invention and optically pure acid-respons, the covalency diastereomer molecule of synthetic inactive form or optical purity isocyanic ester form, described synthetic diastereomer can for example chromatography, distillation method, crystallization process or subliming method be separated through conventional method, hydrolysis then discharges the compound of described enantiomeric pure.Can obtain optically active compound of the present invention equally with the optics activated feedstock.These isomer can be the forms of free acid, free alkali, ester or salt.
Compound of the present invention can use with the form of the salt that generates with mineral acid or organic acid.Described salt comprises, but be not limited only to following salt: acetate, adipate, alginate, Citrate trianion, aspartate, benzoate, benzene sulfonate, hydrosulfate, butyrates, camphorate, camsilate, digluconate, cyclopentane propionate, dodecane sulfonate, esilate, glucoheptose salt, glycerophosphate, Hemisulphate, enanthate, hexanoate, fumarate, hydrochloride, hydrobromate, hydriodate, 2-hydroxyl-esilate, lactic acid salt, maleate, mesylate, nicotinate, the 2-naphthalenesulfonate, oxalate, palmitate, tartaric acid salt, persulphate, 2-phenylpropionic acid salt, picrate, Pivalate, propionic salt, succinate, tartrate, thiocyanate-, tosylate, mesylate and undecane hydrochlorate.In addition, alkaline nitrogen-containing group can be used quaternized as the reagent of elementary alkyl halide, for example the muriate of methyl, ethyl, propyl group and butyl, bromide and iodide; Sulfuric acid dialkyl such as methyl-sulfate, diethyl ester, dibutylester and diamyl ester, long-chain halogenide be decyl, lauryl, myristyl and stearyl chlorination thing, bromide and iodide for example, aralkyl halide such as benzyl, styroyl bromination thing etc.Like this, can obtain water-soluble or oily molten or dispersible products.
The example that can be used for forming the acid of pharmaceutically acceptable acid salt comprises the mineral acid of example hydrochloric acid, sulfuric acid and phosphoric acid and as the organic acid of oxalic acid, toxilic acid, succsinic acid and citric acid.Other examples comprise the salt that forms with basic metal or alkaline-earth metal for example sodium, potassium, calcium or magnesium salts or the salt that forms with organic bases.
When compound of the present invention was used as active agent formulation, they can also be used in combination with one or more The compounds of this invention or other preparations.When using, described therapeutical agent can be mixed with can be at one time or the independently composition of different time administration, and perhaps described therapeutical agent can single composition forms administration.
Above only be used to illustrate the present invention, and unintentionally the present invention be limited on the described compound.Conspicuous for those skilled in the art variation and change all are considered in the scope of the invention and spirit of claim definition.
By foregoing description, those skilled in the art can easily determine essential feature of the present invention, and without departing from the spirit and scope of the present invention, can make various variations and modification to the present invention, so that itself and various service condition and condition adapt.

Claims (32)

1. following formula: compound or its pharmaceutically acceptable salt:
Figure C971815580002C1
Wherein
X is O or S;
Figure C971815580002C2
Condition is that aryl, heteroaryl, cycloalkyl and heterocycloalkyl adds up to 0-2 among-VC (R) W-;
R wherein 1Be-Y or-Z-Y, condition is (1) R 1In aryl, heteroaryl, cycloalkyl and heterocyclic radical add up to 0-3;
Z is
(1) is selected from the C that following substituting group replaces arbitrarily by 1-3 1-C 4Alkyl or C 2-C 5Thiazolinyl: amino, two-(C 1-C 2Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 2Alkoxyl group, C 1-C 2Alkylthio, halogen or be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 2Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, C 1-C 4Heterocyclic radical, aryl or heteroaryl that the group of alkyl or trifluoromethyl replaces arbitrarily;
(2) be selected from amino, two-(C by 1-2 1-C 2Alkyl) amino, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 2Alkoxyl group, C 1-C 2Alkylthio or C 1-C 4The heterocyclic radical that the group of alkyl replaces arbitrarily; Perhaps
(3) be selected from amino, two-(C by 1-3 1-C 2Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 2Alkoxyl group, C 1-C 2Alkylthio, cyano group, halogen, C 1-C 4Aryl or heteroaryl that the group of alkyl or trifluoromethyl replaces arbitrarily;
Y is
(1) hydrogen;
(2) halogen;
(3)-C (O)-R 20,-C (O)-OR 21,-C (O)-NR 5R 21Or-C (NR 5)-NR 5R 21Group;
(4)-OR 21,-O-C (O)-R 21Or-O-C (O)-NR 5R 21Group;
(5)-SR 21,-S (O)-R 20,-S (O) 2-R 20Or-S (O) 2-NR 5R 21Group; Or
(6)-NR 5R 21,-NR 22-C (O)-R 21,-NR 22-C (O)-OR 20,-NR 22-C (O)-NR 5R 21,-NR 22-C (NR 5)-NR 5R 21,-NR 22-S (O) 2-R 20Or-NR 22-S (O) 2-NR 5R 21Group;
Each R 5Be independently
(1) hydrogen;
(2) be selected from amino, two-(C by 1-3 1-C 4Alkyl) amino, hydroxyl, C 1-C 2Alkoxyl group, C 1-C 2The C that the group of alkylthio or halogen replaces arbitrarily 1-C 4Alkyl; Perhaps
(3) be selected from amino, two-(C by 1-3 1-C 2Alkyl) amino, hydroxyl, C 1-C 2Alkoxyl group, C 1-C 2Alkylthio, methoxyl group, methylthio group, cyano group, C 1-C 4Phenyl-C that the group of alkyl or trifluoromethyl replaces arbitrarily 1-C 2-alkyl, heteroaryl-C 1-C 2-alkyl, heterocyclic radical-C 1-C 2-alkyl or C 3-C 6-cycloalkyl-C 1-C 2-alkyl;
Each R 20Be independently
(1) is selected from the C that following substituting group replaces arbitrarily by 1-3 1-C 8Alkyl or C 2-C 5Thiazolinyl :-CO 2R 23, amino, C 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, N-((C 1-C 4Alkoxyl group) carbonyl)-N-(C 1-C 4Alkyl) amino, amino carbonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, C 1-C 4Alkyl sulphinyl, C 1-C 4Alkyl sulphonyl, halogen or be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, C 1-C 5Alkanoyl, (C 1-C 4Alkoxyl group) carbonyl, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 2Aryl-C that the group of haloalkyl replaces arbitrarily 1-C 4-alkoxyl group, aryl-C 1-C 4-alkylthio, aryl-C 1-C 4-alkyl sulphonyl, C 3-C 6Cycloalkyl, heterocyclic radical, aryl or heteroaryl groups;
(2) be selected from amino, C by 1-2 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, (C 1-C 4Alkoxyl group) carbonyl, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio or C 1-C 4The heterocyclic radical that the group of alkyl replaces arbitrarily; Perhaps
(3) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, (C 1-C 4Alkoxyl group) carbonyl, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, azido-, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 2Aryl or heteroaryl that the group of haloalkyl replaces arbitrarily;
Each R 21Be hydrogen or R independently 20
Each R 22Be hydrogen or C independently 1-C 4Alkyl;
Each R 23Be hydrogen or C independently 1-C 4Alkyl, or by individual amino, the two-(C that is selected from of 1-3 1-C 2Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 2Alkoxyl group, C 1-C 2Alkylthio, cyano group, halogen, C 1-C 4Phenyl, heteroaryl, phenyl-C that the group of alkyl or trifluoromethyl replaces arbitrarily 1-C 2-alkyl or heteroaryl-C 1-C 2-alkyl group;
R 4Be
(1) is selected from the C that following substituting group replaces arbitrarily by 1-2 1-C 8Alkyl: amino, C 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, hydroxyl, C 1-C 4Alkoxyl group or be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, halogen, C 1-C 4Aryl or heteroaryl groups that the group of alkyl, trifluoromethoxy or trifluoromethyl replaces arbitrarily; Perhaps
(2) be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, C 1-C 4The heteroaryl that the group of alkyl, trifluoromethoxy or trifluoromethyl replaces arbitrarily;
R 11Be aryl and R 12Be heteroaryl, wherein said aryl and heteroaryl can be selected from following group by 1-2 and replace arbitrarily:
(1)R 30；
(2) halogen or cyano group;
(3)-C (O)-R 30,-C (O)-OR 29,-C (O)-NR 31R 32Or-C (NR 31)-NR 31R 32Group; Or
(4)-OR 29,-SR 29,-S (O)-R 30,-S (O) 2-R 30,-S (O) 2-NR 31R 32,-NR 31R 32Or-NR 33-C (O)-R 29Group;
Condition is, at R 11And R 12Aryl, heteroaryl, cycloalkyl and the heterocyclic radical that go up to replace separately add up to 0-1;
Each R 30Be independently
(1) by phenyl or heteroaryl 1-3 C that is selected from any replacement 1-C 4Alkyl, described substituting group: amino, two-(C 1-C 2Alkyl) amino, kharophen, hydroxyl, C 1-C 2Alkoxyl group, halogen, C 1-C 4The group of alkyl or trifluoromethyl replaces arbitrarily;
(2) trifluoromethyl; Perhaps
(3) be selected from amino, two-(C by 1-3 1-C 2Alkyl) amino, kharophen, hydroxyl, C 1-C 2Alkoxyl group, halogen, C 1-C 4Aryl or heteroaryl that the group of alkyl or trifluoromethyl replaces arbitrarily;
Each R 29Be hydrogen or R independently 30With
Each R 31Be hydrogen or C independently 1-C 4Alkyl; With
Each R 32Be independently
(1) hydrogen;
(2) C 1-C 4Alkyl or the C that is replaced arbitrarily by phenyl or heteroaryl groups 1-C 2Alkyl, described substituting group can be selected from amino, two-(C by 1-3 1-C 2Alkyl) amino, kharophen, hydroxyl, C 1-C 2Alkoxyl group, C 1-C 4The group of alkyl or trifluoromethyl replaces arbitrarily; Perhaps
(3) be selected from amino, two-(C by 1-3 1-C 2Alkyl) amino, kharophen, hydroxyl, C 1-C 2Alkoxyl group, C 1-C 4Phenyl or heteroaryl that the group of alkyl or trifluoromethyl replaces arbitrarily; With
Each R 33Be hydrogen or methyl independently; With
Wherein heterocyclic radical is 1-2 annular atoms monocycle saturated heterocyclic system of 5-6 unit that is oxygen, sulphur or nitrogen heteroatom wherein, and it can at random condense with phenyl ring and at random by 1-2 oxo or thio group replacement; Aryl is a phenyl or naphthyl; With heteroaryl be 1-2 annular atoms monocyclic aromatic heterocycle system of 5-6 unit that is oxygen, sulphur or nitrogen heteroatom wherein, it can at random condense with phenyl ring.
2. the described compound of claim 1 or its pharmaceutically acceptable salt, wherein
R wherein 1Be-Y or-Z-Y, condition is (1) R 1In aryl, heteroaryl, cycloalkyl and heterocyclic radical group add up to 0-2;
Z is
(1) is selected from the C that following substituting group replaces arbitrarily by 1-3 1-C 4Alkyl or C 2-C 5Thiazolinyl: amino, two-(C 1-C 2Alkyl) amino, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 2Alkoxyl group, C 1-C 2Alkylthio or halogen or be selected from amino, two-(C by 1-2 1-C 2Alkyl) amino, kharophen, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 2Alkoxyl group, C 1-C 2Alkylthio, cyano group, halogen, C 1-C 4Aryl or heteroaryl that the group of alkyl or trifluoromethyl replaces arbitrarily; Perhaps
(2) be selected from amino, two-(C by 1-3 1-C 2Alkyl) amino, kharophen, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 2Alkoxyl group, C 1-C 2Alkylthio, cyano group, halogen, C 1-C 4Aryl or heteroaryl that the group of alkyl or trifluoromethyl replaces arbitrarily;
Y is
(1) hydrogen;
(2)-C (O)-R 20,-C (O)-OR 21Or-C (O)-NR 5R 21Group;
(3)-OR 21,-SR 21,-S (O)-R 20,-S (O) 2-R 20Or-S (O) 2-NR 5R 21Group; Or
(4)-NR 5R 21,-NR 22-C (O)-R 21,-NR 22-C (O)-OR 20,-NR 22-C (O)-NR 5R 21,-NR 22-S (O) 2-R 20Or-NR 22-S (O) 2-NR 5R 21Group;
Each R 5Be independently
(1) hydrogen;
(2) C that is replaced arbitrarily by 1-3 halogen 1-C 4Alkyl; Perhaps
(3) by 1-3 any phenyl-C that replaces of group that is selected from amino, dimethylamino, hydroxyl, methoxyl group, methylthio group, methyl or trifluoromethyl 1-C 2-alkyl or heteroaryl-C 1-C 2-alkyl;
Each R 20Be independently
(1) is selected from the C that following substituting group replaces arbitrarily by 1-3 1-C 8Alkyl or C 2-C 5Thiazolinyl :-CO 2R 23, amino, C 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, N-((C 1-C 4Alkoxyl group) carbonyl)-N-(C 1-C 4Alkyl) amino, amino carbonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, C 1-C 4Alkyl sulphinyl, C 1-C 4Alkyl sulphonyl, halogen or be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, C 1-C 5Alkanoyl, (C 1-C 4Alkoxyl group) carbonyl, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 2Aryl-C that the group of haloalkyl replaces arbitrarily 1-C 4-alkoxyl group, aryl-C 1-C 4-alkylthio, aryl-C 1-C 4-alkyl sulphonyl, C 3-C 6Cycloalkyl, heterocyclic radical, aryl or heteroaryl groups;
(2) be selected from amino, two-(C by 1-2 1-C 4Alkyl) amino, (C 1-C 4Alkoxyl group) carbonylamino, (C 1-C 4Alkoxyl group) carbonyl, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio or C 1-C 4The heterocyclic radical that the group of alkyl replaces arbitrarily; Perhaps
(3) be selected from amino, C by 1-2 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, kharophen, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, (C 1-C 4Alkoxyl group) carbonyl, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, azido-, C 1-C 4Aryl or heteroaryl that the group of alkyl or trifluoromethyl replaces arbitrarily;
Each R 21Be hydrogen or R independently 20
Each R 23Be hydrogen or C independently 1-C 4Alkyl, or by individual amino, the two-(C that is selected from of 1-3 1-C 2Alkyl) amino, kharophen, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 2Alkoxyl group, C 1-C 2Alkylthio, cyano group, halogen, C 1-C 4Phenyl-C that the group of alkyl or trifluoromethyl replaces arbitrarily 1-C 2-alkyl or heteroaryl-C 1-C 2-alkyl group;
R 4Be selected from the C that following substituting group replaces arbitrarily by 1-2 1-C 8Alkyl: amino, C 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, hydroxyl, C 1-C 4Alkoxyl group or be selected from amino, C by 1-3 1- C4 alkylaminos, two-(C 1-C 4Alkyl) amino, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, halogen, C 1-C 4Aryl or heteroaryl groups that the group of alkyl, trifluoromethoxy or trifluoromethyl replaces arbitrarily;
R 11Be aryl and R 12Be heteroaryl, wherein said aryl and heteroaryl can be selected from following group by 1-2 and replace arbitrarily:
(1)R 30；
(2) halogen or cyano group; Perhaps
(3)-C (O)-NR 31R 32,-OR 29,-SR 29,-S (O)-R 30,-S (O) 2-R 30,-S (O) 2-NR 31R 32,-NR 31R 32Or-NR 33-C (O)-R 29Group;
Condition is, at R 11And R 12Aryl, heteroaryl, cycloalkyl and the heterocyclic radical that go up to replace separately add up to 0-1;
Each R 30Be independently
(1) by phenyl or any C that replaces of heteroaryl 1-C 4Alkyl, described substituting group can be replaced arbitrarily by 1-3 group that is selected from amino, dimethylamino, kharophen, hydroxyl, halogen, methoxyl group, methyl or trifluoromethyl;
(2) trifluoromethyl; Perhaps
(3) by 1-3 any aryl or the heteroaryl that replaces of group that is selected from amino, dimethylamino, kharophen, hydroxyl, halogen, methoxyl group, methyl or trifluoromethyl;
Each R 29Be hydrogen or R independently 30
Each R 31Be hydrogen, methyl or ethyl independently; With
Each R 32Be independently
(1) hydrogen;
(2) C 1-C 4Alkyl or the C that is replaced by phenyl or heteroaryl groups 1-C 2Alkyl, described substituting group can be replaced arbitrarily by 1-3 group that is selected from amino, dimethylamino, kharophen, hydroxyl, methoxyl group, methyl or trifluoromethyl; Perhaps
(3) by 1-3 any phenyl or the heteroaryl that replaces of group that is selected from amino, dimethylamino, kharophen, hydroxyl, methoxyl group, methyl or trifluoromethyl.
3. the described compound of claim 2 or its pharmaceutically acceptable salt, wherein
R 4Be C 1-C 4Alkyl;
R 11Be to be selected from the aryl that following group replaces arbitrarily by 1-2
(1)R 30；
(2) halogen or cyano group; Perhaps
(3)-C (O)-NR 31R 32,-OR 29,-SR 29,-S (O) 2-R 30,-S (O) 2-NR 31R 32,-NR 31R 32Or-NR 33-C (O)-R 29Group; With
R 12Be to be selected from the heteroaryl that following group replaces arbitrarily by 1 or 2
(1)R 30；
(2) halogen or cyano group; Perhaps
(3)-C (O)-NR 31R 32,-OR 29,-SR 29,-S (O)-R 30,-NR 31R 32Or-NR 33-C (O)-R 29Group;
Condition is, at R 11And R 12Aryl, heteroaryl, cycloalkyl and the heterocyclic radical that go up to replace separately add up to 0-1;
R 30Be independently
(1) by phenyl or any C that replaces of heteroaryl 1-C 4Alkyl, described substituting group can be replaced arbitrarily by 1-2 group that is selected from amino, dimethylamino, kharophen, hydroxyl, halogen, methoxyl group, methyl or trifluoromethyl;
(2) trifluoromethyl; Perhaps
(3) by 1-3 any aryl or the heteroaryl that replaces of group that is selected from amino, dimethylamino, kharophen, hydroxyl, halogen, methoxyl group, methyl or trifluoromethyl;
Each R 29Be hydrogen or R independently 30With
R 32Be independently
(1) hydrogen or C 1-C 4Alkyl; Perhaps
(2) by 1-2 any phenyl or the heteroaryl groups that replaces of group that is selected from amino, dimethylamino, kharophen, hydroxyl, methoxyl group, methyl or trifluoromethyl.
4. the described compound of claim 3 or its pharmaceutically acceptable salt,
R wherein 1Be-Y or-Z-Y, condition is (1) R 1In aryl, heteroaryl, cycloalkyl and heterocyclic radical group add up to 0-1;
Z is selected from the C that following group replaces arbitrarily by 1-2 1-C 4Alkyl: amino, two-(C 1-C 2Alkyl) amino, (C 1-C 4Alkoxyl group) carbonylamino, hydroxyl, C 1-C 2Alkoxyl group, C 1-C 2Alkylthio, halogen or be selected from hydroxyl, C by 1-2 1-C 2Alkoxyl group, C 1-C 2Alkylthio, cyano group, halogen, C 1-C 4Aryl or heteroaryl that the group of alkyl or trifluoromethyl replaces arbitrarily;
Each R 5Be hydrogen or C independently 1-C 4Alkyl;
Each R 20Be independently
(1) is selected from the C that following substituting group replaces arbitrarily by 1-3 1-C 8Alkyl :-CO 2R 23, amino, C 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, N-((C 1-C 4Alkoxyl group) carbonyl)-N-(C 1-C 4Alkyl) amino, amino carbonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, C 1-C 4Alkyl sulphinyl, C 1-C 4Alkyl sulphonyl, halogen or be selected from amino, two-(C by 1-2 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, (C 1-C 4Alkoxyl group) carbonyl, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, C 1-C 4The C that the group of alkyl or trifluoromethyl replaces arbitrarily 3-C 6Cycloalkyl, heterocyclic radical, aryl or heteroaryl groups;
(2) be selected from (C by 1-2 1-C 4Alkoxyl group) carbonyl, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio or C 1-C 4The heterocyclic radical that the group of alkyl replaces arbitrarily; Perhaps
(3) be selected from (C by 1-2 1-C 4Alkoxyl group) carbonyl, amino, C 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, azido-, C 1-C 4Aryl or heteroaryl that the group of alkyl or trifluoromethyl replaces arbitrarily;
Each R 21Be hydrogen or R independently 20
Each R 23Be hydrogen or C independently 1-C 4Alkyl, or by individual hydroxyl, the C of being selected from of 1-2 1-C 2Alkoxyl group, C 1-C 2Alkylthio, cyano group, halogen, C 1-C 4Phenyl-C that the group of alkyl or trifluoromethyl replaces arbitrarily 1-C 2-alkyl;
R 4Be methyl or ethyl;
R 11Be can be by 1-2 aryl that is selected from any replacement of following group, described group be amino, dimethylamino, kharophen, hydroxyl, halogen, cyano group, methoxyl group, methylthio group, methylsulfinyl, methyl sulphonyl, aminocarboxyl, methyl or trifluoromethyl group; With
R 12Be can be by 1-2 heteroaryl that is selected from any replacement of following group, described group be amino, dimethylamino, kharophen, hydroxyl, halogen, cyano group, methoxyl group, methyl or trifluoromethyl group.
5. the described compound of claim 4 or its pharmaceutically acceptable salt, wherein
Z is by 1-2 any C that replaces of group that is selected from amino, t-butoxycarbonyl amino, dimethylamino, hydroxyl, methoxyl group, methylthio group or halogen 1-C 4Alkyl;
Y is
(1) hydrogen;
(2)-C (O)-R 20,-C (O)-OR 21Or-C (O)-NR 5R 21Group;
(3)-OR 21,-SR 21,-S (O)-R 20,-S (O) 2-R 20Or-S (O) 2-NR 5R 21Group; Or
(4)-NR 5R 21,-NR 22-C (O)-R 21Or-NR 22-S (O) 2-R 20Group;
R 5Be hydrogen;
Each R 20Be independently
(1) is selected from the C that following substituting group replaces arbitrarily by 1-3 1-C 6Alkyl :-CO 2R 23, amino, methylamino-, dimethylamino, t-butoxycarbonyl amino, N-((tert.-butoxy) carbonyl)-N-(methyl) amino, amino carbonyl amino, hydroxyl, butoxy, methoxyl group, butylthio, methylthio group, methylsulfinyl, methylsulfonyl, halogen or the C that replaced arbitrarily by 1-2 group that is selected from amino, dimethylamino, kharophen, hydroxyl, methoxyl group, methylthio group, halogen, methyl or trifluoromethyl 5-C 6Cycloalkyl, heterocyclic radical, phenyl or heteroaryl groups;
(2) be selected from tertbutyloxycarbonyl, hydroxyl or C by 1-2 1-C 4The heterocyclic radical that the group of alkyl replaces arbitrarily; Perhaps
(3) by 1-2 any aryl or the heteroaryl that replaces of group that is selected from amino, dimethylamino, hydroxyl, methoxyl group, methylthio group, halogen, methyl or trifluoromethyl;
Each R 21Be hydrogen or R independently 20
Each R 22Be hydrogen or methyl independently;
Each R 23Be hydrogen or C independently 1-C 4Alkyl
R 11Be unsubstituted phenyl or naphthyl or can be selected from the phenyl that following group replaces arbitrarily that described group is amino, dimethylamino, kharophen, hydroxyl, halogen, cyano group, methoxyl group, methylthio group, methylsulfinyl, methyl sulphonyl, aminocarboxyl, methyl or trifluoromethyl group by 1-2; With
R 12Be can be by any 4-pyridyl, 4-quinolyl, 4-imidazolyl or the 4-pyrimidyl that replaces of following groups, described group be amino, dimethylamino, kharophen, hydroxyl, halogen, cyano group, methoxyl group, methyl or trifluoromethyl group.
6. the described compound of claim 5 or its pharmaceutically acceptable salt, wherein
Y is
(1)-C (O)-R 20, or-C (O)-NR 5R 21Group;
(2)-OR 21,-SR 21,-S (O)-R 20,-S (O) 2-R 20Or-S (O) 2-NR 5R 21Group; Or
(3)-NR 5R 21,-NR 22-C (O)-R 21Or-NR 22-S (O) 2-R 20Group;
Each R 20Be independently
(1) is selected from the C that following substituting group replaces arbitrarily by 1-3 1-C 6Alkyl :-CO 2R 23, amino, methylamino-, dimethylamino, t-butoxycarbonyl amino, N-((tert.-butoxy) carbonyl)-N-(methyl) amino, amino carbonyl amino, hydroxyl, butoxy, methoxyl group, butylthio, methylthio group, methylsulfinyl, methylsulfonyl, halogen or the C that replaced arbitrarily by 1-2 group that is selected from amino, dimethylamino, kharophen, hydroxyl, methoxyl group, methylthio group, halogen, methyl or trifluoromethyl 5-C 6Cycloalkyl, heterocyclic radical, phenyl or heteroaryl groups;
(2) heterocyclic radical that is replaced arbitrarily by tertbutyloxycarbonyl; Perhaps
(3) by 1-2 any aryl or the heteroaryl that replaces of group that is selected from amino, dimethylamino, hydroxyl, methoxyl group, methylthio group, halogen, methyl or trifluoromethyl;
Each R 21Be hydrogen or R independently 20
7. the described compound of claim 6 or its pharmaceutically acceptable salt, wherein
Y is-OR 21,-SR 21Or-NR 5R 21Group;
Each R 20Be independently
(1) is selected from the C that following substituting group replaces arbitrarily by 1-3 1-C 6Alkyl: amino, methylamino-, dimethylamino, hydroxyl or the phenyl or the heteroaryl groups that are replaced arbitrarily by the individual group that is selected from amino, dimethylamino, hydroxyl, methoxyl group, methylthio group, halogen, methyl or trifluoromethyl of 1-2;
(2) heterocyclic radical; Perhaps
(3) by 1-2 any aryl or the heteroaryl that replaces of group that is selected from amino, dimethylamino, hydroxyl, methoxyl group, methylthio group, halogen, methyl or trifluoromethyl;
Each R 21Be hydrogen or R independently 20
R 11Be unsubstituted phenyl or be selected from the phenyl that the group of amino, dimethylamino, kharophen, hydroxyl, halogen, cyano group, methoxyl group, methylthio group, methyl sulphonyl, methyl or trifluoromethyl replaces arbitrarily by 1-2; With
R 12Be selected from any 4-pyridyl that replaces of group of amino, dimethylamino, kharophen, hydroxyl, halogen, cyano group, methoxyl group, methyl or trifluoromethyl.
8. following formula: compound or its pharmaceutically acceptable salt:
Wherein
X is O or S;
Each R 21Be independently hydrogen or
(1) is selected from the C that following substituting group replaces arbitrarily by 1-3 1-C 8Alkyl or C 2-C 5Thiazolinyl :-CO 2R 23, amino, C 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, N-((C 1-C 4Alkoxyl group) carbonyl)-N-(C 1-C 4Alkyl) amino, amino carbonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, C 1-C 4Alkyl sulphinyl, C 1-C 4Alkyl sulphonyl, halogen or be selected from amino, C by 1-3 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, C 1-C 5Alkanoyl, (C 1-C 4Alkoxyl group) carbonyl, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, C 1-C 4Alkyl or contain the C of 1-3 halogen 1-C 2Aryl-C that the group of haloalkyl replaces arbitrarily 1-C 4-alkoxyl group, aryl-C 1-C 4-alkylthio, aryl-C 1-C 4-alkyl sulphonyl, C 3-C 6Cycloalkyl, heterocyclic radical, aryl or heteroaryl groups;
(2) be selected from amino, two-(C by 1-2 1-C 4Alkyl) amino, (C 1-C 4Alkoxyl group) carbonylamino, (C 1-C 4Alkoxyl group) carbonyl, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio or C 1-C 4The heterocyclic radical that the group of alkyl replaces arbitrarily; Perhaps
(3) be selected from amino, C by 1-2 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, kharophen, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, (C 1-C 4Alkoxyl group) carbonyl, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, azido-, C 1-C 4Aryl or heteroaryl that the group of alkyl or trifluoromethyl replaces arbitrarily;
Each R 23Be hydrogen or C independently 1-C 4Alkyl, or by individual amino, the two-(C that is selected from of 1-3 1-C 2Alkyl) amino, kharophen, (C 1-C 4Alkane is fluorine-based) carbonylamino, hydroxyl, C 1-C 2Alkoxyl group, C 1-C 2Alkylthio, cyano group, halogen, C 1-C 4Phenyl-C that the group of alkyl or trifluoromethyl replaces arbitrarily 1-C 2-alkyl or heteroaryl-C 1-C 2-alkyl group;
Each R 24Be hydrogen or C independently 1-C 4Alkyl;
N is the integer of 1-3;
R 11Be aryl and R 12Be heteroaryl, wherein said aryl and heteroaryl can be selected from following group by 1-2 and replace arbitrarily:
(1)R 30；
(2) halogen or cyano group; Perhaps
(3)-C (O)-NR 31R 32,-OR 29,-SR 29,-S (O)-R 30,-S (O) 2-R 30,-S (O) 2-NR 31R 32,-NR 31R 32Or-NR 33-C (O)-R 29Group;
Condition is, at R 11And R 12Aryl, heteroaryl, cycloalkyl and the heterocyclic radical that go up to replace separately add up to 0-1;
Each R 30Be independently
(1) by phenyl or any C that replaces of heteroaryl 1-C 4Alkyl, described substituting group can be replaced arbitrarily by 1-3 group that is selected from amino, dimethylamino, kharophen, hydroxyl, halogen, methoxyl group, methyl or trifluoromethyl;
(2) trifluoromethyl; Perhaps
(3) by 1-3 any aryl or the heteroaryl that replaces of group that is selected from amino, dimethylamino, kharophen, hydroxyl, halogen, methoxyl group, methyl or trifluoromethyl;
Each R 29Be hydrogen or R independently 30
Each R 31Be hydrogen, methyl or ethyl independently; With
Each R 32Be independently
(1) hydrogen;
(2) C 1-C 4Alkyl or the C that is replaced by phenyl or heteroaryl groups 1-C 2Alkyl, described substituting group can be replaced arbitrarily by 1-3 group that is selected from amino, dimethylamino, kharophen, hydroxyl, methoxyl group, methyl or trifluoromethyl; Perhaps
(3) by 1-3 any phenyl or the heteroaryl that replaces of group that is selected from amino, dimethylamino, kharophen, hydroxyl, methoxyl group, methyl or trifluoromethyl; With
Each R 33Be hydrogen or methyl independently; With
Wherein heterocyclic radical is 1-2 annular atoms monocycle saturated heterocyclic system of 5-6 unit that is oxygen, sulphur or nitrogen heteroatom wherein, and it can at random condense with phenyl ring and at random by 1-2 oxo or thio group replacement; Aryl is a phenyl or naphthyl; With heteroaryl be 1-2 annular atoms monocyclic aromatic heterocycle system of 5-6 unit that is oxygen, sulphur or nitrogen heteroatom wherein, it can at random condense with phenyl ring.
9. the described compound of claim 8 or its pharmaceutically acceptable salt, wherein
R 11Be to be selected from the aryl that following group replaces arbitrarily by 1-2
(1)R 30；
(2) halogen or cyano group; Perhaps
(3)-C (O)-NR 31R 32,-OR 29,-SR 29,-S (O)-R 30,-S (O) 2-R 30,-S (O) 2-NR 31R 32,-NR 31R 32Or-NR 33-C (O)-R 29Group; With
R 12Be to be selected from the heteroaryl that following group replaces arbitrarily by 1-2:
(1)R 30；
(2) halogen or cyano group; Perhaps
(3)-C (O)-NR 31R 32,-OR 29,-SR 29,-NR 31R 32Or-NR 33-C (O)-R 29Group;
Condition is, at each R 11And R 12The aryl of last replacement, heteroaryl, cycloalkyl and heterocyclic radical add up to 0-1;
R 30Be independently
(1) by phenyl or any C that replaces of heteroaryl 1-C 4Alkyl, described substituting group can be replaced arbitrarily by 1-2 group that is selected from amino, dimethylamino, kharophen, hydroxyl, halogen, methoxyl group, methyl or trifluoromethyl;
(2) trifluoromethyl; Perhaps
(3) by 1-3 any aryl or the heteroaryl that replaces of group that is selected from amino, dimethylamino, kharophen, hydroxyl, halogen, methoxyl group, methyl or trifluoromethyl;
Each R 29Be hydrogen or R independently 30
R 32Be independently
(1) hydrogen or C 1-C 4Alkyl; Perhaps
(2) by 1-2 any phenyl or the heteroaryl groups that replaces of group that is selected from amino, dimethylamino, kharophen, hydroxyl, methoxyl group, methyl or trifluoromethyl.
10. the described compound of claim 9 or its pharmaceutically acceptable salt, wherein
Each R 21Be independently hydrogen or
(1) is selected from the C that following substituting group replaces arbitrarily by 1-3 1-C 8Alkyl :-CO 2R 23, amino, C 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, N-((C 1-C 4Alkoxyl group) carbonyl)-N-(C 1-C 4Alkyl) amino, amino carbonyl amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, C 1-C 4Alkyl sulphinyl, C 1-C 4Alkyl sulphonyl, halogen or be selected from amino, two-(C by 1-2 1-C 4Alkyl) amino, C 1-C 5Alkanoyl amido, (C 1-C 4Alkoxyl group) carbonylamino, C 1-C 4Alkyl sulfonyl amino, (C 1-C 4Alkoxyl group) carbonyl, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, C 1-C 4The C that the group of alkyl or trifluoromethyl replaces arbitrarily 3-C 6Cycloalkyl, heterocyclic radical, aryl or heteroaryl groups;
(2) be selected from (C by 1-2 1-C 4Alkoxyl group) carbonyl, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio or C 1-C 4The heterocyclic radical that the group of alkyl replaces arbitrarily; Perhaps
(3) be selected from (C by 1-2 1-C 4Alkoxyl group) carbonyl, amino, C 1-C 4Alkylamino, two-(C 1-C 4Alkyl) amino, hydroxyl, C 1-C 4Alkoxyl group, C 1-C 4Alkylthio, cyano group, halogen, azido-, C 1-C 4Aryl or heteroaryl that the group of alkyl or trifluoromethyl replaces arbitrarily;
Each R 23Be hydrogen or C independently 1-C 4Alkyl, or by individual hydroxyl, the C of being selected from of 1-2 1-C 2Alkoxyl group, C 1-C 2Alkylthio, cyano group, halogen, C 1-C 4Phenyl-C that the group of alkyl or trifluoromethyl replaces arbitrarily 1-C 2-alkyl;
R 11Be can be by 1-2 aryl that is selected from any replacement of following group, described group be amino, dimethylamino, kharophen, hydroxyl, halogen, cyano group, methoxyl group, methylthio group, methylsulfinyl, methyl sulphonyl, aminocarboxyl, methyl or trifluoromethyl group; With
R 12Be can be by 1-2 heteroaryl that is selected from any replacement of following group, described group be amino, dimethylamino, kharophen, hydroxyl, halogen, cyano group, methoxyl group, methyl or trifluoromethyl group.
11. the described compound of claim 10 or its pharmaceutically acceptable salt, wherein
Figure C971815580017C1
Each R 21Be independently hydrogen or
(1) is selected from the C that following substituting group replaces arbitrarily by 1-3 1-C 6Alkyl :-CO 2R 23, amino, methylamino-, dimethylamino, t-butoxycarbonyl amino, N-((tert.-butoxy) carbonyl)-N-(methyl) amino, amino carbonyl amino, hydroxyl, butoxy, methoxyl group, butylthio, methylthio group, methylsulfinyl, methylsulfonyl, halogen or the C that replaced arbitrarily by 1-2 group that is selected from amino, dimethylamino, kharophen, hydroxyl, methoxyl group, methylthio group, halogen, methyl or trifluoromethyl 5-C 6Cycloalkyl, heterocyclic radical, phenyl or heteroaryl groups;
(2) heterocyclic radical that is replaced arbitrarily by tertbutyloxycarbonyl; Perhaps
(3) by 1-2 any aryl or the heteroaryl that replaces of group that is selected from amino, dimethylamino, hydroxyl, methoxyl group, methylthio group, halogen, methyl or trifluoromethyl;
Each R 23Be hydrogen or C independently 1-C 4Alkyl
R 11Be unsubstituted phenyl or naphthyl or can be selected from the phenyl that following group replaces arbitrarily that described group is amino, dimethylamino, kharophen, hydroxyl, halogen, cyano group, methoxyl group, methylthio group, methylsulfinyl, methyl sulphonyl, aminocarboxyl, methyl or trifluoromethyl group by 1-2; With
R 12Be can be by any 4-pyridyl, 4-quinolyl, 4-imidazolyl or the 4-pyrimidyl that replaces of following groups, described group be amino, dimethylamino, kharophen, hydroxyl, halogen, cyano group, methoxyl group, methyl or trifluoromethyl group.
12. the described compound of claim 11 or its pharmaceutically acceptable salt, wherein
Each R 21Be independently hydrogen or
(1) is selected from the C that following substituting group replaces arbitrarily by 1-3 1-C 6Alkyl: amino, methylamino-, dimethylamino, hydroxyl or the phenyl or the heteroaryl groups that are replaced arbitrarily by the individual group that is selected from amino, dimethylamino, hydroxyl, methoxyl group, methylthio group, halogen, methyl or trifluoromethyl of 1-2;
(2) heterocyclic radical; Perhaps
(3) by 1-2 any aryl or the heteroaryl that replaces of group that is selected from amino, dimethylamino, hydroxyl, methoxyl group, methylthio group, halogen, methyl or trifluoromethyl;
R 11Be unsubstituted phenyl or be selected from the phenyl that the group of amino, dimethylamino, kharophen, hydroxyl, halogen, cyano group, methoxyl group, methylthio group, methyl sulphonyl, methyl or trifluoromethyl group replaces arbitrarily by 1-2; With
R 12By any 4-pyridyl that replaces of the group of amino, dimethylamino, kharophen, hydroxyl, halogen, cyano group, methoxyl group, methyl or trifluoromethyl group.
13. following compounds:
2-(2, the 6-dichloro benzyl)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-(fourth amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-(benzyl amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
5-(4-fluorophenyl)-3-methyl-((R-1-styroyl) amino)-(4-pyridyl)-4 (3H)-pyrimidones,
2-(2-(2-chloro-phenyl-)-ethylamino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
5-(4-fluorophenyl)-2-(2-(4-fluorophenyl)-ethylamino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
5-(4-fluorophenyl)-2-((2-hydroxyl-2-phenyl)-ethylamino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
5-(4-fluorophenyl)-3-methyl-2-((3-hydrocinnamyl)-amino)-6-(4-pyridyl)-4 (3H)-pyrimidones,
5-(4-fluorophenyl)-3-methyl-2-((1-methyl-3-hydrocinnamyl)-amino)-6-(4-pyridyl)-4 (3H)-pyrimidones,
5-(4-fluorophenyl)-3-methyl-2-((R-1-methyl-3-hydrocinnamyl)-amino)-6-(4-pyridyl)-4 (3H)-pyrimidones,
5-(4-fluorophenyl)-3-methyl-2-((2-phenylamino ethyl)-amino)-6-(4-pyridyl)-4 (3H)-pyrimidones,
5-(4-fluorophenyl)-2-((3-imidazolyl propyl group)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-2-(3-(tetramethyleneimine-1-yl)-third amino)-4 (3H)-pyrimidones,
3,6-phenylbenzene-4-(4-pyridyl)-2 (1H)-pyridones
6-(4-aminomethyl phenyl)-3-phenyl-4-(4-pyridyl)-2 (1H)-pyridones
6-(4-ethylphenyl)-3-phenyl-4-(4-pyridyl)-2 (1H)-pyridones
6-(2, the 4-3,5-dimethylphenyl)-3-phenyl-4-(4-pyridyl)-2 (1H)-pyridones
3-phenyl-4-(4-pyridyl)-6-(2-thienyl)-2 (1H)-pyridones
6-(2-furyl)-3-phenyl-4-(4-pyridyl)-2 (1H)-pyridones
2-(((S)-2-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-(((R)-2-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-(((S)-2-N-ethyl-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-((2-amino-2-methyl-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-((2-aminomethyl-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-((3-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
5-(4-fluorophenyl)-3-methyl-2-(3-(2-tolyl) propyl group)-amino)-6-(4-pyridyl)-4 (3H)-pyrimidones,
5-(4-fluorophenyl)-3-methyl-2-((R, S)-2-amino-3-(2 '-fluorophenyl)-propyl group-amino)-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-(((S)-2-acetylaminohydroxyphenylarsonic acid 3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
5-(4-fluorophenyl)-2-(((S)-2-N-isopropylamino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-(((S)-2-N-n-butyl amine base-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-(((S)-2-N, N-dimethylamino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
5-(4-fluorophenyl)-3-methyl-2-((2-methyl-3-phenyl propyl) amino)-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-(((S)-2-amino-3-phenyl propyl)-amino)-3-ethyl-5-(4-fluorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
3-ethyl-5-(4-fluorophenyl)-2-((2-methyl-3-phenyl propyl) amino)-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-(((S)-2-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidone,
2-((2-(3-trifluoromethyl) phenmethyl) amino)-3-methyl-5-(4-fluorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(4-tolyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(4-trifluoromethyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(3-isopropyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(3-4-fluorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(3,5-two (trifluoromethyl) phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(3, the 4-dichlorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(1-naphthyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(3-fluorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
3-methyl-2-(2 (S)-amino-3-phenyl propyl amino)-5-(3-trifluoromethyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
3-methyl-2-(3-phenyl propyl amino)-5-(3, the 5-dichlorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
3-methyl-2-(3-phenyl propyl amino)-5-(4-tolyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
3-methyl-2-(3-phenyl propyl amino)-5-(3-trifluoromethyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
3-methyl-2-(3-phenyl propyl amino)-5-(4-p-methoxy-phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
3-methyl-2-(3-phenyl propyl amino)-5-(4-trifluoromethyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
3-methyl-2-(2-methyl-3-phenyl propyl amino)-5-(3-fluorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
3-methyl-2-(2-methyl-3-phenyl propyl amino)-5-(1-naphthyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
5-(4-fluorophenyl)-2-(((S)-2-N-glycyl amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-(((S)-2-N-glycyl amino-3-phenyl propyl)-amino)-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
5-(4-fluorophenyl)-2-(((S)-2-glycoloyl amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
5-(4-fluorophenyl)-2-(((S)-2-pyrrolidyl-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-((S)-3-benzyl diethylenediamine base)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-((3-amino-3-(2-fluorophenyl) propyl group)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-((3-amino-3-(2-aminomethyl phenyl) propyl group)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-(((S)-3-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-(((R)-3-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-(((S)-3-amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidones,
2-(((R)-3-amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidones,
2-((3-amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidones,
2-((3-amino-3-(2-tolyl) propyl group)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidones,
2-((3-amino-3-(2-fluorophenyl) propyl group)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidones,
2-((3-amino-3-phenyl propyl)-amino)-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-((3-amino-3-(2-fluorophenyl) propyl group)-amino)-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-((3-amino-3-(2-chloro-phenyl-) propyl group)-amino)-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-(((S)-3-amino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-5-(3, the 4-3,5-dimethylphenyl)-4 (3H)-pyrimidones,
2-(((2R, 3R)-3-amino-2-methyl-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-(((2S, 3S)-3-amino-2-methyl-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
5-(4-fluorophenyl)-2-(((S)-3-N-isopropylamino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
5-(4-fluorophenyl)-2-(((R)-3-N-isopropylamino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-2-((S)-tetrahydroisoquinoline-3-base methylamino-)-4 (3H)-pyrimidones,
3-methyl-6-(4-pyridyl)-2-(the basic methylamino-of (S)-tetrahydroisoquinoline-3)-5-(3-trifluoromethyl)-4 (3H)-pyrimidones,
3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-2-((S)-tetrahydroisoquinoline-3-base methylamino-)-4 (3H)-pyrimidones,
3-methyl-5-(4-methylthio group phenyl)-6-(4-pyridyl)-2-(the basic methylamino-of (S)-tetrahydroisoquinoline-3)-4 (3H)-pyrimidones,
2-(((S)-2-amino-3-phenyl propyl)-amino)-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
5-(4-fluorophenyl)-2-((3-hydroxyl-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-(((S)-2-amino-3-phenyl propyl)-amino)-5-(4-fluorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-(((S)-2-amino-3-(2-fluorophenyl) propyl group)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-(((S)-2-amino-3-(4-fluorophenyl) propyl group)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-(((S)-2-amino-3-(2-chloro-phenyl-) propyl group)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl `)-4 (3H)-pyrimidones,
2-(((S)-2-N-isopropylamino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidones,
2-(((S)-2-N-isopropylamino-3-phenyl propyl)-amino)-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
5-(3-chloro-phenyl-)-2-(((S)-2-N-isopropylamino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-(((S)-2-N, N-dimethylamino-3-phenyl propyl)-amino)-3-methyl-5-(3-aminomethyl phenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-(((S)-2-N, N-dimethylamino-3-phenyl propyl)-amino)-3-methyl-5-(3-fluorophenyl)-6-(4-pyridyl)-4 (3H)-pyrimidones,
2-(((S)-2-N, N-dimethylamino-3-phenyl propyl)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl)-4 (3H)-pyrimidones,
5-(4-fluorophenyl)-3-methyl-2-(((S)-2-N-methylamino--3-phenyl propyl)-amino)-6-(4-pyridyl)-4 (3H)-pyrimidones, or its pharmaceutically acceptable salt.
14. a pharmaceutical composition, said composition contain described compound of claim 1-13 and pharmaceutically acceptable carrier.
15. the described compound of each of claim 1-13 is used to prevent or treats purposes aspect the medicine of inflammation in preparation.
16. composition was used to prevent or treats purposes aspect the medicine of inflammation in preparation during claim 14 was described.
17. the described compound of each of claim 1-13 is used for prevention or treatment Mammals rheumatoid arthritis in preparation, Paget's disease, osteoporosis, multiple myeloma, uveitis, acute and chronic lymphocytic leukemia, pancreatic, osteoarthritis, rheumatoid osteomyelitis, urarthritis, enteritis, adult respiratory distress syndrome (ARDS), psoriasis, Crohn disease, rhinallergosis, ulcerative colitis, irritated, contact dermatitis, asthma, muscle deterioration, emaciation, reiter syndrome, I type and type ii diabetes, bone resorption disease, graft-vs-host reaction, presenile dementia, apoplexy, myocardial infarction forms, the ischemia reperfusion damage, atherosclerosis, cerebral trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, because of HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, simplexvirus or zoster infect the purposes of the medicine aspect of the myalgia that causes.
18. the described composition of claim 14 is used for prevention or treatment Mammals rheumatoid arthritis in preparation, Paget's disease, osteoporosis, multiple myeloma, uveitis, acute and chronic lymphocytic leukemia, pancreatic, osteoarthritis, rheumatoid osteomyelitis, urarthritis, enteritis, adult respiratory distress syndrome (ARDS), psoriasis, Crohn disease, rhinallergosis, ulcerative colitis, irritated, contact dermatitis, asthma, muscle deterioration, emaciation, reiter syndrome, I type and type ii diabetes, bone resorption disease, graft-vs-host reaction, presenile dementia, apoplexy, myocardial infarction forms, the ischemia reperfusion damage, atherosclerosis, cerebral trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, because of HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, simplexvirus or zoster infect the purposes of the medicine aspect of the myalgia that causes.
19. the described compound of each of claim 1-13 is used for reducing the purposes aspect the medicine of any one or two kinds of plasma concentration of TNF-α and IL-1 in preparation.
20. the described composition of claim 14 is used for reducing the purposes aspect the medicine of any one or two kinds of plasma concentration of TNF-α and IL-1 in preparation.
21. the described compound of each of claim 1-13 is used for reducing the purposes aspect the medicine of any one or two kinds of plasma concentration of IL-6 and IL-8 in preparation.
22. claim 14 is stated the purposes aspect composition is used for reducing any one or two kinds of plasma concentration of IL-6 and IL-8 in preparation the medicine.
23. the described compound of each of claim 1-13 is used to prevent or treats purposes aspect the medicine of Mammals diabetes in preparation, to produce the antagonistic action to hyperglycemic-glycogenolytic factor.
24. the described composition of claim 14 is used to prevent or treats purposes aspect the medicine of Mammals diabetes in preparation, to produce the antagonistic action to hyperglycemic-glycogenolytic factor.
25. the described compound of each of claim 1-13 is used to prevent or treats purposes aspect the medicine of Mammals pain disease in preparation.
26. the described composition of claim 14 is used to prevent or treats purposes aspect the medicine of Mammals pain disease in preparation.
27. the described compound of claim 1-13 is used to reduce purposes aspect the medicine that the Mammals prostaglandin(PG) produces in preparation.
28. the described composition of claim 14 is used to reduce purposes aspect the medicine that the Mammals prostaglandin(PG) produces in preparation.
29. the described compound of each of claim 1-13 is used to reduce the purposes aspect the medicine of Mammals cyclooxygenase-2 activity in preparation.
30. the described purposes of claim 29, wherein said cyclooxygenase is COX-2.
31. the described composition of claim 14 is used to reduce the purposes aspect the medicine of Mammals cyclooxygenase-2 activity in preparation.
32. the described purposes of claim 31, wherein said cyclooxygenase is COX-2.
CNB971815585A 1996-12-05 1997-12-04 Substituted pyrimidinone and pyridinone compounds and their use Expired - Fee Related CN1328277C (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US3212896P 1996-12-05 1996-12-05
US60/032,128 1996-12-05
US5095097P 1997-06-13 1997-06-13
US60/050,950 1997-06-13
US97605397A 1997-11-21 1997-11-21
US08/976,053 1997-11-21

Publications (2)

Publication Number Publication Date
CN1246857A CN1246857A (en) 2000-03-08
CN1328277C true CN1328277C (en) 2007-07-25

Family

ID=27364029

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB971815585A Expired - Fee Related CN1328277C (en) 1996-12-05 1997-12-04 Substituted pyrimidinone and pyridinone compounds and their use

Country Status (13)

Country Link
EP (1) EP0948496A2 (en)
JP (1) JP2002514196A (en)
KR (1) KR100476586B1 (en)
CN (1) CN1328277C (en)
AU (1) AU735901C (en)
BG (1) BG65129B1 (en)
BR (1) BR9713863A (en)
CA (1) CA2274093C (en)
CZ (1) CZ9902016A3 (en)
HU (1) HUP0001140A3 (en)
IL (1) IL130181A0 (en)
NZ (1) NZ335992A (en)
WO (1) WO1998024780A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110078674A (en) * 2019-04-10 2019-08-02 昆明理工大学 A kind of preparation method of 2- alkyl amine pyrimidine ketone

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410729B1 (en) * 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO1999032121A1 (en) 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
AR023052A1 (en) * 1998-09-25 2002-09-04 Mitsuharu Yoshimura Milton DERIVATIVES OF PIRIMIDONA
DE69914357T2 (en) 1998-11-04 2004-11-11 Smithkline Beecham Corp. PYRIDIN-4-YL OR PYRIMIDIN-4-YL SUBSTITUTED PYRAZINE
GB9910378D0 (en) * 1999-05-05 1999-06-30 Smithkline Beecham Plc Novel compounds
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
US6403596B1 (en) 1999-06-28 2002-06-11 Merck & Co., Inc. Substituted pyridones having cytokine inhibitory activity
WO2001038313A1 (en) 1999-11-23 2001-05-31 Smithkline Beecham Corporation 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p39 kINASE INHIBITORS
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
JP2003514900A (en) 1999-11-23 2003-04-22 スミスクライン・ビーチャム・コーポレイション 3,4-Dihydro- (1H) -quinazolin-2-one compounds as CSBP / p38 kinase inhibitors
JP2005289808A (en) * 2000-03-23 2005-10-20 Sanofi-Aventis 3-substituted-4-pyrimidone derivative
EP1136493A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-(Thienopyridinyl)pyrimidone, 2-(furopyridinyl)pyrimidone 2-(isoquinolinyl)pyrimidone, 2-(pyridoindolyl)pyrimidone and 2-(benzofuropyridinyl)pyrimidone derivatives
EP1136482A1 (en) 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
EP1136099A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-(Indolylalkylamino)pyrimidone derivatives as GSK3beta inhibitors
DE60107835T2 (en) 2000-04-26 2005-12-22 Eisai Co., Ltd. MEDICAL COMPOSITIONS FOR PROMOTING THE ACTIVATION OF THE DIGES
DE60137426D1 (en) 2000-06-12 2009-03-05 Eisai R&D Man Co Ltd 1,2-Dihydropyridine compounds, process for their preparation and their use
JP2004509867A (en) * 2000-09-19 2004-04-02 サントル、ナショナール、ド、ラ、ルシェルシュ、シアンティフィク、（セーエヌエルエス） Pyridinone and pyridinethione derivatives having HIV inhibitory properties
GB0024808D0 (en) * 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
US6821960B2 (en) 2000-11-17 2004-11-23 Noyo Nordisk Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
AU2002223500A1 (en) 2000-11-17 2002-05-27 Novo-Nordisk A/S Glucagon antagonists/inverse agonists
US6706744B2 (en) 2000-11-17 2004-03-16 Novo Nordisk A/S Glucagon antagonists/inverse agonists
KR100754596B1 (en) 2001-09-21 2007-09-05 미쯔비시 웰 파마 가부시키가이샤 3-substituted-4-pyrimidone derivatives
EP1295884A1 (en) * 2001-09-21 2003-03-26 Sanofi-Synthelabo 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 7-Pyrimidinyl-2,3-Dihydroimidazo[1,2-a]Pyrimidin-5(1H)one derivatives
EP1295885A1 (en) * 2001-09-21 2003-03-26 Sanofi-Synthelabo Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives
JP4570361B2 (en) * 2001-09-21 2010-10-27 サノフィ−アベンティス Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido [1,2-a] pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo [1,2-a] pyrimidine-5 (1H) ON derivatives
DK1430057T3 (en) * 2001-09-21 2006-01-16 Sanofi Aventis Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido [1,2-a] pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo [1,2-a] pyrimidine-5 (1H) one derivatives
TWI301834B (en) * 2001-10-22 2008-10-11 Eisai R&D Man Co Ltd Pyrimidone compound and pharmaceutical composition including the same
TWI330183B (en) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
JP2005516955A (en) * 2001-12-21 2005-06-09 バイエル・ヘルスケア・アクチェンゲゼルシャフト Aroyl pyridinone compounds
US20030232813A1 (en) * 2002-04-10 2003-12-18 Orchid Chemicals & Pharmaceuticals Limited Novel amino substituted pyrimidinone derivatives
MXPA04011470A (en) * 2002-05-21 2005-02-14 Amgen Inc Substituted heterocyclic compounds and methods of use.
EP1707205A2 (en) 2002-07-09 2006-10-04 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
JP4616003B2 (en) 2002-12-16 2011-01-19 田辺三菱製薬株式会社 3-substituted-4-pyrimidone derivatives
TWI357408B (en) 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives
US20070167621A1 (en) 2003-04-03 2007-07-19 Pharmacia Corporation Substituted pyrimidinones
US7183287B2 (en) * 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
CA2533684A1 (en) * 2003-07-25 2005-02-10 Amgen Inc. Substituted pyridones and pyrimidinones with antiinflammatory properties
US7579357B2 (en) * 2003-08-13 2009-08-25 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CA2535644A1 (en) 2003-08-20 2005-03-03 Amgen Inc. Substituted pyrimdinone derivatives and methods of use
SE0302486D0 (en) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
EP1557417B1 (en) * 2003-12-19 2007-03-07 Sanofi-Aventis Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP1802589B1 (en) 2004-10-13 2014-04-09 Pharmacia & Upjohn Company LLC Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6h)-yl]-n-(2-hydroxyethyl)-4-methylbenzamide
MX2007007330A (en) 2004-12-16 2007-10-04 Vertex Pharma Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases.
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
ZA200802857B (en) 2005-09-14 2009-09-30 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors for treating diabetes
KR101368988B1 (en) 2005-09-16 2014-02-28 다케다 야쿠힌 고교 가부시키가이샤 Dipeptidyl peptidase inhibitors
TWI417095B (en) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
WO2008104752A1 (en) * 2007-02-26 2008-09-04 Astrazeneca Ab Dihydropyridones as elastase inhibitors
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
EA019085B1 (en) 2007-09-14 2014-01-30 Янссен Фармасьютикалз, Инк. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
CL2008003301A1 (en) 2007-11-06 2009-10-16 Astrazeneca Ab Compounds derived from 3,4-dihydropyrazine-2-carboxamide, inhibitors of elastase of human neutrophils; pharmaceutical compositions; compounding and pharmaceutical composition processes; and use in the treatment of respiratory distress syndrome in adults, cystic fibrosis, cancer, among others.
WO2010025890A1 (en) 2008-09-02 2010-03-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
EP2358371B1 (en) * 2008-10-31 2015-02-11 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
AU2009319387B2 (en) 2008-11-28 2012-05-10 Addex Pharma S.A. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
CA2760259C (en) 2009-05-12 2018-05-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5634506B2 (en) 2009-05-12 2014-12-03 ジャンセン ファーマシューティカルズ， インコーポレイテッド 1,2,3-Triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2011039528A1 (en) 2009-10-02 2011-04-07 Astrazeneca Ab 2-pyridone compounds used as inhibitors of neutrophil elastase
ES2552455T3 (en) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
JP5852666B2 (en) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of the mGluR2 receptor
JP5852665B2 (en) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of the mGluR2 receptor
CA2822017C (en) 2010-12-23 2015-04-07 Pfizer Inc. Glucagon receptor modulators
EP2673260B1 (en) 2011-02-08 2016-08-17 Pfizer Inc Glucagon receptor modulator
RU2013143839A (en) 2011-02-28 2015-04-10 Эррэй Биофарма Инк. SERIN / THREONINE KINASE INHIBITORS
CA2841237C (en) 2011-07-22 2016-05-10 Pfizer Inc. Quinolinyl glucagon receptor modulators
WO2013020062A1 (en) 2011-08-04 2013-02-07 Array Biopharma Inc. Quinazoline compounds as serine/threonine kinase inhibitors
JP5731718B2 (en) 2011-11-11 2015-06-10 ファイザー・インク 2-thiopyrimidinone
CN103130787B (en) * 2011-11-24 2015-06-10 南开大学 Pyrimidone amide compound, and preparation method, anti-HIV activity and anti-TMV activity thereof
RU2650501C2 (en) 2012-03-01 2018-04-16 Эррэй Биофарма Инк. Serine/threonine kinase inhibitors
CA2882750A1 (en) 2012-08-27 2014-03-06 Jim Blake Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
JO3368B1 (en) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JO3367B1 (en) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
LT3096790T (en) 2014-01-21 2019-10-10 Janssen Pharmaceutica, N.V. Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
KR101693781B1 (en) * 2014-10-06 2017-01-09 한양대학교 에리카산학협력단 Method for producing difluoroalkylated amromatics
MA42035A (en) 2015-05-05 2018-03-14 Pfizer 2-THIOPYRIMIDINONES
CN107200731B (en) * 2017-06-11 2020-10-23 湖南科技大学 Thiazole ring-containing pyridone derivative and preparation method and application thereof
KR102598203B1 (en) 2019-11-25 2023-11-03 암젠 인크 Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use
CN115650906A (en) * 2022-11-04 2023-01-31 苏州艾缇克药物化学有限公司 Preparation method of 2-aminoisonicotinic acid
WO2024119067A1 (en) 2022-12-02 2024-06-06 Neumora Therapeutics, Inc. Methods of treating neurological disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1271116B (en) * 1965-05-04 1968-06-27 Bayer Ag Process for the preparation of 4-hydroxypyrimidines
JPS6163680A (en) * 1984-09-05 1986-04-01 Kanto Ishi Pharma Co Ltd Pyrimido(1,2-a)benzimidazole derivative and its preparation
DE69637948D1 (en) * 1995-10-06 2009-07-23 Merck & Co Inc SUBSTITUTED IMIDAZOLE WITH CANCER BREATHERS AND CYTOKININHIBIEREN EFFECT
AU702887B2 (en) * 1995-10-31 1999-03-11 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110078674A (en) * 2019-04-10 2019-08-02 昆明理工大学 A kind of preparation method of 2- alkyl amine pyrimidine ketone
CN110078674B (en) * 2019-04-10 2022-11-01 昆明理工大学 Preparation method of 2-alkyl amino pyrimidone

Also Published As

Publication number Publication date
CN1246857A (en) 2000-03-08
BG65129B1 (en) 2007-03-30
BG103521A (en) 2000-07-31
CZ9902016A3 (en) 1999-11-17
CA2274093C (en) 2006-11-07
WO1998024780A3 (en) 1998-07-30
CA2274093A1 (en) 1998-06-11
JP2002514196A (en) 2002-05-14
AU5525498A (en) 1998-06-29
AU735901B2 (en) 2001-07-19
WO1998024780A2 (en) 1998-06-11
NZ335992A (en) 2001-09-28
AU735901C (en) 2004-02-12
KR20000069329A (en) 2000-11-25
IL130181A0 (en) 2000-06-01
BR9713863A (en) 2000-03-14
HUP0001140A3 (en) 2002-05-28
HUP0001140A2 (en) 2001-04-28
EP0948496A2 (en) 1999-10-13
KR100476586B1 (en) 2005-03-18

Similar Documents

Publication Publication Date Title
CN1328277C (en) Substituted pyrimidinone and pyridinone compounds and their use
US6420385B1 (en) Substituted pyrimidinone and pyridone compounds and methods of use
JP5627574B2 (en) Compounds and methods for treating inflammatory and fibrotic diseases
JP6553236B2 (en) Pyrazole-1-ylbenzenesulfonamide as a CC9 antagonist
CN106467541B (en) Substituted quinolone analog derivative or its pharmaceutically acceptable salt or stereoisomer and its Pharmaceutical composition and application
JP4533534B2 (en) Inhibitor of glycogen synthase kinase 3
RU2264403C2 (en) Substituted 2-aryl-3-(heteroaryl)imidazo[1,2-a]-pyrimidines, pharmaceutical compositions comprising thereof and associated methods
US6610698B2 (en) Substituted pyrimidine compounds and methods of use
KR20000057137A (en) Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
KR20020063934A (en) Corticotropin releasing factor antagonists
PT1042293E (en) Substituted pyridine and pyridazine compounds and their pharmaceutical use
EA010485B1 (en) N,n-diphenyl urea derivative, pharmaceutical composition (embodiments) thereof, and method for the treatment and prevention of diseases and conditions using it (embodiments)
CZ303312B6 (en) Carboxylic acid derivatives inhibiting integrin bond to receptors thereof
CA2825367A1 (en) Diarylacetylene hydrazide containing tyrosine kinase inhibitors
WO2008025526A1 (en) Indole derivatives, their manufacture and use as pharmaceutical agents
US7429594B2 (en) Substituted heterocyclic compounds and methods of use
BG65128B1 (en) Substituted pyramidine compounds and their application
AU8142901A (en) Substituted pyrimidinone and pyridone compounds and methods of use
KR20000069328A (en) Substituted pyrimidine compounds and their use
CA2234701A1 (en) Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
MXPA00006070A (en) Substituted pyridine and pyridazine compounds and their pharmaceutical use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee